Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Anlage 1 Bewertung und Extraktion von Therapiestudien Nr. Feld Hinweise für die Bearbeitung 1 Quelle Fox PA, Nathan M, Francis N, Singh N, Weir J, Dixon G, Barton SE, Bower M. A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with longterm follow-up data including the use of open-label imiquimod. AIDS 2010, 24:2331-2335 2 Studientyp vom Autor bezeichnet als prospektive, doppel-blinde, randomisierte, kontrollierte Studie 3 Studientyp nach Durchsicht Zuordnung zu einem der folgenden Studientypen: X Therapiestudie mit randomisierter Vergleichsgruppe â–¡ Therapiestudie mit nicht-randomisierter Vergleichsgruppe â–¡ Therapiestudie mit Vergleichen über Zeit und Ort (z. B. historische Kontrollen) â–¡ Fallkontrollstudien â–¡ Kohortenstudien â–¡ Therapiestudie ohne Vergleichsgruppen (auch „VorherNachher-Studien“) â–¡ Fallserie â–¡ Fallbericht / Kasuistik (case report) â–¡ Nicht eindeutig zuzuordnen 4 Formale Evidenzkriterien gemäß SIGN Hier folgt eine formale Zuordnung zu den Evidenzstufen gemäß SIGN: â–¡ 1++: Qualitativ hochwertige Metaanalyse bzw. systematischer Review von RCTs oder RCT mit sehr geringem Risiko von Bias X 1+: Gut durchgeführte Metaanalyse bzw. systematischer Review von RCTs oder RCT mit geringem Risiko von Bias â–¡ 1-: Metaanalyse bzw. systematischer Review von RCTs oder RCT mit hohem Risiko von Bias â–¡ 2++: Qualitativ hochwertiger systematischer Review von Fallkontroll- oder Kohortenstudien Qualitativ hochwertige Fallkontroll- oder Kohortenstudie mit sehr geringem Risiko von Confounding, Bias oder Zufallsschwankungen und hoher Wahrscheinlichkeit, dass der Zusammenhang kausal ist â–¡ 2+: Gut durchgeführte Fallkontroll- oder Kohortenstudie mit einem niedrigen Risiko von Confounding, Bias oder Zufallsschwankungen und einer mittleren Wahrscheinlichkeit, dass der Zusammenhang kausal ist â–¡ 2-: Fallkontroll- oder Kohortenstudie mit hohem Risiko von Confounding, Bias oder Zufallsschwankungen und einem signifikanten Risiko, dass der Zusammenhang nicht kausal ist Nr. Feld Hinweise für die Bearbeitung â–¡ 3: Andere Studien wie Einzelfallberichte, Fallserien â–¡ 4: Expertenmeinung 5 Bezugsrahmen Hintergrund (Kontext) der Publikation: Intraepitheliale anale Dysplasien (AIN) treten bei HIV-positiven Patienten häufig auf und können sich zum Analkarzinom weiterentwickeln. Die zur Zeit für die Behandlung der AIN verwendeten Methoden (z.B. Laser, Trichloressigsäure oder chirurgische Exzision) haben eine hohe Rückfallquote und sind für die Patienten belastend. Die Studie wurde in 2 Kliniken des NHS Trust (Chelsea und Westminster Hospital) in England durchgeführt. Unterstützt wurde sie von der Firma 3M Health Care Ltd., die das Verum und das Placebo in äußerlich gleicher Verpackung zur Verfügung stellte und für die Randomisierung verantwortlich war. 6 Indikation Indikation: hochgradige anale intraepitheliale Neoplasie bei HIV-Patienten Behandlungsziel: Rückbildung der Neoplasie zu normalem Analepithel oder zu niedriggradiger analer intraepithelialer Neoplasie 7 Fragestellung / Zielsetzung Klinische Studie mit der Fragestellung, ob Imiquimod effektiver als Placebo in der Behandlung von intraepithelialen analen Dysplasien bei HIV-Patienten ist. Langzeit-Nachbeobachtung zur Ermittlung der Rückfallquote. Erhebung der Nebenwirkungen zum Vergleich mit anderen Behandlungsmethoden 8 Relevante Ein- und Ausschlusskriterien Einschlusskriterien: - hochgradige anale intraepitheliale Dysplasie (HSIL), - HIV-positiv, - HAART seit mind. 3 Monaten, - CD4-Zellzahl mindestens 100/µl, - keine vorangegangene Behandlung des Anus mit Imiquimod. Alle Patienten sind männlich und MSM. 9 Prüfintervention Selbstapplikation eines halben Sachets Imiquimod 3x/Woche für 4 Monate, anschließend hochauflösende Anoskopie (HRA) zur Befunderhebung, im weiteren Verlauf ½ jährliche HRA zur weiteren Verlaufskontrolle. NonRespondern wurde im Anschluss an die Behandlung, die Fortführung mit open-label Imiquimod für weitere 4 Monate angeboten. 10 Vergleichsintervention Selbstapplikation eines halben Sachets Placebo 3x/Woche für 4 Monate, anschließend hochauflösende Anoskopie (HRA) zur Befunderhebung. Im Anschluss wurde den Patienten die Verum-Therapie angeboten (wie unter Punkt 9 aufgeführt), im weiteren Verlauf ½ jährliche HRA zur weiteren Verlaufskontrolle 11 Evtl. weitere Behandlungsgruppen keine 12 Studiendesign Anzahl der Behandlungsarme Typus: X Parallelgruppendesign â–¡ Cross-Over Design â–¡ Prae-Post-Vergleich â–¡ Sonstige:......................... 2 Nr. Feld Hinweise für die Bearbeitung Geplante Fallzahl: 120 Patienten Wurde eine Fallzahlplanung (Power-Kalkulation) durchgeführt? Ja. Bei einer angenommenen Verbesserungsrate von 25% in der Verumgruppe und 5% in der Placebogruppe wären 116 Patienten nötig gewesen um eine Signifikanz von 5% und eine Sicherheit von 80% zu erreichen. Bei einer angenommenen Verbesserungsrate von 40% in der Verumgruppe und 0% in der Placebogruppe wären 50 Patienten nötig gewesen um eine Signifikanz von 5% und eine Sicherheit von 90% zu erreichen. Waren Interimanalysen geplant? nein 13 Subgruppen Enthält die Studie Subgruppen, die für die Fragestellung an die Kommission relevant sind? X keine relevanten Subgruppen â–¡ prospektiv geplante Subgruppenauswertung â–¡ post hoc definierte oder in Auswertung gefundene Subgruppen Subgruppen ggf. benennen 14 Zahl der Zentren An der Studie nahmen 2 Kliniken teil. 15 Randomisierung Die Firma 3M Health Care Ltd. ermöglichte die Randomisierung durch die Herstellung von äußerlich gleich verpacktem Verum und Placebo. Es wurde eine Randomisierungssequenz erstellt und die Patienten bekamen in der Reihenfolge ihrer Teilnahme die jeweils nächste Nummer zugeteilt. 16 Concealment („Maskierung“ der Randomisierung) Die Randomisierung erfolgte maskiert, Behandler und Behandelte erfuhren erst nach Ablauf der 4 Behandlungsmonate, ob sie Verum oder Placebo erhalten hatten. 17 Verblindung der Behandlung Erfolgte eine Verblindung der Behandlung? â–¡ Nein, offene Behandlung â–¡ Patienten verblindet â–¡ Behandler verblindet X Patienten und Behandler verblindet Patienten erhielten Sachets mit Studiennummern. Ob es sich dabei um Verum oder Placebo hielt war nicht erkennbar. 18 Beobachtungsdauer Behandlungsdauer: 4 Monate, danach Follow-up alle 6 Monate. Die Nachbeobachtungszeit betrug durchschnittlich 36 Monate / nach den 4 verblindeten Behandlungsmonaten wurde allen Teilnehmern eine (Weiter-)Behandlung mit open-label Imiquimod angeboten mit Follow-up wie oben. 19 Primäre Zielkriterien Primäres Zielkriterium: Rückbildung der HSIL in normales Analepithel oder in niedriggradige anale intraepitheliale Dysplasie (LSIL). Wichtig war der lange Nachbeobachtungszeitraum von durchschnittlich 3 Jahren, da von anderen Behandlungsmethoden hohe Rückfallquoten bekannt sind. Die Nachbeobachtung wurde mittels ½-jährlicher HRA durchgeführt. Die Befunde wurden jeweils von 2 verschiedenen Pathologen erhoben. Bei ungleichen Befunden wurde der jeweils pathologischere gewertet. 3 Nr. Feld Hinweise für die Bearbeitung 20 Sekundäre Zielkriterien Dauer der Befundbesserung 21 Statistische Methoden für die Analyse der primären Endpunkte χ² = 8,78 unter Anwendung der Yates Korrektur mit einem Freiheitsgrad, P = 0,003 22 Anzahl der behandelten Patienten Es wurden 64 Patienten in die Studie aufgenommen, davon haben 53 die Studie auch komplett durchgeführt. 28 Patienten in der Imiquimod-Gruppe, 25 Patienten in der Placebo-Gruppe. Geplant waren ursprünglich 120 Patienten. Mangels randomisierter Studienmedikation konnten jedoch nicht mehr als 64 Patienten behandelt werden. 23 Zahl und Charakteristika der eingeschlossenen und ausgewerteten Patienten Sind die Ausfälle von Studienteilnehmern (Drop-outs) dokumentiert und begründet? Es gab 11 drop-outs, 5 davon haben die Anwendung der Studienmedikation gar nicht erst begonnen, 1 Patient aus der Placebogruppe entwickelte ein Analkarzinom, 1 Patient der Verumgruppe brach wegen UAW ab, 5 Patienten brachen die Therapie nach wenigen Wochen ab. Häufigst genannter Grund hierfür: Unzufriedenheit mit der Situation mit 50-%iger Wahrscheinlichkeit ein Placebo zu erhalten. Wie wurde in der Analyse mit Drop-outs verfahren? Dropouts wurden nicht in die Analyse aufgenommen. Es erfolgte eine per protocol Analyse. Es gibt keine Hinweise auf systematische und relevante Unterschiede zwischen den Drop-outs und den durchgängig behandelten Patienten. Darstellung des Patientenflusses nach dem CONSORTFlussdiagramm? nein, tabellarische Darstellung mit vergleichbarem Informationsgehalt, siehe unten. 24 Vergleichbarkeit der Behandlungsgruppen Dokumentation: Liegen die Angaben, getrennt nach Behandlungsgruppen, in tabellarischer Form nachvollziehbar vor (z. B. zu Alter, Geschlecht, relevante prognostische Faktoren, Begleittherapien etc.)? Ja Gibt es relevante Unterschiede zwischen den Behandlungsgruppen? Nein Wurden die Gruppen bis auf die Intervention gleich behandelt (Behandlungsgleichheit)? Ja 25 Ergebnisse Darstellung der Ergebnisse s. u. Vorrangig sollten hier die Ergebnisse aus der Intention-totreat-Analyse der primären Zielkriterien dargestellt werden; zusätzlich klinisch besonders relevante Zielkriterien sowie solche, die in mehreren Studien erhoben wurden; Angaben soweit verfügbar, eigene Berechnungen kennzeichnen; für mehrere Studien mit gleichen Zielkriterien kann es sinnvoll sein, eine gemeinsame Tabelle anzulegen. Vergleich zu Annahmen bei Fallzahlplanung. 26 Unerwünschte Therapiewirkung Berücksichtigung von unerwünschten Therapiewirkungen, Risiken und Komplikationen: Dosisfestlegung auf ein halbes Sachet um Resorption im Rektum (und dadurch systemische UAW) zu minimieren / nur ein Studienabbruch in der Verum-Gruppe wegen UAW 4 27 Fazit der Autoren Die Studie zeigt, dass Imiquimod alleine oder in Kombination mit anderen Behandlungsmethoden hochgradige AIN dauerhaft verbessern oder heilen kann. Der Beweis, dass dadurch auch die Entstehung von Analkarzinomen verhindert werden kann, steht allerdings noch aus. 28 Abschließende Bewertung durch den Bearbeiter Die vorliegende Publikation wird X berücksichtigt â–¡ nicht berücksichtigt Wenn nicht berücksichtigt: Gründe angeben: â–¡ Klinisch relevante Patientengruppen nicht berücksichtigt â–¡ Klinisch relevante Alternativen zum Einsatz der Technologie nicht berücksichtigt â–¡ Der in der Studie abgebildete Entwicklungsstatus der Technologie entspricht nicht mehr heutigen Ansprüchen â–¡ Keine (patienten-)relevanten Endpunkte â–¡ Nicht auf den deutschen Versorgungskontext übertragbar â–¡ Erheblich eingeschränkte Validität der Ergebnisse aufgrund schwerwiegender Mängel im Studiendesign â–¡ Es liegen aussagekräftigere Studien vor. â–¡ Sonstige Gründe – und zwar: Ergebnisdarstellung für dichotome Zielkriterien Anzahl Patienten mit Verbesserung o. Heilung / Anzahl Zielkriterium aller Patienten Verum Erfolg nach 12 / 28 (43%) 4-monatiger Behandlung Kontrolle 1 / 25 (4%) Schätzer und Maß für 95% KonfidenzGruppenintervall für unterschied Gruppenunterschied p-Wert (optional) Odds Ratio 2.13-152.35 = 18 0,003 Zu Feld 23+24: 5 Zu Feld 25: 6 Anlage 2 PubMed-MedLine Recherche vom 11. Januar 2011 Suche nach: anal + imiquimod => 38 Treffer 1. AIDS. 2010 Sep 24;24(15):2331-5. A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. Fox PA, Nathan M, Francis N, Singh N, Weir J, Dixon G, Barton SE, Bower M. Chelsea and Westminster Hospital NHS Trust, London, UK. [email protected] OBJECTIVE: To determine whether imiquimod was more effective than placebo for the treatment of high-grade anal canal intraepithelial neoplasia (HG-ACIN). DESIGN: Double-blind, randomized placebo-controlled clinical trial. METHODS: Sixty-four HIV-positive patients were randomized to self-application of imiquimod cream or matched placebo into the anal canal three times a week for 4 months. Response was assessed by cytology, high-resolution anoscopy and biopsy 2 months after therapy. All patients who failed to resolve were offered treatment with open-label imiquimod for a further 4 months. RESULTS: Fifty-three patients completed the study, of which 28 patients were on active drug and 25 patients on placebo. In the imiquimod group, four patients resolved and eight patients downgraded to low-grade squamous intraepithelial lesion (LSIL) with a median follow-up of 33 months. In the placebo group, one patient resolved. Imiquimod was significantly associated with a positive outcome (P = 0.003). Only one patient discontinued owing to side effects. Twenty-one patients entered a second open-label phase of treatment. Five of these patients cleared their anal canal intraepithelial neoplasia (ACIN) and four patients downgraded to LSIL. The overall mean duration of follow-up was 36 months. During this extended follow-up period, 61% have exhibited sustained absence of high-grade squamous intraepithelial lesion (HSIL). CONCLUSION: This study demonstrates the effectiveness of imiquimod for the treatment of ACIN, and the benefit of prolonged or repeated treatments. This form of therapy is likely to be especially valuable for patients with widespread multifocal ACIN who are otherwise difficult to treat, and should be considered as an adjunct to ablative therapy. PMID: 20729710 [PubMed - in process] 2. Clin Colon Rectal Surg. 2009 May;22(2):127-35. Malignancies of the anal margin and perianal skin. Wietfeldt ED, Thiele J. Department of Surgery, Southern Illinois University School of Medicine, Springfield, Illinois, USA. Malignancies of the anal margin and perianal skin are relatively uncommon lesions, comprising 3 to 4% of all anorectal malignancies. Commonly included in this group of cancers are Bowen's disease (intraepithelial squamous cell cancer), perianal Paget's disease (intraepithelial adenocarcinoma), invasive squamous cell cancer, basal cell cancer, and malignant melanoma. Buschke-Lowenstein tumor, or giant condyloma acuminatum, is not always included because this lesion is technically benign, although it displays aggressive local invasive behavior that makes it difficult to manage. Complaints are usually nonspecific, such as itching or burning, bleeding, pain, drainage, or a mass. Proper diagnosis requires a high index of suspicion on the part of the surgeon. Innocent local irritations will resolve in a short time with appropriate therapy; those that persist must be biopsied for tissue diagnosis. Wide local excision is the mainstay of treatment for early stage tumors as it preserves continence and obtains adequate local control. Adjunct therapies have been utilized in more advanced or recurrent lesions, including radiotherapy, photodynamic therapy, and imiquimod. All have met with a fair amount of success in controlling local disease; however, the number of patients treated in each instance is small, making it difficult to design an evidence-based treatment strategy. Invasion and metastasis are relatively rare in this group of neoplasms; perianal Paget's disease has the highest risk of associated underlying neoplasm. The most important consideration in developing a treatment strategy is which strategy would achieve the best clinical result with the least morbidity to the patient. PMCID: PMC2780245 PMID: 20436838 [PubMed] 3. Colorectal Dis. 2010 Mar 10. [Epub ahead of print] What Should We Do About Anal Condyloma and Anal Intraepithelial Neoplasia? Results of a Survey. Dindo D, Nocito A, Schettle M, Clavien PA, Hahnloser D. Department of Surgery, Division of Visceral and Transplantation Surgery, University Hospital, CH-8091 Zurich, Switzerland. Abstract Aim: The incidence of human papilloma virus (HPV) related anal infection and invasive anal squamous cell cancer is increasing dramatically. At present there is a lack of standardization regarding diagnosis, treatment and surveillance of patients with anal HPV infection. Method: An internet-based survey was sent to members of international, surgical and dermatological societies. Answers were obtained from 1017 dermatologists and 393 colorectal surgeons (n=1410). Results: More dermatologists than surgeons provided non-invasive treatment of anal condyloma with 5% imiquimod (80.4 percent vs. 28.2 percent; P<0.001) whereas the situation is reversed for surgical excision (56.8 percent vs. 91.3 percent; P<0.001). To detect dyplastic lesions, 42.0 percent of surgeons used acetic acid only, 23.2 percent use this in combination with high-resolution anoscopy (HRA) and 19.5 percent applied intra-anal cytological smears. Similarly, 64.6 percent of dermatologists applied acetic acid only, 16.5 percent combined acetic acid with HRA, and 30.2 percent performed intra-anal cytological smears (all P<0.001 compared to surgeons). The therapy for anal intraepithelial lesions was not influenced by the grade of dysplasia but it was by immune status. Conclusions: There were significant differences in practice between colorectal surgeons and dermatologists. These findings highlight the need for international and cross-disciplinary clinical guidelines. PMID: 20236146 [PubMed - as supplied by publisher] 4. Surg Clin North Am. 2010 Feb;90(1):99-112, Table of Contents. Condyloma and other infections including human immunodeficiency virus. Lee PK, Wilkins KB. UMDNJ-Robert Wood Johnson University Hospital, New Brunswick, NJ, USA. Sexually transmitted diseases (STDs) are a common public health problem and as such may be more common in a surgical practice than is believed. The recognition that a virus can be responsible for a cancer has profound significant public health implications. This article reviews the presentation and management of the more common perianal STDs including human immunodeficiency virus, as well as the pathogenesis and management of anal intraepithelial neoplasia. PMID: 20109635 [PubMed - indexed for MEDLINE] 5. Int J STD AIDS. 2010 Jan;21(1):8-16. More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia. Mahto M, Nathan M, O'Mahony C. Department of Genitourinary Medicine, Cheshire East Community Health (Central and Eastern Cheshire PCT), Assura Health and Wellness Centre, Sunderland Street, Macclesfield SK11 6JL. [email protected] To assess the effectiveness of 5% imiquimod cream (IQ) in the treatment of vulvar, penile and anal intraepithelial neoplasias (VIN, PIN and AIN), we searched Medline, Embase, PubMed and Cochrane Library databases. With regard to VIN there were two randomized controlled trials (RCTs), eight uncontrolled/cohort studies, nine case reports and one review article. Use of IQ in PIN and AIN were only supported by cohort studies (two each for PIN and AIN) and case reports (15 for PIN and 3 for AIN). On pooled analysis of RCTs, uncontrolled and cohort studies, the mean complete response (CR) rate for VIN, PIN and AIN were 51%, 70% and 48%, respectively. The mean partial response (PR) rate for VIN, PIN and AIN were 25%, 30% and 34% respectively. The recurrence (RR) rate for VIN, PIN and AIN were 16%, 0% and 36%, respectively. The follow-up period for VIN, PIN and AIN ranged from 2 to 32 months, 10 to 12 months and 11 to 39 months, respectively. Although the results for PIN look the best, the strongest evidence regarding efficacy of IQ in anogenital intraepithelial neoplasia is for VIN supported by RCTs. Evidence for use of IQ in AIN was essentially limited to HIV-positive men who have sex with men. IQ was reasonably well tolerated with side-effects being managed with reduction in frequency of drug usage and/or rest periods. Based on these results, IQ seems to be a safe mode of treatment and is possibly an alternative to currently available methods of treatment. However, there are no comparative studies assessing its efficacy against traditional modes of treatment. PMID: 20029061 [PubMed - indexed for MEDLINE] 6. Vaccine. 2009 Apr 14;27(17):2326-34. Epub 2009 Feb 20. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles. Fraillery D, Zosso N, Nardelli-Haefliger D. Institute of Microbiology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Bugnon 48, CH-1011 Lausanne, Switzerland. Human papillomavirus (HPV) vaccines based on L1 virus-like particle (VLP) can prevent genital HPV infection and associated lesions after three intramuscular injections. Needle-free administration might facilitate vaccine implementation, especially in developing countries. Here we have investigated rectal and vaginal administration of HPV16 L1 VLPs in mice and their ability to induce anti-VLP and HPV16-neutralizing antibodies in serum and in genital, rectal and oral secretions. Rectal and vaginal immunizations were not effective in the absence of adjuvant. Cholera toxin was able to enhance systemic and mucosal anti-VLPs responses after rectal immunization, but not after vaginal immunization. Rectal immunization with Resiquimod and to a lesser extent Imiquimod, but not monophosphoryl lipid A, induced anti-HPV16 VLP antibodies in serum and secretions. Vaginal immunization was immunogenic only if administered in mice treated with nonoxynol-9, a disrupter of the cervico-vaginal epithelium. Our findings show that rectal and vaginal administration of VLPs can induce significant HPV16-neutralizing antibody levels in secretions, despite the fact that low titers are induced in serum. Imidazoquinolines, largely used to treat genital and anal warts, and nonoxonol-9, used as genital microbicide/spermicide were identified as adjuvants that could be safely used by the rectal or vaginal route, respectively. PMID: 19428847 [PubMed - indexed for MEDLINE] 7. Acta Dermatovenerol Alp Panonica Adriat. 2009 Mar;18(1):7-11. Proctoscopy should be mandatory in men that have sex with men with external anogenital warts. Mlakar B. RoZna Dolina Surgical Centre, Department for Abdominal Surgery and Proctology, RoZna dolina cesta IV/45, 1000 Ljubljana, Slovenia. INTRODUCTION: The aim of this study was to evaluate anal pathology in men having sex with men (MSM) seen at our proctology outpatient clinics. METHODS: The charts of 74 MSM treated by the author between January 2002 and April 2006 were reviewed. RESULTS: Three of 74 patients (4%) had proctitis and 96% had anogenital condylomata acuminata (warts). 49 out of 71 (69%) had external anogenital as well as intra-anal warts and 13 (18%) had only intra-anal warts. In 14 an intra-anal dysplasia and in 2 patients intra-anal verrucous carcinomas were detected. The average duration of disease before referral to our institutions was more than 9 months. Half of the patients were previously treated for anogenital warts with ointments and suppositories at other institutions, including 17 that were "treated" with ointments and/or suppositories for hemorrhoids prescribed by family physicians. The patients mostly had widespread disease and sixty-nine of them required surgery. In the follow-up period there was no recurrence of warts and only itching was observed in 31 (44%) patients. Therapy with imiquimod was introduced for 3 months in twenty-two cases with intra-anal dysplasia. No major side effects were noticed despite intra-anal use. CONCLUSION: Proctoscopy and histological examination of intra-anal lesions in cases of external anogenital warts should be mandatory in MSM patients. I would like to encourage other physicians to use this approach, which enables detection of intra-anal warts, dysplasia, and even carcinoma in the asymptomatic stage. PMID: 19350182 [PubMed - indexed for MEDLINE] 8. Dermatol Online J. 2009 Jan 15;15(1):14. Comparison of podophyllotoxin and imiquimod as anal condyloma acuminata therapy. Krishna S. Comment on: Dermatol Online J. 2008;14(12):8. Herein we revisit the published evidence for comparison of the efficacy of imiquimod and podophyllotoxin for anal condyloma acuminata. PMID: 19281719 [PubMed - indexed for MEDLINE] 9. J Dtsch Dermatol Ges. 2008 Nov;6(11):925-34. Epub 2008 Apr 12. Anal intraepithelial neoplasia in HIV infection. [Article in English, German] Kreuter A, Brockmeyer NH, Altmeyer P, Wieland U; German Competence Network HIV/AIDS. Department of Dermatology, Ruhr University Bochum, Germany. [email protected] Human papillomavirus (HPV) infections belong to the most common sexually transmitted infections worldwide. While the immune system eliminates most HPV infections over time in immunocompetent individuals, HPV infections tend to persist in immunodeficient individuals. In HIV-infected men who have sex with men (MSM), anal HPV prevalence is more than 90% and infections with multiple HPV types are common. Consequently, HPV-associated anogenital malignancies occur with high frequency in patients with HIV infection. Anal intraepithelial neoplasia (AIN) is a potential precursor lesion of squamous cell carcinoma of the anus. Like its cervical counterpart, cervical intraepithelial neoplasia (CIN), AIN is causally linked to persistent infections with high-risk HPV types such as HPV16 or HPV18. As AIN and CIN share distinct biological similar-ities, AIN screenings analogous to Pap smear programs for CIN have been recommended in high-risk populations to reduce the incidence of anal carcinoma. These screenings include cytological analysis followed by high resolution anoscopy in case of anal dysplasia. Treatment guidelines for AIN are not yet available. Therapeutic strategies can be divided into topical (e.g. trichloroacetic acid, podophyllotoxin, imiquimod, photodynamic therapy) and ablative (e. g. surgical excision, laser ablation, infrared coagulation, electrocautery) measures. However, controlled studies on AIN treatment have not been performed. The impact of HPV vaccination on AIN development will also need to be assessed. Long-term follow-up of these patients is essential to gain more insight into the natural history of anogenital HPV infection in HIV-positive MSM. PMID: 18410393 [PubMed - indexed for MEDLINE] 10. J Invest Dermatol. 2008 Aug;128(8):2078-83. Epub 2008 Feb 14. Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Stücker M, Altmeyer P, Swoboda J, Pfister H, Wieland U; German Competence Network HIV/AIDS. Collaborators: Adam A, Schewe K, Weitner L, Aratesh K, Arendt G, Bartz C, Behrens G, Beichert M, Bieniek B, Cordes C, Bochow M, Brockmeyer N, Buchholz B, Bogner JR, Buhk T, Clad A, Dannecker M, Dupke S, von Einsiedel R, Esser S, Faetkenheuer G, Fischer K, Freiwald M, Friebe-Hoffmann U, Fenske S, Funk M, Ganschow R, Gingelmaier A, Glaunsinger T, Goebel FD, Gölz J, Grosch-Wörner I, Haberl A, Hamouda O, Harrer T, Hartmann M, Hartl H, Hölscher M, Hower M, Husstedt IW, Jansen K, Jäger H, Jessen H, Jessen A, Karwat M, Klausen G, Kirchhoff F, Knechten H, Köppe S, Kreuter A, Kuhlmann B, Langer P, Lauenroth-Mai, Lehmacher W, Lehmann M, Levin C, Lübke M, Maschke M, Marcus U, Mauss S, Meyerhans A, Meyer-Olson D, ter Meulen V, Michalik C, Moll A, Mosthaf FA, Mutz A, Neuen-Jacob E, Niehues T, Oette M, Paulus U, Plettenberg A, Potthoff A, Racz P, Racz K, Rasokat H, Rausch M, Reichelt D, Reitter A, Rieke A, Rockstroh J, Salzberger B, Schafberger A, Schauer J, Schlote F, Schmidt B, Schranz D, Scholten S, Schuler C, Schwab M, Schmidt W, Schmidt R, Schwarze S, Siffert W, Skaletz-Rorowski A, Sonnenberg-Schwan U, Sopper S, Spengler U, Staszewski S, Steffan E, Stellbrink HJ, Stoll M, Goecke T, Taubert S, Telschik A, Ulmer A, Ullrich R, Uberla K, Usadel S, Vogel M, Wagner R, Walter H, Warnatz K, Wasem J, Wiesel W, Von Weizsäcker K, Wieland U, Wintergerst U, Wolf E, Wolf H, Wünsche T, Wyen Ch, Zeitz M, Zylka-Menhorn V. 1Department of Dermatology, Ruhr-University Bochum, Bochum, Germany. Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated precursor lesion of anal carcinoma, is highly prevalent in HIV-infected men having sex with men (MSM). This prospective follow-up study evaluated the long-term results of imiquimod treatment of AIN in 19 HIV-infected MSM. Standardized follow-up examinations included high-resolution anoscopy, anal cytology/histology, HPV typing, and DNA load determination for HPV types 16, 18, 31, and 33. Mean follow-up time was 30.3 months. A total of 74% (14/19) of the patients remained free of AIN at the previously treated site. Five patients (26%) had recurrent high-grade AIN after a mean time of 24.6 months. At the end of follow-up, the numbers of HPV types as well as high-risk HPV-DNA loads were significantly lower than before therapy. During follow-up, 58% of all patients (11/19) developed new anal cytological abnormalities in previously normal, untreated anal regions. 55% of these new AIN lesions were high-grade lesions and most of them were located intra-anally and associated with high-risk HPV types not detectable before therapy. These results demonstrate that imiquimod leads to a high rate of long-term clearance of AIN in HIV-positive men together with a prolonged decrease of high-risk HPV-DNA load. However, new AIN lesions associated with previously undetected HPV types frequently occur in untreated areas. PMID: 18273049 [PubMed - indexed for MEDLINE] 11. Dermatol Online J. 2008 Dec 15;14(12):8. Intra-anal condyloma: surgical or topical treatment? Dianzani C, Pierangeli A, Avola A, Borzomati D, Persichetti P, Degener AM. Department of Dermatology, "Campus Biomedico," University of Rome, Italy. [email protected] Comment in: Dermatol Online J. 2009;15(1):14. Human Papillomavirus infections are the strongest risk factors for genital cancer and are the causative agents of anogenital warts. Although the viral types associated with condylomata usually do not cause carcinoma, in women with a history of these lesions there is an increased risk of intraepithelial neoplasia and cancer. Generally the lesions are not life-threatening, but they provoke significant morbidity, are difficult to treat, and are a source of psychosocial stress. Thus, condylomata represent not only a health problem for the patient but also an economic burden for the society. Considering the individual episodes of care, men experience a longer duration of the lesions and incur greater costs than women. We report a case of a male patient with external and intra-anal condyloma resistant to laser therapy. Initially, surgical intervention appeared required because of florid and intra-anal growth. HPV DNA testing and sequencing revealed the presence of HPV 6. After initial discomfort, the lesions were successfully cleared with topical imiquimod 5 percent cream therapy. PMID: 19265621 [PubMed - indexed for MEDLINE] 12. Br J Dermatol. 2007 Dec;157 Suppl 2:52-5. Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies. Schöfer H. Department of Dermatology and Venerology, University Hospital, J.W. Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt/M, Germany. [email protected] External genital and anal warts (acuminate condyloma) were the first medical indication the topical immune response modifier imiquimod was approved for in 1997. Since then, many placebo controlled randomized clinical trials have demonstrated the efficacy and safety of this synthetic imidazoquinoline derivate for the treatment of different human papillomavirus infections and tumours. Treatment modalities for genital warts (5% cream, three times weekly, minimum duration 4 weeks, control of side-effects) have been optimized and assured by further clinical trials and meta-analyses. For a few years clinical studies focussed on the long-term efficacy of the immunomodulatory therapy (sustained clearance from warts) and most recent studies compared the efficacy of ablative, destructive and imiquimod monotherapy as well as combination therapies. PMID: 18067633 [PubMed - indexed for MEDLINE] 13. Dis Colon Rectum. 2007 Dec;50(12):2173-9. Earlier eradication of intra-anal warts with argon plasma coagulator combined with imiquimod cream compared with argon plasma coagulator alone: a prospective, randomized trial. Viazis N, Vlachogiannakos J, Vasiliadis K, Theodoropoulos I, Saveriadis A, Karamanolis DG. 2nd Department of Gastroenterology, Evangelismos Hospital, 59 Niriidon Street, 17561 P. Faliro, Athens, Greece. [email protected] PURPOSE: Despite the increasing incidence of condylomata acuminate, optimal treatment of anal warts is still undecided. This prospective, randomized study was designed to compare the efficacy of combined argon plasma coagulation and imiquimod cream vs. argon plasma coagulation alone in the management of intra-anal warts. METHODS: From October 2002 to March 2005, 49 patients with intra-anal warts were randomly assigned to argon plasma coagulation plus imiquimod cream (n = 24) vs. argon plasma coagulation alone (n = 25). Therapeutic sessions were repeated until the elimination of the warts. Efficacy of therapy was defined as the time needed for eradication. All patients were followed up for a mean period of 12 months for signs of recurrence. RESULTS: Elimination of warts was achieved earlier in patients receiving combination therapy compared with those receiving monotherapy with argon plasma coagulation (62.5 +/- 5.4 days vs. 91.2 +/- 6.4 days; P = 0.0016). A subgroup analysis performed in HIV-positive patients showed similar results (combination therapy 95 +/- 22.6 days; monotherapy 124.3 +/- 20.7 days; P = 0.033); however, in HIV-positive patients warts were eradicated later compared with HIV-negative patients (110.8 +/- 25.7 days vs. 65 +/- 25.4 days; P < 0.0001). No major complications were observed in our study population. After the follow-up period, recurrence of warts was evident in 22.7 percent of patients in the combination group compared with 34.7 percent of patients in the monotherapy group (P = 0.51). Recurrence was significantly higher in HIV-positive patients compared with HIV-negative patients (P = 0.0039). CONCLUSIONS: Combination therapy with argon plasma coagulator plus imiquimod cream results in earlier clearance of intra-anal warts in both immunocompetent and immunocompromised patients; however, it does not affect the rate of recurrence. PMID: 17914655 [PubMed - indexed for MEDLINE] 14. J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1054-60. Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. Sanclemente G, Herrera S, Tyring SK, Rady PL, Zuleta JJ, Correa LA, He Q, Wolff JC. Dermatology Section, Department of Internal Medicine, University of Antioquia, Medellín, Colombia. [email protected] OBJECTIVE: To evaluate the efficacy of 5% imiquimod in HIV-positive male patients with anogenital warts or anal intraepithelial neoplasia (AIN), and to elucidate whether human papillomavirus (HPV) type and viral load were important for clinical outcome and recurrences. METHODS: Thirty-seven patients with histologically proven anogenital warts or AIN were enrolled. Topical 5% imiquimod was applied three times per week for more than 8 h overnight for 16 weeks, although patients were allowed to continue therapy for 4 more weeks if they did not have complete clearance of lesions. RESULTS: Mean age was 34 years. The perianal area was the main lesion location. Thirty-three patients had CD4 counts of < 500 cells/mm(3). Eighteen patients had a histopathological diagnosis of AIN-1. Main HPV types detected corresponded to low-risk HPV types. At 20 weeks of therapy, 46% patients achieved total clearance whereas 14 patients had > 50% clearance. Recurrence was observed in 5 of 17 patients who cleared. Clearance was not influenced by patients' CD4 counts, wart location, HIV viral load or HPV viral load. CONCLUSIONS: The assumption that visible perianal warts are benign lesions in HIV-positive patients has to be reevaluated since an important number of such lesions could correspond to low-grade anal disease, which in turn could progress to high-grade anal disease or cancer. In addition, our results in this preliminary study indicate that imiquimod appears to be effective in treating AIN in HIV-positive patients. Further studies are needed to document its utility to prevent high-grade dysplasia and/or anal cancer. PMID: 17714124 [PubMed - indexed for MEDLINE] 15. Br J Dermatol. 2007 Sep;157(3):523-30. Epub 2007 Jun 15. p16ink4a expression decreases during imiquimod treatment of anal intraepithelial neoplasia in human immunodeficiency virus-infected men and correlates with the decline of lesional high-risk human papillomavirus DNA load. Kreuter A, Wieland U, Gambichler T, Altmeyer P, Pfister H, Tenner-Racz K, Racz P, Potthoff A, Brockmeyer NH; for the German Network of Competence HIV/AIDS. Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany. [email protected] BACKGROUND: Human papillomavirus (HPV)-associated anogenital cancers and their precursor lesions occur in excess in human immunodeficiency virus (HIV)-infected patients despite the initiation of highly active antiretroviral therapy. In this context, a drastically increased relative risk for anal intraepithelial neoplasia (AIN) exists in HIV-infected men having sex with men (MSM). In a pilot study, imiquimod, a topical immune response modifier, has been reported to be beneficial in the treatment of AIN. OBJECTIVES: To investigate the role of several biomarkers as potential adjuncts in the course of imiquimod treatment for AIN, and to determine whether these markers correlate with the course of high-risk HPV DNA load during imiquimod therapy. METHODS: Immunohistochemical staining was performed for p16(ink4a), minichromosome maintenance protein (MCM), Ki67, proliferating cell nuclear antigen (PCNA) and p21(waf1) expression before and after 16 weeks of imiquimod treatment for AIN. High-risk HPV DNA load determinations were performed by real-time polymerase chain reaction with type-specific primers and probes for HPV types 16, 18, 31 and 33. RESULTS: Histopathological and virological analyses were performed in 21 HIV-infected MSM with histologically confirmed AIN. Eighteen (86%) patients had a complete histological clearance of AIN after imiquimod therapy. As previously shown, lesional high-risk HPV DNA load significantly decreased during imiquimod therapy. Moreover, a significant decline of p16(ink4a), Ki67, MCM and PCNA expression after treatment was observed, while p21(waf1) expression changed nonsignificantly after imiquimod therapy. A significant correlation between the course of high-risk HPV DNA load and p16(ink4a) expression was observed during imiquimod treatment of AIN, whereas the decline of high-risk HPV DNA load did not significantly correlate with MCM, Ki67, PCNA or p21(waf1) expression. CONCLUSIONS: The significant decrease in p16(ink4a) expression in correlation with the drop of lesional high-risk HPV load suggests that p16(ink4a) may be a useful adjunct for the evaluation of treatment response in HPV-associated malignancies and their precursor lesions. PMID: 17573882 [PubMed - indexed for MEDLINE] 16. Med Sci Monit. 2007 Jun;13(6):CS75-7. A therapeutic approach to perianal extramammary Paget's disease: topical imiquimod can be useful to prevent or defer surgery. Vereecken P, Awada A, Ghanem G, Marques da Costa C, Larsimont D, Simoens C, Mendes da Costa P, Hendlisz A. Departments of Dermatology, CHU-Brugmann Hospital, Brussels, Belgium. [email protected] BACKGROUND: Extramammary Paget's disease (EMPD) is a rare skin disease which can be limited to the epidermis and can sometimes also be associated with underlying carcinomas. At clinical examination, lesions are well-defined eczematous areas and have been described typically in the anogenital region. Surgery is the cornerstone treatment. CASE REPORT: In this report the case of a 66-year-old patient presenting with a long-lasting EMPD of perianal region without deep gastrointestinal neoplasia is described. Because of the extension of the lesion, surgery should have led to abdominoperineal amputation, but the patient rejected this option. Three months of daily application of topical imiquimod was prescribed as an alternative treatment. Biopsy-confirmed complete regression could be observed thereafter, and no recurrence has been noted during a 12-month follow-up. CONCLUSIONS: This successful treatment of a perianal-located EMPD by topical imiquimod warrants further investigations. PMID: 17534239 [PubMed - indexed for MEDLINE] 17. Transpl Infect Dis. 2008 Feb;10(1):56-8. Epub 2007 May 19. Giant anal condylomatosis after allogeneic bone marrow transplantation: a rare complication of human papilloma virus infection. Ganguly N, Waller S, Stasik CJ, Skikne BS, Ganguly S. Department of Medicine, The University of Kansas Medical Center, Kansas City, Kansas 66160, USA. [email protected] Condyloma acuminata or genital warts are caused by human papilloma virus (HPV). Ongoing proliferation of HPV in patients with congenital or acquired immunodeficiency states leads to the development of rapidly progressive and sometimes locally invasive tumor with or without dysplasia. Aggressive treatment, diagnostic immuno-typing, and follow-up are necessary in patients with ongoing immunosuppression. We report a case of giant ano-genital condylomatosis due to HPV types 6 and 11 in a patient with chronic myeloid leukemia after allogeneic bone marrow transplantation. The tumor was successfully treated with surgical excision and local application of 5% imiquimod cream. PMID: 17511821 [PubMed - indexed for MEDLINE] 18. Int J Dermatol. 2007 Mar;46(3):318-9. Successful treatment of perianal Bowen's disease with imiquimod. van Egmond S, Hoedemaker C, Sinclair R. University of Melbourne Department of Medicine (Dermatology), St. Vincent's Hospital, Fitzroy, Australia. Although perianal Bowen's disease (BD) is a relatively uncommon malignancy, it is being detected with increasing frequency. It has a strong tendency for local recurrence and treatment remains controversial. The effectiveness of different treatment modalities, ranging from aggressive wide local excision with skin grafting to the application of a topical immune response modifier, remains uncertain. To our knowledge only two cases of perianal BD, successfully treated with imiquimod, have been reported. We wish to present the third case, effectively treated with imiquimod. PMID: 17343595 [PubMed - indexed for MEDLINE] 19. Arch Dermatol. 2006 Nov;142(11):1438-44. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Wieland U, Brockmeyer NH, Weissenborn SJ, Hochdorfer B, Stücker M, Swoboda J, Altmeyer P, Pfister H, Kreuter A. Institute of Virology, University of Cologne, Cologne, Germany. OBJECTIVE: To evaluate the treatment of anal intraepithelial neoplasia (AIN) with the local immune response modifier imiquimod in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM). DESIGN: Prospective, nonrandomized, open-label pilot study, with a mean follow-up time of 9(1/2) months. SETTING: Dermatology department of a university hospital. Patients Twenty-eight consecutive HIV-positive MSM with histologically confirmed perianal (n = 23) or intra-anal (n = 5) AIN. Intervention Overnight treatment with self-applied imiquimod cream (perianal AIN) or suppositories (intra-anal AIN) 3 times a week for 16 weeks. MAIN OUTCOME MEASURES: Response to treatment was documented using clinical, cytologic, and histologic criteria. Human papillomavirus (HPV) typing and HPV DNA load determination for the high-risk HPV types 16, 18, 31, and 33 were performed. RESULTS: Seventeen (61%) of all 28 patients included in the study and 17 (77%) of the 22 patients with AIN, who applied imiquimod as instructed, showed clinical and histologic clearance at the end of therapy. Four patients had residual AIN and 1 patient did not improve. Clinical response was accompanied by a sharp decline in HPV DNA loads and by a reduction in the number of HPV types, but long-term HPV clearance was rarely achieved. In the follow-up period, AIN cleared in 3 patients with residual AIN. Fourteen (78%) of 18 imiquimod responders with at least 5 five months of follow-up had a normal cytologic and clinical picture at the end of the follow-up period. Three primary responders developed a recurrence. In 6 noncompliant patients, there was no clinical or morphological improvement and the HPV DNA loads remained high. CONCLUSIONS: Imiquimod appears to be a safe and effective treatment option for AIN in HIV-positive MSM. Clinical response is accompanied by a significant decrease in high-risk HPV DNA load. These results should encourage controlled randomized studies of imiquimod treatment of AIN. PMID: 17116834 [PubMed - indexed for MEDLINE] 20. Ann Urol (Paris). 2006 Jun;40(3):175-8. [Buschke-Löwenstein tumour: diagnosis and treatment]. [Article in French] Lévy A, Lebbe C. Service de dermatologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France. [email protected] Buschke-Löwenstein tumour is classified as a verrucous carcinoma. It presents like an exophytic tumour of the genital or peri-anal area, with ulceration and sometimes fistulae and sinuses. It is preferentially seen in men and immunocompromised patients. Histological appearance is not far from condyloma acuminata, but with a tendency to compress and displace deeper tissues, without basement membrane disruption. HPV types 6 or 11 are regularly found in association with this tumour. Other STI have to be searched. Physical examination and precise imagery are useful to chose the right treatment regimen. Radical excision is recommended to avoid malignant transformation, but has to be large because of the high number of recurrences. Other treatment modalities such as chemotherapy or imiquimod could be of interest to avoid mutilating surgical interventions. A regular follow-up is necessary because of frequent recurrences and possible malignant transformation. PMID: 16869538 [PubMed - indexed for MEDLINE] 21. Arch Dermatol. 2006 Feb;142(2):243-4. 5% imiquimod suppositories decrease the DNA load of intra-anal HPV types 6 and 11 in HIV-infected men after surgical ablation of condylomata acuminata. Kreuter A, Brockmeyer NH, Weissenborn SJ, Wafaisade A, Pfister H, Altmeyer P, Wieland U; German Competence Network HIV/AIDS. PMID: 16490857 [PubMed - indexed for MEDLINE] 22. Curr Opin Infect Dis. 2006 Feb;19(1):62-6. Human papillomavirus and anal intraepithelial neoplasia. Fox PA. Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital, London, UK. [email protected] PURPOSE OF REVIEW: A review of recent developments in the understanding of the natural history of anal squamous carcinoma arising from areas of high-grade anal intraepithelial neoplasia. RECENT FINDINGS: Anal intraepithelial neoplasia is a consequence of chronic human papillomavirus infection in the anal canal and appears to be driven by high viral loads of human papillomavirus. In men who have sex with men with multiple sexual partners prevalent human papillomavirus infection does not decline with age, in contrast to heterosexual patients. Anal intraepithelial neoplasia is equally prevalent in different age groups of men who have sex with men, but in other respects what is known of its natural history resembles that of cervical intraepithelial neoplasia. Low-grade lesions frequently resolve, but high-grade lesions are much more stable. HIV-positives who practise receptive anal intercourse are at highest risk of anal intraepithelial neoplasia. Screening is easy to perform using cytology; the limitations of anal cytology being similar to those of cervical cytology. Patients with any grade of cytological abnormality require further investigation, ideally with high-resolution anoscopy, every 6 months. Successful treatments for individual small to medium-sized high-grade lesions include trichloroacetic acid, infra-red coagulation and laser. In HIV-positive patients the development of new lesions elsewhere is very likely. Topical agents for multifocal disease include imiquimod and cidofovir. SUMMARY: There is a need for large prospective cohort studies in men who have sex with men and HIV-positive patients to further our understanding of this disease and to evaluate treatment strategies. PMID: 16374220 [PubMed - indexed for MEDLINE] 23. J Dtsch Dermatol Ges. 2005 Apr;3(4):271-5. [Controlled layered removal of anogenital warts by argon-plasma coagulation]. [Article in German] Weyandt GH, Benoit S, Becker JC, Bröcker EB, Hamm H. Klinik und Poliklinik für Haut-und Geschlechtskrankheiten der Universität Wurzburg. [email protected] BACKGROUND: According to guidelines of the German STD Association, appropriate treatment of extensive anogenital warts with comparable recurrence rates includes cryotherapy, surgical excision, electrosurgery, CO2- and Nd:YAG-laser vaporisation. All these procedures are associated with varying degrees of risk for bleeding, release of potentially infectious aerosol, deep thermal destruction, slow wound healing, and scarring. METHODS: Using argon-plasma coagulation anogenital warts can be removed in layers in a controlled manner. High frequency current flows through the argon plasma to the tissue, allowing well-controlled, superficial tissue destruction. RESULTS: From January 2001 to March 2003, 54 patients with extensive genital, anal or anogenital warts were treated. After one treatment, 66% of the pa- tients remained disease-free in the following 4 months. Thirteen patients (24%) showed early recurrence after 4 weeks, five patients (9%) at a later date. In these patients, further treatment, in 9 cases combined with topical imiquimod cream, were necessary for complete remission. CONCLUSION: Compared to other therapeutic procedures, argon-plasma coagulation is a better controlled, quick and low-risk option for the treatment of anogenital warts. Depending on the type of involvement and individual risk factors, postoperative treatment with topical imiquimod cream may be useful. PMID: 16370475 [PubMed - indexed for MEDLINE] 24. Clin Exp Obstet Gynecol. 2005;32(2):138-40. Grade 3 vulvar and anal intraepithelial neoplasia in a HIV seropositive child--therapeutic result: case report. de Góis NM, Costa RR, Kesselring F, de Freitas VG, Ribalta JC, Kobata MP, Taha NS. Sector of Pathology of the Inferior Genital Tract, Department of Gynecology, UNIFESP, Department of Gynecology, Hospital AC Camargo, São Paulo, Brazil. A case report of a HIV seropositive 8-year-old child with vulvar and anal border neoplasia, both grade 3, and the adopted therapeutic management are presented. The mother reported the history of a progressively growing verrucous lesion in the vulva since the age of three and a half years. On physical examination a pigmented and elevated lesion was observed in the whole vulvar region extending to the anal region and intergluteal sulcus. After biopsies and anatomic pathological examination, antiretroviral therapy, adequate for age, and topical application of podophyllotoxin associated with Thuya officinalis extract was started. Three months afterwards vaporization and CO2 laser excision were performed in five sequential sessions, thereafter associated with topical imiquimod application. After the first two sessions of laser therapy early relapses occurred. After four weeks of imiquimod use, already a significant improvement of the lesions was observed, making the following laser therapy sessions easier. We conclude that antiretroviral therapy associated with podophyllotoxin and Thuya was not effective regarding regression of the lesions. Laser therapy alone led to early relapses. The local use of imiquimod associated with laser was effective in decreasing and controling the lesions. PMID: 16108402 [PubMed - indexed for MEDLINE] 25. Br J Surg. 2005 Mar;92(3):277-90. Anal intraepithelial neoplasia. Abbasakoor F, Boulos PB. Department of Surgery, Royal Free and University College Medical School, London, UK. BACKGROUND: Anal intraepithelial neoplasia (AIN) is believed to be a precursor of anal squamous cell cancer and its incidence is rising in high-risk groups, particularly those infected with the human immunodeficiency virus (HIV). The natural history of AIN is unclear and management strategies are lacking. METHODS: This review is based on a literature search (Medline and PubMed) with manual cross-referencing of all articles related to AIN. RESULTS AND CONCLUSIONS: The aetiology of AIN is intricately linked with human papilloma viruses. The pathological processes involved in the progression of AIN are becoming clearer but the natural history, particularly the rate of progression to invasive cancer, remains unknown. There is no standard management for AIN and this is mainly due to difficulties in both diagnosis and treatment. A variety of treatment options have been tried with varying success. Surgery is associated with significant recurrence, particularly in HIV-positive patients. Non surgical approaches with imiquimod, photodynamic therapy and vaccination are appealing, and further work is required. Long-term follow-up of these patients is essential until the natural history of AIN becomes clearer. PMID: 15736144 [PubMed - indexed for MEDLINE] 26. Ann Dermatol Venereol. 2004 Nov;131(11):947-51. [Effects of imiquimod on latent human papillomavirus anal infection in HIV-infected patients]. [Article in French] Pelletier F, Drobacheff-Thiebaut C, Aubin F, Venier AG, Mougin C, Laurent R. Service de Dermatologie, CHU Saint-Jacques, Besançon. INTRODUCTION: High risk human papillomaviruses (HPV) have emerged as risk factors for anal carcinoma particularly in HIV-infected patients who demonstrate a high rate of anal HPV infection. Considering the relationship between the presence of anal infection and the development of neoplastic lesions, we wished to assess the capacity of imiquimod to eradicate latent HPV infection in HIV-infected patients. PATIENTS AND METHODS: We conducted a prospective, randomized, double-blind and vehicle controlled study. Two consecutive anal swabs were taken at 2 month intervals and only patients with two consecutive tests positive for the detection of HPV-DNA (Hybrid Capture II) were included. Patients with persistent latent HPV infection were divided into 2 groups who applied imiquimod versus vehicle during 6 weeks. HPV-DNA presence was then investigated 2 and 4 months following the onset of treatment. RESULTS: Among the 80 HIV-infected patients, 26 (32.5 p. 100) had 2 positive consecutive assays, and 19 patients were included in the study. After randomization, 9 patients received imiquimod and 10 vehicle. There was no significant difference between treatment groups according to the following criteria: gender, route of HIV transmission, CDC stage, prior medical history of sexually transmitted diseases or anogenital warts. 33.3 p. 100 (3/9) of patients treated with imiquimod were negative at M2, whereas 100 p. 100 (10/10) vehicle treated-patients remained positive (p=0.08). Similar results were observed at the M4 visit. DISCUSSION: Our study confirmed the increased prevalence of latent HPV-DNA infection in HIV-infected patients. In spite of the low number of treated patients, we did not observe a statistically significant decrease in HPV-DNA in anal swabs from imiquimod-treated patients as compared to placebo-treated patients. PMID: 15602380 [PubMed - indexed for MEDLINE] 27. J Am Acad Dermatol. 2004 Jun;50(6):980-1. Treatment of anal intraepithelial neoplasia in patients with acquired HIV with imiquimod 5% cream. Kreuter A, Hochdorfer B, Stücker M, Altmeyer P, Weiland U, Conant MA, Brockmeyer NH. PMID: 15153912 [PubMed - indexed for MEDLINE] 28. Minerva Ginecol. 2003 Dec;55(6):541-6. [Topical imiquimod cream in the treatment of external anogenital warts: personal experience]. [Article in Italian] Senatori R, Dionisi B, Lippa P, Inghirami P. Ambulatorio MST-AIED, Roma. [email protected] AIM: The clinical effects of home-therapy with 5% imiquimod cream in the treatment of cutaneous anogenital warts are evaluated. METHODS: From March 2000 to January 2002, 57 women presenting clinical cutaneous external genital and perianal warts were selected in the base-population observed at our clinical of vulvar pathology and sexually transmitted diseases, AIED Rome. The patients were divided into 2 groups: Group A, with new cutaneous viral lesions and Group B with recurrent anogenital warts pre-treated with CO2-laser therapy. A total of 36% (20) of all patients presented contemporaneous HPV lesions of cervix and/or vaginal wall. The follow-up was carried out at 4 weeks, 3 months and 6 months, evaluating the safety, clinical efficacy and tolerance of women. The Pearson chi2 test was used to evaluate trends significance. All lesions were photo-documented. RESULTS: Sixty-four per cent (64%) of the patients had complete clearance of anogenital warts within 16 weeks, for 3 times per week self-application of imiquimod, with clinical remission at short term (6/8 weeks) (chi2=1.42; p<0.05); 12% had partial clearance (<50%) and 20% had a clearance of about 75%. The coexistent lesions of cervix and/or vaginal walls had a high remission (>50%) and required surgical additional therapy with CO2-laser; 28% of patients (16/57) experienced mild to moderate drug-related side effects. There was a significant increase in the severity of local skin reactions due to the increased time and number of applications. CONCLUSION: These data confirm that imiquimod cream at the dose regimen of 3 times per week, is effective and well tolerated in the treatment of cutaneous external warts and is associated to a reduction of coexistent mucous viral lesions due to enhancement of local immune response. PMID: 14676745 [PubMed - indexed for MEDLINE] 29. Ther Umsch. 2003 Oct;60(10):595-604. [Human papillomaviruses]. [Article in German] Gross G. Klinik und Poliklinik für Dermatologie und Venerologie, Universität Rostock, Deutschland. [email protected] Human papillomaviruses (HPV) infect exclusively the basal cells of the skin and of mucosal epithelia adjacent to the skin such as the mouth, the upper respiratory tract, the lower genital tract and the anal canal. HPV does not lead to a viremia. Basically there are three different types of HPV infection: Clinically visible lesions, subclinical HPV infections and latent HPV infections. Distinct HPV types induce morphologically and prognostically different clinical pictures. The most common HPV associated benign tumor of the skin is the common wart. Infections of the urogenitoanal tract with specific HPV-types are recognised as the most frequent sexually transmitted viral infections. So-called "high-risk" HPV-types (HPV16, 18 and others) are regarded by the world health organisation as important risk-factors for the development of genital cancer (mainly cervical cancer), anal cancer and upper respiratory tract cancer in both genders. Antiviral substances with a specific anti-HPV effect are so far unknown. Conventional therapies of benign skin warts and of mucosal warts are mainly nonspecific. They comprise tissue-destroying therapies such as electrocautery, cryotherapy and laser. In addition cytotoxic substances such as podophyllotoxin and systemic therapy with retinoids are in use. Systemically and topically administered immunotherapies represent a new approach for treatment. Both interferons and particularly the recently developed imiquimod, an interferon-alpha and cytokine-inductor lead to better results and are better tolerated then conventional therapies. HPV-specific vaccines have been developed in the last 5 years and will be used in future for prevention and treatment of benign and malignant HPV-associated tumors of the genitoanal tract in both sexes. PMID: 14610898 [PubMed - indexed for MEDLINE] 30. Pediatr Dermatol. 2003 Sep-Oct;20(5):440-2. Imiquimod is highly effective for extensive, hyperproliferative condyloma in children. Majewski S, Pniewski T, Malejczyk M, Jablonska S. Department of Dermatology and Venereology, Warsaw School of Medicine, Warsaw, Poland. We describe a dramatic response to imiquimod of long-lasting, highly proliferative extensive perianal condylomas involving the anal canal in a 19-month-old girl. Her mother was free of condyloma and allegedly had no human papillomavirus (HPV) infection during pregnancy. There was no evidence of sexual abuse. Application of 5% imiquimod cream to the child every other day for 3 weeks resulted in almost complete resolution of the warts, with total clearance within another 2 weeks. The inflammatory reaction was moderate. Since there is still discussion of whether imiquimod may be prescribed for small children, this case of very extensive condyloma provides evidence that the compound is safe and highly effective. PMID: 14521566 [PubMed - indexed for MEDLINE] 31. Tumori. 2003 Jul-Aug;89(4 Suppl):16-8. [Perianal Bowen's disease: a case report and review of the literature]. [Article in Italian] Bertagni A, Vagliasindi A, Ascari Raccagni A, Valmori L, Verdecchia GM. UO di Chirurgia Generale II, Unità di Chirurgia Oncologica, Ospedale GB Morgagni-L Pierantoni, Forlì. Perianal Bowen's disease is a uncommon, slow growing, intraepidermal squamous-cell carcinoma (carcinoma in situ) of the anal region and may be a precursor to squamous carcinoma of the anus. It is associated with cervical and vulvar intraepithelial neoplasia and have human papillomavirus as a common cause. Both sexes and all races are affected, with the highest prevalence in patients aged 20 to 45 years. The symptoms of anal Bowen's disease are unspecific and the clinical findings are uncharacteristic and include pain, itching, bleeding and a disturbing lump. Biopsy and histopathologic examination is required for diagnosis and to distinguish other perianal dermatoses; thus an anogenital warts that fail to respond to conventional therapy, or change in appearance, warrant a biopsy and, where the technique is available, DNA typing to identify the viral pathogen. Infact the etiologic agent, the human papillomavirus (HPV), has been classified by DNA techniques into at least 42 types, of which 16 and 18 are considered to carry a high risk for cancer. The intraoperative findings is a lesion at the anocutaneous line: perianal or intra-anal tumor, erosion or ulceration as well as lichenoid lesion or hyperpigmentation. The disease has a proclivity for recurrence and there are many controversies concerning treatment that effectiveness remains uncertain and range from aggressive wide local excision with skin grafting when necessary to laser vaporization (argon or CO2), radiotherapy or a new immune response modifier (Imiquimod). We report a case of a 50-years-old woman with recurrence of Bowen's disease associated with vulvar HPV infection and review the literature. PMID: 12903534 [PubMed - indexed for MEDLINE] 32. Dermatology. 2003;207(1):119-22. Treatment of verrucous carcinoma with imiquimod and CO2 laser ablation. Heinzerling LM, Kempf W, Kamarashev J, Hafner J, Nestle FO. University Hospital Zürich, Zürich, Switzerland. An 82-year-old female patient presented with a large perianal hyperkeratotic tumor extending into the anal canal. Staging did not reveal any metastatic spread. Diagnosis of verrucous carcinoma or Buschke-Löwenstein tumor, respectively, was based on typical clinical and histologic features. Moreover, human papillomavirus 6b DNA sequences could be detected by PCR. Surgical excision could not be performed due to the general health status of the patient; thus, alternative therapy methods were necessary. Treatment with imiquimod cream 5% (Aldara), a topical immune response modifier applied once a day and left for 12 h, led to significant partial tumor regression and clear demarcation of the tumor. The remaining tumor, now feasible for treatment with CO2 laser, was removed in two sessions in local anesthesia. In a third session, tumor parts in the anal canal were vaporized. This case demonstrates that the combination of imiquimod and CO2 laser ablation is an effective treatment option for verrucous carcinoma. PMID: 12835572 [PubMed - indexed for MEDLINE] 33. J Eur Acad Dermatol Venereol. 2003 May;17(3):363-5. Bowenoid papulosis successfully treated with imiquimod. Loo WJ, Holt PJ. PMID: 12702095 [PubMed - indexed for MEDLINE] 34. Br J Dermatol. 2002 Oct;147(4):757-9. Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma. Kaspari M, Gutzmer R, Kaspari T, Kapp A, Brodersen JP. Department of Dermatology and Allergology, Hannover Medical University, Ricklinger Strasse 5, Germany. [email protected] BACKGROUND: After surgical removal, anal canal condyloma (ACC) has a higher risk of recurrence compared with extragenital warts. OBJECTIVES: To reduce local recurrences of ACC using follow-up treatment with imiquimod-containing suppositories (anal tampons). METHODS: After ablation of ACC, 10 male patients received treatment with imiquimod suppositories three times weekly for 3-4 months. RESULTS: Treatment with imiquimod anal tampons was well tolerated. Early initial recurrences in some patients cleared after treatment with the imiquimod suppositories. Within a mean follow-up of 9 months no patient demonstrated recurrence of ACC. CONCLUSIONS: These data suggest that imiquimod anal tampons may represent a new therapeutic option to prevent recurrences of ACC following ablative surgery. PMID: 12366425 [PubMed - indexed for MEDLINE] 35. J Reprod Med. 2002 May;47(5):395-8. Treatment of vulvar intraepithelial neoplasia 2/3 with imiquimod. Jayne CJ, Kaufman RH. Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, USA. OBJECTIVE: To retrospectively review the charts of 13 women diagnosed with vulvar intraepithelial neoplasia (VIN) 2/3 treated with imiquimod and to evaluate the efficacy of this treatment. STUDY DESIGN: Retrospective review. All 13 women were treated and evaluated by a single gynecologist. The extent of the lesions prior to treatment and the extent and degree of improvement were documented. Biopsy confirmation of disease was obtained for each individual. Response to treatment was categorized as complete regression, at least 75% regression or not improved. RESULTS: The mean duration of treatment was 3.3 months, and follow-up after completion of therapy was 5.5 months. Eight of the 13 women had complete regression of the VIN. Four patients demonstrated 75% regression of disease, and in one diabetic woman no improvement was seen. In two women demonstrating 75% lesion regression, invasive carcinoma of the vulva was found in the area of residual disease. In one instance this was determined to be superficially invasive squamous cell carcinoma (1 mm of invasion), and in the second an anal tag was found to have invasive squamous cell carcinoma. CONCLUSION: Medical management of VIN 2/3 with imiquimod is worth considering. However, careful evaluation of the patient must be carried out prior to the institution of therapy to exclude the presence of invasive squamous cell carcinoma. PMID: 12063878 [PubMed - indexed for MEDLINE] 36. J Chir (Paris). 2001 Oct;138(5):277-80. [Anal condyloma: its management is still difficult]. [Article in French] Sultan S. Service de Coloproctologie, Hôpital des Diaconesses, 18, rue du Sergent-Bauchat, F 75012 Paris. Anal condylomas result from papillomavirus infection, the most common sexually transmitted disease. The principal risk is the development of cancer of the anal canal. The risk of contamination is high, even after a single sexual contact. No specific antiviral treatment is available and no consensus has been reached on the appropriate treatment of anal condylomas. Despite the development of various methods (interferon, imiquimod), electrocoagulation remains the treatment of choice. Finally, regular follow-up and treatment of the partner(s) are essential. PMID: 11894692 [PubMed - indexed for MEDLINE] 37. Arch Dermatol. 2001 Jan;137(1):14-6. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Pehoushek J, Smith KJ. National Naval Medical Center, Bethesda, MD 20889-5600, USA. PMID: 11176654 [PubMed - indexed for MEDLINE] 38. Treat Rev. 1995 Nov;(no 20):7. Warts treatment. [No authors listed] AIDS: New York University Medical Center is testing an alpha-interferon-stimulating cream, imiquimod, for anal and genital wart treatment. More information can be obtained by calling The Network at (800)734-7104. PMID: 11363030 [PubMed - indexed for MEDLINE] Anlage 3 DIMID/EMBASE – Recherche vom 11. Januar 2011 Suchschritt : FT=anal AND FT=imiquimod => 102 Treffer » Volltext-Angebot » 2/1 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2010704199 Newsom-Davis T; Bower M Titel: HIV-associated anal cancer Source: F1000 Medicine Reports; VOL: 2 (1) /20101208/ http://f1000.com/reports/m/2/85/pdf ANR: M2-85 DOI: 10.3410/M2-85 PU: Faculty of 1000 Ltd SU: EMBASE Sprache: English AL: English CY: United Kingdom EISSN: 1757-5931 Institution: Bower M, Department of Oncology, Chelsea, Westminster Hospital NHS Foundation Trust, 369 Fulham Road, London SW10 9NH, United Kingdom, [email protected] COU: United Kingdom DT: Journal Article RN: 0041 Keywords CT: ANUS CANCER/*diagnosis; ANUS CANCER/*drug therapy; ANUS CANCER/*epidemiology; ANUS CANCER/*etiology; ANUS CANCER/*therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; AIDS PATIENT; ARTICLE; BLEEDING/complication; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SCREENING; COLONOSCOPY; CONDYLOMA ACUMINATUM/drug therapy; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFRARED RADIATION; SKIN DEFECT/drug therapy; STANDARDIZED INCIDENCE RATIO; WART VIRUS; IMIQUIMOD/drug therapy; IMIQUIMOD/pharmacology; TRICHLOROACETIC ACID/drug therapy; WART VIRUS VACCINE/drug therapy DN: Gardasil/Merck, United States MN: Merck, United States ET: Cancer; Public Health, Social Medicine and Epidemiology; Clinical and Experimental Pharmacology; Drug Literature Index; Gastroenterology TE: CR: AB: AU: AU: PU: CNOTE: imiquimod/99011-02-6; trichloroacetic acid/14357-05-2; trichloroacetic acid/7603-9 99011-02-6; 14357-05-2; 76-03-9 HIV-associated anal carcinoma, a non-AIDS-defining cancer, is a human papillomavirus-associated malignancy with a spectrum of preinvasive changes. The standardized incidence ratio for anal cancer in patients with HIV/AIDS is 2050. Algorithms for anal cancer screening include anal cytology followed by highresolution anoscopy for those with abnormal findings. Outpatient topical treatments for anal intraepithelial neoplasia include infrared coagulation therapy, trichloroacetic acid, and imiquimod. The development of cost-effective national screening programs for HIV-associated anal cancer remains a challenge. © 2010 Faculty of 1000 Ltd. Newsom-Davis T Newsom-Davis Thomas Department of Oncology, Chelsea, Westminster Hospital NHS Foundation Trust, 369 Fulham Road, London SW10 9NH, United Kingdom Bower M Bower Mark Department of Oncology, Chelsea, Westminster Hospital NHS Foundation Trust, 369 Fulham Road, London SW10 9NH, United Kingdom [email protected] Faculty of 1000 Ltd 34-42 Cleveland Street, London, W1T 4LB, United Kingdom Copyright 2011 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/2 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2010544798 Forcier M; Musacchio N Titel: An overview of human papillomavirus infection for the dermatologist: Disease, diagnosis, management, and prevention Source: Dermatologic Therapy; VOL: 23 (5); p. 458-476 /September-October 2010/ DOI: 10.1111/j.1529-8019.2010.01350.x PU: Blackwell Publishing Inc. SU: EMBASE Sprache: English AL: English CY: United States ISSN: 1396-0296 EISSN: 1529-8019 CO: DETHF Institution: Forcier M, Dr. Prof., Department of Pediatrics, Brown University, Hasbro and Rhode Island Hospitals, Potter 200.2 593 Eddy Street, Providence, RI 02903, United States, [email protected] COU: DT: RN: Keywords CT: UT: DN: MN: ET: TE: CR: AB: AU: United States Review; Journal Article 0118 CONDYLOMA ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*surgery; CONDYLOMA ACUMINATUM/*therapy; PAPILLOMAVIRUS INFECTION/*; BEDTIME DOSAGE; CANCER PREVENTION; CRYOTHERAPY; DISEASE ASSOCIATION; HUMAN; INCIDENCE; INFECTION PREVENTION; LASER SURGERY; REVIEW; SCREENING; SEXUAL INTERCOURSE; SURGICAL TECHNIQUE; UTERINE CERVIX CANCER/drug therapy; UTERINE CERVIX CANCER/prevention; UTERINE CERVIX DISEASE; VACCINATION; VAGINA CANCER; VIRUS TRANSMISSION; VULVA CANCER; DICHLOROACETIC ACID/drug therapy; IMIQUIMOD/drug therapy; INTERFERON/drug therapy; PLACEBO; PODOPHYLLIN/drug therapy; PODOPHYLLOTOXIN/drug therapy; POLYPHENON E/drug therapy; TRICHLOROACETIC ACID/drug therapy; WART VIRUS VACCINE/drug therapy anogenital; cervical cancer; condyloma; genital warts; HPV; human papillomavirus; vaccine Cervarix/Glaxo SmithKline, United Kingdom; Gardasil/Merck, United States Glaxo SmithKline, United Kingdom; Merck, United States Microbiology: Bacteriology, Mycology, Parasitology and Virology; Obstetrics and Gynecology; Cancer; Public Health, Social Medicine and Epidemiology; Drug Literature Index dichloroacetic acid/13425-80-4; dichloroacetic acid/2156-56-1; dichloroacetic acid/79-43-6; imiquimod/99011-02-6; podophyllin/9000-55-9; podophyllotoxin/518-28-5; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 13425-80-4; 2156-56-1; 79-43-6; 99011-02-6; 9000-55-9; 518-28-5; 14357-05-2; 76-03-9 Genital human papillomavirus (HPV) is a common, usually transient, dermatologic infection transmitted by genital contact that can cause a variety of anogenital diseases, including warts (condyloma), dysplasia (cervical, vaginal, vulvar, anal), and squamous cell carcinoma. A number of treatment modalities are available to treat anogenital warts, both patient- and provider-applied. Treatment is efficacious, but lesions can recur. Bivalent and quadrivalent vaccines are approved to prevent HPV infection. Both are indicated to prevent cervical cancer, while the quadrivalent vaccine is also approved to prevent vaginal/vulvar cancers as well as genital warts in males and females. Providers should clearly explain the natural history and potential sequelae of HPV disease, counsel patients on prevention strategies, and recommend vaccination as an effective method of prevention to their patients. © 2010 Wiley Periodicals, Inc. Forcier M Forcier Michelle Department of Pediatrics, Brown University, Hasbro and Rhode Island Hospitals, Potter 200.2 593 Eddy Street, Providence, RI 02903, United States [email protected] AU: PU: CNOTE: Musacchio N Musacchio Najah Department of Pediatrics, Brown University, Hasbro and Rhode Island Hospitals, Potter 200.2 593 Eddy Street, Providence, RI 02903, United States Blackwell Publishing Inc. 350 Main Street, Malden, MA 02148, United States Copyright 2010 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/3 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2010539809 Fox PA; Nathan M; Francis N; Singh N; Weir J; Dixon G; Barton SE; Bower M Titel: A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term followup data including the use of open-label imiquimod Source: AIDS; VOL: 24 (15); p. 2331-2335 /20100924/ DOI: 10.1097/QAD.0b013e32833d466c PU: Lippincott Williams and Wilkins SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 0269-9370 EISSN: 1473-5571 CO: AIDSE Institution: Fox PA, Chelsea and Westminster Hospital NHS Trust, 369 Fulham Road, London SW10 9NH, United Kingdom, [email protected] COU: United Kingdom DT: Journal Article JSC: E.5.3 ... Virology; E.4.1 ... Allergy & Clinical Immunology RN: 0010 Keywords CT: ANUS TUMOR/*drug therapy; HIGH GRADE ANAL CANAL INTRAEPITHELIAL NEOPLASIA/*drug therapy; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY/*; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*; PRECANCER AND CANCER-IN-SITU/*drug therapy; ADULT; ARTICLE; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; CYTOLOGY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED UT: ET: TE: CR: AB: AU: AU: AU: AU: TRIAL; RECTOSCOPY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT/side effect; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*clinical trial; IMIQUIMOD/*drug therapy; IMIQUIMOD/*rectal drug administration; PLACEBO anal intraepithelial neoplasia; high-grade squamous intraepithelial lesion; imiquimod; low-grade squamous intraepithelial lesion; placebo-controlled studies Microbiology: Bacteriology, Mycology, Parasitology and Virology; Cancer; Drug Literature Index; Adverse Reactions Titles; Gastroenterology imiquimod/99011-02-6 99011-02-6 Objective: To determine whether imiquimod was more effective than placebo for the treatment of high-grade anal canal intraepithelial neoplasia (HG-ACIN). Design: Double-blind, randomized placebo-controlled clinical trial. Methods: Sixty-four HIV-positive patients were randomized to self-application of imiquimod cream or matched placebo into the anal canal three times a week for 4 months. Response was assessed by cytology, high-resolution anoscopy and biopsy 2 months after therapy. All patients who failed to resolve were offered treatment with open-label imiquimod for a further 4 months. Results: Fifty-three patients completed the study, of which 28 patients were on active drug and 25 patients on placebo. In the imiquimod group, four patients resolved and eight patients downgraded to low-grade squamous intraepithelial lesion (LSIL) with a median follow-up of 33 months. In the placebo group, one patient resolved. Imiquimod was significantly associated with a positive outcome (P = 0.003). Only one patient discontinued owing to side effects. Twenty-one patients entered a second openlabel phase of treatment. Five of these patients cleared their anal canal intraepithelial neoplasia (ACIN) and four patients downgraded to LSIL. The overall mean duration of follow-up was 36 months. During this extended followup period, 61% have exhibited sustained absence of high-grade squamous intraepithelial lesion (HSIL). Conclusion: This study demonstrates the effectiveness of imiquimod for the treatment of ACIN, and the benefit of prolonged or repeated treatments. This form of therapy is likely to be especially valuable for patients with widespread multifocal ACIN who are otherwise difficult to treat, and should be considered as an adjunct to ablative therapy. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins. Fox PA Fox Paul A. Chelsea and Westminster Hospital NHS Trust, 369 Fulham Road, London SW10 9NH, United Kingdom [email protected] Nathan M Nathan Mayura Homerton Hospital NHS Trust, United Kingdom Francis N Francis Nicholas Department of Cellular Pathology, Imperial College Healthcare NHS Trust, United Kingdom Singh N AU: AU: AU: AU: PU: CNOTE: Singh Naveena Department of Pathology, Barts and the London NHS Trust, London, United Kingdom Weir J Weir Justin Department of Cellular Pathology, Imperial College Healthcare NHS Trust, United Kingdom Dixon G Dixon Glen Department of Cellular Pathology, Imperial College Healthcare NHS Trust, United Kingdom Barton SE Barton Simon E. Chelsea and Westminster Hospital NHS Trust, 369 Fulham Road, London SW10 9NH, United Kingdom Bower M Bower Mark Chelsea and Westminster Hospital NHS Trust, 369 Fulham Road, London SW10 9NH, United Kingdom Lippincott Williams and Wilkins 250 Waterloo Road, London, SE1 8RD, United Kingdom Copyright 2010 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/4 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2010459680 Oon SF; Hanly A; Winter DC Titel: Pap smears for men: A vision of the future? Source: Irish Journal of Medical Science; VOL: 179 (3); p. 459-462 /September 2010/ DOI: 10.1007/s11845-009-0340-6 PU: Springer London SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 0021-1265 CO: IJMSA Institution: Oon SF, Department of Colorectal Surgery, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland, [email protected] COU: Ireland DT: Journal Article JSC: C.0 ... Clinical Medicine RN: 0007 Keywords CT: ANAL INTRAEPITHELIAL NEOPLASM/*diagnosis; ANAL INTRAEPITHELIAL NEOPLASM/*epidemiology; ANAL INTRAEPITHELIAL NEOPLASM/*etiology; ANAL INTRAEPITHELIAL NEOPLASM/*prevention; ANAL SQUAMOUS CARCINOMA/*diagnosis; ANAL SQUAMOUS CARCINOMA/*epidemiology; ANAL SQUAMOUS CARCINOMA/*etiology; ANAL SQUAMOUS CARCINOMA/*prevention; ANAL SQUAMOUS INTRAEPITHELIAL LESION/*diagnosis; ANAL SQUAMOUS INTRAEPITHELIAL LESION/*epidemiology; ANAL SQUAMOUS INTRAEPITHELIAL LESION/*etiology; ANAL SQUAMOUS INTRAEPITHELIAL LESION/*prevention; ANUS CARCINOMA/*diagnosis; ANUS CARCINOMA/*epidemiology; ANUS CARCINOMA/*etiology; ANUS CARCINOMA/*prevention; CONDYLOMA/*diagnosis; CONDYLOMA/*drug therapy; CONDYLOMA/*etiology; CONDYLOMA/*surgery; PAPANICOLAOU TEST/*; PERIANAL CONDYLOMATA/*diagnosis; PERIANAL CONDYLOMATA/*etiology; PERIANAL CONDYLOMATA/*surgery; ABLATION THERAPY; ADULT; ANUS TUMOR/diagnosis; ANUS TUMOR/epidemiology; ANUS TUMOR/etiology; ANUS TUMOR/prevention; ARTICLE; CANCER RISK; CANCER SCREENING; CARBON DIOXIDE LASER; CASE REPORT; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; CURETTAGE; EXCISION; FEMALE; HEALTH CARE COST; HIGH RISK POPULATION; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOMODULATION; INFRARED RADIATION; LOW LEVEL LASER THERAPY; MALE; MALE HOMOSEXUAL; NEODYMIUM LASER; PRACTICE GUIDELINE; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE/epidemiology; SEXUALLY TRANSMITTED DISEASE/prevention; SQUAMOUS CELL CARCINOMA/diagnosis; SQUAMOUS CELL CARCINOMA/epidemiology; SQUAMOUS CELL CARCINOMA/etiology; SQUAMOUS CELL CARCINOMA/prevention; UTERINE CERVIX CANCER/diagnosis; UTERINE CERVIX CANCER/epidemiology; UTERINE CERVIX CANCER/etiology; UTERINE CERVIX CANCER/prevention; WART VIRUS; WOUND CLOSURE; ADRENALIN/drug administration; ADRENALIN/drug combination; ADRENALIN/drug therapy; ADRENALIN/topical drug administration; ALPHA INTERFERON/drug therapy; ANTIBIOTIC AGENT/drug administration; ANTIBIOTIC AGENT/drug therapy; ANTIBIOTIC AGENT/topical drug administration; BCG VACCINE/drug administration; BCG VACCINE/drug therapy; BCG VACCINE/topical drug administration; CIDOFOVIR/drug administration; CIDOFOVIR/drug therapy; CIDOFOVIR/topical drug administration; FLUOROURACIL/drug administration; FLUOROURACIL/drug combination; FLUOROURACIL/drug therapy; FLUOROURACIL/topical drug administration; IMIQUIMOD/drug therapy; PODOPHYLLIN/drug administration; PODOPHYLLIN/drug therapy; PODOPHYLLIN/topical drug administration; TRICHLOROACETIC ACID/drug administration; TRICHLOROACETIC ACID/drug therapy; TRICHLOROACETIC ACID/topical drug administration UT: AIN; Anal cancer; Anal intraepithelial neoplasm; Anal squamous carcinoma; Anal squamous intraepithelial lesion; ASIL; Perianal condylomata; Screening ET: TE: CR: AB: AU: AU: AU: PU: CNOTE: Microbiology: Bacteriology, Mycology, Parasitology and Virology; Cancer; Public Health, Social Medicine and Epidemiology; Drug Literature Index; Gastroenterology adrenalin/51-43-4; adrenalin/55-31-2; adrenalin/6912-68-1; cidofovir/113852-372; fluorouracil/51-21-8; imiquimod/99011-02-6; podophyllin/9000-55-9; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 51-43-4; 55-31-2; 6912-68-1; 113852-37-2; 51-21-8; 99011-02-6; 9000-55-9; 14357-05-2; 76-03-9 Background: Anal intraepithelial neoplasia (AIN) rarely receives as much publicity as its neighbouring orifice, the cervix. As in the cervix, intraepithelial neoplasias are precursors to cancer in the anal canal. AIN and cervical interstitial neoplasia (CIN) undergo dysplasia as a consequence of human papillomavirus (HPV) infection. Since the advent of screening with the Pap smear in CIN, cervical cancer has plummeted to a fifth of its initial incidence. Anal cancer, however, has been rising, with a predilection for human immunodeficiency virusinfected men. HPV causes a squamous epithelial dysplasia and converts healthy tissue into AINs of increasing severity until anal cancer manifests. Clinical case: This article describes a clinical case of anogenital HPV infection refractory to medical and surgical therapy. It also describes an effective surgical excision technique associated with a good cosmetic outcome. Conclusions: The paper concludes by briefly discussing the implications of a national screening programme against AIN in the future. © 2009 Royal Academy of Medicine in Ireland. Oon SF Oon SF Department of Colorectal Surgery, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland [email protected] Hanly A Hanly A Department of Colorectal Surgery, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland [email protected] Winter DC Winter DC Department of Colorectal Surgery, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland [email protected] Springer London The Guildway, Old Portsmouth Road, Artington, Guildford, GU3 1LP, United Kingdom Copyright 2010 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/5 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2010331200 Park IU; Palefsky JM Titel: Evaluation and management of anal intraepithelial neoplasia in HIV-negative and HIV-positive men who have sex with men Source: Current Infectious Disease Reports; VOL: 12 (2); p. 126-133 /March 2010/ DOI: 10.1007/s11908-010-0090-7 PU: Current Science Ltd SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 1523-3847 CO: CIDRC Institution: Park IU, Department of Family and Community Medicine, University of California San Francisco, San Francisco, CA 94143, United States, [email protected] COU: United States DT: Review; Journal Article JSC: E.5 ... Clinical Microbiology RN: 0046 Keywords CT: ANAL INTRAEPITHELIAL NEOPLASIA/*diagnosis; ANAL INTRAEPITHELIAL NEOPLASIA/*disease management; ANAL INTRAEPITHELIAL NEOPLASIA/*drug therapy; ANAL INTRAEPITHELIAL NEOPLASIA/*epidemiology; ANAL INTRAEPITHELIAL NEOPLASIA/*prevention; ANAL INTRAEPITHELIAL NEOPLASIA/*surgery; ANAL INTRAEPITHELIAL NEOPLASIA/*therapy; ANUS CANCER/*diagnosis; ANUS CANCER/*disease management; ANUS CANCER/*drug therapy; ANUS CANCER/*epidemiology; ANUS CANCER/*prevention; ANUS CANCER/*surgery; ANUS CANCER/*therapy; MALE HOMOSEXUAL/*; ANTICOAGULANT THERAPY; BLEEDING/complication; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; CANCER SURGERY; CANCER THERAPY; CARBON DIOXIDE LASER; CAUTERIZATION; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DIAGNOSTIC IMAGING; DRUG EFFICACY; FOLLOW UP; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PAIN/complication; RECTUM BIOPSY; REVIEW; CARBON DIOXIDE; IMIQUIMOD/pharmacoeconomics; LIQUID NITROGEN/pharmacoeconomics; TRICHLOROACETIC ACID/pharmacoeconomics; WART VIRUS VACCINE/drug therapy; WART VIRUS VACCINE/pharmacoeconomics UT: Anal cancer; Anal intraepithelial neoplasia; HIV; Human papillomavirus; Prevention; Screening ET: Microbiology: Bacteriology, Mycology, Parasitology and Virology; Public Health, Social Medicine and Epidemiology; Health Policy, Economics and Management; Drug Literature Index; Gastroenterology TE: CR: AB: AU: AU: PU: CNOTE: carbon dioxide/124-38-9; carbon dioxide/58561-67-4; imiquimod/99011-02-6; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 124-38-9; 58561-67-4; 99011-02-6; 14357-05-2; 76-03-9 The incidence of human papillomavirus (HPV)- associated anal cancer in men who have sex with men (MSM) is striking and has not been mitigated by the use of highly active antiretroviral therapy. Detection and treatment of highgrade anal intraepithelial neoplasia (HGAIN) may reduce the incidence of anal cancer. Anal cytology is a useful tool to detect HGAIN; annual screening of HIV-positive MSM and biennial screening of HIV-negative MSM appears to be costeffective. MSMwith abnormal cytology should be referred for high-resolution anoscopy and biopsy. Individuals with HGAIN should receive treatment; treatment modalities for HGAIN demonstrate moderate efficacy and are usually well tolerated, but greater study is required to determine which treatment is optimal. Large prospective studies are needed to document the efficacy of screening and treatment of HGAIN on anal cancer incidence. The HPV vaccine holds promise for primary prevention of anal cancer in MSM, but significant implementation challenges remain. © The Author(s) 2010. Park IU Park Ina U. Department of Family and Community Medicine, University of California San Francisco, San Francisco, CA 94143, United States [email protected] Palefsky JM Palefsky Joel M. Department of Medicine, University of California San Francisco, San Francisco, CA 94143, United States [email protected] Current Science Ltd 34-42 Cleveland Street, London, W1P 6LB, United Kingdom Copyright 2010 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/6 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2010305523 Ma B; Xu Y; Hung C-F; Wu T-C Titel: HPV and therapeutic vaccines: Where are we in 2010? Source: DOI: PU: SU: Sprache: AL: CY: ISSN: Current Cancer Therapy Reviews; VOL: 6 (2); p. 81-103 /2010/ 10.2174/157339410791202583 Bentham Science Publishers B.V. EMBASE English English Netherlands 1573-3947 Institution: Wu T-C, Department of Pathology, The Johns Hopkins University School of Medicine, CRBII 309, 1550 Orleans Street, Baltimore, Maryland 21231, United States, [email protected] COU: United States DT: Journal Article RN: 0202 Keywords CT: UTERINE CERVIX CANCER/*drug therapy; WART VIRUS/*; ABSENCE OF SIDE EFFECTS/side effect; ANAL INTRAEPITHELIAL NEOPLASIA/drug therapy; ANORECTAL INTRAEPITHELIAL NEOPLASIA/drug therapy; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA/drug therapy; CYTOTOXIC T LYMPHOCYTE; DNA REPLICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; ELECTROPORATION; EPITHELIUM TUMOR/drug therapy; FEVER/side effect; GENE GUN; HIGH GRADE SQUAMOUS INTRAEPITHELIAL/drug therapy; HUMAN; HYPOTENSION/side effect; IMMUNOGENICITY; IMMUNOMODULATION; LACTOBACILLUS PLANTARUM; LACTOCOCCUS LACTIS; LISTERIA MONOCYTOGENES; MOLECULAR BIOLOGY; PAPILLOMATOSIS/drug therapy; PRIORITY JOURNAL; RECURRENT CANCER/drug therapy; REPLICON; RESPIRATORY PAPILLOMATOSIS/drug therapy; SALMONELLA ENTERICA; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT/side effect; UTERINE CERVIX CARCINOMA IN SITU/drug therapy; VACCINIA VIRUS; VAGINAL INTRAEPITHELIAL NEOPLASIA/drug therapy; VIRION; VIRUS ENTRY; VIRUS LIKE AGENT; VULVAR INTRAEPITHELIAL NEOPLASIA/drug therapy; WART VIRUS VACCINE/*adverse drug reaction; WART VIRUS VACCINE/*clinical trial; WART VIRUS VACCINE/*drug combination; WART VIRUS VACCINE/*drug dose; WART VIRUS VACCINE/*drug therapy; WART VIRUS VACCINE/*intradermal drug administration; WART VIRUS VACCINE/*intramuscular drug administration; WART VIRUS VACCINE/*intraurethral drug administration; WART VIRUS VACCINE/*intrauterine drug administration; WART VIRUS VACCINE/*intravenous drug administration; WART VIRUS VACCINE/*subcutaneous drug administration; ADXS 11 001/adverse drug reaction; ADXS 11 001/clinical trial; ADXS 11 001/drug therapy; ADXS 11 001/intravenous drug administration; AMOLIMOGENE BEPIPLASMID/clinical trial; AMOLIMOGENE BEPIPLASMID/drug therapy; AMOLIMOGENE BEPIPLASMID/intramuscular drug administration; APIGENIN/drug combination; BACTERIAL VECTOR; DENDRITIC CELL VACCINE/clinical trial; DENDRITIC CELL VACCINE/drug combination; DENDRITIC CELL VACCINE/drug therapy; DENDRITIC CELL VACCINE/subcutaneous drug administration; DNA VACCINE/drug combination; DNA VACCINE/intradermal drug administration; DNA VACCINE/intramuscular drug administration; E2 PROTEIN/clinical trial; E2 PROTEIN/drug comparison; E2 PROTEIN/drug therapy; E2 PROTEIN/intraurethral drug administration; E2 PROTEIN/intrauterine drug administration; EPIGALLOCATECHIN UT: DN: MN: ET: TE: CR: AB: AU: GALLATE/drug combination; FLT3 LIGAND; FLUOROURACIL/drug comparison; FLUOROURACIL/drug therapy; HEAT SHOCK PROTEIN 70; HLA ANTIGEN/endogenous compound; IMIQUIMOD/drug combination; IMIQUIMOD/drug therapy; INTERLEUKIN 2/drug combination; INTERLEUKIN 2/drug therapy; KEYHOLE LIMPET HEMOCYANIN/drug combination; KEYHOLE LIMPET HEMOCYANIN/drug therapy; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NUCLEIC ACID; PROTEIN E6/endogenous compound; PROTEIN E7/endogenous compound; SGN 00101/clinical trial; SGN 00101/drug therapy; SGN 00101/subcutaneous drug administration; TG 4001/clinical trial; TG 4001/drug therapy; TG 4001/subcutaneous drug administration; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VGX 3100/clinical trial; VGX 3100/drug therapy; VIRUS ANTIGEN/endogenous compound; VIRUS DNA/endogenous compound; VIRUS RNA/endogenous compound; VIRUS VECTOR; ZYC 101/clinical trial; ZYC 101/drug therapy; ZYC 101/intramuscular drug administration; ZYC 101/subcutaneous drug administration Cervical cancer; Clinical trials; Hpv; Therapeutic vaccine Cervarix/Glaxo SmithKline; Gardasil/Merck; Sgn 00101/Nventa; Tg 4001/Hoffmann La Roche; Tg 4001/Transgene; Zyc 101/Eisai Eisai; Glaxo SmithKline; Hoffmann La Roche; Merck; Nventa; Transgene Microbiology: Bacteriology, Mycology, Parasitology and Virology; Obstetrics and Gynecology; Immunology, Serology and Transplantation; Drug Literature Index; Adverse Reactions Titles Flt3 ligand/171404-15-2; apigenin/520-36-5; epigallocatechin gallate/989-51-5; fluorouracil/51-21-8; imiquimod/99011-02-6; interleukin 2/85898-30-2 171404-15-2; 520-36-5; 989-51-5; 51-21-8; 99011-02-6; 85898-30-2 The discovery of human papillomavirus (HPV) as a necessary etiological factor for cervical cancer has spurred the development of preventive and therapeutic HPV vaccines for the control of HPV-associated malignancies including cervical, vulvar, vaginal, and a subset of head and neck cancers. The commercial preventive HPV vaccines, Gardasil and Cervarix, use HPV virus-like particles to generate neutralizing antibodies against HPV major capsid protein L1. However, they do not exert therapeutic effects on existing lesions and are unlikely to have an immediate impact on the prevalence of cervical cancer due to their cost and limited availability in developing countries, which account for more than 80% of cer- vical cancers. Thus, there is an urgent need for therapeutic HPV vaccines. Therapeutic HPV vaccines can eliminate pre- existing lesions and infections by generating cellular immunity against HPV-infected cells. HPV E6 and E7 oncoproteins represent ideal targets for therapeutic intervention because of their constitutive expression in HPV-associated tumors and their crucial role in the induction and maintenance of HPV-associated disease. This review discusses the current progress of various therapeutic HPV vaccine approaches, including live vector-based, peptide/protein-based, nucleic acid-based and cell-based vaccines targeting E6 and/or E7 antigens, and their future prospects for the control of HPVassociated ma- lignancies. © 2010 Bentham Science Publishers Ltd. Ma B Ma Barbara Department of Pathology, The Johns Hopkins University School of Medicine, CRBII 309, 1550 Orleans Street, Baltimore, Maryland 21231, United States AU: AU: AU: PU: CNOTE: Xu Y Xu Yijie Department of Pathology, The Johns Hopkins University School of Medicine, CRBII 309, 1550 Orleans Street, Baltimore, Maryland 21231, United States Hung C-F Hung Chien-Fu Department of Pathology, The Johns Hopkins University School of Medicine, CRBII 309, 1550 Orleans Street, Baltimore, Maryland 21231, United States Wu T-C Wu T-C Department of Pathology, The Johns Hopkins University School of Medicine, CRBII 309, 1550 Orleans Street, Baltimore, Maryland 21231, United States; Departments of Obstetrics and Gynecology, The Johns Hopkins Medical Institutions, Baltimore, MD, United States; Departments of Molecular Microbiology and Immunology, The Johns Hopkins Medical Institutions, Baltimore, MD, United States; Departments of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, United States [email protected] Bentham Science Publishers B.V. P.O. Box 294, Bussum, 1400 AG, Netherlands Copyright 2010 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/7 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2010068534 Mahto M; Nathan M; O'Mahony C Titel: More than a decade on: Review of the use of imiquimod in lower anogenital intraepithelial neoplasia Source: International Journal of STD and AIDS; VOL: 21 (1); p. 8-16 /January 2010/ http://ijsa.rsmjournals.com/cgi/reprint/21/1/8 DOI: 10.1258/ijsa.2009.009309 PU: Royal Society of Medicine Press Ltd SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 0956-4624 CO: INSAE Institution: Mahto M, Dr., Department of Genitourinary Medicine, Cheshire East Community Health (Central and Eastern Cheshire PCT), Assura Health and Wellness Centre, Sunderland Street, Macclesfield SK11 6JL, United Kingdom, [email protected] COU: United Kingdom DT: JSC: Review; Journal Article C.5 ... Dermatology & Venereology; B.2 ... Public Health; E.5 ... Clinical Microbiology 0069 RN: Keywords CT: ANUS CARCINOMA/*drug therapy; INTRAEPITHELIAL ANAL NEOPLASIA/*drug therapy; INTRAEPITHELIAL PENILE NEOPLASIA/*drug therapy; INTRAEPITHELIAL VULVAR NEOPLASIA/*; PENIS CARCINOMA/*drug therapy; VULVA CARCINOMA/*drug therapy; CANCER RECURRENCE; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EMBASE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTRAEPITHELIAL VULVAR CARCINOMA/drug therapy; MALE HOMOSEXUAL; MEDLINE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT/side effect; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug administration UT: Anal intraepithelial neoplasia; Anogenital; Imiquimod; Intraepithelial neoplasia; Penile intraepithelial neoplasia; Vulvar intraepithelial neoplasia DN: Aldara; Zartra ET: Obstetrics and Gynecology; Urology and Nephrology; Drug Literature Index; Adverse Reactions Titles; Gastroenterology TE: imiquimod/99011-02-6 CR: 99011-02-6 AB: To assess the effectiveness of 5% imiquimod cream (IQ) in the treatment of vulvar, penile and anal intraepithelial neoplasias (VIN, PIN and AIN), we searched Medline, Embase, PubMed and Cochrane Library databases. With regard to VIN there were two randomized controlled trials (RCTs), eight uncontrolled/cohort studies, nine case reports and one review article. Use of IQ in PIN and AIN were only supported by cohort studies (two each for PIN and AIN) and case reports (15 for PIN and 3 for AIN). On pooled analysis of RCTs, uncontrolled and cohort studies, the mean complete response (CR) rate for VIN, PIN and AIN were 51%, 70% and 48%, respectively. The mean partial response (PR) rate for VIN, PIN and AIN were 25%, 30% and 34% respectively. The recurrence (RR) rate for VIN, PIN and AIN were 16%, 0% and 36%, respectively. The follow-up period for VIN, PIN and AIN ranged from 2 to 32 months, 10 to 12 months and 11 to 39 months, respectively. Although the results for PIN look the best, the strongest evidence regarding efficacy of IQ in anogenital intraepithelial neoplasia is for VIN supported by RCTs. Evidence for use of IQ in AIN was essentially limited to HIV-positive men who have sex with men. IQ was reasonably well tolerated with side-effects being managed with reduction in frequency of drug usage and/or rest periods. Based on these results, IQ seems to be a safe mode of treatment and is possibly an alternative to currently available methods of treatment. However, there are no comparative studies assessing its efficacy against traditional modes of treatment. AU: Mahto M Mahto M Department of Genitourinary Medicine, Cheshire East Community Health AU: AU: PU: CNOTE: (Central and Eastern Cheshire PCT), Assura Health and Wellness Centre, Sunderland Street, Macclesfield SK11 6JL, United Kingdom [email protected] Nathan M Nathan M Department of Sexual Health, Homerton Hospital NHS Trust, Homerton Row, London E9 6SR, United Kingdom O'Mahony C O'Mahony C Department of Sexual Health (Genitourinary Medicine), Countess of Chester Foundation Trust Hospital, Liverpool Road, Chester CH2 1UL, United Kingdom Royal Society of Medicine Press Ltd P.O. Box 9002, London, W1A 0ZA, United Kingdom Copyright 2010 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/8 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2010089410 Van Kemseke C Titel: Sexually transmitted diseases and anorectum Source: Acta Gastro-Enterologica Belgica; VOL: 72 (4); p. 413-419 /2009/ PU: Universa Press SU: EMBASE Sprache: English AL: English CY: Belgium ISSN: 0001-5644 CO: AGEBA Institution: Van Kemseke C, Department of Gatroenterology, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman B35, 4000 Liège, Belgium, [email protected] COU: Belgium DT: Conference Paper; Journal Article JSC: C.1.8 ... Gastroenterology RN: 0051 Keywords CT: SEXUALLY TRANSMITTED DISEASE/*diagnosis; SEXUALLY TRANSMITTED DISEASE/*disease management; ANUS; CHLAMYDIA TRACHOMATIS; CLINICAL FEATURE; CONDYLOMA ACUMINATUM/diagnosis; CONDYLOMA ACUMINATUM/disease management; CONDYLOMA ACUMINATUM/drug therapy; CONDYLOMA ACUMINATUM/etiology; CONDYLOMA ACUMINATUM/surgery; CONFERENCE PAPER; CONSULTATION; CRYOTHERAPY; DIAGNOSTIC DN: ET: TE: TEST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCOAGULATION; EPIDEMIC; EXCISION; GASTROINTESTINAL SYMPTOM/side effect; GONOCOCCAL URETHRITIS/diagnosis; GONOCOCCAL URETHRITIS/disease management; GONOCOCCAL URETHRITIS/drug resistance; GONOCOCCAL URETHRITIS/drug therapy; GONOCOCCAL URETHRITIS/etiology; GONORRHEA/diagnosis; GONORRHEA/disease management; GONORRHEA/drug resistance; GONORRHEA/drug therapy; GONORRHEA/etiology; HERPES SIMPLEX/diagnosis; HERPES SIMPLEX/disease management; HERPES SIMPLEX/drug therapy; HERPES SIMPLEX/etiology; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERXHEIMER REACTION/side effect; HETEROSEXUALITY; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LYMPHOGRANULOMA VENEREUM/diagnosis; LYMPHOGRANULOMA VENEREUM/disease management; LYMPHOGRANULOMA VENEREUM/drug therapy; LYMPHOGRANULOMA VENEREUM/epidemiology; LYMPHOGRANULOMA VENEREUM/etiology; LYMPHOGRANULOMA VENEREUM/prevention; NEISSERIA GONORRHOEAE; PATHOGENESIS; PUBLIC HEALTH PROBLEM; RECTUM; RISK ASSESSMENT; SECONDARY SYPHILIS/drug therapy; SEXUAL BEHAVIOR; SINGLE DRUG DOSE; SYPHILIS/diagnosis; SYPHILIS/disease management; SYPHILIS/drug therapy; SYPHILIS/epidemiology; SYPHILIS/etiology; SYPHILIS/prevention; TREPONEMA PALLIDUM; WART VIRUS; ACICLOVIR/drug therapy; ACICLOVIR/oral drug administration; ANALGESIC AGENT; ANTIPYRETIC AGENT; AZITHROMYCIN/adverse drug reaction; AZITHROMYCIN/drug therapy; AZITHROMYCIN/oral drug administration; BENZATHINE PENICILLIN/adverse drug reaction; BENZATHINE PENICILLIN/drug therapy; BENZATHINE PENICILLIN/intramuscular drug administration; CEFOTAXIME/drug therapy; CEFTRIAXONE/drug combination; CEFTRIAXONE/drug therapy; CEFTRIAXONE/intramuscular drug administration; CIPROFLOXACIN/drug therapy; CIPROFLOXACIN/oral drug administration; DOXYCYCLINE/drug combination; DOXYCYCLINE/drug therapy; DOXYCYCLINE/oral drug administration; ERYTHROMYCIN/drug therapy; ERYTHROMYCIN/oral drug administration; FLUOROURACIL/drug therapy; IMIQUIMOD/drug therapy; OFLOXACIN/drug therapy; OFLOXACIN/oral drug administration; PENICILLIN G/adverse drug reaction; PENICILLIN G/drug therapy; PENICILLIN G/intravenous drug administration; PODOPHYLLIN/drug therapy; POVIDONE IODINE; SPECTINOMYCIN/drug therapy; VALACICLOVIR/drug therapy; WART VIRUS VACCINE/drug therapy Cervarix; Ciproxine; Claforan; Gardasil; Imiquimod; Rocephine; Tarivid; Trobicin Microbiology: Bacteriology, Mycology, Parasitology and Virology; Obstetrics and Gynecology; Public Health, Social Medicine and Epidemiology; Drug Literature Index; Adverse Reactions Titles aciclovir/59277-89-3; azithromycin/83905-01-5; benzathine penicillin/1538-09-6; cefotaxime/63527-52-6; cefotaxime/64485-93-4; ceftriaxone/73384-59-5; ceftriaxone/74578-69-1; ciprofloxacin/85721-33-1; doxycycline/10592-13-9; doxycycline/17086-28-1; doxycycline/564-25-0; erythromycin/114-07-8; CR: AB: AU: PU: CNOTE: erythromycin/70536-18-4; fluorouracil/51-21-8; imiquimod/99011-02-6; ofloxacin/82419-36-1; penicillin G/1406-05-9; penicillin G/61-33-6; podophyllin/9000-55-9; povidone iodine/25655-41-8; spectinomycin/1695-77-8; spectinomycin/21736-83-4; spectinomycin/23312-56-3; valaciclovir/124832-26-4 59277-89-3; 83905-01-5; 1538-09-6; 63527-52-6; 64485-93-4; 73384-59-5; 74578-69-1; 85721-33-1; 10592-13-9; 17086-28-1; 564-25-0; 114-07-8; 7053618-4; 51-21-8; 99011-02-6; 82419-36-1; 1406-05-9; 61-33-6; 9000-55-9; 2565541-8; 1695-77-8; 21736-83-4; 23312-56-3; 124832-26-4 Sexually transmitted diseases (STD) are a major public health problem because their incidence is increasing worldwide despite prevention campaigns and because they raise the risk of HIV infection. Anorectal localisations of STD are common among men who have sex with men (MSM) but can also be seen among heterosexuals (men or women). Transmission of such infections is due to anal sex or to other sexual behaviours like "fisting". Although some pathogens (like Human Papillomavirus-HPV) are common in gastroenterologist/proctologist consultations, others are not so well-known. Furthermore during the last years, sexual risky behaviours have led to resurgence of old affections (like syphilis) or to emergence of unknown diseases (like lymphogranuloma venereum) in our countries. This presentation tends to focus on clinical manifestation, diagnosis and treatment of different STD : HPV, Herpes Simplex Virus, Neisseria gonorrhoeae, Chlamydia trachomatis (in particularly lymphogranuloma venereum) and Treponema pallidum. Van Kemseke C Van Kemseke C Department of Gastroenterology, ULG CHU Liège [email protected] Universa Press Hoenderstraat 24, Wetteren, B-9230, Belgium Copyright 2010 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/9 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2010009060 Garrett K; Kalady MF Titel: Anal Neoplasms Source: DOI: PU: SU: Sprache: AL: CY: ISSN: CO: PII: Surgical Clinics of North America; VOL: 90 (1); p. 147-161 /February 2010/ 10.1016/j.suc.2009.09.008 W.B. Saunders EMBASE English English United States 0039-6109 SCNAA S0039610909001261 Institution: Kalady MF, Dr., Department of Colorectal Surgery, Digestive Disease Institute, 9500 Euclid Avenue, Cleveland, OH 44195, United States, [email protected] COU: United States DT: Review; Journal Article JSC: D.1 ... General & Abdominal Surgery RN: 0105 Keywords CT: ANUS CANCER/*drug therapy; ANUS INTRAEPITHELIAL NEOPLASIA/diagnosis; ANUS INTRAEPITHELIAL NEOPLASIA/drug therapy; ANUS INTRAEPITHELIAL NEOPLASIA/etiology; ANUS TUMOR/diagnosis; ANUS TUMOR/drug therapy; ANUS TUMOR/etiology; BASAL CELL CARCINOMA/diagnosis; BASAL CELL CARCINOMA/surgery; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER RECURRENCE/surgery; CANCER SURGERY; CARCINOGENESIS/etiology; CLINICAL TRIAL; COLON ADENOCARCINOMA/diagnosis; COLON ADENOCARCINOMA/drug therapy; COLON ADENOCARCINOMA/radiotherapy; COLON ADENOCARCINOMA/surgery; COLON ADENOCARCINOMA/therapy; CONTINUOUS INFUSION; CYTOLOGY; DIAGNOSTIC IMAGING; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE SEQUENCE; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL STROMAL TUMOR/drug therapy; GASTROINTESTINAL STROMAL TUMOR/surgery; HUMAN; KAPOSI SARCOMA/radiotherapy; LYMPH NODE METASTASIS/complication; LYMPH NODE METASTASIS/surgery; MELANOMA/diagnosis; MELANOMA/surgery; NEUROENDOCRINE TUMOR/drug therapy; NEUROENDOCRINE TUMOR/radiotherapy; NEUROENDOCRINE TUMOR/surgery; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CANCER/surgery; REPEATED DRUG DOSE; REVIEW; SALVAGE THERAPY; SARCOMA/diagnosis; SARCOMA/surgery; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA/diagnosis; SQUAMOUS CELL CARCINOMA/drug therapy; SQUAMOUS CELL CARCINOMA/radiotherapy; SQUAMOUS CELL CARCINOMA/surgery; SURGICAL TECHNIQUE; TREATMENT INDICATION; VERRUCOUS CARCINOMA/diagnosis; VERRUCOUS CARCINOMA/drug therapy; VERRUCOUS CARCINOMA/radiotherapy; VERRUCOUS CARCINOMA/surgery; ALPHA INTERFERON/drug therapy; CAPECITABINE/drug therapy; CETUXIMAB/drug therapy; CISPLATIN/drug comparison; CISPLATIN/drug therapy; ETOPOSIDE/drug therapy; FLUOROURACIL/drug combination; FLUOROURACIL/drug comparison; FLUOROURACIL/drug dose; FLUOROURACIL/drug therapy; FLUOROURACIL/topical drug administration; IMATINIB/drug therapy; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; INTERFERON/drug therapy; MITOMYCIN/drug combination; MITOMYCIN/drug comparison; MITOMYCIN/drug therapy; MITOMYCIN C/clinical trial; MITOMYCIN C/drug dose; MITOMYCIN C/drug therapy; MITOMYCIN C/intravenous drug administration; OXALIPLATIN/drug therapy; PODOPHYLLIN/drug therapy; PODOPHYLLIN/topical drug administration UT: Anal canal; Anal cancer; Anal margin; Carcinoma in-situ; Epidermoid cancer; Squamous cell carcinoma DN: ET: TE: CR: AB: AU: AU: PU: CNOTE: Gleevec Cancer; Drug Literature Index; Gastroenterology capecitabine/154361-50-9; cetuximab/205923-56-4; cisplatin/15663-27-1; cisplatin/26035-31-4; cisplatin/96081-74-2; etoposide/33419-42-0; fluorouracil/51-21-8; imatinib/152459-95-5; imatinib/220127-57-1; imiquimod/99011-02-6; mitomycin/1404-00-8; mitomycin C/50-07-7; mitomycin C/74349-48-7; oxaliplatin/61825-94-3; podophyllin/9000-55-9 154361-50-9; 205923-56-4; 15663-27-1; 26035-31-4; 96081-74-2; 33419-42-0; 51-21-8; 152459-95-5; 220127-57-1; 99011-02-6; 1404-00-8; 50-07-7; 74349-487; 61825-94-3; 9000-55-9 A variety of lesions comprise tumors of the anal canal, with carcinoma in situ and epidermoid cancers being the most common. Less common anal neoplasms include adenocarcinoma, melanoma, gastrointestinal stromal cell tumors, neuroendocrine tumors, and Buschke-Lowenstein tumors. Treatment strategies are based on anatomic location and histopathology. In this article different tumors and management of each, including a brief review of local excision for rectal cancer, are discussed in turn. © 2010 Elsevier Inc. All rights reserved. Garrett K Garrett Kelly Department of Colorectal Surgery, Digestive Disease Institute, 9500 Euclid Avenue, Cleveland, OH 44195, United States Kalady MF Kalady Matthew F. Department of Colorectal Surgery, Digestive Disease Institute, 9500 Euclid Avenue, Cleveland, OH 44195, United States; Department of Cancer Biology, 9500 Euclid Avenue, Cleveland, OH 44195, United States [email protected] W.B. Saunders Independence Square West, Philadelphia, PA 19106-3399, United States Copyright 2010 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/10 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2010006172 Lee PK; Wilkins KB Titel: Condyloma and Other Infections Including Human Immunodeficiency Virus Source: DOI: PU: SU: Sprache: AL: CY: Surgical Clinics of North America; VOL: 90 (1); p. 99-112 /February 2010/ 10.1016/j.suc.2009.09.005 W.B. Saunders EMBASE English English United States ISSN: 0039-6109 CO: SCNAA PII: S0039610909001236 Institution: Wilkins KB, Dr., UMDNJ-Robert Wood Johnson University Hospital, New Brunswick, NJ, United States, [email protected] COU: United States DT: Review; Journal Article JSC: D.1 ... General & Abdominal Surgery RN: 0042 Keywords CT: CONDYLOMA/*diagnosis; CONDYLOMA/*drug therapy; CONDYLOMA/*epidemiology; CONDYLOMA/*etiology; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*etiology; ANUS CANCER/diagnosis; ANUS CANCER/epidemiology; ANUS CANCER/etiology; ANUS CANCER/surgery; ANUS CANCER/therapy; ANUS INTRAEPITHELIAL NEOPLASIA/diagnosis; ANUS INTRAEPITHELIAL NEOPLASIA/epidemiology; ANUS INTRAEPITHELIAL NEOPLASIA/etiology; ANUS INTRAEPITHELIAL NEOPLASIA/surgery; ANUS INTRAEPITHELIAL NEOPLASIA/therapy; BACTERIUM CULTURE; BEDTIME DOSAGE; BIOPSY; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; ENTERITIS/diagnosis; ENTERITIS/drug therapy; ENTERITIS/etiology; GENITAL ULCER/diagnosis; GENITAL ULCER/etiology; GIARDIASIS/drug therapy; GONORRHEA/diagnosis; GONORRHEA/drug therapy; GONORRHEA/etiology; GRANULOMA INGUINALE/diagnosis; GRANULOMA INGUINALE/drug therapy; GRANULOMA INGUINALE/etiology; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LYMPHOGRANULOMA VENEREUM/diagnosis; LYMPHOGRANULOMA VENEREUM/drug therapy; LYMPHOGRANULOMA VENEREUM/epidemiology; LYMPHOGRANULOMA VENEREUM/etiology; NONHUMAN; PRIORITY JOURNAL; PROCTITIS/diagnosis; PROCTITIS/drug therapy; PROCTITIS/etiology; PROCTOCOLITIS/diagnosis; PROCTOCOLITIS/drug therapy; PROCTOCOLITIS/etiology; REVIEW; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE/etiology; SIGMOIDOSCOPY; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA/drug therapy; SYPHILIS/diagnosis; SYPHILIS/drug therapy; SYPHILIS/etiology; ULCUS MOLLE/diagnosis; ULCUS MOLLE/drug therapy; ULCUS MOLLE/etiology; VIRUS INFECTION/drug therapy; WART VIRUS; ACICLOVIR/drug therapy; ACICLOVIR/oral drug administration; AZITHROMYCIN/drug dose; AZITHROMYCIN/drug therapy; AZITHROMYCIN/oral drug administration; BENZATHINE PENICILLIN/drug dose; BENZATHINE PENICILLIN/drug therapy; BENZATHINE PENICILLIN/intramuscular drug administration; CEFIXIME/drug therapy; CEFIXIME/oral drug administration; CEFTRIAXONE/drug dose; CEFTRIAXONE/drug therapy; CEFTRIAXONE/intramuscular drug administration; CIPROFLOXACIN/drug therapy; CIPROFLOXACIN/oral drug administration; COTRIMOXAZOLE/drug therapy; COTRIMOXAZOLE/oral drug administration; DICHLOROACETIC ACID/drug therapy; DIIODOHYDROXYQUIN/drug therapy; DIIODOHYDROXYQUIN/oral drug UT: ET: TE: CR: AB: AU: AU: administration; DOXYCYCLINE/drug therapy; DOXYCYCLINE/oral drug administration; ERYTHROMYCIN/drug therapy; ERYTHROMYCIN/oral drug administration; ERYTHROMYCIN ETHYLSUCCINATE/drug therapy; ERYTHROMYCIN ETHYLSUCCINATE/oral drug administration; FAMCICLOVIR/drug therapy; FAMCICLOVIR/oral drug administration; IMIQUIMOD/clinical trial; IMIQUIMOD/drug dose; IMIQUIMOD/drug therapy; LEVOFLOXACIN/drug therapy; LEVOFLOXACIN/oral drug administration; METRONIDAZOLE/drug therapy; METRONIDAZOLE/oral drug administration; OFLOXACIN/drug therapy; OFLOXACIN/oral drug administration; PODOPHYLLIN/drug therapy; TETRACYCLINE/drug therapy; TETRACYCLINE/oral drug administration; TINIDAZOLE/drug dose; TINIDAZOLE/drug therapy; TINIDAZOLE/oral drug administration; TRICHLOROACETIC ACID/drug therapy; VALACICLOVIR/drug therapy; VALACICLOVIR/oral drug administration Anal intraepithelial neoplasia; High resolution anoscopy; Human papillomavirus; Perianal sexually transmitted diseases Microbiology: Bacteriology, Mycology, Parasitology and Virology; Dermatology and Venereology; Drug Literature Index; Gastroenterology aciclovir/59277-89-3; azithromycin/83905-01-5; benzathine penicillin/1538-09-6; cefixime/79350-37-1; ceftriaxone/73384-59-5; ceftriaxone/74578-69-1; ciprofloxacin/85721-33-1; cotrimoxazole/8064-90-2; dichloroacetic acid/1342580-4; dichloroacetic acid/2156-56-1; dichloroacetic acid/79-43-6; diiodohydroxyquin/8054-64-6; diiodohydroxyquin/83-73-8; doxycycline/1059213-9; doxycycline/17086-28-1; doxycycline/564-25-0; erythromycin/114-07-8; erythromycin/70536-18-4; erythromycin ethylsuccinate/1264-62-6; famciclovir/104227-87-4; imiquimod/99011-02-6; levofloxacin/100986-85-4; levofloxacin/138199-71-0; metronidazole/39322-38-8; metronidazole/443-48-1; ofloxacin/82419-36-1; podophyllin/9000-55-9; tetracycline/23843-90-5; tetracycline/60-54-8; tetracycline/64-75-5; tinidazole/19387-91-8; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9; valaciclovir/124832-26-4 59277-89-3; 83905-01-5; 1538-09-6; 79350-37-1; 73384-59-5; 74578-69-1; 85721-33-1; 8064-90-2; 13425-80-4; 2156-56-1; 79-43-6; 8054-64-6; 83-73-8; 10592-13-9; 17086-28-1; 564-25-0; 114-07-8; 70536-18-4; 1264-62-6; 10422787-4; 99011-02-6; 100986-85-4; 138199-71-0; 39322-38-8; 443-48-1; 82419-361; 9000-55-9; 23843-90-5; 60-54-8; 64-75-5; 19387-91-8; 14357-05-2; 76-03-9; 124832-26-4 Sexually transmitted diseases (STDs) are a common public health problem and as such may be more common in a surgical practice than is believed. The recognition that a virus can be responsible for a cancer has profound significant public health implications. This article reviews the presentation and management of the more common perianal STDs including human immunodeficiency virus, as well as the pathogenesis and management of anal intraepithelial neoplasia. © 2010 Elsevier Inc. All rights reserved. Lee PK Lee Peter K. UMDNJ-Robert Wood Johnson University Hospital, New Brunswick, NJ, United States; 5965 E. Broad Street, Suite 120, Columbus, OH 43213, United States Wilkins KB Wilkins Kirsten Bass PU: CNOTE: UMDNJ-Robert Wood Johnson University Hospital, New Brunswick, NJ, United States; 3900 Park Avenue, Suite 101, Edison, NJ 08820, United States [email protected] W.B. Saunders Independence Square West, Philadelphia, PA 19106-3399, United States Copyright 2010 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/11 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009634138 Graziottin A Titel: HPV infection in women: Clinical consequences, psychosexual impact and the chances of prevention Source: Italian Journal of Gynaecology and Obstetrics; VOL: 21 (3); p. 141-151 /2009/ http://www.sigo.it/Documenti/Journal/italianjournal3_09.pdf PU: S.I.G.O. Publishing Co SU: EMBASE Sprache: English AL: English; Italian CY: Italy ISSN: 1121-8339 CO: IJGOE Institution: Graziottin A, Center of Gynecology and Medical Sexology, H. San Raffaele Resnati, Milan, Italy COU: Italy DT: Review; Journal Article JSC: C.4 ... Obstetrics & Gynecology RN: 0053 Keywords CT: CONDYLOMA ACUMINATUM/*diagnosis; CONDYLOMA ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*epidemiology; CONDYLOMA ACUMINATUM/*etiology; CONDYLOMA ACUMINATUM/*prevention; CONDYLOMA ACUMINATUM/*therapy; PSYCHOSEXUAL DISORDER/*complication; ANAL INTRAEPITHELIAL NEOPLASIA/complication; ANAL INTRAEPITHELIAL NEOPLASIA/diagnosis; ANAL INTRAEPITHELIAL NEOPLASIA/epidemiology; ANGER; ANUS CANCER/complication; ANUS CANCER/diagnosis; ANUS CANCER/epidemiology; ANXIETY; CLINICAL FEATURE; CLINICAL TRIAL; CRYOTHERAPY; DEPRESSION/complication; DISEASE ASSOCIATION; DISTRESS SYNDROME/complication; DRUG INDICATION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION PREVENTION; LASER SURGERY; MALIGNANT TRANSFORMATION; NONHUMAN; PAPANICOLAOU TEST; PRECANCER/drug therapy; PRIMARY PREVENTION; RECURRENT UT: ET: TE: CR: AB: AU: INFECTION/complication; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; UTERINE CERVIX CANCER/complication; UTERINE CERVIX CANCER/diagnosis; UTERINE CERVIX CANCER/drug therapy; UTERINE CERVIX CANCER/etiology; UTERINE CERVIX CANCER/prevention; VIRUS DETECTION; VIRUS GENOME; WOMEN'S HEALTH; ALPHA INTERFERON/clinical trial; ALPHA INTERFERON/drug therapy; ALPHA INTERFERON/intramuscular drug administration; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; PODOPHYLLOTOXIN/drug therapy; PODOPHYLLOTOXIN/topical drug administration; TRICHLOROACETIC ACID/drug therapy; TRICHLOROACETIC ACID/topical drug administration; WART VIRUS VACCINE/drug therapy; WART VIRUS VACCINE/intramuscular drug administration Anal HPV infection; Cervical cancer; Genital warts; HPV; HPV vaccine; Intraepithelial neoplasia; Psychosexual issues Microbiology: Bacteriology, Mycology, Parasitology and Virology; Obstetrics and Gynecology; Cancer; Public Health, Social Medicine and Epidemiology; Drug Literature Index imiquimod/99011-02-6; podophyllotoxin/518-28-5; trichloroacetic acid/14357-052; trichloroacetic acid/76-03-9 99011-02-6; 518-28-5; 14357-05-2; 76-03-9 Introduction. Human Papillomavirus (HPV) infection is the most common genital viral infection in humans. It is highly prevalent and increasing, due to promiscuity and unprotected sex. HPV is a wide family of DNA viruses, which may cause benign skin and mucosal tumours (genital, anal or oral warts), intraepithelial neoplasias and/or malignant cancers in different organs. Women are more susceptible to the oncogenic effect of HPVs, mostly at the genital site. Aims. This paper analyses the main characteristics of HPVs, the clinical consequences of their infections in women, with the current epidemiology; some highlights on the actual measure of prevention, with a focus on the psychosexual consequences of HPV infections. Conclusion. The HR-HPVs (High Risk Human Papillomavirus) have been causally related to several cancers in human (cervical, vulvar, vaginal, anal), and the LR-HPV (Low Risk Human Papillomavirus) types related mainly to a benign sexually transmitted disease: genital warts. Primary measures of prevention such as vaccination can protect against a panel of HPV related diseases, while secondary prevention, such as pap test or HPV test are specific for a precocious diagnosis, and is currently standardized as a screening measure, only in the field of cervical cancer. To guarantee the most effective preventive strategies both measures had to continue together. Psychosexual vulnerability increases with number of recurrences of HPV infections. Depression, anxiety and anger are the emotions most frequently reported. However, no specific correlation has been proved so far between HPV infection and a specific female sexual disorder. A practical approach is offered to the reader with clinically relevant tips, useful in his/her daily practice, when dealing with HPV infected women and couples. © Copyright 2009, CIC Edizioni Internazionali. Graziottin A Graziottin A Center of Gynecology and Medical Sexology, H. San Raffaele Resnati, Milan, Italy PU: CNOTE: S.I.G.O. Publishing Co Via dei Soldati 25, Rome, 00186, Italy Copyright 2010 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/12 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009602532 Kolodziejczak M; Ciesielski P; Nawrocki G Titel: Co nowego w chorobach odbytu i kanalu odbytu What is new in anus and anal canal diseases Source: Gastroenterologia Polska; VOL: 16 (2); p. 163-169 /2009/ http://www.cornetis.com.pl/pliki/download.php?issn=12329886&rok=2009&numer=2&str_p=163 PU: Cornetis SU: EMBASE Sprache: Polish AL: English; Polish CY: Poland ISSN: 1232-9886 CO: GASPF Institution: Kolodziejczak M, Dr., Oddzial Chirurgii Ogólnej Z Pododzialem Proktologii Szpitala na Solcu, ul. Solec 93, 00-382 Warszawa, Poland, [email protected] COU: Poland DT: Review; Journal Article JSC: C.1.8 ... Gastroenterology RN: 0040 Keywords CT: ANUS DISEASE/*; ANUS; ANUS CANCER/drug therapy; ANUS FISSURE/drug therapy; ANUS FISSURE/surgery; ANUS FISTULA; CONDYLOMA; CONSERVATIVE TREATMENT; CROHN DISEASE/drug therapy; FECES INCONTINENCE; HEMORRHOID/surgery; HEMORRHOIDECTOMY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIANAL ABSCESS; PRACTICE GUIDELINE; RECTOSCOPY; REVIEW; ANTIINFLAMMATORY AGENT; BOTULINUM TOXIN A/drug therapy; IMIQUIMOD/drug therapy; INFLIXIMAB/drug therapy; METRONIDAZOLE; MITOMYCIN/drug therapy UT: Anal cancer; Anal fissure; Crohn's disease; Haemorrhoids; Incontinence ET: Microbiology: Bacteriology, Mycology, Parasitology and Virology; Surgery; Cancer; Drug Literature Index; Gastroenterology TE: botulinum toxin A/93384-43-1; imiquimod/99011-02-6; infliximab/170277-31-3; metronidazole/39322-38-8; metronidazole/443-48-1; mitomycin/1404-00-8 CR: 93384-43-1; 99011-02-6; 170277-31-3; 39322-38-8; 443-48-1; 1404-00-8 AB: In recent years there has been a significant progress in the diagnostics and therapy of diseases of anus and anal canal. The progress in diagnostics includes both AU: AU: AU: PU: CNOTE: advancement in imaging diagnostics, such as 2D and 3D ultrasonography or MRI, and improvement in functional examinations, such as non-invasive EMG. In the surgical treatment of proctological diseases, as in other fields of surgery, development of minimally invasive techniques is observed. On the other hand, however, many surgeons are going back to old treatment methods, changing only some technical details. It is not always possible to evaluate the efficacy of such methods explicitly, mainly because of a short period of observation and the fact that the groups of patients are not always homogeneous. This article discusses advancements in the treatment of such inflammatory diseases as anal fissure, haemorrhoids, abscesses, fistulas, condylomas and ano-rectal Crohn's disease. Major changes have been observed in the surgical treatment of anal fistules. Due to the large percentage of complications related to the surgical treatment of anal fistules, for a few years there have been attempts to use conservative methods of treatment of this disease. Such methods include tissue glue and so called "plugs", which are used to close the internal ostium of the fistula. Progress in the treatment of ano-rectal Crohn's disease mainly includes introduction of anti-inflammatory medicines of a newer generation, and the most recent novelty is biological treatment. In addition, current guidelines in the diagnostics and treatment of incontinence have been discussed, as well as contemporary trends in the management of patients with anal cancers. The article provides a review of the current literature on the treatment of proctological inflammatory diseases and anal cancers. Copyright © 2009 Cornetis. Ciesielski P Ciesielski Przemyslaw Oddzial Chirurgii Ogólnej Szpitala Powiatowego W Wolominie Kolodziejczak M Kolodziejczak Malgorzata Oddzial Chirurgii Ogólnej Z Pododzialem Proktologii Szpitala na Solcu, ul. Solec 93, 00-382 Warszawa, Poland [email protected] Nawrocki G Nawrocki Grzegorz Oddzial Chirurgii Kliniki Onkologicznej, Centrum Onkologii - Instytut Im. Marii Sklodowskiej-Curie W Warszawie Cornetis ul. Dlugosza 2-6, Wroclaw, 51-162, Poland Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/13 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009465878 Palefsky JM Titel: Anal cancer prevention in HIV-positive men and women Source: DOI: Current Opinion in Oncology; VOL: 21 (5); p. 433-438 /September 2009/ 10.1097/CCO.0b013e32832f511a PU: Lippincott Williams and Wilkins SU: EMBASE Sprache: English AL: English CY: United States ISSN: 1040-8746 CO: CUOOE Institution: Palefsky JM, Dr., Department of Medicine, University of California, San Francisco, Box 0126, 505 Parnassus Ave, San Francisco, CA 94143, United States, [email protected] COU: United States DT: Review; Journal Article JSC: C.1.3.1 ... Clinical Oncology RN: 0017 Keywords CT: ANUS CANCER/*disease management; ANUS CANCER/*drug therapy; ANUS CANCER/*epidemiology; ANUS CANCER/*prevention; ANUS CANCER/*radiotherapy; ANUS CANCER/*surgery; CANCER PREVENTION/*; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; ANAL INTRAEPITHELIAL NEOPLASIA/disease management; ANAL INTRAEPITHELIAL NEOPLASIA/drug therapy; ANAL INTRAEPITHELIAL NEOPLASIA/surgery; ANAL INTRAEPITHELIAL NEOPLASIA/therapy; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SCREENING; CAUTERIZATION; CLINICAL TRIAL; COLPOSCOPY; CONDYLOMA/disease management; CONDYLOMA/drug therapy; CONDYLOMA/surgery; CONDYLOMA/therapy; CRYOTHERAPY; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; LOW LEVEL LASER THERAPY; MALE HOMOSEXUAL; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; TREATMENT FAILURE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU/diagnosis; UTERINE CERVIX CARCINOMA IN SITU/surgery; UTERINE CERVIX CYTOLOGY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT/drug therapy; CATECHIN/drug therapy; CATECHIN/topical drug administration; IMIQUIMOD/clinical trial; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; LIQUID NITROGEN; PODOPHYLLOTOXIN/drug therapy; PODOPHYLLOTOXIN/topical drug administration; SINECATECHIN DERIVATIVE/drug therapy; SINECATECHIN DERIVATIVE/topical drug administration; TRICHLOROACETIC ACID; UNCLASSIFIED DRUG UT: Anal cancer; Anal intraepithelial neoplasia; Cancer prevention; HIV; Human papillomavirus; Screening ET: Cancer; Public Health, Social Medicine and Epidemiology; Immunology, Serology and Transplantation; Drug Literature Index; Gastroenterology TE: catechin/13392-26-2; catechin/154-23-4; imiquimod/99011-02-6; podophyllotoxin/518-28-5; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 CR: 13392-26-2; 154-23-4; 99011-02-6; 518-28-5; 14357-05-2; 76-03-9 AB: AU: PU: CNOTE: PURPOSE OF REVIEW: The incidence of human papillomavirus-associated anal cancer is unacceptably high among HIV-positive men who have sex with men, and possibly in HIV-positive women. Unlike most other malignancies occurring in the HIV-positive population, anal cancer is potentially preventable, using methods similar to those used to prevent cervical cancer in women. This review discusses the issues around screening to prevent anal cancer. RECENT FINDINGS: Recent studies show that the incidence of anal cancer has increased since the introduction of highly active antiretroviral therapy in this population and now exceeds the highest incidence of cervical cancer among women reported anywhere in the world. SUMMARY: The high incidence of anal cancer among HIV-positive individuals must not be ignored, since it may be preventable. Given the current evidence and analogy with the cervical cancer prevention model, many clinicians believe that identification and treatment of high-grade anal intraepithelial neoplasia to prevent anal cancer are warranted. When the expertise to do so exists, this is a reasonable approach, particularly if coupled with efforts to optimize further screening and treatment approaches, as well as efforts to document the efficacy of high-grade anal intraepithelial neoplasia treatment to reduce the incidence of anal cancer. © 2009 Lippincott Williams & Wilkins, Inc. Palefsky JM Palefsky Joel M. Department of Medicine, University of California, San Francisco, Box 0126, 505 Parnassus Ave, San Francisco, CA 94143, United States [email protected] Lippincott Williams and Wilkins 530 Walnut Street, Philadelphia, PA 19106-3621, United States Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/14 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009395225 Fox P Titel: Anal cancer screening in men who have sex with men Source: Current Opinion in HIV and AIDS; VOL: 4 (1); p. 64-67 /January 2009/ DOI: 10.1097/COH.0b013e32831a6fe0 PU: Lippincott Williams and Wilkins SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 1746-630X EISSN: 1746-6318 Institution: Fox P, Dr., Chelsea and Westminster Hospital, St. Stephen's Centre, 369 Fulham Road, London SW10 9NH, United Kingdom, [email protected] COU: United Kingdom DT: Review; Journal Article RN: 0025 Keywords CT: ANUS CANCER/*; CANCER SCREENING/*; MALE HOMOSEXUAL/*; ANAL CYTOLOGY; ANUS INTRAEPITHELIAL NEOPLASIA/diagnosis; ANUS INTRAEPITHELIAL NEOPLASIA/drug therapy; ANUS INTRAEPITHELIAL NEOPLASIA/therapy; CANCER RISK; CONDYLOMA ACUMINATUM; CYTOLOGY; DIGITAL RECTAL EXAMINATION; DRUG EFFICACY; DYSPLASIA/diagnosis; DYSPLASIA/drug therapy; DYSPLASIA/therapy; HIGH RESOLUTION ANOSCOPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE ENDOSCOPY; PRIORITY JOURNAL; REVIEW; SELF EXAMINATION; SENSITIVITY AND SPECIFICITY; VIRUS LOAD; WART VIRUS; CYCLIN DEPENDENT KINASE INHIBITOR 2A; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; PLACEBO; TRICHLOROACETIC ACID/drug therapy UT: Anal cancer; Anal cytology; Anal intraepithelial neoplasia; Natural history; Treatment ET: Dermatology and Venereology; Cancer; Public Health, Social Medicine and Epidemiology; Drug Literature Index; Gastroenterology TE: imiquimod/99011-02-6; trichloroacetic acid/14357-05-2; trichloroacetic acid/7603-9 CR: 99011-02-6; 14357-05-2; 76-03-9 AB: Purpose of review: To determine whether current evidence and expert opinion support the routine use of anal cytology and high-resolution anoscopy in men who have sex with men. Recent findings: Most recently published guidelines do not recommend routine anal cytology, but anal cancer is undoubtedly a serious and growing problem for HIV-positive patients. Two recent cohort studies have provided data that suggest that the precursor lesion (highgrade squamous intraepithelial lesion) might not be more prevalent in patients on highly active antiretroviral therapy than in historical pre-highly active antiretroviral therapy cohorts or in HIV-negative men who have sex with men. If substantiated by further studies, this would make it easier to focus intervention with highresolution anoscopy on a smaller group of patients. This would be helpful because high-resolution anoscopy remains a resource that is both costly and difficult to access in most countries. The sensitivity and specificity of anal cytology is poor and adjuncts to cytology such as p16ink4a staining and human papillomavirus viral loads might be utilized to further reduce the number of patients requiring high-resolution anoscopy. Despite the burden of high-grade squamous intraepithelial lesion in HIV negative men who have sex with men, anal cancer remains uncommon in this group. Summary: Although routine anal cytology is not advisable for men who have sex with men at present, be they HIV positive or negative, clinicians should be regularly performing digital rectal examination in those at high risk of anal cancer, both to facilitate early detection of anal cancer and in the interests of health promotion. © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins. AU: Fox P Fox Paul Chelsea and Westminster Hospital, St. Stephen's Centre, 369 Fulham Road, London SW10 9NH, United Kingdom PU: CNOTE: [email protected] Lippincott Williams and Wilkins 250 Waterloo Road, London, SE1 8RD, United Kingdom Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/15 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009395223 Palefsky J Titel: Human papillomavirus-related disease in people with HIV Source: Current Opinion in HIV and AIDS; VOL: 4 (1); p. 52-56 /January 2009/ DOI: 10.1097/COH.0b013e32831a7246 PU: Lippincott Williams and Wilkins SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 1746-630X EISSN: 1746-6318 Institution: Palefsky J, Dr. Prof., Department of Medicine, University of California, 505 Parnassus Ave, Box 0126, San Francisco, CA 94143, United States, [email protected] COU: United States DT: Review; Journal Article RN: 0036 Keywords CT: ANUS CANCER/*epidemiology; ANUS CANCER/*prevention; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; UTERINE CERVIX CANCER/*epidemiology; WART VIRUS/*; ANUS INTRAEPITHELIAL NEOPLASIA/drug therapy; ANUS INTRAEPITHELIAL NEOPLASIA/surgery; ANUS INTRAEPITHELIAL NEOPLASIA/therapy; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; CONDYLOMA ACUMINATUM/drug therapy; DISEASE ASSOCIATION; DRUG MECHANISM; DYSPLASIA/drug therapy; DYSPLASIA/surgery; DYSPLASIA/therapy; HUMAN; MALE HOMOSEXUAL; MORBIDITY; MOUTH CANCER; PENIS CANCER; PREVALENCE; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; ANTIRETROVIRUS AGENT/drug therapy; IMIQUIMOD/drug therapy; IMIQUIMOD/pharmacology; IMIQUIMOD/topical drug administration UT: Anal cancer; Anal intraepithelial neoplasia; Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus ET: Obstetrics and Gynecology; Cancer; Immunology, Serology and Transplantation; Drug Literature Index; Gastroenterology TE: imiquimod/99011-02-6 CR: AB: AU: PU: CNOTE: 99011-02-6 Purpose of review: The incidence of human papillomavirus (HPV)-related cancers has increased among people with HIV infection compared with the general population. This review will describe recent findings in HPV-associated cancer incidence since the introduction of antiretroviral therapy, HPV/disease prevalence at sites other than cervix and anus, and recent data on screening and treatment of anal intraepithelial neoplasia. Recent findings: Consistent with high prevalence of anogenital HPV infection, new data on cervical intraepithelial neoplasia and anal intraepithelial neoplasia in HIV-positive men and women show that the incidence of cervical cancer has not declined since the introduction of antiretroviral therapy and that the incidence of anal cancer is rising. Several studies also highlight high rates of HPV infection and HPV-associated disease at sites other than the cervix and anus, including the penis and the mouth. Treatment methods for anal intraepithelial neoplasia have been described and show reasonable efficacy. Summary: New data imply that the problem of HPV-related cancers will not decline among HIV-positive men and women in the antiretroviral therapy era, highlighting the need to perform studies to determine if screening and treatment of anal intraepithelial neoplasia will prevent development of anal cancer. Recent data show progress in both these areas. © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins. Palefsky J Palefsky Joel Department of Medicine, University of California, 505 Parnassus Ave, Box 0126, San Francisco, CA 94143, United States [email protected] Lippincott Williams and Wilkins 250 Waterloo Road, London, SE1 8RD, United Kingdom Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/16 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009329201 Coremans G; Snoeck R Titel: Cidofovir: Clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions Source: Expert Opinion on Pharmacotherapy; VOL: 10 (8); p. 1343-1352 /June 2009/ http://www.informapharmascience.com/doi/pdf/10.1517/14656560902960154 10.1517/14656560902960154 Informa Healthcare EMBASE English English United Kingdom 1465-6566 DOI: PU: SU: Sprache: AL: CY: ISSN: CO: EOPHF Institution: Coremans G, University Hospital Gasthuisberg, Department of Gastroenterology, Herestraat 49, 3000 Leuven, Belgium, [email protected] COU: Belgium DT: Review; Journal Article JSC: A.1.1 ... Clinical Pharmacology RN: 0063 Keywords CT: CONDYLOMA ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*surgery; CONDYLOMA ACUMINATUM/*therapy; PRECANCER/*; VIRUS INFECTION/*drug therapy; VIRUS INFECTION/*surgery; VIRUS INFECTION/*therapy; ANAL LESION/drug therapy; ANTIVIRAL ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BOWEN DISEASE/drug therapy; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER/side effect; DRUG FORMULATION; DRUG INDUCED HEADACHE/side effect; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE/side effect; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/drug therapy; LESIONS AND DEFECTS/drug therapy; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MYALGIA/side effect; NEOPLASM/drug therapy; NEPHROTOXICITY/side effect; NONHUMAN; PENIS DISEASE/drug therapy; PROTEINURIA/side effect; RECURRENT INFECTION/drug therapy; REVIEW; UTERINE CERVIX CARCINOMA IN SITU/drug therapy; UTERINE CERVIX DYSPLASIA/drug therapy; VULVA DISEASE/drug therapy; CIDOFOVIR/*adverse drug reaction; CIDOFOVIR/*clinical trial; CIDOFOVIR/*drug combination; CIDOFOVIR/*drug concentration; CIDOFOVIR/*drug dose; CIDOFOVIR/*drug therapy; CIDOFOVIR/*drug toxicity; CIDOFOVIR/*intralesional drug administration; CIDOFOVIR/*intravenous drug administration; CIDOFOVIR/*pharmacokinetics; CIDOFOVIR/*pharmacology; CIDOFOVIR/*subconjunctival drug administration; CIDOFOVIR/*topical drug administration; ACYCLIC NUCLEOSIDE; ALPHA2 INTERFERON/adverse drug reaction; ALPHA2 INTERFERON/drug therapy; ALPHA2 INTERFERON/pharmacology; ALPHA2 INTERFERON/topical drug administration; CYTOSINE; FLUOROURACIL/drug therapy; FLUOROURACIL/pharmacology; IMIQUIMOD/drug therapy; IMIQUIMOD/pharmacology; PHOSPHONIC ACID DERIVATIVE; PHOTOSENSITIZING AGENT/drug therapy; ZIDOVUDINE/drug combination; ZIDOVUDINE/drug therapy UT: AIN; Antiviral activity; Apoptosis; Cidofovir; Condylomata acuminata; HPMPC; HPV-associated anogenital lesions; Nephrotoxicity; Phosphorylated metabolites ET: Microbiology: Bacteriology, Mycology, Parasitology and Virology; Obstetrics and Gynecology; Dermatology and Venereology; Drug Literature Index; Adverse Reactions Titles TE: cidofovir/113852-37-2; cytosine/71-30-7; fluorouracil/51-21-8; imiquimod/9901102-6; zidovudine/30516-87-1 CR: 113852-37-2; 71-30-7; 51-21-8; 99011-02-6; 30516-87-1 AB: AU: AU: PU: CNOTE: Background: Cidofovir, a nucleotide analog with antiviral activity against a broad range of DNA viruses including human papilloma viruses (HPV), is available off label to clinicians. Objective: To provide a better knowledge of pharmacology and effects when topically applied. Methods: After reviewing the chemistry, physiology, and animal studies, an overview of clinical studies is provided. Results/conclusions: Cidofovir, as a result of its antiviral and antiproliferative activity and its ability to induce apoptosis, can offer a solution for the treatment of severe recurrent HPV-induced lesions. It can also be used to attempt to treat dysplastic lesions and as an adjuvant treatment. The long-lasting antiviral activity allows infrequent dosing. As a rule, cidofovir applied on the skin is well tolerated, even in long-term treatment. The dose-limiting nephrotoxicity of the drug is not a concern in patients with a glomerular filtration rate within the normal range. Cidofovir has clearly influenced the landscape of refractory and dysplastic anogenital condylomata acuminata and its use has increased over the last decade. However, further controlled clinical trials are needed to assess the role of cidofovir and its derivatives. © 2009 Informa UK Ltd. All rights reserved. Coremans G Coremans Georges University Hospital Gasthuisberg, Department of Gastroenterology, Herestraat 49, 3000 Leuven, Belgium [email protected] Snoeck R Snoeck Robert Rega Institute for Medical Research, KU Leuven, Belgium Informa Healthcare Telephone House, 69 - 77 Paul Street, EC2A 4LQ, United Kingdom Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/17 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009322231 Longacre TA; Kong CS; Welton ML Titel: Diagnostic problems in anal pathology Source: Advances in Anatomic Pathology; VOL: 15 (5); p. 263-278 /September 2008/ DOI: 10.1097/PAP.0b013e318183234b PU: Lippincott Williams and Wilkins SU: EMBASE Sprache: English AL: English CY: United States ISSN: 1072-4109 EISSN: 1533-4031 PII: 0012548020080900000002 Institution: Longacre TA, Dr., Department of Pathology, Stanford University, School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, United States, [email protected] United States Review; Journal Article E.7 ... Anatomy, Histology, Cytology & Anthropology 0073 COU: DT: JSC: RN: Keywords CT: ANUS DISEASE/*diagnosis; ANUS DISEASE/*epidemiology; ANUS DISEASE/*etiology; DIAGNOSTIC VALUE/*; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOCARCINOMA/diagnosis; ANAL CANAL; ANAL CONDYLOMA/diagnosis; ANOPLASTY; ANUS CANCER/diagnosis; ANUS CARCINOMA/epidemiology; ANUS CARCINOMA/etiology; ANUS INTERCOURSE; BASAL CELL CARCINOMA/diagnosis; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SURGERY; CIGARETTE SMOKING; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONDYLOMA/diagnosis; CONDYLOMA ACUMINATUM/diagnosis; CYTOLOGY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DYSPLASIA; GENITAL TRACT CANCER; HEMORRHOIDECTOMY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERPLASIA/diagnosis; IMMUNE DEFICIENCY; INFECTION RISK; INVASIVE CARCINOMA; MELANOMA/diagnosis; NEUROENDOCRINE TUMOR/diagnosis; NOMENCLATURE; NONHUMAN; PATHOLOGIST; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RECTUM BIOPSY; REVIEW; SCREENING; SERODIAGNOSIS; SMALL CELL CARCINOMA/diagnosis; SQUAMOUS CELL CARCINOMA/epidemiology; SQUAMOUS CELL CARCINOMA/etiology; SQUAMOUS CELL METAPLASIA/diagnosis; TUMOR DIFFERENTIATION; VERRUCOUS CARCINOMA/diagnosis; VERRUCOUS CARCINOMA/surgery; VIRUS INFECTION/drug therapy; VIRUS TYPING; WART VIRUS; BIOLOGICAL MARKER/endogenous compound; CYCLIN DEPENDENT KINASE INHIBITOR 2A/endogenous compound; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration UT: Anal carcinoma; Anal dysplasia; Anal intraepithelial neoplasia; Buschke and Lowenstein; Condyloma acuminatum; HPV; Human papilloma virus; p16; ProEx C; Verrucous carcinoma ET: Microbiology: Bacteriology, Mycology, Parasitology and Virology; Internal Medicine; Cancer; Public Health, Social Medicine and Epidemiology; Drug Literature Index; Gastroenterology TE: imiquimod/99011-02-6 CR: 99011-02-6 AB: Anal squamous cell carcinoma and its precursor lesions are increasing in incidence in the United States and Europe. This trend predates human immunodeficiency virus/acquired immune deficiency syndrome and has been associated with persistent high-risk human papilloma virus (HPV) genotype infection, previous lower genital tract dysplasia/carcinoma, high frequency anoreceptive intercourse, heavy cigarette smoking, immunosuppression in solid organ transplant and immune disorders, and human immunodeficiency virus AU: AU: AU: PU: CNOTE: seropositivity. Screening protocols for at-risk patients are under active investigation and pathologists are often asked to assess anal canal and perianal biopsies for the presence of dysplasia and/or invasive carcinoma. Because underdiagnosis and overdiagnosis of anal cancer and precancer may lead to inappropriate treatment, it is important for the pathologist to be aware of current screening strategies, specific risk lesions, and the role of pathology in initial diagnosis and evaluation of anal biopsy and/or resection specimens. Standardized histologic criteria and uniform terminology should be used for reporting all anal canal and perianal squamous intraepithelial lesions. HPV subtyping, anal cytology, and recently identified biomarkers, such as p16 and Becton Dickinson ProEx C may provide additional information in problematic cases, but it is important to be aware of the limitations of these assays. HPV has been linked to all the major histologic subtypes of anal carcinoma (eg, basaloid, cloacogenic, transitional, etc.) and this association is strongest for anal canal lesions. With the possible exception of the microcystic pattern, histologic subtype does not seem to predict prognosis; and anal squamous cell carcinomas should be classified as either keratinizing or nonkeratinizing. Poorly differentiated squamous cell carcinomas have a worse prognosis and should be distinguished from poorly differentiated adenocarcinoma, melanoma, and neuroendocrine tumors. Very well differentiated squamous cell carcinoma with pushing margins (so-called giant condyloma of Buschke and Lowenstein) should be classified as verrucous carcinoma; this tumor shows aggressive local infiltration but does not metastasize. As all anal condylomata may harbor foci of high-grade dysplasia or invasive carcinoma, careful sectioning and complete histologic examination is required. © 2008 Lippincott Williams & Wilkins, Inc. Longacre TA Longacre Teri A. Department of Pathology, Stanford University, School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, United States [email protected] Kong CS Kong Christina S. Department of Pathology, Stanford University, School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, United States Welton ML Welton Mark L. Department of Surgery, Stanford University, Stanford, CA, United States Lippincott Williams and Wilkins 530 Walnut Street, Philadelphia, PA 19106-3621, United States Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/18 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009302522 Gibbon KL; Ekeowa-Anderson AL; Leigh IM Titel: External anogenital premalignant and malignant disease Source: Cancer Treatment and Research; VOL: 146; p. 279-298 /2009/ BTI: Skin Cancer after Organ Transplantation DOI: 10.1007/978-0-387-78574-5_23 PU: Springer Science and Business Media Netherlands SU: EMBASE Sprache: English AL: English CY: Netherlands ISSN: 0927-3042 ISBN: 9780387785738 Institution: Gibbon KL, Barts and the London NHS Trust, London, E1 1BB, United Kingdom COU: United Kingdom DT: Review; Book Series RN: 0090 Keywords CT: ANOGENITAL INTRAEPITHELIAL NEOPLASIA/*drug therapy; ANOGENITAL INTRAEPITHELIAL NEOPLASIA/*prevention; GENITAL TRACT TUMOR/*drug therapy; GENITAL TRACT TUMOR/*prevention; ANAL INTRAEPITHELIAL NEOPLASIA/drug therapy; ANAL INTRAEPITHELIAL NEOPLASIA/surgery; ANUS CANCER/drug therapy; ANUS TUMOR/drug therapy; ANUS TUMOR/surgery; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CHEMOSURGERY; CLINICAL TRIAL; DISEASE ASSOCIATION; GRAFT RECIPIENT; HUMAN; ORGAN TRANSPLANTATION; PENILE INTRAEPITHELIAL NEOPLASIA; PENIS TUMOR; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER/drug therapy; UTERINE CERVIX CANCER/prevention; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL INTRAEPITHELIAL NEOPLASIA/drug therapy; VAGINAL INTRAEPITHELIAL NEOPLASIA/prevention; VAGINAL INTRAEPITHELIAL NEOPLASIA/surgery; VERRUCA VULGARIS/drug therapy; VERRUCA VULGARIS/prevention; VULVA TUMOR/drug therapy; VULVA TUMOR/prevention; VULVA TUMOR/surgery; VULVAR INTRAEPITHELIAL NEOPLASIA/drug therapy; VULVAR INTRAEPITHELIAL NEOPLASIA/prevention; VULVAR INTRAEPITHELIAL NEOPLASIA/surgery; CIDOFOVIR/drug combination; CIDOFOVIR/drug therapy; CIDOFOVIR/topical drug administration; COVAL; FLUOROURACIL/drug combination; FLUOROURACIL/drug therapy; FLUOROURACIL/topical drug administration; HEAT SHOCK PROTEIN E7/drug development; HEAT SHOCK PROTEIN E7/drug therapy; IMIQUIMOD/clinical trial; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; INTERFERON/drug combination; INTERFERON/drug therapy; ISOTRETINOIN/drug combination; ISOTRETINOIN/drug therapy; ISOTRETINOIN/oral drug administration; MITOMYCIN C/drug combination; MITOMYCIN C/drug therapy; RECOMBINANT PROTEIN/drug development; RECOMBINANT PROTEIN/drug therapy; RETINOID/drug therapy; RETINOID/oral drug administration; TRICHLOROACETIC ACID/drug therapy; TRICHLOROACETIC ACID/topical drug administration; UNCLASSIFIED DN: MN: ET: TE: CR: AB: AU: AU: AU: PU: CNOTE: DRUG; WART VIRUS VACCINE/clinical trial; WART VIRUS VACCINE/drug therapy Cervarix/Glaxo SmithKline; Coval; Gardasil/Sanofi Pasteur Glaxo SmithKline; Sanofi Pasteur Dermatology and Venereology; Cancer; Immunology, Serology and Transplantation; Urology and Nephrology; Drug Literature Index cidofovir/113852-37-2; fluorouracil/51-21-8; imiquimod/99011-02-6; isotretinoin/4759-48-2; mitomycin C/50-07-7; mitomycin C/74349-48-7; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 113852-37-2; 51-21-8; 99011-02-6; 4759-48-2; 50-07-7; 74349-48-7; 14357-05-2; 76-03-9 The external anogenital area comprises the anus, perianal skin, and the adjacent external genitalia including the vulva and vaginal introitus in the female, and the penis and scrotum in the male. Immunosuppressed organ transplant recipients (OTR) are prone to viral infections, and have an increased incidence of human papillomavirus (HPV) associated premalignant and malignant neoplasms, which specifically target the anogenital tract. The cumulative risk of the development of a solid-organ neoplasm is 5-6% [1-3]. Nearly all of these neoplasms occur on a background of premalignant disease (i.e., carcinoma in situ). The most common presentation of anogenital disease in OTR is condyloma accuminata or genital viral warts and these are regarded as a marker of immunosuppression in this group. © 2009 Springer US. Gibbon KL Gibbon Karen L. Barts and the London NHS Trust, London, E1 1BB, United Kingdom Ekeowa-Anderson AL Ekeowa-Anderson Arucha L. Royal London Hospital, Whitechapel, London, E1 1BB, United Kingdom Leigh IM Leigh Irene M. College of Medicine, Dentistry and Nursing, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9YS, United Kingdom Springer Science and Business Media Netherlands Van Godewijckstraat 30, Dordrecht, 3311, Netherlands Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/19 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009259014 Stier EA; Baranoski AS Titel: Human papillomavirus-related diseases in HIV-infected individuals Source: DOI: PU: Current Opinion in Oncology; VOL: 20 (5); p. 541-546 /September 2008/ 10.1097/CCO.0b013e3283094ed8 Lippincott Williams and Wilkins SU: EMBASE Sprache: English AL: English CY: United States ISSN: 1040-8746 CO: CUOOE Institution: Stier EA, Dr., Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston Medical Center, 85 East Concord Street, Boston, MA 02118, United States, [email protected] COU: United States DT: Review; Journal Article JSC: C.1.3.1 ... Clinical Oncology RN: 0049 Keywords CT: HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; WART VIRUS/*; ANAL DYSPLASIA/therapy; ANUS CANCER/drug therapy; ANUS CANCER/radiotherapy; ANUS DISEASE/therapy; BLOOD TOXICITY/side effect; CANCER INCIDENCE; CARCINOGENESIS/etiology; CONDYLOMA ACUMINATUM/drug therapy; CONDYLOMA ACUMINATUM/etiology; DYSPLASIA/therapy; GASTROINTESTINAL TOXICITY/side effect; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INTENSITY MODULATED RADIATION THERAPY; NONHUMAN; OROPHARYNX CANCER/etiology; PREVALENCE; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY/side effect; TREATMENT OUTCOME; UTERINE CERVIX CANCER/drug therapy; UTERINE CERVIX CANCER/etiology; UTERINE CERVIX CANCER/prevention; UTERINE CERVIX CARCINOMA IN SITU/drug therapy; UTERINE CERVIX CARCINOMA IN SITU/etiology; UTERINE CERVIX CARCINOMA IN SITU/prevention; UTERINE CERVIX DYSPLASIA/etiology; ANTIRETROVIRUS AGENT/drug therapy; CISPLATIN/adverse drug reaction; CISPLATIN/drug combination; CISPLATIN/drug therapy; FLUOROURACIL/adverse drug reaction; FLUOROURACIL/drug combination; FLUOROURACIL/drug therapy; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; MITOMYCIN/adverse drug reaction; MITOMYCIN/drug combination; MITOMYCIN/drug therapy; WART VIRUS VACCINE/drug therapy UT: Cervical and anal dysplasia; HIV; Human papillomavirus ET: Microbiology: Bacteriology, Mycology, Parasitology and Virology; Obstetrics and Gynecology; Cancer; Drug Literature Index; Adverse Reactions Titles TE: cisplatin/15663-27-1; cisplatin/26035-31-4; cisplatin/96081-74-2; fluorouracil/5121-8; imiquimod/99011-02-6; mitomycin/1404-00-8 CR: 15663-27-1; 26035-31-4; 96081-74-2; 51-21-8; 99011-02-6; 1404-00-8 AB: Purpose of review To present recent publications in human papillomavirusassociated diseases and their relationship to HIV-infected patients. Recent findings Studies assessing geographic variations in human papillomavirus types and prevalence in cervical dysplasia and cancer in HIV-infected women suggest that AU: AU: PU: CNOTE: although human papillomavirus types 16 and 18 dominate, multiple other human papillomavirus types may play a role in carcinogenesis. Anal dysplasia and cancer incidence continues to rise in the highly active antiretroviral therapy era; however, data on outcomes following therapy for anal dysplasia (infrared coagulator, highresolution anoscopy-guided ablation) and anal cancer (chemoradiation and possibly intensity-modulated radiation therapy) have been encouraging. Oral human papillomavirus may be associated with lower genital tract human papillomavirus infection and may have implications in the development of oropharyngeal cancer. Summary As HIV-infected patients in the highly active antiretroviral therapy era continue to have high rates of cervical and anal cancer, it is important to continue screening efforts and treatment of preinvasive disease. Treatment options for anal dysplasia and anal cancer in HIV-infected individuals are expanding and may lead to decreased morbidity and mortality. Trials assessing safety and immunogenicity of the human papillomavirus quadrivalent vaccine in people with HIV have started enrollment, and if successful, may prevent many human papillomavirus-associated cancers. © 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins. Stier EA Stier Elizabeth A. Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston Medical Center, Boston, MA, United States; Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston Medical Center, 85 East Concord Street, Boston, MA 02118, United States [email protected] Baranoski AS Baranoski Amy S. Section of Infectious Diseases, Boston University School of Medicine, Boston Medical Center, Boston, MA, United States Lippincott Williams and Wilkins 530 Walnut Street, Philadelphia, PA 19106-3621, United States Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/20 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009202399 Handisurya A; Schellenbacher C; Kirnbauer R Titel: Erkrankungen durch humane Papillomviren (HPV) Diseases caused by human papillomaviruses (HPV): Academy CME Source: JDDG - Journal of the German Society of Dermatology; VOL: 7 (5); p. 453-467 /May 2009/ 10.1111/j.1610-0387.2009.06988.x Blackwell Publishing Ltd EMBASE German; English English; German DOI: PU: SU: Sprache: AL: CY: United Kingdom ISSN: 1610-0379 EISSN: 1610-0387 CO: JJDDA Institution: Handisurya A, Dr., M.D. Medical University Vienna, Department of Dermatology, Division of Immunology Allergy and Infectious Diseases, Währinger Gürtel 18-20, A-1090 Vienna, Austria, [email protected] COU: Austria DT: Review; Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0011 Keywords CT: WART VIRUS/*; ADD ON THERAPY; BONE MARROW SUPPRESSION/side effect; BOWEN DISEASE; BOWENOID PAPULOSIS; BUTCHER WART; CAUTERIZATION; COLPOSCOPY; CONDYLOMA ACUMINATUM/drug therapy; CONDYLOMA ACUMINATUM/prevention; CONDYLOMA ACUMINATUM/surgery; CONDYLOMA ACUMINATUM/therapy; CRYOTHERAPY; DNA DETERMINATION; EPIDERMODYSPLASIA VERRUCIFORMIS; FEVER/side effect; FOCAL EPITHELIUM HYPERPLASIA; HEADACHE/side effect; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFLAMMATION/side effect; KERATOLYSIS; LARYNX PAPILLOMATOSIS; LASER SURGERY; MALE HOMOSEXUAL; MYALGIA/side effect; NONHUMAN; OPEN READING FRAME; PAIN/side effect; PATHOGENESIS; PHYLOGENY; POLYMERASE CHAIN REACTION; RECTOSCOPY; REVIEW; SEROLOGY; SEXUALLY TRANSMITTED DISEASE; SKIN CANCER; SKIN PRURITUS/side effect; SQUAMOUS CELL CARCINOMA; TAXONOMY; URETHROSCOPY; VERRUCA VULGARIS/drug therapy; VERRUCA VULGARIS/surgery; VERRUCA VULGARIS/therapy; VIRUS GENOME; VIRUS LIKE AGENT; VIRUS TRANSMISSION; ACETIC ACID/drug therapy; ACETIC ACID/topical drug administration; CAPSID PROTEIN; CIDOFOVIR/adverse drug reaction; CIDOFOVIR/drug therapy; FLUOROURACIL/adverse drug reaction; FLUOROURACIL/drug therapy; IMIQUIMOD/drug therapy; INTERFERON/adverse drug reaction; INTERFERON/drug therapy; INTERFERON/intralesional drug administration; INTERFERON/topical drug administration; PODOPHYLLOTOXIN/drug therapy; WART VIRUS VACCINE/drug therapy UT: Condylomata acuminata; Epidermodysplasia verruciformis; HPV vaccine; Human papillomavirus; Skin warts DN: Cervarix/Glaxo SmithKline; Gardasil/Labaz MN: Glaxo SmithKline; Labaz ET: Microbiology: Bacteriology, Mycology, Parasitology and Virology; Dermatology and Venereology; Immunology, Serology and Transplantation; Drug Literature Index; Adverse Reactions Titles TE: acetic acid/127-08-2; acetic acid/127-09-3; acetic acid/64-19-7; acetic acid/71-501; cidofovir/113852-37-2; fluorouracil/51-21-8; imiquimod/99011-02-6; CR: AB: AU: AU: AU: PU: CNOTE: podophyllotoxin/518-28-5 127-08-2; 127-09-3; 64-19-7; 71-50-1; 113852-37-2; 51-21-8; 99011-02-6; 51828-5 Human papillomaviruses (HPV) are non-enveloped tumor viruses with a double stranded DNA approximately 8 kilobases in length. The viral genome is enclosed by a spherical capsid with icosahedral symmetry and a diameter of about 55 nm. More than 100 HPV types have been identified. They infect the squamous epithelia of skin and mucosa and usually cause benign papillomas or warts. Persistent infection with high-risk oncogenic HPV causes all cervical cancers, most anal cancers, and a subset of vulvar, vaginal, penile and oropha-ryngeal cancers. In recent years cutaneous beta-HPV types have been associated with the pathogenesis of non-melanoma skin cancers. Two prophylactic HPV vaccines based on virus-like particles (VLP) are licensed. These are up to 100% effective in preventing HPV 16 and HPV 18 infections and associated genital lesions in women, who have not been previously infected with these types. One vaccine also prevents genital warts caused by HPV 6 and HPV 11. © Blackwell Verlag GmbH, Berlin. Handisurya A Handisurya Alessandra Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna, Austria; M.D. Medical University Vienna, Department of Dermatology, Division of Immunology Allergy and Infectious Diseases, Währinger Gürtel 18-20, A-1090 Vienna, Austria [email protected] Schellenbacher C Schellenbacher Christina Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna, Austria Kirnbauer R Kirnbauer Reinhard Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna, Austria Blackwell Publishing Ltd 9600 Garsington Road, Oxford, OX4 2XG, United Kingdom Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/21 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009198456 Mlakar B Titel: Proctoscopy should be mandatory in men that have sex with men with external anogenital warts Source: Acta Dermatovenerologica Alpina, Pannonica et Adriatica; VOL: 18 (1); p. 7-11 /March 2009/ Slovenian Medical Society PU: SU: EMBASE Sprache: English AL: English CY: Slovenia ISSN: 1318-4458 CO: ADPAE Institution: Mlakar B, Dr., Rozna Dolina Surgical Centre, Department for Abdominal Surgery and Proctology, Rozna dolina cesta IV/45, 1000 Ljubljana, Slovenia COU: Slovenia DT: Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0019 Keywords CT: CONDYLOMA ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*surgery; RECTOSCOPY/*; ADULT; AGED; ARTICLE; BURNING SENSATION/side effect; DISEASE DURATION; DRUG WITHDRAWAL; DYSPLASIA; FLU LIKE SYNDROME/side effect; FOLLOW UP; HUMAN; LEUKOPENIA/side effect; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PROCTITIS/drug therapy; RECURRENCE RISK; SINGLE DRUG DOSE; VERRUCOUS CARCINOMA; ALPHA INTERFERON/subcutaneous drug administration; AZITHROMYCIN/drug combination; AZITHROMYCIN/drug therapy; AZITHROMYCIN/oral drug administration; CIPROFLOXACIN/drug combination; CIPROFLOXACIN/drug therapy; IMIQUIMOD/adverse drug reaction; IMIQUIMOD/drug therapy; IMIQUIMOD/rectal drug administration UT: Condylomata acuminata; Intra-anal dysplasia; Proctoscopy; Recurrence; Sexually transmitted diseases; Therapy with imiquimod; Verrucous carcinoma ET: Microbiology: Bacteriology, Mycology, Parasitology and Virology; Dermatology and Venereology; Drug Literature Index; Adverse Reactions Titles TE: azithromycin/83905-01-5; ciprofloxacin/85721-33-1; imiquimod/99011-02-6 CR: 83905-01-5; 85721-33-1; 99011-02-6 AB: Introduction: The aim of this study was to evaluate anal pathology in men having sex with men (MSM) seen at our proctology outpatient clinics. Methods: The charts of 74 MSM treated by the author between January 2002 and April 2006 were reviewed. Results: Three of 74 patients (4%) had proctitis and 96% had anogenital condylomata acuminata (warts). 49 out of 71 (69%) had external anogenital as well as intra-anal warts and 13 (18%) had only intra-anal warts. In 14 an intra-anal dysplasia and in 2 patients intra-anal verrucous carcinomas were detected. The average duration of disease before referral to our institutions was more than 9 months. Half of the patients were previously treated for anogenital warts with ointments and suppositories at other institutions, including 17 that were "treated" with ointments and/or suppositories for hemorrhoids prescribed by family physicians. The patients mostly had widespread disease and sixty-nine of them required surgery. In the follow-up period there was no recurrence of warts and only itching was observed in 31 (44%) patients. Therapy with imiquimod was introduced for 3 months in twenty-two cases with intra-anal dysplasia. No major side effects were noticed despite intra-anal use. Conclusion: Proctoscopy and AU: PU: CNOTE: histological examination of intra-anal lesions in cases of external anogenital warts should be mandatory in MSM patients. I would like to encourage other physicians to use this approach, which enables detection of intra-anal warts, dysplasia, and even carcinoma in the asymptomatic stage. Mlakar B Mlakar Bostjan Rozna Dolina Surgical Centre, Department for Abdominal Surgery and Proctology, Rozna dolina cesta IV/45, 1000 Ljubljana, Slovenia; Zdrav Splet Surgical Center, Outpatient Proctology Clinic, Lackova 54, 2000 Maribor, Slovenia Slovenian Medical Society Komenskega 4, Ljubljana, 61000, Slovenia Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/22 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009168185 Kreutei A; Wieland U Titel: Human papillomavirus-associated diseases in HIV-infected men who have sex with men Source: Current Opinion in Infectious Diseases; VOL: 22 (2); p. 109-114 /April 2009/ DOI: 10.1097/QCO.0b013e3283229fc8 PU: Lippincott Williams and Wilkins SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 0951-7375 CO: COIDE Institution: Kreutei A, Department of Dermatology, Ruhr University Bochum, Gudrunstr. 56, 44791 Bochum, Germany, [email protected] COU: Germany DT: Journal Article JSC: E.5 ... Clinical Microbiology RN: 0040 Keywords CT: HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*etiology; SEXUAL BEHAVIOR/*; WART VIRUS/*; ANAL CONDYLOMA; ANAL DYSPLASIA/diagnosis; ANOSCOPY; ANUS CANCER/drug therapy; ANUS CANCER/epidemiology; ANUS CANCER/etiology; ANUS CANCER/radiotherapy; ANUS DISEASE/diagnosis; ANUS TUMOR/diagnosis; ANUS TUMOR/drug therapy; ANUS TUMOR/epidemiology; ANUS TUMOR/etiology; ANUS TUMOR/surgery; ANUS TUMOR/therapy; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER UT: ET: TE: CR: AB: AU: RADIOTHERAPY; CANCER SCREENING; CONDYLOMA; CYTOLOGY; DIAGNOSTIC PROCEDURE; HETEROSEXUAL MALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFORMATION; INTROSPECTION; MEDICAL LITERATURE; MOUTH INFECTION/epidemiology; MOUTH INFECTION/etiology; PENIS DISEASE/etiology; PENIS INFECTION/etiology; PENIS INFECTION/surgery; PENIS INFECTION/therapy; POPULATION; PRACTICE GUIDELINE; RISK; TREATMENT OUTCOME; ANTINEOPLASTIC AGENT/drug therapy; ANTIRETROVIRUS AGENT/drug therapy; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; LIQUID NITROGEN/drug therapy; LIQUID NITROGEN/topical drug administration; PODOPHYLLOTOXIN/drug therapy; PODOPHYLLOTOXIN/topical drug administration; TRICHLOROACETIC ACID/drug therapy; TRICHLOROACETIC ACID/topical drug administration Anal; Anal cancer; HIV; Human papillomavirus infection; Men who have sex with men; Oral intraepithelial neoplasia; Penile Microbiology: Bacteriology, Mycology, Parasitology and Virology; Psychiatry; Drug Literature Index imiquimod/99011-02-6; podophyllotoxin/518-28-5; trichloroacetic acid/14357-052; trichloroacetic acid/76-03-9 99011-02-6; 518-28-5; 14357-05-2; 76-03-9 Purpose of review Persistent human papillomavirus (HPV) infection is very frequent in HIV-positive men who have sex with men. This review summarizes recent data on papillomavirus-induced anal intraepithelial neoplasia and anal cancer in these patients. Moreover, data are provided on penile and oral HPVassociated diseases, for which only limited information is available in the literature. Recent findings The incidence of anal intraepithelial neoplasia rises in HIV-positive men who have sex with men despite the introduction of highly active antiretroviral therapy. Increasing evidence indicates that high-grade lesions can progress to anal cancer over time. Anal cytology has been recommended as the primary screening tool for anal dysplasia in the at-risk population. Individuals with abnormal cytology should undergo high-resolution anoscopy to appropriately identify and treat dysplastic lesions. Anal cancer has become one of the most common non-AIDS-defining tumors in HIV-infected individuals. In the era of highly active antiretroviral therapy, the outcome of combined chemoradiotherapy in HIV-positive individuals with anal cancer is similar to that in HIV-negative persons. Penile and oral HPV-associated diseases seem to be more frequent in HIV-positive men than reported for HIV-negative heterosexual men. Summary Diagnostic and therapeutic guidelines should be implemented for at-risk populations for anal dysplasia/anal cancer, such as HIV-positive men who have sex with men. More study is required to get better insights into the natural history of penile and oral HPV-associated benign and malignant lesions. 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins. Kreutei A Kreutei Alexander Department of Dermatology, Ruhr University Bochum, Bochum, Germany; Department of Dermatology, Ruhr University Bochum, Gudrunstr. 56, 44791 Bochum, Germany [email protected] AU: PU: CNOTE: Wieland U Wieland Ulrike Institute of Virology, University of Köln, Cologne, Germany Lippincott Williams and Wilkins 250 Waterloo Road, London, SE1 8RD, United Kingdom Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/23 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009153775 Palefsky JM; Rubin M Titel: The Epidemiology of Anal Human Papillomavirus and Related Neoplasia Source: Obstetrics and Gynecology Clinics of North America; VOL: 36 (1); p. 187-200 /March 2009/ DOI: 10.1016/j.ogc.2009.02.003 PU: W.B. Saunders SU: EMBASE Sprache: English AL: English CY: United States ISSN: 0889-8545 CO: OGCAE PII: S0889854509000084 Institution: Palefsky JM, Dr., Division of Infectious Disease, Department of Medicine, University of California, Box 0126, Room M1203, San Francisco, CA 94143, United States, [email protected] COU: United States DT: Review; Journal Article JSC: C.4 ... Obstetrics & Gynecology RN: 0049 Keywords CT: ANAL INTRAEPITHELIAL NEOPLASIA/*diagnosis; ANAL INTRAEPITHELIAL NEOPLASIA/*epidemiology; ANAL INTRAEPITHELIAL NEOPLASIA/*etiology; ANAL INTRAEPITHELIAL NEOPLASIA/*prevention; ANAL INTRAEPITHELIAL NEOPLASIA/*surgery; ANAL INTRAEPITHELIAL NEOPLASIA/*therapy; ANUS CANCER/*diagnosis; ANUS CANCER/*epidemiology; ANUS CANCER/*etiology; ANUS CANCER/*prevention; ANUS CANCER/*surgery; ANUS CANCER/*therapy; UTERINE CERVIX CANCER/*epidemiology; UTERINE CERVIX CANCER/*etiology; UTERINE CERVIX CANCER/*prevention; UTERINE CERVIX CANCER/*surgery; UTERINE CERVIX CANCER/*therapy; VERRUCA VULGARIS/*drug therapy; VERRUCA VULGARIS/*epidemiology; VERRUCA VULGARIS/*therapy; UT: ET: TE: CR: AB: AU: AU: PU: CNOTE: WART VIRUS/*; ALGORITHM; ANOSCOPY; BIOPSY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CAUTERIZATION; COLPOSCOPY; CONDYLOMA/drug therapy; CRYOTHERAPY; CYTODIAGNOSIS; CYTOLOGY; DIAGNOSTIC PROCEDURE; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN PAPILLOMAVIRUS TYPE 16; INFECTION RISK; LOW LEVEL LASER THERAPY; MASS SCREENING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING; UTERINE CERVIX CYTOLOGY; DICHLOROACETIC ACID/drug therapy; GREEN TEA EXTRACT/drug therapy; IMIQUIMOD/drug therapy; PODOPHYLLOTOXIN/drug therapy; TRICHLOROACETIC ACID/drug therapy Anal cytology; Geriatric; High resolution anoscopy (HRA); Human papillomavirus (HPV); Management Microbiology: Bacteriology, Mycology, Parasitology and Virology; Cancer; Public Health, Social Medicine and Epidemiology dichloroacetic acid/13425-80-4; dichloroacetic acid/2156-56-1; dichloroacetic acid/79-43-6; imiquimod/99011-02-6; podophyllotoxin/518-28-5; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 13425-80-4; 2156-56-1; 79-43-6; 99011-02-6; 518-28-5; 14357-05-2; 76-03-9 The relationship between cervical cancer and human papillomavirus (HPV) is well known. Like cervical cancer, anal cancer is preceded by a series of precancerous changes, raising the possibility that like cervical cancer, anal cancer can be prevented. Further, given the known risk factors for anal cancer, prevention efforts could be targeted to high-risk groups, providing a unique example of a screening program targeted to high-risk individuals. This article describes the epidemiology of anal HPV infection, anal intraepithelial neoplasia, and anal cancer among men and women, as well as current efforts to prevent anal cancers. © 2009 Elsevier Inc. All rights reserved. Palefsky JM Palefsky Joel M. Division of Infectious Disease, Department of Medicine, University of California, Box 0126, Room M1203, San Francisco, CA 94143, United States; Anal Neoplasia Clinic, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States; Clinical and Translational Research School of Medicine, CA, United States [email protected] Rubin M Rubin Mary Anal Neoplasia Clinic, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States; School of Nursing, University of California, San Francisco, CA, United States W.B. Saunders Independence Square West, Philadelphia, PA 19106-3399, United States Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/24 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009126761 Fraillery D; Zosso N; Nardelli-Haefliger D Titel: Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles Source: Vaccine; VOL: 27 (17); p. 2326-2334 /20090414/ DOI: 10.1016/j.vaccine.2009.02.029 PU: Elsevier Ltd SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 0264-410X CO: VACCD PII: S0264410X09002436 Institution: Nardelli-Haefliger D, Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Bugnon 48, CH-1011 Lausanne, Switzerland, [email protected] COU: Switzerland DT: Journal Article JSC: E.4 ... Immunology & Serology; E.5 ... Clinical Microbiology RN: 0041 Keywords CT: DRUG ADMINISTRATION ROUTE/*; HUMAN PAPILLOMAVIRUS TYPE 16/*; IMMUNIZATION/*; VIRUS LIKE AGENT/*; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BAGG ALBINO MOUSE; CONDYLOMA ACUMINATUM/drug therapy; FEMALE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX CANCER/drug therapy; UTERINE CERVIX CANCER/etiology; UTERINE CERVIX CANCER/prevention; HUMAN PAPILLOMA VIRUS TYPE 16 L1 VIRUS LIKE PARTICLE VACCINE/*drug development; HUMAN PAPILLOMA VIRUS TYPE 16 L1 VIRUS LIKE PARTICLE VACCINE/*drug therapy; HUMAN PAPILLOMA VIRUS TYPE 16 L1 VIRUS LIKE PARTICLE VACCINE/*intranasal drug administration; HUMAN PAPILLOMA VIRUS TYPE 16 L1 VIRUS LIKE PARTICLE VACCINE/*intravaginal drug administration; HUMAN PAPILLOMA VIRUS TYPE 16 L1 VIRUS LIKE PARTICLE VACCINE/*oral drug administration; HUMAN PAPILLOMA VIRUS TYPE 16 L1 VIRUS LIKE PARTICLE VACCINE/*pharmaceutics; HUMAN PAPILLOMA VIRUS TYPE 16 L1 VIRUS LIKE PARTICLE VACCINE/*rectal drug administration; HUMAN PAPILLOMA VIRUS TYPE 16 L1 VIRUS LIKE PARTICLE VACCINE/*subcutaneous drug administration; WART VIRUS VACCINE/*drug development; WART VIRUS VACCINE/*drug therapy; WART VIRUS VACCINE/*pharmaceutics; BICARBONATE; CHOLERA TOXIN/intranasal drug administration; CHOLERA TOXIN/pharmaceutics; CHOLERA UT: DN: MN: ET: TE: CR: AB: AU: AU: TOXIN/rectal drug administration; ESTRADIOL/subcutaneous drug administration; IMIQUIMOD/pharmaceutics; IMIQUIMOD/rectal drug administration; IMMUNOGLOBULIN A ANTIBODY/endogenous compound; IMMUNOGLOBULIN G ANTIBODY/endogenous compound; IMMUNOLOGICAL ADJUVANT/pharmaceutics; MEDROXYPROGESTERONE ACETATE/subcutaneous drug administration; NEUTRALIZING ANTIBODY/endogenous compound; NONOXINOL 9/intravaginal drug administration; NONOXINOL 9/pharmaceutics; RESIQUIMOD/drug therapy; RESIQUIMOD/intranasal drug administration; RESIQUIMOD/pharmaceutics; RESIQUIMOD/rectal drug administration; RESIQUIMOD/subcutaneous drug administration; UNCLASSIFIED DRUG Human papillomavirus virus-like particles; Mucosal immunity; Rectal and vaginal immunization Aldara/Glaxo SmithKline Biologicals, Belgium; Conceptrol/Advanced Care, United States; Depo Provera/Pfizer, Switzerland; R 848/huang lisheng pharmatec, China Advanced Care, United States; Glaxo SmithKline Biologicals, Belgium; huang lisheng pharmatec, China; Pfizer, Switzerland; Sigma Microbiology: Bacteriology, Mycology, Parasitology and Virology; Immunology, Serology and Transplantation; Drug Literature Index; Pharmacy bicarbonate/144-55-8; bicarbonate/71-52-3; estradiol/50-28-2; imiquimod/9901102-6; medroxyprogesterone acetate/71-58-9; nonoxinol 9/96827-50-8; resiquimod/144875-48-9 144-55-8; 71-52-3; 50-28-2; 99011-02-6; 71-58-9; 96827-50-8; 144875-48-9 Human papillomavirus (HPV) vaccines based on L1 virus-like particle (VLP) can prevent genital HPV infection and associated lesions after three intramuscular injections. Needle-free administration might facilitate vaccine implementation, especially in developing countries. Here we have investigated rectal and vaginal administration of HPV16 L1 VLPs in mice and their ability to induce anti-VLP and HPV16-neutralizing antibodies in serum and in genital, rectal and oral secretions. Rectal and vaginal immunizations were not effective in the absence of adjuvant. Cholera toxin was able to enhance systemic and mucosal anti-VLPs responses after rectal immunization, but not after vaginal immunization. Rectal immunization with Resiquimod and to a lesser extent Imiquimod, but not monophosphoryl lipid A, induced anti-HPV16 VLP antibodies in serum and secretions. Vaginal immunization was immunogenic only if administered in mice treated with nonoxynol-9, a disrupter of the cervico-vaginal epithelium. Our findings show that rectal and vaginal administration of VLPs can induce significant HPV16-neutralizing antibody levels in secretions, despite the fact that low titers are induced in serum. Imidazoquinolines, largely used to treat genital and anal warts, and nonoxonol-9, used as genital microbicide/spermicide were identified as adjuvants that could be safely used by the rectal or vaginal route, respectively. © 2009 Elsevier Ltd. All rights reserved. Fraillery D Fraillery Dominique Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Bugnon 48, CH-1011 Lausanne, Switzerland Zosso N AU: PU: CNOTE: Zosso Nathalie Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Bugnon 48, CH-1011 Lausanne, Switzerland Nardelli-Haefliger D Nardelli-Haefliger Denise Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Bugnon 48, CH-1011 Lausanne, Switzerland [email protected] Elsevier Ltd Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/25 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009108873 Graziottin A; Serafini A Titel: HPV infection in women: Psychosexual impact of genital warts and intraepithelial lesions Source: Journal of Sexual Medicine; VOL: 6 (3); p. 633-645 /2009/ DOI: 10.1111/j.1743-6109.2008.01151.x PU: Blackwell Publishing Ltd SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 1743-6095 EISSN: 1743-6109 Institution: Graziottin A, Dr., H. San Raffaele Resnati Center of Gynecology and Medical Sexology, Via Enrico Panzacchi 6, 20123 Milano, Italy, [email protected] COU: Italy DT: Review; Journal Article JSC: C.4 ... Obstetrics & Gynecology; D.5 ... Urological Surgery RN: 0074 Keywords CT: CONDYLOMA ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*etiology; CONDYLOMA ACUMINATUM/*prevention; CONDYLOMA ACUMINATUM/*surgery; CONDYLOMA ACUMINATUM/*therapy; PSYCHOSEXUAL DISORDER/*; ANGER; ANXIETY; CARBON DIOXIDE LASER; CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DNA VIRUS; DYSPAREUNIA; FEMALE; FEMALE SEXUAL DYSFUNCTION; HUMAN; LASER SURGERY; LOW LEVEL LASER THERAPY; MEDICAL RESEARCH; MEDLINE; PATHOGENESIS; UT: ET: TE: CR: AB: AU: PATIENT COUNSELING; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION/etiology; REVIEW; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SEXUALLY TRANSMITTED DISEASE/etiology; THERMOCOAGULATION; UTERINE CERVIX CARCINOMA IN SITU/drug therapy; UTERINE CERVIX CARCINOMA IN SITU/etiology; UTERINE CERVIX CARCINOMA IN SITU/prevention; VULVAR VESTIBULITIS; VULVODYNIA; WART VIRUS; ALPHA INTERFERON/clinical trial; ALPHA INTERFERON/drug therapy; ALPHA INTERFERON/intramuscular drug administration; IMIQUIMOD/drug therapy; WART VIRUS VACCINE/drug therapy Anal HPV Infection; Anxiety; Cervical Cancer; Depression; Dyspareunia; Female Sexual Dysfunctions; Genital Warts; High-Risk Partners; HPV; HPV Vaccine; Intraepithelial Neoplasia; Oral HPV Infection; Psychosexual Issues Microbiology: Bacteriology, Mycology, Parasitology and Virology; Obstetrics and Gynecology; Cancer; Public Health, Social Medicine and Epidemiology; Psychiatry; Drug Literature Index imiquimod/99011-02-6 99011-02-6 Introduction. Genital Human Papillomavirus (HPV) infection is the most commonly occurring sexually transmitted viral infection in humans. HPV is a wide family of DNA viruses, which may cause benign skin and mucosal tumors (genital, anal, or oral warts), intraepithelial neoplasias, and/ or malignant cancers in different organs. Women are more susceptible to the oncogenic effect of HPVs, mostly at the genital site on the uterine cervix. Aims. This review analyzes the impact of: (i) genital warts (GWs) and their treatment; (ii) HPV-related genital, oral, and anal precancerous lesions on women's sexual function. Methods. A Medline search was carried out. Search terms were HPV, GWs, intraepithelial neoplasia, cervical cancer, anal cancer, oral cancer, epidemiology, HPV risk factors, sexual dysfunctions, desire disorders, arousal disorders, dyspareunia, vulvar vestibulitis, vulvodynia, orgasmic difficulties, sexual repertoire, couple sexual problems, depression, anxiety, pap smear, screening program, therapy, and vaccines. Main Outcome Measures. Sexual consequences of HPV infection in women, specifically GWs and intraepithelial HPV-related neoplasia. Results. Psychosexual vulnerability increases with number of recurrences of HPV infections. Depression, anxiety, and anger are the emotions most frequently reported. However, to date, there is no conclusive evidence of a specific correlation between HPV infection and a specific female sexual disorder. The relationship between HPV and vulvar vestibulitis/ vulvodynia-related dyspareunia seems not to be direct. Counseling problems, the role of anti-HPV vaccine, and the concept of the high-risk partner are discussed. The reader is offered a practical approach with clinically relevant recommendations that may prove useful in his/her daily practice when dealing with HPV-infected women and couples. Conclusion. The evidence of psychosexual consequences of HPV-related GWs and intraepithelial lesions is limited. Specific research on the sexual impact of GWs and intraepithelial HPV-related lesion in women is urgently needed. © 2009 International Society for Sexual Medicine. Graziottin A Graziottin Alessandra H. San Raffaele Resnati Center of Gynecology and Medical Sexology, Via Enrico AU: PU: CNOTE: Panzacchi 6, 20123 Milano, Italy [email protected] Serafini A Serafini Audrey IRCCS San Raffaele Department of Obstetrics and Gynecology, Milan, Italy Blackwell Publishing Ltd 9600 Garsington Road, Oxford, OX4 2XG, United Kingdom Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/26 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009080569 Marini A; Hengge UR Titel: Wichtige virale und bakterielle infektionen der haut und schleimhäute Important viral and bacterial infections of the skin and mucous membrane Source: Internist; VOL: 50 (2); p. 160-170 /February 2009/ DOI: 10.1007/s00108-008-2209-6 PU: Springer Verlag SU: EMBASE Sprache: German AL: English; German CY: Germany ISSN: 0020-9554 CO: INTEA Institution: Hengge UR, Dr. Prof., Klinik für Dermatologie, Heinrich-Heine-Universität, Moorenstrae 5, 40225 Düsseldorf, Germany, [email protected] COU: Germany DT: Review; Journal Article JSC: C.1 ... Internal Medicine RN: 0015 Keywords CT: BACTERIAL SKIN DISEASE/*drug therapy; BACTERIAL SKIN DISEASE/*etiology; SKIN INFECTION/*drug therapy; SKIN INFECTION/*etiology; VIRAL SKIN DISEASE/*drug therapy; VIRAL SKIN DISEASE/*etiology; ANUS CANCER; CONDYLOMA ACUMINATUM/drug therapy; CRYOTHERAPY; CURETTAGE; DISEASE SEVERITY; ECTHYMA; ERYSIPELAS; FASCIA; GENITAL HERPES; HERPES ZOSTER; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/etiology; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOCOMPROMISED PATIENT; IMPETIGO; KAPOSI SARCOMA/etiology; KERATOLYSIS/drug therapy; KERATOLYSIS/therapy; UT: ET: TE: CR: AB: AU: LOW LEVEL LASER THERAPY; LYMPHADENITIS; LYMPHANGITIS; MUSCLE NECROSIS; MYCOSIS; PENIS CANCER; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN NECROSIS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PYOGENES; SURGICAL TECHNIQUE; UTERINE CERVIX CANCER; VERRUCA VULGARIS/etiology; WART VIRUS; 5 (2 BROMOVINYL) 2' DEOXYURIDINE/drug therapy; ACICLOVIR/drug therapy; AZITHROMYCIN/drug therapy; CEFALEXIN/drug therapy; CEFAZOLIN/drug therapy; CLINDAMYCIN/drug therapy; DICLOXACILLIN/drug therapy; ERYTHROMYCIN/drug therapy; FAMCICLOVIR/drug therapy; FLUCLOXACILLIN/drug therapy; GANCICLOVIR/drug therapy; GENTAMICIN/drug therapy; IMIQUIMOD/drug therapy; NEOMYCIN/drug therapy; OXACILLIN/drug therapy; PENICILLIN G/drug therapy; PODOPHYLLIN/drug therapy; SALICYLIC ACID/drug therapy; VALACICLOVIR/drug therapy Bacterial infections; Herpes simplex virus; Human papillomavirus; Variella zoster virus; Viral infections Microbiology: Bacteriology, Mycology, Parasitology and Virology; Internal Medicine; Dermatology and Venereology; Drug Literature Index 5 (2 bromovinyl) 2' deoxyuridine/69304-47-8; 5 (2 bromovinyl) 2' deoxyuridine/82768-44-3; aciclovir/59277-89-3; azithromycin/83905-01-5; cefalexin/15686-71-2; cefalexin/23325-78-2; cefazolin/25953-19-9; cefazolin/27164-46-1; clindamycin/18323-44-9; dicloxacillin/13412-64-1; dicloxacillin/3116-76-5; dicloxacillin/343-55-5; erythromycin/114-07-8; erythromycin/70536-18-4; famciclovir/104227-87-4; flucloxacillin/1847-24-1; flucloxacillin/5250-39-5; ganciclovir/82410-32-0; gentamicin/1392-48-9; gentamicin/1403-66-3; gentamicin/1405-41-0; imiquimod/99011-02-6; neomycin/11004-65-2; neomycin/1404-04-2; neomycin/1405-10-3; neomycin/8026-22-0; oxacillin/1173-88-2; oxacillin/66-79-5; oxacillin/7240-38-2; penicillin G/1406-05-9; penicillin G/61-33-6; podophyllin/9000-55-9; salicylic acid/63-36-5; salicylic acid/69-72-7; valaciclovir/124832-26-4 69304-47-8; 82768-44-3; 59277-89-3; 83905-01-5; 15686-71-2; 23325-78-2; 25953-19-9; 27164-46-1; 18323-44-9; 13412-64-1; 3116-76-5; 343-55-5; 114-078; 70536-18-4; 104227-87-4; 1847-24-1; 5250-39-5; 82410-32-0; 1392-48-9; 1403-66-3; 1405-41-0; 99011-02-6; 11004-65-2; 1404-04-2; 1405-10-3; 8026-220; 1173-88-2; 66-79-5; 7240-38-2; 1406-05-9; 61-33-6; 9000-55-9; 63-36-5; 6972-7; 124832-26-4 Skin infections are more frequent in immunodeficient patients, seniors and infants than in healthy individuals with an intact immune system. The severity of infections ranges from localized, self-limiting cutaneous infections to widespread necrosis of the skin, muscle, and fascia. The most frequent infections of the skin and mucous membranes are caused by bacterial and viral infectious agents. Fungal infection are also important especially in immunocompromised patients. In particular, viruses play an important and increasing role in the development of several tumors including HPV-associated cervical, anal and penile cancer or HHV-8-induced Kaposi sarcoma. 2008 Springer Medizin Verlag. Marini A Marini A Klinik für Dermatologie, Heinrich-Heine-Universität, Düsseldorf, Germany AU: PU: CNOTE: Hengge UR Hengge UR Klinik für Dermatologie, Heinrich-Heine-Universität, Düsseldorf, Germany; Klinik für Dermatologie, Heinrich-Heine-Universität, Moorenstrae 5, 40225 Düsseldorf, Germany [email protected] Springer Verlag Tiergartenstrasse 17, Heidelberg, D-69121, Germany Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/27 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009054032 Krishna S Titel: Comparison of podophyllotoxin and imiquimod as anal condyloma accuminata therapy Source: Dermatology Online Journal; VOL: 15 (1) /January 2009/ http://dermatology-s10.cdlib.org/1501/letters/podophyllotoxin/krishna.html ANR: 14 PU: Dermatology Online Journal SU: EMBASE Sprache: English AL: English CY: United States EISSN: 1087-2108 Institution: Krishna S, Faculty of Medicine, Imperial College London, United Kingdom, [email protected] COU: United Kingdom DT: Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0012 Keywords CT: CONDYLOMA ACUMINATUM/*drug therapy; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; NECROSIS; PODOPHYLLUM; TREATMENT CONTRAINDICATION; UNSPECIFIED SIDE EFFECT/side effect; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug comparison; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug administration; PODOPHYLLOTOXIN/*adverse drug reaction; PODOPHYLLOTOXIN/*drug comparison; PODOPHYLLOTOXIN/*drug therapy; PODOPHYLLOTOXIN/*pharmacology; PODOPHYLLOTOXIN/*topical drug administration ET: Dermatology and Venereology; Drug Literature Index; Adverse Reactions Titles TE: imiquimod/99011-02-6; podophyllotoxin/518-28-5 CR: AB: AU: PU: CNOTE: 99011-02-6; 518-28-5 Herein we revisit the published evidence for comparison of the efficacy of imiquimod and podophyllotoxin for anal condyloma accuminata 2009 Dermatology Online Journal. Krishna S Krishna Sreedhar Faculty of Medicine, Imperial College London, United Kingdom [email protected] Dermatology Online Journal United States Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/28 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009040569 Gervaz P; Buchs N; Morel P Titel: Diagnosis and management of anal cancer Source: Current Gastroenterology Reports; VOL: 10 (5); p. 502-506 /2008/ DOI: 10.1007/s11894-008-0092-x PU: Current Science Ltd SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 1522-8037 CO: CGRUA Institution: Gervaz P, Dr., Clinique de Chirurgie Viscérale, Hôpital Cantonal Universitaire de Genève, Rue Micheli-du-Crest 24, 1211 Genève, Switzerland, [email protected] COU: Switzerland DT: Review; Journal Article JSC: C.1.8 ... Gastroenterology RN: 0045 Keywords CT: ANUS CANCER/*diagnosis; ANUS CANCER/*drug therapy; ANUS CANCER/*prevention; ANUS CANCER/*radiotherapy; ANUS CANCER/*surgery; BLOOD TOXICITY/side effect; CANCER SCREENING; CLINICAL TRIAL; DRUG TOLERABILITY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/diagnosis; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/drug therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/prevention; IMMUNOCOMPETENCE; INTENSITY MODULATED RADIATION THERAPY; MONOTHERAPY; PATIENT CARE PLANNING; PRECANCER; REVIEW; SQUAMOUS CELL DN: MN: ET: TE: CR: AB: AU: AU: AU: PU: CARCINOMA/diagnosis; SQUAMOUS CELL CARCINOMA/drug therapy; SQUAMOUS CELL CARCINOMA/prevention; SQUAMOUS CELL CARCINOMA/radiotherapy; SQUAMOUS CELL CARCINOMA/surgery; SURVIVAL RATE; TREATMENT OUTCOME; ANTIRETROVIRUS AGENT/drug therapy; CISPLATIN/clinical trial; CISPLATIN/drug combination; CISPLATIN/drug therapy; FLUOROURACIL/drug combination; FLUOROURACIL/drug therapy; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; MITOMYCIN C/adverse drug reaction; MITOMYCIN C/clinical trial; MITOMYCIN C/drug combination; MITOMYCIN C/drug therapy; PROTEIN E7/clinical trial; PROTEIN E7/drug therapy; PROTEIN E7/subcutaneous drug administration; SGN 00101/clinical trial; SGN 00101/drug therapy; SGN 00101/subcutaneous drug administration; UNCLASSIFIED DRUG; WART VIRUS VACCINE/drug therapy Gardasil/Merck and Co, United States; Sgn 00101 Merck and Co, United States Cancer; Public Health, Social Medicine and Epidemiology; Drug Literature Index; Adverse Reactions Titles; Gastroenterology cisplatin/15663-27-1; cisplatin/26035-31-4; cisplatin/96081-74-2; fluorouracil/5121-8; imiquimod/99011-02-6; mitomycin C/50-07-7; mitomycin C/74349-48-7 15663-27-1; 26035-31-4; 96081-74-2; 51-21-8; 99011-02-6; 50-07-7; 74349-48-7 During the past three decades, anal cancer has served as a paradigm for the successful application of chemoradiation to solid tumors. Since the early 1990s, the increasing incidence of anal cancer in homosexual men has highlighted the causative role of oncogenic human papillomavirus infection. This review focuses on significant trends and developments in the management of patients with squamous cell carcinoma of the anal canal, emphasizing three major aspects of diagnosis and treatment: routine screening and eradication of premalignant lesions in high-risk individuals; outcome of chemoradiation therapy in HIV-positive individuals in the era of highly active antiretroviral therapy; and potential improvements in chemoradiation protocols through improved radiation delivery technique and the combination of mitomycin with cisplatin in current prospective randomized trials. Springer Science+Business Media, LLC 2008. Gervaz P Gervaz Pascal Clinique de Chirurgie Viscérale, Hôpital Cantonal Universitaire de Genève, Rue Micheli-du-Crest 24, 1211 Genève, Switzerland [email protected] Buchs N Buchs Nicolas Clinique de Chirurgie Viscérale, Hôpital Cantonal Universitaire de Genève, Rue Micheli-du-Crest 24, 1211 Genève, Switzerland Morel P Morel Philippe Clinique de Chirurgie Viscérale, Hôpital Cantonal Universitaire de Genève, Rue Micheli-du-Crest 24, 1211 Genève, Switzerland Current Science Ltd 34-42 Cleveland Street, London, W1P 6LB, United Kingdom CNOTE: Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/29 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2009013203 Dianzani C; Pierangeli A; Avola A; Borzomati D; Persichetti P; Degener AM Titel: Intra-anal condyloma: Surgical or topical treatment? Source: Dermatology Online Journal; VOL: 14 (12) /December 2008/ http://dermatologys10.cdlib.org/1412/case_presentations/intraanal_condyloma/dianzani.html ANR: 8 PU: Dermatology Online Journal SU: EMBASE Sprache: English AL: English CY: United States EISSN: 1087-2108 Institution: Dianzani C, Department of Dermatology, Campus Biomedico, University of Rome, Italy, [email protected] COU: Italy DT: Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0010 Keywords CT: CONDYLOMA/*diagnosis; CONDYLOMA/*drug therapy; CONDYLOMA/*surgery; ADULT; ANUS; ARTICLE; CASE REPORT; COLONOSCOPY; HETEROSEXUAL MALE; HUMAN; HYPERKERATOSIS; LOW LEVEL LASER THERAPY; LYMPHOCYTE COUNT; MALE; SKIN BIOPSY; ANTIINFLAMMATORY AGENT/drug therapy ET: Dermatology and Venereology; Drug Literature Index AB: Human Papillomavirus infections are the strongest risk factors for genital cancer and are the causative agents of anogenital warts. Although the viral types associated with condylomata usually do not cause carcinoma, in women with a history of these lesions there is an increased risk of intraepithelial neoplasia and cancer. Generally the lesions are not life-threatening, but they provoke significant morbidity, are difficult to treat, and are a source of psychosocial stress. Thus, condylomata represent not only a health problem for the patient but also an economic burden for the society. Considering the individual episodes of care, men experience a longer duration of the lesions and incur greater costs than women. We report a case of a male patient with external and intra-anal condyloma resistant to laser therapy. Initially, surgical intervention appeared required because of florid and intra-anal growth. HPV DNA testing and sequencing revealed the presence of HPV 6. After initial discomfort, the lesions were successfully cleared with topical imiquimod 5 percent cream therapy. © 2008 Dermatology Online Journal. AU: AU: AU: AU: AU: AU: PU: CNOTE: Dianzani C Dianzani Caterina Department of Dermatology, Campus Biomedico, University of Rome, Italy [email protected] Pierangeli A Pierangeli Alessandra Department of Experimental Medicine, Section of Virology, Sapienza University, Rome, Italy Avola A Avola Alessandra Department of Dermatology, Campus Biomedico, University of Rome, Italy Borzomati D Borzomati Domenico General Surgery Campus Biomedico, University of Rome, Italy Persichetti P Persichetti Paolo Plastic Surgery, Campus Biomedico, University of Rome, Italy Degener AM Degener Anna Marta Department of Experimental Medicine, Section of Virology, Sapienza University, Rome, Italy Dermatology Online Journal United States Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/30 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2008589814 Bussen S; Herold A; Schmittner M; Krammer H; Bussen D Titel: Koloproktologische erkrankungen in der schwangerschaft und dem wochenbett Coloproctologic disorders during pregnancy and in the postpartum period Source: DOI: PU: SU: Sprache: AL: CY: ISSN: CO: Geburtshilfe und Frauenheilkunde; VOL: 68 (11); p. 1069-1073 /November 2008/ 10.1055/s-2008-1039050 Georg Thieme Verlag EMBASE German English; German Germany 0016-5751 GEFRA Institution: Bussen S, Dr., Rathausstr. 25, 68519 Viernheim, [email protected] DT: Review; Journal Article JSC: C.4 ... Obstetrics & Gynecology RN: 0034 Keywords CT: COLORECTAL DISEASE/*; PREGNANCY/*; PUERPERIUM/*; ANUS FISSURE; ANUS FISTULA; COLORECTAL CANCER; CONDYLOMA ACUMINATUM; ENTERITIS; HEMORRHOID; HUMAN; MEDICAL CARE; PERIANAL ABSCESS; REVIEW; THROMBOSIS; AZATHIOPRINE; BOTULINUM TOXIN; BUPIVACAINE; CYCLOSPORIN; DICLOFENAC; FLUOROURACIL; GLYCERYL TRINITRATE; HYDROCORTISONE; IBUPROFEN; IMIQUIMOD; LIDOCAINE; MEPIVACAINE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; PARACETAMOL; PODOPHYLLIN; PREDNISOLONE; PROCAINE; SALAZOSULFAPYRIDINE; TACROLIMUS UT: Anal fissure; Anal fistula; Colorectal cancer; Condylomata acuminata; Haemorrhoids; Inflammatory bowel disease; Postpartum period; Pregnancy ET: Obstetrics and Gynecology; Radiology; Drug Literature Index; Gastroenterology TE: azathioprine/446-86-6; bupivacaine/18010-40-7; bupivacaine/2180-92-9; bupivacaine/55750-21-5; cyclosporin/79217-60-0; diclofenac/15307-79-6; diclofenac/15307-86-5; fluorouracil/51-21-8; glyceryl trinitrate/55-63-0; hydrocortisone/50-23-7; ibuprofen/15687-27-1; imiquimod/99011-02-6; lidocaine/137-58-6; lidocaine/24847-67-4; lidocaine/56934-02-2; lidocaine/73-789; mepivacaine/1722-62-9; mepivacaine/96-88-8; mercaptopurine/31441-78-8; mercaptopurine/50-44-2; mercaptopurine/6112-76-1; mesalazine/89-57-6; methotrexate/15475-56-6; methotrexate/59-05-2; methotrexate/7413-34-5; methylprednisolone/6923-42-8; methylprednisolone/83-43-2; metronidazole/39322-38-8; metronidazole/443-48-1; paracetamol/103-90-2; podophyllin/9000-55-9; prednisolone/50-24-8; procaine/51-05-8; procaine/59-461; salazosulfapyridine/599-79-1; tacrolimus/104987-11-3 CR: 446-86-6; 18010-40-7; 2180-92-9; 55750-21-5; 79217-60-0; 15307-79-6; 1530786-5; 51-21-8; 55-63-0; 50-23-7; 15687-27-1; 99011-02-6; 137-58-6; 24847-67-4; 56934-02-2; 73-78-9; 1722-62-9; 96-88-8; 31441-78-8; 50-44-2; 6112-76-1; 8957-6; 15475-56-6; 59-05-2; 7413-34-5; 6923-42-8; 83-43-2; 39322-38-8; 443-481; 103-90-2; 9000-55-9; 50-24-8; 51-05-8; 59-46-1; 599-79-1; 104987-11-3 AB: During pregnancy the anatomy and physiology of the pelvic floor and the perianal region is modified, due to endocrine, metabolic and immunologic changes. This can lead to a change in the observed incidence of coloproctologic disorders or an alteration of pre-existing coloproctologic diseases. In patients requiring specific treatment prior to or during pregnancy the possibility of adverse effects on the antenatal or postnatal development of the child has to be considered carefully. It is necessary to evaluate whether the therapeutic strategy needs to be modified or even discontinued. The aim of this review is to present the current state of knowledge on the medical care and treatment of coloproctologic disorders during pregnancy. Diagnostic approaches and therapeutic options for haemorrhoids, anal fissures, perianal thrombosis, perianal abscesses and fistulas, anogenitals warts, colorectal malignomas and inflammatory bowel diseases are presented. AU: AU: AU: AU: AU: PU: CNOTE: Therapeutic options are discussed with regard to their applicability during pregnancy and in the postpartum period. © Georg Thieme Verlag KG Stuttgart. Krammer H Krammer H Magen-Darm-Praxis Mannheim Bussen S Bussen Stefanie Konsiliarärztin der Universitäts-Frauenklinik Mannheim; Rathausstr. 25, 68519 Viernheim [email protected] Herold A Herold A End- und Dickdarmzentrum Mannheim Schmittner M Schmittner M Klinik für Anästhesiologie und Operative Intensivmedizin, Universität Mannheim Bussen D Bussen D End- und Dickdarmzentrum Mannheim Georg Thieme Verlag Rudigerstrasse 14, Stuttgart, D-70469, Germany Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/31 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2008532390 De Parades V Titel: Pathologie anale: Des progrès indéniables Anal pathology: Undeniable progress made Source: Revue du Praticien; VOL: 58 (16); p. 1751-1753 /20081031/ PU: Huveaux France SU: EMBASE Sprache: French CY: France ISSN: 0035-2640 CO: REPRA Institution: De Parades V, Service de Proctologie Médico-interventionnelle, Groupe Hospitalier Diaconesses Croix-Saint-Simon, Site Reuilly, 75012 Paris, France, [email protected] COU: France DT: Short Survey; Journal Article JSC: C.0 ... Clinical Medicine Keywords CT: ANUS DISEASE/*epidemiology; ANUS DISEASE/*etiology; ANORECTAL DISEASE; ANUS; COLON CROHN DISEASE/drug therapy; CONDYLOMA/drug therapy; CULTURAL PERIOD; HEMORRHOID/etiology; HOMOSEXUALITY; HUMAN; PREVALENCE; RECTOSCOPY; RELIGION; SEXUAL BEHAVIOR; SHORT SURVEY; IMIQUIMOD/drug therapy; NITRIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY/drug therapy ET: General Pathology and Pathological Anatomy; Drug Literature Index; Gastroenterology TE: imiquimod/99011-02-6 CR: 99011-02-6 AU: De Parades V De Parades Vincent Service de Proctologie Médico-interventionnelle, Groupe Hospitalier Diaconesses Croix-Saint-Simon, Site Reuilly, 75012 Paris, France; Service d'Hépatogastroentérologie, Hôpital Européen Georges-Pompidou, 75015 Paris, France [email protected] PU: Huveaux France 114 Avenue Charles de Gaulle, Neuilly sur Seine, 92200, France CNOTE: Copyright 2009 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/32 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2008513151 Kreuter A; Brockmeyer NH; Altmeyer P; Wieland U Titel: Anale intraepitheliale neoplasie bei HIV-infektion Anal intraepithelial neoplasia in HIV infection Source: JDDG - Journal of the German Society of Dermatology; VOL: 6 (11); p. 925-934 /November 2008/ DOI: 10.1111/j.1610-0387.2008.06737.x PU: Blackwell Publishing Ltd SU: EMBASE Sprache: German; English AL: English; German CY: United Kingdom ISSN: 1610-0379 EISSN: 1610-0387 CO: JJDDA Institution: Kreuter A, Dr. Prof., Klinik für Dermatologie und Allergologie, Ruhr-Universität Bochum, Gudrunstraße 56, D-44791 Bochum, [email protected] DT: Review; Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0046 Keywords CT: ANAL INTRAEPITHELIAL NEOPLASIA/*diagnosis; ANAL INTRAEPITHELIAL NEOPLASIA/*drug therapy; ANAL INTRAEPITHELIAL NEOPLASIA/*surgery; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*epidemiology; NEOPLASM/*diagnosis; NEOPLASM/*drug therapy; NEOPLASM/*surgery; CANCER CLASSIFICATION; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CAUTERIZATION; CLINICAL TRIAL; CYTOLOGY; FLU LIKE SYNDROME/side effect; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOCOMPETENCE; INJECTION SITE REACTION/side effect; LASER SURGERY; MALE HOMOSEXUAL; PATHOGENESIS; PHOTODYNAMIC THERAPY; POSTOPERATIVE COMPLICATION/complication; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; ANTIRETROVIRUS AGENT/drug therapy; IMIQUIMOD/adverse drug reaction; IMIQUIMOD/clinical trial; IMIQUIMOD/drug therapy; PODOPHYLLOTOXIN/drug therapy; SGN 00101/adverse drug reaction; SGN 00101/clinical trial; SGN 00101/drug therapy; TRICHLOROACETIC ACID/drug therapy; UNCLASSIFIED DRUG; WART VIRUS VACCINE/drug therapy; ZYC 101/adverse drug reaction; ZYC 101/clinical trial; ZYC 101/drug therapy UT: Anal dysplasia; Anal intraepithelial neoplasia; High-resolution anoscopy; HIV infection; Human papillomavirus DN: Sgn 00101; Zyc 101 ET: Dermatology and Venereology; Cancer; Drug Literature Index; Adverse Reactions Titles; Gastroenterology TE: imiquimod/99011-02-6; podophyllotoxin/518-28-5; trichloroacetic acid/14357-052; trichloroacetic acid/76-03-9 CR: 99011-02-6; 518-28-5; 14357-05-2; 76-03-9 AB: Human papillomavirus (HPV) infections belong to the most common sexually transmitted infections worldwide. While the immune system eliminates most HPV infections over time in immunocompetent individuals, HPV infections tend to persist in immunodeficient individuals. In HIV-infected men who have sex with men (MSM), anal HPV prevalence is more than 90% and infections with multiple HPV types are common. Consequently, HPV-associated anogenital malignancies occur with high frequency in patients with HIV infection. Anal intraepithelial neoplasia (AIN) is a potential precursor lesion of squamous cell carcinoma of the anus. Like its cervical counterpart, cervical intraepithelial neoplasia (CIN), AIN is causally linked to persistent infections with high-risk HPV types such as HPV16 or HPV18. As AIN and CIN share distinct biological similar-ities, AIN screenings analogous to Pap smear programs for CIN have been recommended in high-risk populations to reduce the incidence of anal carcinoma. These screenings include cytological analysis followed by high resolution anoscopy in case of anal dysplasia. Treatment guidelines for AIN are not yet available. Therapeutic strategies can be divided into topical (e.g. trichloroacetic acid, podophyllotoxin, imiquimod, photodynamic therapy) and ablative (e. g. surgical excision, laser ablation, infrared coagulation, electrocautery) measures. However, controlled studies on AIN treatment have not been performed. The impact of HPV AU: AU: AU: AU: PU: CNOTE: vaccination on AIN development will also need to be assessed. Long-term followup of these patients is essential to gain more insight into the natural history of anogenital HPV infection in HIV-positive MSM. © The Authors. Kreuter A Kreuter Alexander Department of Dermatology, Ruhr University Bochum, Germany; Klinik für Dermatologie und Allergologie, Ruhr-Universität Bochum, Gudrunstraße 56, D44791 Bochum [email protected] Brockmeyer NH Brockmeyer Norbert H. Department of Dermatology, Ruhr University Bochum, Germany Altmeyer P Altmeyer Peter Department of Dermatology, Ruhr University Bochum, Germany Wieland U Wieland Ulrike Institute of Virology, University of Cologne, Germany Blackwell Publishing Ltd 9600 Garsington Road, Oxford, OX4 2XG, United Kingdom Copyright 2008 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/33 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2008409082 Senéjoux A Titel: Traitement des condylomes anaux récidivants Treatment of recurrent anal warts Source: Gastroenterologie Clinique et Biologique; VOL: 32 (5 SUPPL. PART 2); p. S231S234 /May 2008/ DOI: 10.1016/j.gcb.2008.04.015 PU: Elsevier Masson SAS SU: EMBASE Sprache: French CY: France ISSN: 0399-8320 CO: GCBID PII: S039983200800225X Institution: Senéjoux A, Coloproctologie, hôpital Léopold-Bellan, 19, rue Vercingétorix, 75014 Paris, France, [email protected] COU: France DT: Journal Article JSC: C.1.8 ... Gastroenterology RN: 0047 Keywords CT: CONDYLOMA ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*surgery; ADULT; ARTICLE; BIOPSY; CASE REPORT; COLPOSCOPY; ELECTROCOAGULATION; EXCISION; FEMALE; GYNECOLOGICAL EXAMINATION; HUMAN; ONCOGENE; PROCTOLOGY; RECURRENT DISEASE; YAG LASER; ALPHA INTERFERON/drug therapy; ALPHA INTERFERON/intralesional drug administration; CIDOFOVIR/drug therapy; CIDOFOVIR/topical drug administration; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; PODOPHYLLIN/drug therapy; PODOPHYLLIN/topical drug administration; TRICHLOROACETIC ACID/drug therapy; TRICHLOROACETIC ACID/topical drug administration ET: Microbiology: Bacteriology, Mycology, Parasitology and Virology; Drug Literature Index; Gastroenterology TE: cidofovir/113852-37-2; imiquimod/99011-02-6; podophyllin/9000-55-9; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 CR: 113852-37-2; 99011-02-6; 9000-55-9; 14357-05-2; 76-03-9 AU: Senéjoux A Senéjoux A Coloproctologie, hôpital Léopold-Bellan, 19, rue Vercingétorix, 75014 Paris, France [email protected] PU: Elsevier Masson SAS 62 rue Camille Desmoulins, Issy les Moulineaux Cedex, 92442, France CNOTE: Copyright 2008 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/34 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2008390004 Kreuter A; Brockmeyer NH; Weissenborn SJ; Gambichler T; Stücker M; Altmeyer P; Pfister H; Wieland U Titel: Penile intraepithelial neoplasia is frequent in HIV-positive men with anal dysplasia Source: Journal of Investigative Dermatology; VOL: 128 (9); p. 2316-2324 /September 2008/ ClinicalTrials.gov-NCT00365729 10.1038/jid.2008.72 Nature Publishing Group EMBASE English English United States NCT: DOI: PU: SU: Sprache: AL: CY: ISSN: 0022-202X EISSN: 1523-1747 CO: JIDEA PII: JID200872 Institution: Wieland U, Dr., Institute of Virology, University of Cologne, Fuerst-PuecklerStrasse 56, Koeln 50935, Germany, [email protected] COU: Germany DT: Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0045 Keywords CT: ANAL INTRAEPITHELIAL NEOPLASIA/*drug therapy; ANAL INTRAEPITHELIAL NEOPLASIA/*epidemiology; ANAL INTRAEPITHELIAL NEOPLASIA/*surgery; ANUS CANCER/*drug therapy; ANUS CANCER/*epidemiology; ANUS CANCER/*surgery; PENILE INTRAEPITHELIAL NEOPLASIA/*epidemiology; PENILE INTRAEPITHELIAL NEOPLASIA/*surgery; PENIS CANCER/*epidemiology; PENIS CANCER/*surgery; ADULT; AGED; ARTICLE; CANCER GRADING; CAUTERIZATION; CIRCUMCISION; CONTROLLED STUDY; CYTOLOGY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PATIENT ATTITUDE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS LOAD; BETA GLOBIN/endogenous compound; CYCLIN DEPENDENT KINASE INHIBITOR 2A/endogenous compound; IMIQUIMOD/drug therapy; TRICHLOROACETIC ACID/drug therapy; VIRUS DNA/endogenous compound ET: Microbiology: Bacteriology, Mycology, Parasitology and Virology; Dermatology and Venereology; Public Health, Social Medicine and Epidemiology; Urology and Nephrology; Drug Literature Index TE: imiquimod/99011-02-6; trichloroacetic acid/14357-05-2; trichloroacetic acid/7603-9 CR: 99011-02-6; 14357-05-2; 76-03-9 AB: Anogenital human papillomavirus (HPV)-infection is common in HIV-infected men who have sex with men (HIV+MSM). These patients have a strongly increased risk of HPV-induced anal cancer and its precursor lesion, anal intraepithelial neoplasia (AIN), and a moderately increased risk for penile cancer. Only limited data exist on penile intraepithelial neoplasia (PIN) in HIV+MSM. We determined the prevalence and evaluated the virologic characteristics of PIN and AIN in 263 HIV+MSM. In case of histologically confirmed PIN (and AIN), HPV-typing, HPV-DNA load determination, and immunohistochemical staining for p16<sup>INK4a</sup> were performed. PIN was detected in 11 (4.2%) and AIN in 156 (59.3%) patients. Ten PIN patients also had AIN within the observation period. Four clinical types of PINs could be distinguished. High-riskalpha -HPV-DNA was found in 10 PIN lesions, with HPV16 being the most frequent type. Infections with multiple HPV-types were common. All high-grade lesions had high-risk-HPV-DNA-loads >=1 HPV-copy/ beta -globin-gene-copy. Cutaneous beta -HPVs were found in PIN and AIN, but beta -HPV-DNA loads AU: AU: AU: AU: AU: AU: AU: AU: PU: CNOTE: were very low, irrespective of the histological grade. p16<sup>INK4a</sup> Expression was detectable in all PIN lesions and correlated both with the histological grade and with high-risk HPV-DNA loads. In view of the PIN prevalence found in our study, all HIV+MSM should be screened for PIN in addition to AIN screening. © 2008 The Society for Investigative Dermatology. Kreuter A Kreuter Alexander Department of Dermatology, Ruhr-University Bochum, Bochum, Germany Brockmeyer NH Brockmeyer Norbert H. Department of Dermatology, Ruhr-University Bochum, Bochum, Germany Weissenborn SJ Weissenborn Soenke J. Institute of Virology, University of Cologne, Koeln, Germany Gambichler T Gambichler Thilo Department of Dermatology, Ruhr-University Bochum, Bochum, Germany Stücker M Stücker Markus Department of Dermatology, Ruhr-University Bochum, Bochum, Germany Altmeyer P Altmeyer Peter Department of Dermatology, Ruhr-University Bochum, Bochum, Germany Pfister H Pfister Herbert Institute of Virology, University of Cologne, Koeln, Germany Wieland U Wieland Ulrike Institute of Virology, University of Cologne, Koeln, Germany; Institute of Virology, University of Cologne, Fuerst-Pueckler-Strasse 56, Koeln 50935, Germany [email protected] Nature Publishing Group Houndmills, Basingstoke, Hampshire, RG21 6XS, United Kingdom Copyright 2008 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/35 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2008355760 Bushby SA; Chauhan M Titel: Management of internal genital warts: Do we all agree? A postal survey Source: International Journal of STD and AIDS; VOL: 19 (6); p. 367-369 /June 2008/ http://ijsa.rsmjournals.com/cgi/reprint/19/6/367 DOI: 10.1258/ijsa.2008.007292 PU: Royal Society of Medicine Press Ltd SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 0956-4624 CO: INSAE Institution: Bushby SA, Dr., Department of Genito-urinary Medicine, Sunderland Royal Hospital, Kayll Road, Sunderland, Tyne and Wear SR4 7TP, United Kingdom, [email protected] COU: United Kingdom DT: Journal Article JSC: C.5 ... Dermatology & Venereology; B.2 ... Public Health; E.5 ... Clinical Microbiology RN: 0008 Keywords CT: CONDYLOMA ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*surgery; ARTICLE; COLPOSCOPY; CRYOTHERAPY; ELECTROSURGERY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; PRIORITY JOURNAL; RECTOSCOPY; RECTUM SURGERY; UNITED KINGDOM; UROLOGIC SURGERY; UTERINE CERVIX CARCINOMA IN SITU; IMIQUIMOD/drug therapy; TRICHLOROACETIC ACID/drug therapy UT: Anal intraepithelial neoplasia; HIV; Papillomavirus ET: Microbiology: Bacteriology, Mycology, Parasitology and Virology; Internal Medicine; Obstetrics and Gynecology; Urology and Nephrology; Drug Literature Index; Gastroenterology TE: imiquimod/99011-02-6; trichloroacetic acid/14357-05-2; trichloroacetic acid/7603-9 CR: 99011-02-6; 14357-05-2; 76-03-9 AB: A postal survey was undertaken to determine whether there was any consensus of opinion regarding the management of internal genital warts in genitourinary medicine clinics in the UK. Overall, 110 forms were returned (57% response). The majority of clinics would refer patients with cervical warts for colposcopy especially if the patient was over the age of 25 or HIV-positive. Proctoscopy or anoscopy was performed in 60% of clinics for patients with perianal warts to determine the presence of warts within the anal canal or rectum. Only 24% of patients with intra-anal warts are referred directly to surgery for biopsy, increasing to 61% if the patient has HIV infection. Cryotherapy is the main treatment for all types of internal warts. Our findings suggest there is no consensus and we recommend that all HIV-positive patients with anal or cervical condyloma should be investigated for evidence of intraepithelial neoplasia. AU: Chauhan M AU: PU: CNOTE: Chauhan M Department of Genito-urinary Medicine, Sunderland Royal Hospital, Kayll Road, Sunderland, Tyne and Wear SR4 7TP, United Kingdom Bushby SA Bushby Stephen A. Department of Genito-urinary Medicine, Sunderland Royal Hospital, Kayll Road, Sunderland, Tyne and Wear SR4 7TP, United Kingdom [email protected] Royal Society of Medicine Press Ltd P.O. Box 9002, London, W1A 0ZA, United Kingdom Copyright 2008 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/36 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2008355739 Nathan M; Hickey N; Mayuranathan L; Vowler SL; Singh N Titel: Treatment of anal human papillomavirus-associated disease: A long term outcome study Source: International Journal of STD and AIDS; VOL: 19 (7); p. 445-449 /July 2008/ http://ijsa.rsmjournals.com/cgi/reprint/19/7/445 DOI: 10.1258/ijsa.2007.007290 PU: Royal Society of Medicine Press Ltd SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 0956-4624 CO: INSAE Institution: Nathan M, Dr., Department of Sexual Health, Homerton University Hospital, London E9 6SR, United Kingdom, [email protected] COU: United Kingdom DT: Journal Article JSC: C.5 ... Dermatology & Venereology; B.2 ... Public Health; E.5 ... Clinical Microbiology RN: 0025 Keywords CT: ANAL INTRAEPITHELIAL NEOPLASIA/*drug therapy; ANAL INTRAEPITHELIAL NEOPLASIA/*surgery; ANUS DISEASE/*drug therapy; ANUS DISEASE/*surgery; CONDYLOMA ACUMINATUM/*; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/drug therapy; HUMAN TISSUE; LASER SURGERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT UT: ET: TE: CR: AB: AU: AU: AU: AU: AU: OUTCOME; WART VIRUS; ANTIRETROVIRUS AGENT/drug therapy; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration Anal cancer screening; Anal intraepithelial neoplasia; Anal warts; Laser treatment Microbiology: Bacteriology, Mycology, Parasitology and Virology; Dermatology and Venereology; Drug Literature Index imiquimod/99011-02-6 99011-02-6 Treatment for human papillomavirus (HPV)-associated anal canal disease has been unsatisfactory. The objective of our study was to determine the treatment outcome in our cohort with anal HPV disease. Overall, 181 patients were evaluated over a median period of 19.1 months (range = 2.8-125.5). Eighty-eight patients (48.6%) with high-grade anal intraepithelial neoplasia (AIN) and 82 patients (45.3%) with low-grade AIN underwent treatment. One hundred and forty-one patients (77.9%) received laser ablative treatment as an outpatient procedure. The treatment yielded cure, defined as a disease-free state at 12 months after treatment, in 63.0% (114/181). Median time to cure for the cohort was 31.5 months (95% confidence interval: 23.0-40.0). Treatment outcome showed no evidence of being affected by age, sexual preference, history of smoking or presence of high-grade disease. Median time to cure was significantly affected by a positive HIV status (P = 0.02) and the extent (volume) of the disease (P = 0.01). Contrary to the current view that treatment of HPV-related anal disease is difficult, unrewarding due to recurrences and may lead to substantial morbidity, we demonstrate that effective treatment is possible for both low- and high-grade AIN. These findings should help with the general desire to introduce screening for AIN for at-risk groups. Nathan M Nathan Mayura Department of Sexual Health, Homerton University Hospital, London E9 6SR, United Kingdom [email protected] Hickey N Hickey N Department of Sexual Health, Homerton University Hospital, London E9 6SR, United Kingdom Mayuranathan L Mayuranathan L Department of Sexual Health, Homerton University Hospital, London E9 6SR, United Kingdom Vowler SL Vowler SL Centre for Applied Medical Statistics, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB2 0SR, United Kingdom Singh N Singh N Department of Pathology, Barts and the London NHS Trust, London E1 1BB, PU: CNOTE: United Kingdom Royal Society of Medicine Press Ltd P.O. Box 9002, London, W1A 0ZA, United Kingdom Copyright 2008 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/37 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2008342149 Kreuter A; Potthoff A; Brockmeyer NH; Gambichler T; Stücker M; Altmeyer P; Swoboda J; Pfister H; Wieland U Titel: Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIVinfected men Source: Journal of Investigative Dermatology; VOL: 128 (8); p. 2078-2083 /August 2008/ DOI: 10.1038/jid.2008.24 PU: Nature Publishing Group SU: EMBASE Sprache: English AL: English CY: United States ISSN: 0022-202X EISSN: 1523-1747 CO: JIDEA PII: JID200824 Institution: Kreuter A, Prof., Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, Bochum 44791, Germany, [email protected] COU: Germany DT: Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0030 Keywords CT: ANAL INTRAEPITHELIAL NEOPLASIA/*diagnosis; ANAL INTRAEPITHELIAL NEOPLASIA/*drug therapy; ANAL INTRAEPITHELIAL NEOPLASIA/*surgery; ANUS TUMOR/*diagnosis; ANUS TUMOR/*drug therapy; ANUS TUMOR/*surgery; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*etiology; WART VIRUS/*; ANOSCOPY; ANUS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC IMAGING; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; SEXUAL BEHAVIOR; TIME; VIRUS TYPING; IMIQUIMOD/*drug therapy; VIRUS DNA/*; ANTIRETROVIRUS AGENT/drug therapy; TRICHLOROACETIC ACID/drug therapy DN: MN: ET: TE: CR: AB: AU: AU: AU: AU: AU: AU: Aldara/3M, Germany 3M, Germany Microbiology: Bacteriology, Mycology, Parasitology and Virology; Drug Literature Index; Gastroenterology imiquimod/99011-02-6; trichloroacetic acid/14357-05-2; trichloroacetic acid/7603-9 99011-02-6; 14357-05-2; 76-03-9 Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated precursor lesion of anal carcinoma, is highly prevalent in HIV-infected men having sex with men (MSM). This prospective follow-up study evaluated the long-term results of imiquimod treatment of AIN in 19 HIV-infected MSM. Standardized follow-up examinations included high-resolution anoscopy, anal cytology/histology, HPV typing, and DNA load determination for HPV types 16, 18, 31, and 33. Mean follow-up time was 30.3 months. A total of 74% (14/19) of the patients remained free of AIN at the previously treated site. Five patients (26%) had recurrent high-grade AIN after a mean time of 24.6 months. At the end of follow-up, the numbers of HPV types as well as high-risk HPV-DNA loads were significantly lower than before therapy. During follow-up, 58% of all patients (11/19) developed new anal cytological abnormalities in previously normal, untreated anal regions. 55% of these new AIN lesions were high-grade lesions and most of them were located intra-anally and associated with high-risk HPV types not detectable before therapy. These results demonstrate that imiquimod leads to a high rate of long-term clearance of AIN in HIV-positive men together with a prolonged decrease of high-risk HPV-DNA load. However, new AIN lesions associated with previously undetected HPV types frequently occur in untreated areas. © 2008 The Society for Investigative Dermatology. Swoboda J Swoboda Jochen Institute of Cytology, Bonn-Bad Godesberg, Germany Kreuter A Kreuter Alexander Department of Dermatology, Ruhr-University Bochum, Bochum, Germany; Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, Bochum 44791, Germany [email protected] Potthoff A Potthoff Anja Department of Dermatology, Ruhr-University Bochum, Bochum, Germany Brockmeyer NH Brockmeyer Norbert H. Department of Dermatology, Ruhr-University Bochum, Bochum, Germany Gambichler T Gambichler Thilo Department of Dermatology, Ruhr-University Bochum, Bochum, Germany Stücker M Stücker Markus AU: AU: AU: PU: CNOTE: Department of Dermatology, Ruhr-University Bochum, Bochum, Germany Altmeyer P Altmeyer Peter Department of Dermatology, Ruhr-University Bochum, Bochum, Germany Pfister H Pfister Herbert Institute of Virology, University of Cologne, Koeln, Germany Wieland U Wieland Ulrike Institute of Virology, University of Cologne, Koeln, Germany Nature Publishing Group Houndmills, Basingstoke, Hampshire, RG21 6XS, United Kingdom Copyright 2008 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/38 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2008238467 Diaz ML Titel: Human Papilloma Virus - Prevention and Treatment Source: Obstetrics and Gynecology Clinics of North America; VOL: 35 (2); p. 199-217 /200806/ DOI: 10.1016/j.ogc.2008.03.002 SU: EMBASE Sprache: English AL: English CY: United States ISSN: 0889-8545 CO: OGCAE PII: S0889854508000193 Institution: Diaz ML, Dr., Section of Ambulatory Gynecology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, United States, [email protected] COU: United States DT: Review; Journal Article JSC: C.4 ... Obstetrics & Gynecology RN: 0081 Keywords CT: CONDYLOMA ACUMINATUM/*disease management; CONDYLOMA ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*epidemiology; CONDYLOMA ACUMINATUM/*etiology; CONDYLOMA ACUMINATUM/*prevention; CONDYLOMA ACUMINATUM/*surgery; WART VIRUS/*; ADENOCARCINOMA/diagnosis; ADENOCARCINOMA/drug therapy; ADENOCARCINOMA/surgery; ADENOCARCINOMA IN SITU/diagnosis; ADENOCARCINOMA IN ET: TE: CR: AB: SITU/drug therapy; ADENOCARCINOMA IN SITU/surgery; ANAL INTRAEPITHELIAL NEOPLASIA; ANUS CARCINOMA/drug therapy; ANUS CARCINOMA/epidemiology; ANUS CARCINOMA/surgery; ANUS DISEASE; BEDTIME DOSAGE; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; HUMAN; INCIDENCE; INFECTION PREVENTION; PAPANICOLAOU TEST; PAPILLOMATOSIS/diagnosis; PAPILLOMATOSIS/drug therapy; PAPILLOMATOSIS/epidemiology; PAPILLOMATOSIS/etiology; PAPILLOMATOSIS/surgery; PRIMARY PREVENTION; PRIORITY JOURNAL; RESPIRATORY RECURRENT PAPILLOMATOSIS/diagnosis; RESPIRATORY RECURRENT PAPILLOMATOSIS/drug therapy; RESPIRATORY RECURRENT PAPILLOMATOSIS/epidemiology; RESPIRATORY RECURRENT PAPILLOMATOSIS/etiology; RESPIRATORY RECURRENT PAPILLOMATOSIS/surgery; REVIEW; SECONDARY PREVENTION; SKIN IRRITATION/side effect; SQUAMOUS CELL CARCINOMA/epidemiology; UTERINE CERVIX CANCER/diagnosis; UTERINE CERVIX CANCER/epidemiology; UTERINE CERVIX CANCER/prevention; UTERINE CERVIX CANCER/radiotherapy; UTERINE CERVIX CANCER/surgery; UTERINE CERVIX CARCINOMA IN SITU/prevention; UTERINE CERVIX CARCINOMA IN SITU/surgery; UTERINE CERVIX CYTOLOGY; VACCINATION; VAGINA CARCINOMA/diagnosis; VAGINA CARCINOMA/epidemiology; VAGINA CARCINOMA/radiotherapy; VAGINA CARCINOMA/surgery; VAGINAL INTRAEPITHELIAL NEOPLASIA/drug therapy; VAGINAL INTRAEPITHELIAL NEOPLASIA/epidemiology; VAGINAL INTRAEPITHELIAL NEOPLASIA/surgery; VIRUS LIKE AGENT; VIRUS STRAIN; VULVA CARCINOMA/diagnosis; VULVA CARCINOMA/epidemiology; VULVA CARCINOMA/surgery; VULVA DISEASE/drug therapy; VULVA DISEASE/surgery; VULVAR INTRAEPITHELIAL NEOPLASIA/drug therapy; VULVAR INTRAEPITHELIAL NEOPLASIA/surgery; ALPHA INTERFERON/drug therapy; ANTINEOPLASTIC AGENT/drug therapy; CIDOFOVIR/drug therapy; DICHLOROACETIC ACID/drug therapy; DICHLOROACETIC ACID/topical drug administration; FLUOROURACIL/drug therapy; FLUOROURACIL/topical drug administration; IMIQUIMOD/adverse drug reaction; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; NONSTEROID ANTIINFLAMMATORY AGENT/oral drug administration; PLACEBO; TRICHLOROACETIC ACID/drug therapy; TRICHLOROACETIC ACID/topical drug administration; WART VIRUS VACCINE/clinical trial; WART VIRUS VACCINE/drug therapy; WART VIRUS VACCINE/pharmacoeconomics Obstetrics and Gynecology; Cancer; Health Policy, Economics and Management; Drug Literature Index; Adverse Reactions Titles; Internal Medicine cidofovir/113852-37-2; dichloroacetic acid/13425-80-4; dichloroacetic acid/215656-1; dichloroacetic acid/79-43-6; fluorouracil/51-21-8; imiquimod/99011-02-6; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 113852-37-2; 13425-80-4; 2156-56-1; 79-43-6; 51-21-8; 99011-02-6; 14357-05-2; 76-03-9 Knowledge regarding the relationship between the human papillomavirus (HPV) AU: CNOTE: and many diseases continues to grow. Clinicians should not only understand how to treat HPV-related diseases but offer strategies to prevent them. This understanding encompasses patient education and counseling regarding modifiable lifestyle factors and patient participation in organized secondary screening programs. Finally, for the first time in history, patients may be offered safe and effective vaccines that promise to have a dramatic impact on these conditions. © 2008 Elsevier Inc. All rights reserved. Diaz ML Diaz Maria Lina Section of Ambulatory Gynecology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, United States [email protected] Copyright 2008 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/39 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2008227984 Palefsky J Titel: Human papillomavirus and anal neoplasia Source: Current HIV/AIDS Reports; VOL: 5 (2); p. 78-85 /200805/ DOI: 10.1007/s11904-008-0013-5 SU: EMBASE Sprache: English AL: English CY: United States ISSN: 1548-3568 EISSN: 1548-3576 Institution: Palefsky J, Dr., University of California, San Francisco, Box 0126, 505 Parnassus Avenue, San Francisco, CA 94143, United States, [email protected] COU: United States DT: Review; Journal Article RN: 0057 Keywords CT: ANUS CANCER/*diagnosis; ANUS CANCER/*drug therapy; ANUS CANCER/*epidemiology; ANUS CANCER/*etiology; ANUS CANCER/*prevention; ANUS CANCER/*surgery; WART VIRUS/*; ANUS SURGERY; BASAL CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUTERIZATION; CHLAMYDIA TRACHOMATIS; DIGITAL RECTAL EXAMINATION; EPITHELIUM CELL; HIGH RISK POPULATION; HUMAN; OVERALL SURVIVAL; RECTUM BIOPSY; REVIEW; TUMOR BIOPSY; UTERINE CERVIX CANCER; IMIQUIMOD/drug therapy; PODOPHYLLOTOXIN/drug therapy; WART VIRUS VACCINE/drug therapy DN: MN: ET: TE: CR: AB: AU: CNOTE: Cervarix/Glaxo SmithKline, United States; Gardasil/Merck and Co, United States Glaxo SmithKline, United States; Merck and Co, United States Cancer; Public Health, Social Medicine and Epidemiology; Immunology, Serology and Transplantation; Drug Literature Index; Gastroenterology imiquimod/99011-02-6; podophyllotoxin/518-28-5 99011-02-6; 518-28-5 Anal cancer is a rare disease in the general population, but the incidence of anal cancer is higher in certain at-risk groups, such as men who have sex with men (MSM), and immunosuppressed individuals, including those with HIV infection. Among HIV-positive MSM, the incidence of anal cancer may be as high as 10 times greater than current rates of cervical cancer in the general population of women. Anal cancer is associated with human papillomavirus (HPV) infection and may be preceded by high-grade anal intraepithelial neoplasia (HGAIN). HGAIN and anal HPV infection are both highly prevalent in groups at risk for anal cancer. Current issues include determining the effect of antiretroviral therapy on the natural history of HGAIN and the incidence of anal cancer, optimizing diagnostic and therapeutic approaches to HGAIN, and determining the potential for prophylactic HPV vaccines to prevent anal HPV infection and anal cancer in at-risk groups. Copyright © 2008 by Current Medicine Group LLC. Palefsky J Palefsky Joel University of California, San Francisco, Box 0126, 505 Parnassus Avenue, San Francisco, CA 94143, United States [email protected] Copyright 2008 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/40 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2008183406 Karelovic D; Krzelj V; Pezelj D Titel: Genitalne infekcije uzrokovane ljudskim papilomavirusima u pedijatriji Pediatrics genital human papilomavirus infection Source: Paediatria Croatica, Supplement; VOL: 49 (1); p. 226-233 /2005/ SU: EMBASE Sprache: Croatian AL: English; Croatian CY: Croatia ISSN: 1330-724X Institution: Karelovic D, Dr., Klinika za Zenske Bolesti I Porode, Klinicka Bolnica Split, Spinciceva 1, 21000 Split, [email protected] DT: Conference Paper; Journal Article RN: 0087 Keywords CT: DN: MN: ET: TE: CR: AB: AU: VERRUCA VULGARIS/*drug therapy; VERRUCA VULGARIS/*epidemiology; VERRUCA VULGARIS/*surgery; VERRUCA VULGARIS/*therapy; WART VIRUS/*; ADOLESCENT; ANTIMICROBIAL THERAPY; ANUS CANCER/complication; CANCER PREVENTION; CAUTERIZATION; CONDYLOMA; CONDYLOMA ACUMINATUM/drug therapy; CONDYLOMA ACUMINATUM/epidemiology; CONDYLOMA ACUMINATUM/surgery; CONDYLOMA ACUMINATUM/therapy; CONFERENCE PAPER; FEMALE GENITAL SYSTEM; HEALTH PROGRAM; HUMAN; IMMUNOMODULATION; INCUBATION TIME; MORPHOLOGY; MOUTH CANCER/complication; OROPHARYNX CANCER/complication; PAPOVAVIRUS; PENIS CANCER/complication; PROSTATE CANCER/complication; PUBLIC HEALTH PROBLEM; RECURRENCE RISK; SEXUALLY TRANSMITTED DISEASE/etiology; TREATMENT INDICATION; UTERINE CERVIX; UTERINE CERVIX CANCER/complication; VULVA CANCER/complication; ALPHA INTERFERON/drug therapy; BCG VACCINE/drug therapy; BETA INTERFERON/drug therapy; CIDOFOVIR/drug therapy; FLUOROURACIL/drug therapy; GAMMA INTERFERON/drug therapy; IMIQUIMOD/drug therapy; PODOPHYLLIN/drug therapy; PODOPHYLLOTOXIN/drug therapy; WART VIRUS VACCINE Aldara; Podofilox Glaxo SmithKline Dermatology and Venereology; Public Health, Social Medicine and Epidemiology; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Internal Medicine; Pediatrics and Pediatric Surgery cidofovir/113852-37-2; fluorouracil/51-21-8; gamma interferon/82115-62-6; imiquimod/99011-02-6; podophyllin/9000-55-9; podophyllotoxin/518-28-5 113852-37-2; 51-21-8; 82115-62-6; 99011-02-6; 9000-55-9; 518-28-5 Human papillomaviruses (HPV) belong to the family Papovariridae and genus Papillomavirus. Today more than 150 HPV types are known and approximately 40 types infect the female genital tract. Genital HPV infection is the most common sexually transmitted disease. HPV infection of the uterine cervix can be found in as many as 65% urban adolescent girls. Warts occur in 10% of children, with a peak between the ages of 12 and 16. HPV infection is increasingly the subject of investigation because it is the major factor for the development of cervical, vulvar, anal and penile cancers but may also be implicated in the prostate cancer and cancers of the oropharynx, oral cavity and gullet. HPV infection is a global public health problem so every state should create prevention programs. The incubation period of condylomata after exposure ranges from three weeks to eight months. Most infections are often asymptomatic and transient. No antiviral drugs are currently licensed for the treatment of HPV infection. Treatment choice depends on the morphology, number, and distribution of genital warts. Treatement of genital warts includes ablative therapy, immune modulations, chemical or physical agents and antimicrobical therapy. From data literature HPV treatments can be classified by mode of action as either patient - applied (home) or physician applied (office) therapies. HPV vaccines are likely to become available in the next few years and may become an important prevention tool. Karelovic D Karelovic Deni AU: AU: CNOTE: Klinika za Zenske Bolesti I Porode; Klinika za Zenske Bolesti I Porode, Klinicka Bolnica Split, Spinciceva 1, 21000 Split [email protected] Krzelj V Krzelj Vjekoslav Klinika za Djecje Bolesti Pezelj D Pezelj Damir Odjel za Kozne I Spolne Bolesti, Klinicka Bolnica Split Copyright 2008 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/41 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2008074944 Gross G; Ikenberg H; Petry KU; Pfister H; Schneede P; Schöfer H; Szeimies R-M Titel: Condylomata acuminata und andere HPV-assoziierte krankheitsbilder von genitale, anus und harnröhre Guideline for Condylomata acuminata and other HPV-associated diseases of the genitals, the anus and the urethra Source: JDDG - Journal of the German Society of Dermatology; VOL: 6 (2); p. 153-162 /200802/ DOI: 10.1111/j.1610-0387.2007.06659.x SU: EMBASE Sprache: German CY: United Kingdom ISSN: 1610-0379 EISSN: 1610-0387 CO: JJDDA Institution: Gross G, Dr. Prof., Klinik und Poliklinik für Dermatologie und Venerologie, Klinikum der Universität Rostock AÖR, Augustenstraße 80-84, D-18055 Rostock, [email protected] DT: Review; Journal Article JSC: C.5 ... Dermatology & Venereology Keywords CT: CONDYLOMA ACUMINATUM/*diagnosis; CONDYLOMA ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*epidemiology; CONDYLOMA ACUMINATUM/*etiology; CONDYLOMA ACUMINATUM/*prevention; WART VIRUS/*; ACETIC ACID TEST; ANAL CANAL; ANAL COMPLAINT; ANAL INTRAEPITHELIAL NEOPLASIA; ANTIVIRAL THERAPY; ANUS CARCINOMA; BOWEN DISEASE; BOWENOID PAPULOSIS; CANCER INVASION; CARCINOMA IN SITU; CHILDHOOD; CHLAMYDIA; CLINICAL EXAMINATION; COLONOSCOPY; COLPOSCOPY; CONDOM; CRYOTHERAPY; CYTOLOGY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ET: TE: CR: AU: AU: AU: AU: AU: AU: AU: CNOTE: COURSE; DISEASE TRANSMISSION; EPITHELIUM TUMOR; ERYTHROPLASIA; ERYTHROPLASIA QUEYRAT; FLUORESCENCE; FLUORIDE TEST; GENITAL HERPES; GENITAL SYSTEM; HIGH RISK PATIENT; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE DEFICIENCY; IMMUNOASSAY; INTRAEPITHELIUM NEOPLASIA; MOLECULAR BIOLOGY; MULTIPLE CANCER; NEWBORN INFECTION; PENILE INTRAEPITHELIAL NEOPLASIA; PENIS TUMOR; PERIANAL INTRAEPITHELIAL NEOPLASIA; PHOTODYNAMIC THERAPY; PREGNANCY; PREVALENCE; PROPHYLAXIS; RECTOSCOPY; REVIEW; SELF CARE; SEROLOGY; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; SURGICAL TECHNIQUE; SYMPTOM; SYPHILIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TRICHOMONAS; TUMOR LOCALIZATION; URETHRA; URETHROSCOPY; UTERINE CERVIX; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VAGINA TUMOR; VAGINAL INTRAEPITHELIAL NEOPLASIA; VULVA CARCINOMA; VULVAR INTRAEPITHELIAL NEOPLASIA; BETA INTERFERON/drug therapy; GREEN TEA EXTRACT; IMIQUIMOD/drug therapy Dermatology and Venereology; Public Health, Social Medicine and Epidemiology; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology; General Pathology and Pathological Anatomy imiquimod/99011-02-6 99011-02-6 Gross G Gross Gerd Klinik und Poliklinik für Dermatologie und Venerologie, Klinikum der Universität Rostock AÖR, Augustenstraße 80-84, D-18055 Rostock [email protected] Ikenberg H Ikenberg Hans Petry KU Petry Karl Ulrich Pfister H Pfister Herbert Schneede P Schneede Peter Schöfer H Schöfer Helmut Szeimies R-M Szeimies Rolf-Markus Copyright 2008 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/42 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2008052215 Ganguly N; Waller S; Stasik CJ; Skikne BS; Ganguly S Titel: Giant anal condylomatosis after allogeneic bone marrow transplantation: A rare complication of human papilloma virus infection Source: Transplant Infectious Disease; VOL: 10 (1); p. 56-58 /200802/ DOI: 10.1111/j.1399-3062.2007.00233.x SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 1398-2273 EISSN: 1399-3062 CO: TIDSF Institution: Ganguly S, Dr., Department of Hematology, University of Kansas Medical Center, MS 4038, 3901 Rainbow Blvd, Kansas City, KS 66160, United States, [email protected] COU: United States DT: Journal Article JSC: D.4 ... Transplantation; E.5 ... Clinical Microbiology RN: 0005 Keywords CT: CONDYLOMA/*complication; CONDYLOMA/*drug therapy; CONDYLOMA/*etiology; CONDYLOMA/*surgery; GIANT ANAL CONDYLOMATOSIS/*complication; GIANT ANAL CONDYLOMATOSIS/*drug therapy; GIANT ANAL CONDYLOMATOSIS/*etiology; GIANT ANAL CONDYLOMATOSIS/*surgery; ADULT; ANAMNESIS; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CLINICAL FEATURE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; RECTUM SURGERY; VIRUS INFECTION; WART VIRUS; IMIQUIMOD/drug therapy ET: Immunology, Serology and Transplantation; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Gastroenterology; General Pathology and Pathological Anatomy TE: imiquimod/99011-02-6 CR: 99011-02-6 AB: Condyloma acuminata or genital warts are caused by human papilloma virus (HPV). Ongoing proliferation of HPV in patients with congenital or acquired immunodeficiency states leads to the development of rapidly progressive and sometimes locally invasive tumor with or without dysplasia. Aggressive treatment, diagnostic immuno-typing, and follow-up are necessary in patients with ongoing immunosuppression. We report a case of giant ano-genital condylomatosis due to HPV types 6 and 11 in a patient with chronic myeloid leukemia after allogeneic bone marrow transplantation. The tumor was successfully treated with surgical excision and local application of 5% imiquimod cream. Copyright © Blackwell AU: AU: AU: AU: AU: CNOTE: Munksgaard 2007. Ganguly N Ganguly N Department of Medicine, University of Kansas Medical Center, Kansas City, KS, United States Waller S Waller S Department of Infectious Diseases, University of Kansas Medical Center, Kansas City, KS, United States Stasik CJ Stasik CJ Department of Pathology, University of Kansas Medical Center, Kansas City, KS, United States Skikne BS Skikne BS Ganguly S Ganguly S Department of Hematology, University of Kansas Medical Center, MS 4038, 3901 Rainbow Blvd, Kansas City, KS 66160, United States; Department of Hematology, University of Kansas Medical Center, Kansas City, KS, United States [email protected] Copyright 2008 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/43 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2008026579 Fleshner PR; Chalasani S; Chang GJ; Levien DH; Hyman NH; Buie WD; Bastawrous A; Sigurdson E; Kumar R; Steele S; Newstead R; Strong S; Phang T; Tjandra J; Shellito P Titel: Practice parameters for anal squamous neoplasms Source: Diseases of the Colon and Rectum; VOL: 51 (1); p. 2-9 /200801/ DOI: 10.1007/s10350-007-9093-3 SU: EMBASE Sprache: English CY: United States ISSN: 0012-3706 EISSN: 1530-0358 CO: DICRA Institution: Hyman NH, Dr., Fletcher Allen Health Care, 111 Colchester Avenue, Fletcher 301, Burlington, VT 05401, United States, [email protected] COU: United States DT: Journal Article JSC: C.1.8 ... Gastroenterology RN: 0082 Keywords CT: ANAL INTRAEPITHELIAL NEOPLASIA/*diagnosis; ANAL INTRAEPITHELIAL NEOPLASIA/*drug therapy; ANAL INTRAEPITHELIAL NEOPLASIA/*surgery; ANAL INTRAEPITHELIAL NEOPLASIA/*therapy; ANUS CANCER/*diagnosis; ANUS CANCER/*drug therapy; ANUS CANCER/*etiology; ANUS CANCER/*radiotherapy; ANUS CANCER/*surgery; ANUS CANCER/*therapy; CARCINOMA IN SITU/*diagnosis; SQUAMOUS CELL CARCINOMA/*diagnosis; SQUAMOUS CELL CARCINOMA/*drug therapy; SQUAMOUS CELL CARCINOMA/*etiology; SQUAMOUS CELL CARCINOMA/*radiotherapy; SQUAMOUS CELL CARCINOMA/*surgery; SQUAMOUS CELL CARCINOMA/*therapy; ANOSCOPY; ARTICLE; BONE MARROW TOXICITY/side effect; CANCER CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; COLONOSCOPY; COLORECTAL CANCER/diagnosis; COLORECTAL CANCER/drug therapy; COLORECTAL CANCER/etiology; COLORECTAL CANCER/radiotherapy; COLORECTAL CANCER/surgery; COLORECTAL CANCER/therapy; COLORECTAL SURGERY; COLOSTOMY; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; ENDOSCOPIC BIOPSY; ENDOSCOPIC ECHOGRAPHY; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE QUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/drug therapy; INGUINAL LYMPH NODE; LYMPH NODE METASTASIS/complication; LYMPH NODE METASTASIS/radiotherapy; MULTIMODALITY CANCER THERAPY; PHOTODYNAMIC THERAPY; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRECANCER; PREOPERATIVE EVALUATION; PROGNOSIS; RADIATION DOSE; RECTUM ABDOMINOPERINEAL RESECTION; SIGMOIDOSCOPY; SURGEON; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT/side effect; WART VIRUS; CISPLATIN/*adverse drug reaction; CISPLATIN/*drug combination; CISPLATIN/*drug therapy; FLUOROURACIL/*adverse drug reaction; FLUOROURACIL/*drug administration; FLUOROURACIL/*drug combination; FLUOROURACIL/*drug therapy; FLUOROURACIL/*topical drug administration; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug administration; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug administration; MITOMYCIN/*adverse drug reaction; MITOMYCIN/*drug combination; MITOMYCIN/*drug therapy; ACETIC ACID; ANTIRETROVIRUS AGENT/drug therapy; LUGOL ET: Cancer; Drug Literature Index; Adverse Reactions Titles; Gastroenterology; Surgery TE: acetic acid/127-08-2; acetic acid/127-09-3; acetic acid/64-19-7; acetic acid/71-501; cisplatin/15663-27-1; cisplatin/26035-31-4; cisplatin/96081-74-2; fluorouracil/51-21-8; imiquimod/99011-02-6; lugol/12298-68-9; mitomycin/140400-8 CR: 127-08-2; 127-09-3; 64-19-7; 71-50-1; 15663-27-1; 26035-31-4; 96081-74-2; 51- AU: AU: AU: AU: AU: AU: AU: AU: AU: AU: AU: AU: AU: AU: AU: CNOTE: 21-8; 99011-02-6; 12298-68-9; 1404-00-8 Fleshner PR Fleshner Phillip R. Steele S Steele Scott Newstead R Newstead Raham Strong S Strong Scott Phang T Phang Terry Tjandra J Tjandra Joe Shellito P Shellito Paul Chalasani S Chalasani Sridhar Chang GJ Chang George J. Levien DH Levien David H. Hyman NH Hyman Neil H. Fletcher Allen Health Care, 111 Colchester Avenue, Fletcher 301, Burlington, VT 05401, United States [email protected] Buie WD Buie W. Donald Bastawrous A Bastawrous Amir Sigurdson E Sigurdson Elin Kumar R Kumar Ravin Copyright 2008 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/44 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2007613487 Viazis N; Vlachogiannakos J; Vasiliadis K; Theodoropoulos I; Saveriadis A; Karamanolis DG Titel: Earlier eradication of intra-anal warts with argon plasma coagulator combined with imiquimod cream compared with argon plasma coagulator alone: A prospective, randomized trial Source: Diseases of the Colon and Rectum; VOL: 50 (12); p. 2173-2179 /200712/ DOI: 10.1007/s10350-007-9041-2 SU: EMBASE Sprache: English AL: English CY: United States ISSN: 0012-3706 EISSN: 1530-0358 CO: DICRA Institution: Viazis N, Dr., 59 Niriidon Street, 17561 P. Faliro, Athens, Greece, [email protected] COU: Greece DT: Journal Article JSC: C.1.8 ... Gastroenterology RN: 0021 Keywords CT: ARGON PLASMA COAGULATION/*; ERADICATION THERAPY/*; VERRUCA VULGARIS/*drug therapy; VERRUCA VULGARIS/*therapy; ADULT; ARTICLE; BURNING SENSATION/side effect; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ERYTHEMA/side effect; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; MALE; PRURITUS/side effect; RECURRENT DISEASE; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*clinical trial; IMIQUIMOD/*drug therapy ET: Dermatology and Venereology; Drug Literature Index; Adverse Reactions Titles; Gastroenterology TE: imiquimod/99011-02-6 CR: 99011-02-6 AB: PURPOSE: Despite the increasing incidence of condylomata acuminate, optimal treatment of anal warts is still undecided. This prospective, randomized study was designed to compare the efficacy of combined argon plasma coagulation and imiquimod cream vs. argon plasma coagulation alone in the management of intraanal warts. METHODS: From October 2002 to March 2005, 49 patients with intra-anal warts were randomly assigned to argon plasma coagulation plus imiquimod cream (n=24) vs. argon plasma coagulation alone (n=25). Therapeutic sessions were repeated until the elimination of the warts. Efficacy of therapy was defined as the time needed for eradication. All patients were followed up for a mean period of 12 months for signs of recurrence. RESULTS: Elimination of warts was achieved earlier in patients receiving combination therapy compared with those receiving monotherapy with argon plasma coagulation (62.5±5.4 days vs. 91.2±6.4 days; P=0.0016). A subgroup analysis performed in HIV-positive patients showed similar results (combination therapy 95±22.6 days; monotherapy AU: AU: AU: AU: AU: AU: CNOTE: 124.3±20.7 days; P=0.033); however, in HIV-positive patients warts were eradicated later compared with HIV-negative patients (110.8±25.7 days vs. 65±25.4 days; P<0.0001). No major complications were observed in our study population. After the follow-up period, recurrence of warts was evident in 22.7 percent of patients in the combination group compared with 34.7 percent of patients in the monotherapy group (P=0.51). Recurrence was significantly higher in HIV-positive patients compared with HIV-negative patients (P=0.0039). CONCLUSIONS: Combination therapy with argon plasma coagulator plus imiquimod cream results in earlier clearance of intra-anal warts in both immunocompetent and immunocompromised patients; however, it does not affect the rate of recurrence. © 2007 American Society of Colon and Rectal Surgeons. Viazis N Viazis Nikos 2nd Department of Gastroenterology, Evangelismos Hospital, Athens, Greece; 59 Niriidon Street, 17561 P. Faliro, Athens, Greece [email protected] Vlachogiannakos J Vlachogiannakos John 2nd Department of Gastroenterology, Evangelismos Hospital, Athens, Greece Vasiliadis K Vasiliadis Konstantinos 2nd Department of Gastroenterology, Evangelismos Hospital, Athens, Greece Theodoropoulos I Theodoropoulos Ioannis 2nd Department of Gastroenterology, Evangelismos Hospital, Athens, Greece Saveriadis A Saveriadis Adamos 2nd Department of Gastroenterology, Evangelismos Hospital, Athens, Greece Karamanolis DG Karamanolis Dimitrios G. 2nd Department of Gastroenterology, Evangelismos Hospital, Athens, Greece Copyright 2008 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/45 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2007579514 Schöfer H Titel: Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies Source: DOI: SU: Sprache: British Journal of Dermatology; VOL: 157 (SUPPL. 2); p. 52-55 /200712/ 10.1111/j.1365-2133.2007.08274.x EMBASE English AL: English CY: United Kingdom ISSN: 0007-0963 EISSN: 1365-2133 CO: BJDEA Institution: Schöfer H, Department of Dermatology and Venerology, University Hospital, J.W. Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt/M, Germany, [email protected] COU: Germany DT: Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0025 Keywords CT: ANUS/*; CONDYLOMA ACUMINATUM/*complication; CONDYLOMA ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*etiology; CONDYLOMA ACUMINATUM/*prevention; GENITAL SYSTEM/*; VERRUCA VULGARIS/*complication; VERRUCA VULGARIS/*drug therapy; VERRUCA VULGARIS/*etiology; VERRUCA VULGARIS/*prevention; ARTICLE; BURNING SENSATION/side effect; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; COST MINIMIZATION ANALYSIS; CREAM; DEPRESSION/side effect; DRUG EFFICACY; DRUG FEVER/side effect; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ERYTHEMA/side effect; FLU LIKE SYNDROME/side effect; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/drug therapy; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; INFLAMMATION/side effect; LONG TERM CARE; MONOTHERAPY; OINTMENT; PAIN/side effect; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS/side effect; SKIN INDURATION/side effect; SKIN MANIFESTATION/side effect; SKIN ULCER/side effect; TAMPON; TOPICAL TREATMENT; TREATMENT DURATION; VIRUS REPLICATION; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*clinical trial; IMIQUIMOD/*drug administration; IMIQUIMOD/*drug comparison; IMIQUIMOD/*drug therapy; IMIQUIMOD/*pharmacology; IMIQUIMOD/*topical drug administration; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT/drug therapy; CYTOKINE/endogenous compound; IMIDAZOQUINOLINE DERIVATIVE/drug therapy; IMIDAZOQUINOLINE DERIVATIVE/pharmacology; IMIDAZOQUINOLINE DERIVATIVE/topical drug administration; INTERFERON/adverse drug reaction; INTERFERON/drug therapy; INTERFERON/topical drug administration; PEGINTERFERON/drug therapy; PODOPHYLLOTOXIN/adverse drug reaction; PODOPHYLLOTOXIN/drug comparison; PODOPHYLLOTOXIN/drug therapy ET: Dermatology and Venereology; Drug Literature Index; Adverse Reactions Titles; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Internal Medicine TE: CR: AB: AU: CNOTE: imiquimod/99011-02-6; podophyllotoxin/518-28-5 99011-02-6; 518-28-5 External genital and anal warts (acuminate condyloma) were the first medical indication the topical immune response modifier imiquimod was approved for in 1997. Since then, many placebo controlled randomized clinical trials have demonstrated the efficacy and safety of this synthetic imidazoquinoline derivate for the treatment of different human papillomavirus infections and tumours. Treatment modalities for genital warts (5% cream, three times weekly, minimum duration 4 weeks, control of side-effects) have been optimized and assured by further clinical trials and meta-analyses. For a few years clinical studies focussed on the long-term efficacy of the immunomodulatory therapy (sustained clearance from warts) and most recent studies compared the efficacy of ablative, destructive and imiquimod monotherapy as well as combination therapies. © 2007 The Author. Schöfer H Schöfer H Department of Dermatology and Venerology, University Hospital, J.W. Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt/M, Germany [email protected] Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/46 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2007497375 Monk BJ; Tewari KS Titel: The spectrum and clinical sequelae of human papillomavirus infection Source: Gynecologic Oncology; VOL: 107 (2 SUPPL.); p. S6-S13 /200711/ DOI: 10.1016/j.ygyno.2007.07.076 SU: EMBASE Sprache: English AL: English CY: United States ISSN: 0090-8258 EISSN: 1095-6859 CO: GYNOA PII: S0090825807005719 Institution: Monk BJ, The Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Chao Family Comprehensive Cancer Center, 101 The City Drive, Orange, CA 92868-3298, United States, [email protected] COU: United States DT: Journal Article JSC: C.4 ... Obstetrics & Gynecology; C.1.3.1 ... Clinical Oncology RN: 0035 Keywords CT: CONDYLOMA/*drug therapy; CONDYLOMA/*therapy; SEXUALLY TRANSMITTED DISEASE/*; UTERINE CERVIX CARCINOMA/*; VIRUS INFECTION/*etiology; WART VIRUS/*; ANUS CANCER; ARTICLE; CARCINOGENESIS; CHILD CARE; ESOPHAGUS CANCER; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; OROPHARYNX TUMOR; PAPILLOMATOSIS/disease management; PENIS CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; SKIN BIOPSY; VAGINA CANCER; VULVA CARCINOMA; WOMEN'S HEALTH; CATECHIN/drug therapy; IMIQUIMOD/drug therapy; PODOPHYLLIN/drug therapy; PODOPHYLLOTOXIN/drug therapy; VEREGEN/drug therapy ET: Obstetrics and Gynecology; Dermatology and Venereology; Cancer; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology TE: catechin/13392-26-2; catechin/154-23-4; imiquimod/99011-02-6; podophyllin/9000-55-9; podophyllotoxin/518-28-5 CR: 13392-26-2; 154-23-4; 99011-02-6; 9000-55-9; 518-28-5 AB: Infection with the human papillomavirus (HPV) is the most common sexually transmitted disease afflicting approximately 80% of the population. HPV infection is an essential factor in cervical carcinogenesis and cervical carcinoma is the second most common cause of cancer among women worldwide. In addition to cervical cancer, other malignancies in both men and women such as esophageal, oropharyngeal, and anal cancer have been causally associated with this virus. Other gender-specific HPV-related cancers include penile, vulvar and vaginal cancer. HPV-16 is the most common HPV type associated with a malignant phenotype regardless of organ of origin. HPV-16 together with HPV-18 accounts for approximately 70% of cervical cancers. Other non-oncogenic HPV types including HPV types 6 and 11 are associated with over 90% of benign HPVrelated lesions such as genital warts and juvenile respiratory papillomatosis. © 2007 Elsevier Inc. All rights reserved. AU: Monk BJ Monk Bradley J. The Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Chao Family Comprehensive Cancer Center, 101 The City Drive, Orange, CA 92868-3298, United States [email protected] AU: Tewari KS Tewari Krishnansu S. The Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Chao Family Comprehensive Cancer Center, 101 The City Drive, Orange, CA 92868-3298, United States CNOTE: Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/47 von 102 ND: DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. EM2007415567 Autoren: Sanclemente G; Herrera S; Tyring SK; Rady PL; Zuleta J-J; Correa L-A; He Q; Wolff J-C Titel: Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia Source: Journal of the European Academy of Dermatology and Venereology; VOL: 21 (8); p. 1054-1060 /200709/ DOI: 10.1111/j.1468-3083.2007.02169.x SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 0926-9959 EISSN: 1468-3083 CO: JEAVE Institution: Sanclemente G, University of Antioquia, Clinica El Rosario, Carrera 20 # 2 Sur185, El Tesoro, Medellin, Colombia, [email protected] COU: Colombia DT: Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0035 Keywords CT: ANUS TUMOR/*diagnosis; CONDYLOMA/*diagnosis; CONDYLOMA/*drug therapy; EPITHELIUM TUMOR/*diagnosis; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*; WART VIRUS/*; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG EFFICACY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALIGNANT TRANSFORMATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION; TUMOR CLASSIFICATION; VIRUS DETECTION; VIRUS LOAD; VIRUS STRAIN; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug administration ET: Dermatology and Venereology; Urology and Nephrology; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Gastroenterology TE: imiquimod/99011-02-6 CR: 99011-02-6 AB: Objective: To evaluate the efficacy of 5% imiquimod in HIV-positive male patients with anogenital warts or anal intraepithelial neoplasia (AIN), and to elucidate whether human papillomavirus (HPV) type and viral load were important for clinical outcome and recurrences. Methods: Thirty-seven patients with histologically proven anogenital warts or AIN were enrolled. Topical 5% imiquimod was applied three times per week for more than 8 h overnight for 16 weeks, although patients were allowed to continue therapy for 4 more weeks if they did not have complete clearance of lesions. Results: Mean age was 34 years. The perianal area was the main lesion location. Thirty-three patients had CD4 AU: AU: AU: AU: AU: AU: AU: AU: counts of < 500 cells/mm 3. Eighteen patients had a histopathological diagnosis of AIN-1. Main HPV types detected corresponded to low-risk HPV types. At 20 weeks of therapy, 46% patients achieved total clearance whereas 14 patients had > 50% clearance. Recurrence was observed in 5 of 17 patients who cleared. Clearance was not influenced by patients' CD4 counts, wart location, HIV viral load or HPV viral load. Conclusions: The assumption that visible perianal warts are benign lesions in HIV-positive patients has to be reevaluated since an important number of such lesions could correspond to low-grade anal disease, which in turn could progress to high-grade anal disease or cancer. In addition, our results in this preliminary study indicate that imiquimod appears to be effective in treating AIN in HIV-positive patients. Further studies are needed to document its utility to prevent high-grade dysplasia and/or anal cancer. © 2007 The Authors Journal compilation © 2007 European Academy of Dermatology and Venereology. Sanclemente G Sanclemente G Dermatology Section, Department of Internal Medicine, University of Antioquia, Medellín, Colombia; Grid -Dermatology Section, Department of Internal Medicine University of Antioquia, Medellín, Colombia; University of Antioquia, Clinica El Rosario, Carrera 20 # 2 Sur-185, El Tesoro, Medellin, Colombia [email protected] Herrera S Herrera S Dermatology Section, Department of Internal Medicine, University of Antioquia, Medellín, Colombia Tyring SK Tyring SK Department of Dermatology, University of Texas Health Science Center, Houston, TX, United States Rady PL Rady PL Department of Dermatology, University of Texas Health Science Center, Houston, TX, United States Zuleta J-J Zuleta J-J Escuela de Investigacion Medica Aplicada-School of Medicine, University of Antioquia, Medellín, Colombia Correa L-A Correa L-A Dermatology Section, Department of Internal Medicine, University of Antioquia, Medellín, Colombia He Q He Q Department of Dermatology, University of Texas Health Science Center, Houston, TX, United States Wolff J-C CNOTE: Wolff J-C Dermatology Section, Department of Internal Medicine, University of Antioquia, Medellín, Colombia Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/48 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2007401262 Kreuter A; Wieland U; Gambichler T; Altmeyer P; Pfister H; Tenner-Racz K; Racz P; Potthoff A; Brockmeyer NH Titel: p16<sup>ink4a</sup> expression decreases during imiquimod treatment of anal intraepithelial neoplasia in human immunodeficiency virus-infected men and correlates with the decline of lesional high-risk human papillomavirus DNA load Source: British Journal of Dermatology; VOL: 157 (3); p. 523-530 /200709/ DOI: 10.1111/j.1365-2133.2007.08004.x SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 0007-0963 EISSN: 1365-2133 CO: BJDEA Institution: Kreuter A, Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany, [email protected] COU: Germany DT: Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0030 Keywords CT: ANUS INTRAEPITHELIAL TUMOR/*drug therapy; ANUS TUMOR/*drug therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT/*; VIRUS LOAD/*; ARTICLE; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WART VIRUS; IMIQUIMOD/*drug therapy; PROTEIN P16INK4A/*endogenous compound; VIRUS DNA/*endogenous compound; CYCLIN DEPENDENT KINASE INHIBITOR 1/endogenous compound; KI 67 ANTIGEN/endogenous compound; MINICHROMOSOME MAINTENANCE PROTEIN/endogenous compound ET: Dermatology and Venereology; Cancer; Immunology, Serology and TE: CR: AB: AU: AU: AU: AU: Transplantation; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology imiquimod/99011-02-6; minichromosome maintenance protein/290875-10-4 99011-02-6; 290875-10-4 Background: Human papillomavirus (HPV)-associated anogenital cancers and their precursor lesions occur in excess in human immunodeficiency virus (HIV)infected patients despite the initiation of highly active antiretroviral therapy. In this context, a drastically increased relative risk for anal intraepithelial neoplasia (AIN) exists in HIV-infected men having sex with men (MSM). In a pilot study, imiquimod, a topical immune response modifier, has been reported to be beneficial in the treatment of AIN. Objectives: To investigate the role of several biomarkers as potential adjuncts in the course of imiquimod treatment for AIN, and to determine whether these markers correlate with the course of high-risk HPV DNA load during imiquimod therapy. Methods: Immunohistochemical staining was performed for p16<sup>ink4a</sup>, minichromosome maintenance protein (MCM), Ki67, proliferating cell nuclear antigen (PCNA) and p21<sup>waf1</sup> expression before and after 16 weeks of imiquimod treatment for AIN. High-risk HPV DNA load determinations were performed by real-time polymerase chain reaction with type-specific primers and probes for HPV types 16, 18, 31 and 33. Results: Histopathological and virological analyses were performed in 21 HIV-infected MSM with histologically confirmed AIN. Eighteen (86%) patients had a complete histological clearance of AIN after imiquimod therapy. As previously shown, lesional high-risk HPV DNA load significantly decreased during imiquimod therapy. Moreover, a significant decline of p16<sup>ink4a</sup>, Ki67, MCM and PCNA expression after treatment was observed, while p21<sup>waf1</sup> expression changed nonsignificantly after imiquimod therapy. A significant correlation between the course of high-risk HPV DNA load and p16<sup>ink4a</sup> expression was observed during imiquimod treatment of AIN, whereas the decline of high-risk HPV DNA load did not significantly correlate with MCM, Ki67, PCNA or p21<sup>waf1</sup> expression. Conclusions: The significant decrease in p16<sup>ink4a</sup> expression in correlation with the drop of lesional high-risk HPV load suggests that p16 <sup>ink4a</sup> may be a useful adjunct for the evaluation of treatment response in HPV-associated malignancies and their precursor lesions. © 2007 The Authors. Kreuter A Kreuter A Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany [email protected] Wieland U Wieland U Institute of Virology, University of Cologne, Cologne, Germany Gambichler T Gambichler T Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany Altmeyer P AU: AU: AU: AU: AU: CNOTE: Altmeyer P Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany Pfister H Pfister H Institute of Virology, University of Cologne, Cologne, Germany Tenner-Racz K Tenner-Racz K Bernhard-Nocht Institute for Tropical Diseases, Hamburg, Germany Racz P Racz P Bernhard-Nocht Institute for Tropical Diseases, Hamburg, Germany Potthoff A Potthoff A Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany Brockmeyer NH Brockmeyer NH Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/49 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2007379879 Herat A; Whitfeld M; Hillman R Titel: Anal intraepithelial neoplasia and anal cancer in dermatological practice Source: Australasian Journal of Dermatology; VOL: 48 (3); p. 143-155 /200708/ DOI: 10.1111/j.1440-0960.2007.00369.x SU: EMBASE Sprache: English AL: English CY: Australia ISSN: 0004-8380 EISSN: 1440-0960 CO: AJDEB Institution: Herat A, Dr., Department of Dermatology, Clatterbridge Hospital, Bebington, Wirral CH63 4JY, United Kingdom, [email protected] COU: United Kingdom DT: Review; Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0113 Keywords CT: ANUS CANCER/*diagnosis; ANUS CANCER/*drug therapy; ANUS CANCER/*epidemiology; ANUS CANCER/*surgery; ANUS CANCER/*therapy; BOWEN DISEASE/drug therapy; BOWEN DISEASE/surgery; BOWENOID PAPULOSIS/drug therapy; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA/drug therapy; EROSION/side effect; ERYTHEMA/side effect; FLU LIKE SYNDROME/side effect; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL PRACTICE; MORBIDITY; PATHOGENESIS; REVIEW; VAGINAL INTRAEPITHELIAL NEOPLASIA/drug therapy; VERRUCA VULGARIS/drug therapy; VERRUCA VULGARIS/etiology; VERRUCA VULGARIS/prevention; VULVA TUMOR/drug therapy; AMINOLEVULINIC ACID/drug therapy; AMINOLEVULINIC ACID/oral drug administration; AMINOLEVULINIC ACID/topical drug administration; CIDOFOVIR/drug therapy; CIDOFOVIR/topical drug administration; FLUOROURACIL/drug combination; FLUOROURACIL/drug comparison; FLUOROURACIL/drug therapy; FLUOROURACIL/topical drug administration; IMIQUIMOD/adverse drug reaction; IMIQUIMOD/drug combination; IMIQUIMOD/drug comparison; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; PHOTOSENSITIZING AGENT/drug therapy; PHOTOSENSITIZING AGENT/oral drug administration; PODOPHYLLOTOXIN/drug therapy; PODOPHYLLOTOXIN/topical drug administration; WART VIRUS VACCINE/clinical trial; WART VIRUS VACCINE/drug therapy ET: Dermatology and Venereology; Cancer; Immunology, Serology and Transplantation; Drug Literature Index; Adverse Reactions Titles TE: aminolevulinic acid/106-60-5; cidofovir/113852-37-2; fluorouracil/51-21-8; imiquimod/99011-02-6; podophyllotoxin/518-28-5 CR: 106-60-5; 113852-37-2; 51-21-8; 99011-02-6; 518-28-5 AB: Anal intraepithelial neoplasia is considered to be a precursor lesion of invasive anal cancer. It is now increasingly recognized in high-risk groups, such as men who have sex with men and HIV-infected patients. Human papillomaviruses are considered to be an important aetiological agent in both anal intraepithelial neoplasia and anal cancer. Dermatologists are likely to encounter these conditions among the differential diagnoses to be considered in high-risk patients presenting with perianal and anal lesions. Anal cancer rates are also increasing among the HIV-infected and HIV-non-infected population. The successful treatment of anal intraepithelial neoplasia may reduce the risk of subsequent development of anal cancer. However, current therapies for anal intraepithelial neoplasia may be associated with treatment-related morbidity and are not well validated. It is currently not proven that they reduce the likelihood of the development of anal cancer. Nevertheless, screening for anal intraepithelial neoplasia is being advocated for high-risk groups and may become standard dermatological care for these patients. In view of recent developments in the understanding of this condition, this article reviews the current understanding of anal intraepithelial neoplasia and its treatment from a dermatological perspective. © 2007 The Australasian College of Dermatologists. AU: AU: AU: CNOTE: Herat A Herat Asoka Skin and Cancer Foundation, Darlinghurst, NSW, Australia; Department of Dermatology, Clatterbridge Hospital, Bebington, Wirral CH63 4JY, United Kingdom [email protected] Whitfeld M Whitfeld Margot Skin and Cancer Foundation, Darlinghurst, NSW, Australia Hillman R Hillman Richard Sexually Transmitted Infections Research Centre, Westmead Hospital, Sydney, NSW, Australia Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/50 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2007331548 Fradet-Turcotte A; Archambault J Titel: Recent advances in the search for antiviral agents against human papillomaviruses Source: Antiviral Therapy; VOL: 12 (4); p. 431-451 /2007/ SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 1359-6535 CO: ANTHF Institution: Archambault J, Laboratory of Molecular Virology, Institut de Recherches Cliniques de Montréal, Montreal, Que., Canada, [email protected] COU: Canada DT: Review; Journal Article JSC: A.1 ... Pharmacology & Drug Therapy RN: 0192 Keywords CT: CONDYLOMA/*drug therapy; CONDYLOMA/*etiology; CONDYLOMA/*surgery; VERRUCA VULGARIS/*drug therapy; VERRUCA VULGARIS/*etiology; VERRUCA VULGARIS/*surgery; ANUS CANCER/drug therapy; CANCER SURGERY; CLINICAL TRIAL; DNA REPLICATION; DNA SYNTHESIS; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ELECTROSURGERY; EPISOME; HEAD AND NECK CANCER/drug therapy; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN DN: MN: ET: TE: CR: AB: PAPILLOMAVIRUS TYPE 6; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE/drug therapy; SKIN DEFECT/drug therapy; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER/drug therapy; VIRUS REPLICATION; WART VIRUS; ANTIVIRUS AGENT/*drug development; ANTIVIRUS AGENT/*drug therapy; ANTIVIRUS AGENT/*pharmacology; CYTOTOXIC AGENT/*drug therapy; CYTOTOXIC AGENT/*topical drug administration; VIRUS VACCINE/*drug development; VIRUS VACCINE/*drug therapy; VIRUS VACCINE/*pharmacology; WART VIRUS VACCINE/*drug therapy; WART VIRUS VACCINE/*pharmacology; ARTEMISININ/pharmacology; BENZODIAZEPINE DERIVATIVE/pharmacology; BIPHENYLSULPHONACETIC ACID INHIBITOR/drug analysis; BIPHENYLSULPHONACETIC ACID INHIBITOR/pharmacology; CARRAGEENAN/drug analysis; CARRAGEENAN/pharmacology; CYCLIN DEPENDENT KINASE 2 INHIBITOR/pharmacology; DEPSIPEPTIDE/drug analysis; DEPSIPEPTIDE/pharmacology; GLYCOPROTEIN E1/drug development; GLYCOPROTEIN E1/pharmacology; GLYCOPROTEIN E2/drug development; GLYCOPROTEIN E2/pharmacology; HISTONE DEACETYLASE INHIBITOR/drug analysis; HISTONE DEACETYLASE INHIBITOR/pharmacology; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; INDANDIONE INHIBITOR/drug analysis; INDANDIONE INHIBITOR/drug development; INDANDIONE INHIBITOR/pharmacology; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE/drug analysis; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE/pharmacology; POLYAMIDE/drug therapy; POLYAMIDE/pharmacology; POLYPHENON E/drug therapy; POLYPHENON E/topical drug administration; PROTEIN E6/drug development; PROTEIN E6/pharmacology; PROTEIN E7/drug development; PROTEIN E7/pharmacology; ROSCOVITINE/drug analysis; ROSCOVITINE/pharmacology; VALPROATE MAGNESIUM/clinical trial; VALPROATE MAGNESIUM/drug therapy; VALPROATE MAGNESIUM/pharmacology; VALPROIC ACID/drug analysis; VALPROIC ACID/pharmacology; VORINOSTAT/drug analysis; VORINOSTAT/pharmacology Cervarix/Glaxo SmithKline, United Kingdom; Gardasil/Merck, United States; Polyphenon E Glaxo SmithKline, United Kingdom; Merck, United States Dermatology and Venereology; Cancer; Clinical and Experimental Pharmacology; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology artemisinin/63968-64-9; carrageenan/9000-07-1; carrageenan/9049-05-2; carrageenan/9061-82-9; carrageenan/9064-57-7; imiquimod/99011-02-6; polyamide/63428-83-1; roscovitine/186692-46-6; valproate magnesium/62959-43-7; valproic acid/1069-66-5; valproic acid/99-66-1; vorinostat/149647-78-9 63968-64-9; 9000-07-1; 9049-05-2; 9061-82-9; 9064-57-7; 99011-02-6; 63428-83-1; 186692-46-6; 62959-43-7; 1069-66-5; 99-66-1; 149647-78-9 Infection by human papillomavirus (HPV) is extremely common and associated with the development of benign warts or malignant lesions of the skin and mucosa. Infection by a high-risk (oncogenic) anogenital HPV type, most often through sexual contacts, is the starting point of virtually all cases of cervical cancers and the majority of anal cancers. The same viral types are also increasingly being linked with a subset of head-and-neck and non-melanoma skin cancers. Although prophylactic vaccines are now available to protect against the four types most commonly found in cervical and anal cancers AU: AU: CNOTE: (HPV16 and HPV18) and anogenital warts (HPV6 and HPV11), these neither protect against all genital HPVs nor are of therapeutic utility for already infected patients. Thus, the need for antiviral agents to treat HPV-associated diseases remains great, but none currently exist. This article reviews the recent progress made towards the development of antiviral agents to treat HPV infections, from target identification and validation to the discovery of lead compounds with therapeutic potential. Emphasis has been placed on novel low-molecular-weight compounds that antagonize HPV proteins or, alternatively, inhibit cellular proteins which have been usurped by papillomaviruses and are mediating their pathogenic effects. © 2007 International Medical Press. Fradet-Turcotte A Fradet-Turcotte Amélie Laboratory of Molecular Virology, Institut de Recherches Cliniques de Montréal, Montreal, Que., Canada Archambault J Archambault Jacques Laboratory of Molecular Virology, Institut de Recherches Cliniques de Montréal, Montreal, Que., Canada; Department of Biochemistry, University of Montreal, Montreal, Que., Canada [email protected] Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/51 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2007321114 Palefsky JM Titel: HPV infection in men Source: Disease Markers; VOL: 23 (4); p. 261-272 /2007/ BTI: HUMAN PAPILLOMAVIRUSES AND CERVICAL CANCER SU: EMBASE Sprache: English AL: English CY: Netherlands ISSN: 0278-0240 CO: DMARD Institution: Palefsky JM, Dr., Box 0126, Department of Medicine, University of California, San Francisco, 505 Parnassus Ave, San Francisco, CA 94143, United States, [email protected] COU: United States DT: Review; Journal Article JSC: C.0 ... Clinical Medicine RN: 0078 Keywords CT: VIRUS INFECTION/*drug therapy; VIRUS INFECTION/*etiology; ANUS CANCER/drug therapy; ANUS CANCER/radiotherapy; ANUS DISEASE; ET: TE: CR: AB: AU: CNOTE: CANCER RADIOTHERAPY; CANCER SCREENING; CARCINOGENESIS; CONDYLOMA/drug therapy; DISEASE ASSOCIATION; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE GENITAL SYSTEM; MALE HOMOSEXUAL; MORTALITY; NONHUMAN; PENIS DISEASE/drug therapy; PENIS DISEASE/etiology; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SAMPLING; SEX DIFFERENCE; SEXUAL TRANSMISSION; SEXUALITY; UTERINE CERVIX; UTERINE CERVIX CANCER; WART VIRUS; WOMEN'S HEALTH; ANTIRETROVIRUS AGENT/drug therapy; FLUOROURACIL/drug therapy; IMIQUIMOD/drug therapy; INTERFERON/drug therapy; LIQUID NITROGEN/drug therapy; PODOPHYLLOTOXIN/drug therapy; TRICHLOROACETIC ACID/drug therapy; TRICHLOROACETIC ACID/topical drug administration; WART VIRUS VACCINE/drug therapy Cancer; Urology and Nephrology; Drug Literature Index; General Pathology and Pathological Anatomy fluorouracil/51-21-8; imiquimod/99011-02-6; podophyllotoxin/518-28-5; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 51-21-8; 99011-02-6; 518-28-5; 14357-05-2; 76-03-9 While much is known about the natural history of cervical human papillomavirus (HPV) infection and its consequences, including cervical intraepithelial neoplasia and cervical cancer, relatively little is known about the natural history of anogenital HPV infection and diseases in men. In part this reflects difficulties in penile sampling and visual assessment of penile lesions. Anal HPV infection and disease also remain poorly understood. Although HPV is transmitted sexually and infects the genitals of both sexes, the cervix remains biologically more vulnerable to malignant transformation than does the penis or anus in men. An understanding of male HPV infection is therefore important in terms of reducing transmission of HPV to women and improving women's health. However, it is also important due to the burden of disease in men, who may develop both penile and anal cancer, particularly among HIV-positive men who have sex with men. Improved sampling techniques of the male genitalia and cohort studies in progress should provide important information on the natural history of anogenital HPV infection and disease in men, including risk factors for HPV acquisition and transmission. The impact of HPV vaccination in women on male anogenital HPV infection will also need to be assessed. © 2007 - IOS Press and the authors. All rights reserved. Palefsky JM Palefsky Joel M. Box 0126, Department of Medicine, University of California, San Francisco, 505 Parnassus Ave, San Francisco, CA 94143, United States; Department of Medicine, University of California, San Francisco, CA 94143, United States [email protected] Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/52 von 102 ND: DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. EM2007160777 Autoren: Serarslan G Titel: Imiquimoda bagli siddetli ülserasyon Severe genital ulceration induced by imiquimod: Letter to the editor Source: Turkiye Klinikleri Journal of Medical Sciences; VOL: 27 (1); p. 146-148 /200702/ SU: EMBASE Sprache: Turkish AL: English; Turkish CY: Turkey ISSN: 1300-0292 Institution: Serarslan G, Dr., Dermatoloji AD, Mustafa Kemal Üniversitesi Tip Fakültesi, Hatay, [email protected] DT: Journal Article RN: 0010 Keywords CT: CONDYLOMA/*drug therapy; GENITAL ULCER/*diagnosis; GENITAL ULCER/*side effect; ADULT; ANTIVIRAL ACTIVITY; ANUS; ARTICLE; BURNING SENSATION/side effect; CASE REPORT; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG ACTIVITY; ERYTHEMA/side effect; HUMAN; LOCAL SKIN REACTION/side effect; MALE; PERINEUM; PRURITUS/side effect; WART VIRUS; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug therapy; IMIQUIMOD/*pharmacology; IMIQUIMOD/*topical drug administration; ALPHA INTERFERON/endogenous compound ET: Dermatology and Venereology; Clinical and Experimental Pharmacology; Drug Literature Index; Adverse Reactions Titles; Microbiology: Bacteriology, Mycology, Parasitology and Virology TE: imiquimod/99011-02-6 CR: 99011-02-6 AB: Genital warts are benign, proliferative tumours, caused by human papilloma viruses, occurring in the genital, anal, perineal and/or perianal areas. Imiquimod shows antiviral activity by stimulating the production of interferon- alpha and various other cytokines and it is used for the topical treatment of genital warts. Although local skin reactions including erythema, itching and burning may occur after application of imiquimod, ulceration is not a common adverse reaction. Here, we present a 25-year-old man with severe ulceration occurring after application of imiquimod for genital wart. Copyright © 2007 by Türkiye Klinikleri. AU: Serarslan G Serarslan Gamze Dermatoloji AD, Mustafa Kemal Üniversitesi Tip Fakültesi, Hatay [email protected] CNOTE: Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/53 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2007085779 Bonatti H; Aigner F; De Clercq E; Boesmueller C; Widschwendner A; Larcher C; Margreiter R; Schneeberger S Titel: Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients Source: Transplant International; VOL: 20 (3); p. 238-246 /200703/ DOI: 10.1111/j.1432-2277.2006.00430.x SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 0934-0874 EISSN: 1432-2277 CO: TRINE Institution: Bonatti H, Department of General and Transplant Surgery, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria, [email protected] COU: Austria DT: Journal Article JSC: D.4 ... Transplantation RN: 0046 Keywords CT: SKIN INFECTION/*drug therapy; SKIN INFECTION/*etiology; SKIN INFECTION/*surgery; VERRUCA VULGARIS/*drug therapy; VERRUCA VULGARIS/*etiology; VERRUCA VULGARIS/*side effect; VERRUCA VULGARIS/*surgery; WART VIRUS/*; ADULT; ANUS DISEASE/drug therapy; ANUS DISEASE/etiology; ANUS DISEASE/surgery; ARTICLE; CLINICAL ARTICLE; CONDYLOMA/drug therapy; CONDYLOMA/etiology; CONDYLOMA/surgery; CRYOTHERAPY; CYTOMEGALOVIRUS INFECTION/drug therapy; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION/complication; GRAFT REJECTION/drug therapy; GRAFT REJECTION/prevention; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LASER SURGERY; MALE; PENIS DISEASE/drug therapy; PENIS DISEASE/etiology; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; CIDOFOVIR/*drug therapy; CIDOFOVIR/*intralesional drug administration; CIDOFOVIR/*topical drug administration; ALEMTUZUMAB/drug therapy; ALEMTUZUMAB/intravenous drug administration; AMPHOTERICIN B LIPID COMPLEX; BASILIXIMAB/drug therapy; CALCINEURIN INHIBITOR/adverse drug reaction; CALCINEURIN INHIBITOR/drug therapy; GANCICLOVIR/drug therapy; IMIQUIMOD/drug therapy; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE/drug therapy; RAPAMYCIN/drug therapy; STEROID/drug therapy; TACROLIMUS/adverse drug reaction; TACROLIMUS/drug therapy; THYMOCYTE ANTIBODY/drug therapy; VALGANCICLOVIR/drug therapy DN: Aldara ET: TE: CR: AB: AU: AU: AU: AU: AU: Drug Literature Index; Adverse Reactions Titles; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Surgery alemtuzumab/216503-57-0; cidofovir/113852-37-2; ganciclovir/82410-32-0; imiquimod/99011-02-6; mycophenolic acid 2 morpholinoethyl ester/116680-01-4; mycophenolic acid 2 morpholinoethyl ester/128794-94-5; prednisone/53-03-2; rapamycin/53123-88-9; tacrolimus/104987-11-3; valganciclovir/175865-59-5; valganciclovir/175865-60-8; valganciclovir/175865-61-9; valganciclovir/17586562-0; valganciclovir/175865-64-2; valganciclovir/175865-67-5 216503-57-0; 113852-37-2; 82410-32-0; 99011-02-6; 116680-01-4; 128794-94-5; 53-03-2; 53123-88-9; 104987-11-3; 175865-59-5; 175865-60-8; 175865-61-9; 175865-62-0; 175865-64-2; 175865-67-5 Human papilloma virus (HPV)-associated diseases are increasingly diagnosed in solid organ recipients. Cidofovir (CDV) is a broad-spectrum antiviral agent with activity against all human herpes viruses and HPV. From 2000-2004, a total of 1303 solid organ transplants (SOT) were performed at our center. Six transplant recipients were treated with topical CDV for HPV-associated lesions. One cardiac recipient responded to a single injection of CDV into his recurrent anal condylomata. In a renal recipient with recurrent penile condylomata CDV was injected into the lesions four times (2 week interval) until lesions regressed. One renal recipient developed multiple vaginal and anal intradermal neoplasias, which relapsed after laser ablation. The lesions were repeatedly injected with CDV and completely disappeared. Two renal recipients with widespread verrucae vulgares were treated with CDV gel, which resulted in regression of the lesions. One patient developed donor derived verrucae vulgares on both transplanted hands, which responded to CDV gel. Four of the six patients were switched from calcineurin inhibitors (CNIs) to Sirolimus (SIR). CDV was found effective in the treatment of HPV-associated skin lesions in SOT recipients. It needs to be determined whether switch from CNIs to SIR might have contributed to the beneficial effect of CDV. © 2007 The Authors. Bonatti H Bonatti Hugo Department of General and Transplant Surgery, Innsbruck, Austria; Department of General and Transplant Surgery, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria [email protected] Aigner F Aigner Felix Department of General and Transplant Surgery, Innsbruck, Austria De Clercq E De Clercq Eric Rega Institute for Medical Research, K.U.Leuven, Leuven, Belgium Boesmueller C Boesmueller Claudia Department of General and Transplant Surgery, Innsbruck, Austria Widschwendner A Widschwendner Andreas Department of Gynecology, Medical University, Innsbruck, Austria AU: AU: AU: CNOTE: Larcher C Larcher Clara Department of Microbiology, Hygiene and Social Medicine, Medical University, Innsbruck, Austria Margreiter R Margreiter Raimund Department of General and Transplant Surgery, Innsbruck, Austria Schneeberger S Schneeberger Stefan Department of General and Transplant Surgery, Innsbruck, Austria Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/54 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2007010407 Parés D; Mullerat J; Pera M Titel: Neoplasia intraepitelial anal Anal intraepithelial neoplasia Source: Medicina Clinica; VOL: 127 (19); p. 749-755 /20061118/ DOI: 10.1157/13095527 SU: EMBASE Sprache: Spanish AL: English; Spanish CY: Spain ISSN: 0025-7753 CO: MCLBA Institution: Parés D, Dr., Unidad de Cirugía Colorrectal, Hospital del Mar, Pg. Marítim, 2529, 08003 Barcelona, Spain, [email protected] COU: Spain DT: Review; Journal Article JSC: C.0 ... Clinical Medicine RN: 0058 Keywords CT: ANUS TUMOR/*diagnosis; ANUS TUMOR/*drug therapy; ANUS TUMOR/*surgery; ANAMNESIS; CANCER SCREENING; CANCER SURGERY; CONDYLOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MEDICAL EDUCATION; REVIEW; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TUMOR LOCALIZATION; UTERINE CERVIX CANCER; IMIQUIMOD/drug therapy ET: Cancer; Drug Literature Index; Gastroenterology; General Pathology and Pathological Anatomy; Surgery TE: CR: AB: AU: AU: AU: CNOTE: imiquimod/99011-02-6 99011-02-6 Human papillomavirus (HPV) is responsible for anal condylomata, anal intraepithelial neoplasia (AIN) and anal squamous cell carcinoma. AIN is a premalignant condition that can progress to invasive carcinoma through different grades of severity of the disease called AIN I, AIN II and AIN III. This paper looks at the current definition, diagnostic methods and management of AIN. The incidence of AIN has increased significantly in the last decades. The groups at risk are mainly patients with infection with human immunodeficiency virus, immunossuppressed patients and patients affected by HPV related diseases (e.g., cervical cancer or anal condyloma). Accurate diagnosis of AIN lesions consists of accurate grading and disease extension. Low grade AIN (AIN I) or in extensive lesions, follow-up is advised to determine the possible evolution to anal squamous cell carcinoma. In cases of more severe and localized lesions (AIN II and AIN III), surgical resection should be considered if the predictive postoperative morbidity is low. Screening programs for AIN are not currently in place and there might be much effort to study the management of HPV in these patients. Parés D Parés David Unidad de Cirugía Colorrectal, Hospital del Mar, Barcelona, Spain; Unidad de Cirugía Colorrectal, Hospital del Mar, Pg. Marítim, 25-29, 08003 Barcelona, Spain [email protected] Mullerat J Mullerat José Department of Surgery, Royal Free and University College Medical School, Londres, United Kingdom Pera M Pera Miguel Unidad de Cirugía Colorrectal, Hospital del Mar, Barcelona, Spain Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/55 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2006578475 Kreuter A; Wieland U; Potthoff A; Altmeyer P; Brockmeyer N Titel: HPV-assoziierte tumoren bei HIV-infektion HPV-associated tumours in HIV-infection Source: SU: Sprache: AL: CY: ISSN: Medizinische Welt; VOL: 57 (11); p. 498-502 /200611/ EMBASE German English; German Germany 0025-8512 CO: MEWEA Institution: Kreuter A, Prof. Dr., Klinik für Dermatologie und Allergologie, Ruhr-Universität Bochum, Gudrunstr. 56, 44791 Bochum, Germany, [email protected] COU: Germany DT: Journal Article JSC: C.0 ... Clinical Medicine RN: 0005 Keywords CT: ANUS INTRAEPITHELIAL NEOPLASIA/*diagnosis; ANUS INTRAEPITHELIAL NEOPLASIA/*epidemiology; ANUS INTRAEPITHELIAL NEOPLASIA/*etiology; ANUS TUMOR/*diagnosis; ANUS TUMOR/*epidemiology; ANUS TUMOR/*etiology; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; ARTICLE; CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; PREVALENCE; RISK ASSESSMENT; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; ANTIRETROVIRUS AGENT/drug therapy ET: Public Health, Social Medicine and Epidemiology; Immunology, Serology and Transplantation; Drug Literature Index; Gastroenterology; General Pathology and Pathological Anatomy AB: Human papillomavirus (HPV)-infection belong to the most common sexually transmitted diseases worldwide. HIV-infected men having sex with men (MSM) are strongly associated with a higher prevalence of genital HPV-infecfion, a higher incidence of anal intraepithelial neoplasia (AIN), and consecutively an increased risk for anal cancer. Since the introduction of HMRT, the incidence of several viral-associated neoplasias has significantly fallen in HIV-infected individuals. At the beginning of the era of HAART, a justified hope existed that just as well genitoanal HPV-related neoplasias would decrease based on the success of HAART-induced immune restoration. However, HAART seems to have only little impact on the natural history of AIN as observed in a cohort of HIV-positive MSM before and after the initiation of HAART. As AIN and cancer precursor lesions of the cervix, cervical intraepithelial neoplasia, share distinct clinical similarities, cytologic smear testing for AIN has been recommended to early detect and treat lesions. In on ongoing trial of the German competence network on HIV/Aids in Bochum, clinical, cytological, virological, and histological features of AIN and anol carcinoma are investigated. In this collective, 89% of all patients had anal HPV-infection and 21% had histologically confirmed AIN. To date, controlled clinical trials for the treatment of AIN ore still missing and the literature on this subject is limited. Therefore, a German multicenter trial is currently on the way comparing ablative (electrofulgary and infrared-coagulation) and topical (imiquimod cream and suppositories) strategies in the management of AIN. © 2006 Schattauer GmbH. AU: Kreuter A Kreuter Alexander Dermatologische Klinik, Ruhr-Universität Bochum, Bochum, Germany; Klinik für Dermatologie und Allergologie, Ruhr-Universität Bochum, Gudrunstr. 56, 44791 Bochum, Germany AU: AU: AU: AU: CNOTE: [email protected] Wieland U Wieland U Institut der Virologie des Klinikums, Universität Köln Potthoff A Potthoff A Dermatologische Klinik, Ruhr-Universität Bochum, Bochum, Germany Altmeyer P Altmeyer P Dermatologische Klinik, Ruhr-Universität Bochum, Bochum, Germany Brockmeyer N Brockmeyer N Dermatologische Klinik, Ruhr-Universität Bochum, Bochum, Germany Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/56 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2006574875 Wieland U; Brockmeyer NH; Weissenborn SJ; Hochdorfer B; Stücker M; Swoboda J; Altmeyer P; Pfister H; Kreuter A Titel: Imiquimod treatment of anal intraepithelial neoplasia in HIVpositive men Source: Archives of Dermatology; VOL: 142 (11); p. 1438-1444 /2006/ http://archderm.ama-assn.org/cgi/reprint/142/11/1438 NCT: ClinicalTrials.gov-NCT00365729 DOI: 10.1001/archderm.142.11.1438 SU: EMBASE Sprache: English AL: English CY: United States ISSN: 0003-987X EISSN: 0003-987X CO: ARDEA Institution: Kreuter A, Dr., Department of Dermatology and Allergology, Ruhr University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany, [email protected] COU: Germany DT: Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0037 Keywords CT: ANUS TUMOR/*drug therapy; EPITHELIUM TUMOR/*drug therapy; ADULT; AGED; ARTICLE; BURNING SENSATION/side effect; CLINICAL ARTICLE; ET: TE: CR: AB: AU: AU: AU: CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DRUG DOSAGE FORM; EROSION/side effect; ERYTHEMA/side effect; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION/side effect; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; TREATMENT RESPONSE; VIRUS TYPING; WART VIRUS; IMIQUIMOD/adverse drug reaction; IMIQUIMOD/drug therapy; IMIQUIMOD/pharmaceutics Dermatology and Venereology; Drug Literature Index; Adverse Reactions Titles; Pharmacy; Gastroenterology imiquimod/99011-02-6 99011-02-6 Objective: To evaluate the treatment of anal intraepithelial neoplasia (AIN) with the local immune response modifier imiquimod in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM). Design: Prospective, nonrandomized, open-label pilot study, with a mean follow-up time of 91/2 months. Setting: Dermatology department of a university hospital. Patients: Twenty-eight consecutive HIV-positive MSM with histologically confirmed perianal (n=23) or intraanal (n=5) AIN. Intervention: Overnight treatment with self-applied imiquimod cream (perianal AIN) or suppositories (intraanal AIN) 3 times a week for 16 weeks. Main Outcome Measures: Response to treatment was documented using clinical, cytologic, and histologic criteria. Human papillomavirus (HPV) typing and HPVDNA load determination for the high-risk HPV types 16, 18, 31, and 33 were performed. Results: Seventeen (61%) of all 28 patients included in the study and 17 (77%) of the 22 patients with AIN, who applied imiquimod as instructed, showed clinical and histologic clearance at the end of therapy. Four patients had residual AIN and 1 patient did not improve. Clinical response was accompanied by a sharp decline in HPV DNA loads and by a reduction in the number of HPV types, but long-term HPV clearance was rarely achieved. In the follow-up period, AIN cleared in 3 patients with residual AIN. Fourteen (78%) of 18 imiquimod responders with at least 5 five months of follow-up had a normal cytologic and clinical picture at the end of the follow-up period. Three primary responders developed a recurrence. In 6 noncompliant patients, there was no clinical or morphological improvement and the HPVDNA loads remained high. Conclusions: Imiquimod appears to be a safe and effective treatment option for AIN in HIV-positive MSM. Clinical response is accompanied by a significant decrease in high-risk HPV DNA load. These results should encourage controlled randomized studies of imiquimod treatment of AIN. Trial Registration: clinicaltrials.gov Identifier: NCT00365729 ©2006 American Medical Association. All rights reserved. Wieland U Wieland Ulrike Institute of Virology, University of Cologne, Cologne Brockmeyer NH Brockmeyer Norbert H. Department of Dermatology and Allergology, Ruhr University Bochum, Bochum, Germany Weissenborn SJ AU: AU: AU: AU: AU: AU: CNOTE: Weissenborn Soenke J. Institute of Virology, University of Cologne, Cologne Hochdorfer B Hochdorfer Bettina Department of Dermatology and Allergology, Ruhr University Bochum, Bochum, Germany Stücker M Stücker Markus Department of Dermatology and Allergology, Ruhr University Bochum, Bochum, Germany Swoboda J Swoboda Jochen Institute of Cytology, Godesberg, Germany Altmeyer P Altmeyer Peter Department of Dermatology and Allergology, Ruhr University Bochum, Bochum, Germany Pfister H Pfister Herbert Institute of Virology, University of Cologne, Cologne Kreuter A Kreuter Alexander Department of Dermatology and Allergology, Ruhr University Bochum, Bochum, Germany; Department of Dermatology and Allergology, Ruhr University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany [email protected] Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/57 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2006278290 Lévy A; Lebbe C Titel: Prise en charge des tumeurs de Buschke-Löwenstein Buschke-Löwenstein tumour: diagnosis and treatment Source: DOI: SU: Sprache: AL: CY: ISSN: EISSN: Annales d'Urologie; VOL: 40 (3); p. 175-178 /200606/ 10.1016/j.anuro.2006.02.002 EMBASE French French; English France 0003-4401 1768-3378 CO: AUROA PII: S000344010600026X Institution: Lévy A, Service de dermatologie, hôpital Saint-Louis, 1, avenue ClaudeVellefaux, 75010 Paris, France, [email protected] COU: France DT: Short Survey; Journal Article JSC: D.5 ... Urological Surgery RN: 0018 Keywords CT: BUSCHKE LOWENSTEIN TUMOR/*diagnosis; BUSCHKE LOWENSTEIN TUMOR/*drug therapy; BUSCHKE LOWENSTEIN TUMOR/*radiotherapy; BUSCHKE LOWENSTEIN TUMOR/*surgery; VERRUCOUS CARCINOMA/*diagnosis; VERRUCOUS CARCINOMA/*drug therapy; VERRUCOUS CARCINOMA/*radiotherapy; VERRUCOUS CARCINOMA/*surgery; BASEMENT MEMBRANE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CONDYLOMA ACUMINATUM; CRYOTHERAPY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE DEFICIENCY; MALE; PHYSICAL EXAMINATION; SHORT SURVEY; ALPHA INTERFERON/drug therapy; BLEOMYCIN/drug therapy; CISPLATIN/drug therapy; FLUOROURACIL/drug therapy; IMIQUIMOD/drug therapy; METHOTREXATE/drug therapy; PODOPHYLLIN/drug therapy ET: Radiology; Cancer; Urology and Nephrology; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology TE: bleomycin/11056-06-7; cisplatin/15663-27-1; cisplatin/26035-31-4; cisplatin/96081-74-2; fluorouracil/51-21-8; imiquimod/99011-02-6; methotrexate/15475-56-6; methotrexate/59-05-2; methotrexate/7413-34-5; podophyllin/9000-55-9 CR: 11056-06-7; 15663-27-1; 26035-31-4; 96081-74-2; 51-21-8; 99011-02-6; 1547556-6; 59-05-2; 7413-34-5; 9000-55-9 AB: Buschke-Löwenstein tumour is classified as a verrucous carcinoma. It presents like an exophytic tumour of the genital or peri-anal area, with ulceration and sometimes fistulae and sinuses. It is preferentially seen in men and immunocompromised patients. Histological appearance is not far from condyloma acuminata, but with a tendency to compress and displace deeper tissues, without basement membrane disruption. HPV types 6 or 11 are regularly found in association with this tumour. Other STI have to be searched. Physical examination and precise imagery are useful to chose the right treatment regimen. Radical excision is recommended to avoid malignant transformation, but has to be large because of the high number of recurrences. Other treatment modalities such as chemotherapy or imiquimod could be of interest to avoid mutilating surgical interventions. A regular follow-up is necessary because of frequent recurrences and possible malignant transformation. © 2006 Elsevier SAS. All rights reserved. AU: Lévy A Lévy A Service de dermatologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France AU: CNOTE: [email protected] Lebbe C Lebbe C Service de dermatologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/58 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2006092078 Kreuter A; Brockmeyer NH; Weissenborn SJ; Wafaisade A; Pfister H; Altmeyer P; Wieland U Titel: 5% Imiquimod suppositories decrease the DNA load of intra-anal HPV types 6 and 11 in HIV-infected men after surgical ablation of condylomata acuminata [1] Source: Archives of Dermatology; VOL: 142 (2); p. 243-244 /200602/ http://archderm.ama-assn.org/cgi/reprint/142/2/243 DOI: 10.1001/archderm.142.2.243 SU: EMBASE Sprache: English CY: United States ISSN: 0003-987X EISSN: 0003-987X CO: ARDEA Institution: Kreuter A, Dr., Department of Dermatology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany, [email protected] COU: Germany DT: Letter; Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0008 Keywords CT: CAUTERIZATION/*; CONDYLOMA ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*surgery; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*etiology; SUPPOSITORY/*; VIRUS INFECTION/*drug therapy; VIRUS INFECTION/*etiology; ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOPATHOLOGY; EROSION/side effect; ERYTHEMA/side effect; FLU LIKE SYNDROME/side effect; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPE 6; LETTER; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECTOSCOPY; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*clinical trial; IMIQUIMOD/*drug therapy; IMIQUIMOD/*pharmaceutics; IMIQUIMOD/*pharmacology; ANTIRETROVIRUS AGENT/adverse drug reaction; ANTIRETROVIRUS ET: TE: CR: AU: AU: AU: AU: AU: AU: AU: CNOTE: AGENT/clinical trial; ANTIRETROVIRUS AGENT/drug therapy; ANTIRETROVIRUS AGENT/pharmaceutics; ANTIRETROVIRUS AGENT/pharmacology Dermatology and Venereology; Drug Literature Index; Adverse Reactions Titles; Pharmacy; Microbiology: Bacteriology, Mycology, Parasitology and Virology imiquimod/99011-02-6 99011-02-6 Kreuter A Kreuter Alexander Department of Dermatology, Ruhr-University Bochum, Gudrunstrasse 56, D44791 Bochum, Germany [email protected] Brockmeyer NH Brockmeyer Norbert H. Weissenborn SJ Weissenborn Soenke J. Wafaisade A Wafaisade Arasch Pfister H Pfister Herbert Altmeyer P Altmeyer Peter Wieland U Wieland Ulrike Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/59 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2006044659 Fox PA; Tung M-Y Titel: Human papillomavirus: Burden of illness and treatment cost considerations Source: American Journal of Clinical Dermatology; VOL: 6 (6); p. 365-381 /2005/ http://docstore.ingenta.com/cgibin/ds_deliver/1/u/d/ISIS/25358057.1/adis/derm/2005/00000006/00000006/art00004/A6BF32885 10.2165/00128071-200506060-00004 EMBASE English English New Zealand 1175-0561 1175-0561 AJCDC DOI: SU: Sprache: AL: CY: ISSN: EISSN: CO: Institution: Fox PA, Dr., Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, United COU: United Kingdom DT: Review; Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0136 Keywords CT: VERRUCA VULGARIS/*disease management; VERRUCA VULGARIS/*drug therapy; VERRU INFECTION/*disease management; VIRUS INFECTION/*drug therapy; VIRUS INFECTION/* NEOPLASIA; ANUS; BONE MARROW DEPRESSION/side effect; BOWENOID PAPULOSIS CONDYLOMA/disease management; CONDYLOMA/drug therapy; CONDYLOMA/etiology; C DRUG FATALITY/side effect; EDEMA/side effect; ELECTROSURGERY; ERYTHEMA/side e EXTRAGENITAL WART/etiology; EXTRAGENITAL WART/surgery; EXTRAGENITAL WA HEMATURIA/side effect; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PA effect; LASER SURGERY; LOCAL SKIN REACTION/side effect; LUNG FIBROSIS/side effec PAIN/side effect; POSTOPERATIVE COMPLICATION/complication; PREGNANCY; PRIORI DEPRESSION/side effect; REVIEW; SCAR FORMATION/side effect; SKIN EROSION/side eff CIRCULATION; TOXICITY/side effect; UTERINE CERVIX CARCINOMA IN SITU/drug ther CHLORO 2,4 DINITROBENZENE/adverse drug reaction; 1 CHLORO 2,4 DINITROBENZENE INTERFERON/drug comparison; ALPHA INTERFERON/drug therapy; ALPHA INTERFERON INTERFERON/adverse drug reaction; ALPHA2B INTERFERON/drug therapy; ALPHA2B INTE BLEOMYCIN/intralesional drug administration; BLEOMYCIN/pharmacology; CIDOFOVIR/adv therapy; DIPHENCYPRONE/drug therapy; FLUOROURACIL/adverse drug reaction; FLUOROU FORMALDEHYDE/drug therapy; GLUTARALDEHYDE/drug therapy; IMIQUIMOD/adverse IMIQUIMOD/pharmacoeconomics; IMIQUIMOD/pharmacology; IMIQUIMOD/topical drug combination; PODOPHYLLIN/drug comparison; PODOPHYLLIN/drug therapy; PODOPHYLLI PODOPHYLLOTOXIN/drug comparison; PODOPHYLLOTOXIN/drug therapy; PODOPHYLLO PODOPHYLLOTOXIN/topical drug administration; SALICYLIC ACID/adverse drug reaction; S SALICYLIC ACID/topical drug administration; TRICHLOROACETIC ACID/adverse drug react TRICHLOROACETIC ACID/pharmacoeconomics; WART VIRUS VACCINE/drug developmen ET: Dermatology and Venereology; Health Policy, Economics and Management; Drug Literature Inde TE: 1 chloro 2,4 dinitrobenzene/25567-67-3; 1 chloro 2,4 dinitrobenzene/97-00-7; alpha2b interferon/ diphencyprone/886-38-4; fluorouracil/51-21-8; formaldehyde/50-00-0; glutaraldehyde/111-30-8; podophyllotoxin/518-28-5; salicylic acid/63-36-5; salicylic acid/69-72-7; trichloroacetic acid/143 CR: 25567-67-3; 97-00-7; 99210-65-8; 11056-06-7; 113852-37-2; 51481-61-9; 70059-30-2; 886-38-4 14357-05-2; 76-03-9 AB: The monetary and personal costs to society of human papillomavirus (HPV) infection are enormo treatment from January 1966 to December 2003 using MEDLINE, with particular reference to pub possibility of convenient and, on the whole, pain-free treatment. Podofilox (podophyllotoxin) and cost-effective treatments and, on this basis, they are to be commended as appropriate first-line age possible options include inosine pranobex with cryotherapy or electrosurgery, imiquimod with pa for genital warts would be either some form of surgical removal or imiquimod. The first option m comparative studies do not show any clear difference in efficacy between cryotherapy, trichloroac effectiveness of these therapies is probably similar to that of imiquimod. Cryotherapy and trichlo with certain exceptions, such as cryotherapy for meatal warts. The duration of treatment is signific been present. For recalcitrant anogenital warts third-line treatment options that show promise inclu easily be excised or physically ablated current treatment options include imiquimod and fluoroura added to this list if it becomes commercially available, and that protective and therapeutic HPV va reserved. AU: Fox PA AU: CNOTE: Fox Paul A. Chelsea and Westminster Hospital, London, United Kingdom; Ealing Hospital, Southall, Middles Kingdom [email protected] Tung M-Y Tung Mun-Yee Chelsea and Westminster Hospital, London, United Kingdom Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/60 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2006010974 Fox PA Titel: Human papillomavirus and anal intraepithelial neoplasia Source: Current Opinion in Infectious Diseases; VOL: 19 (1); p. 62-66 /200602/ SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 0951-7375 CO: COIDE Institution: Fox PA, Dr., Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom, [email protected] COU: United Kingdom DT: Review; Journal Article JSC: E.5 ... Clinical Microbiology RN: 0035 Keywords CT: ANUS INTRAEPITHELIAL NEOPLASM/*diagnosis; ANUS INTRAEPITHELIAL NEOPLASM/*drug therapy; ANUS INTRAEPITHELIAL NEOPLASM/*therapy; ANUS TUMOR/*diagnosis; ANUS TUMOR/*drug therapy; ANUS TUMOR/*therapy; VIRUS INFECTION/*; AGE DISTRIBUTION; AGEISM; ANUS CARCINOMA; ANUS INTERCOURSE; CD4 LYMPHOCYTE COUNT; CREAM; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFRARED RADIATION; LOW LEVEL LASER THERAPY; REVIEW; SEX ROLE; SEXUALITY; SMEAR; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA IN SITU/diagnosis; UTERINE CERVIX CYTOLOGY; VIRUS LOAD; WART VIRUS; CD4 ANTIGEN; CIDOFOVIR/drug therapy; CIDOFOVIR/topical drug administration; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; TRICHLOROACETIC ACID/drug therapy ET: TE: CR: AB: AU: CNOTE: Cancer; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Gastroenterology cidofovir/113852-37-2; imiquimod/99011-02-6; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 113852-37-2; 99011-02-6; 14357-05-2; 76-03-9 Purpose of review: A review of recent developments in the understanding of the natural history of anal squamous carcinoma arising from areas of high-grade anal intraepithelial neoplasia. Recent findings: Anal intraepithelial neoplasia is a consequence of chronic human papillomavirus infection in the anal canal and appears to be driven by high viral loads of human papillomavirus. In men who have sex with men with multiple sexual partners prevalent human papillomavirus infection does not decline with age, in contrast to heterosexual patients. Anal intraepithelial neoplasia is equally prevalent in different age groups of men who have sex with men, but in other respects what is known of its natural history resembles that of cervical intraepithelial neoplasia. Low-grade lesions frequently resolve, but high-grade lesions are much more stable. HIV-positives who practise receptive anal intercourse are at highest risk of anal intraepithelial neoplasia. Screening is easy to perform using cytology; the limitations of anal cytology being similar to those of cervical cytology. Patients with any grade of cytological abnormality require further investigation, ideally with high-resolution anoscopy, every 6 months. Successful treatments for individual small to medium-sized highgrade lesions include trichloroacetic acid, infra-red coagulation and laser. In HIVpositive patients the development of new lesions elsewhere is very likely. Topical agents for multifocal disease include imiquimod and cidofovir. Summary: There is a need for large prospective cohort studies in men who have sex with men and HIV-positive patients to further our understanding of this disease and to evaluate treatment strategies. © 2006 Lippincott Williams & Wilkins. Fox PA Fox Paul A. Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital, London, United Kingdom; Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom [email protected] Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/61 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2005403864 Küppers V; Hampl M Titel: Gynäkologisch-onkologische probleme bei HIV-positiven patientinnen Gynecologic-oncologic problems in HIV-seropositive women Source: DOI: SU: Gynakologe; VOL: 38 (8); p. 680-687 /200508/ 10.1007/s00129-005-1722-0 EMBASE Sprache: German AL: English; German CY: Germany ISSN: 0017-5994 CO: GYNKA Institution: Hampl M, Dr., Frauenklinik, Heinrich-Heine-Universität, Moorenstraße 5, 40225 Düsseldorf, Germany, [email protected] COU: Germany DT: Review; Journal Article JSC: C.4 ... Obstetrics & Gynecology RN: 0034 Keywords CT: CANCER SUSCEPTIBILITY/*; GYNECOLOGIC CANCER/*; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*etiology; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*surgery; ANUS CANCER; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CARBON DIOXIDE LASER; COLPOSCOPY; CONDYLOMA/drug therapy; CONDYLOMA/etiology; CONDYLOMA/surgery; EARLY DIAGNOSIS; ELECTROSURGERY; GENITAL HERPES/drug therapy; GENITAL HERPES/etiology; GENITAL HERPES/surgery; HUMAN; INFECTION RATE; LEUKOCYTE COUNT; MEDICAL EXAMINATION; PAPANICOLAOU TEST; PRECANCER/etiology; REVIEW; RISK ASSESSMENT; SCREENING TEST; VIRUS IDENTIFICATION; VULVA CARCINOMA; WART VIRUS; CARBON DIOXIDE; CD4 ANTIGEN; IMIQUIMOD/drug therapy; PODOPHYLLOTOXIN/drug therapy ET: Obstetrics and Gynecology; Cancer; Biophysics, Bioengineering and Medical Instrumentation; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology TE: carbon dioxide/124-38-9; carbon dioxide/58561-67-4; imiquimod/99011-02-6; podophyllotoxin/518-28-5 CR: 124-38-9; 58561-67-4; 99011-02-6; 518-28-5 AB: Among HIV-seropositive women there is a high prevalence of gynecological infectious diseases: genital condidosis, genital herpes and anogenital human papillomavirus (HPV) infection, inducing premalignant and malignant lesions of vulva, vagina and cervix. The gynecological examination should include colposcopy, a Pap smear test, secondary HPV testing and determination of CD4<sup>+</sup> T-lymphocyte counts. Treatment of choice for women with benign external warts is the local application of Condylox<sup>®</sup>, Wartec <sup>®</sup> or Aldara® or CO<inf>2</inf>-lasertreatment. The treatment of cervical intraepithelial neoplasia (CIN) by CO<inf>2</inf>- laservaporisation, Loop Electrosurgical Excision Procedure (LEEP) or cold knife conisation is based on the localization of the lesion. Prior to the treatment of CIN it is mandatory to exclude multicentric intraepithelial neoplasia by colposcopy. HIV infected women are on an increased risk to develop invasive cervical, vulvar and anal cancer. Since these diseases may be more aggressive and less responsive to treatment, the early detection and prevention of these tumors is most important. © Springer Medizin Verlag 2005. AU: AU: CNOTE: Küppers V Küppers V Gynäkologische Schwerpunktpraxis Dysplasie, Düsseldorf, Germany Hampl M Hampl M Frauenklinik, Universität Düsseldorf; Frauenklinik, Heinrich-Heine-Universität, Moorenstraße 5, 40225 Düsseldorf, Germany [email protected] Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/62 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2005360985 Chang LK; Gottesman L; Breen EL; Bleday R Titel: Anal dysplasia: Controversies in management Source: Seminars in Colon and Rectal Surgery; VOL: 15 (4 SPEC. ISS.); p. 233-238 /200512/ DOI: 10.1053/j.scrs.2005.03.005 SU: EMBASE Sprache: English AL: English CY: United States ISSN: 1043-1489 CO: SCRSF PII: S1043148905000151 Institution: Bleday R, Dr., Department of Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, United States, [email protected] COU: United States DT: Review; Journal Article JSC: C.1.8 ... Gastroenterology; D.1 ... General & Abdominal Surgery RN: 0086 Keywords CT: ANAL DYSPLASIA/*drug therapy; ANUS DISEASE/*drug therapy; DYSPLASIA/*drug therapy; ANUS CANCER; CANCER RISK; CANCER SCREENING; CONDYLOMA/drug therapy; HUMAN; INCIDENCE; PAPANICOLAOU TEST; REVIEW; RISK FACTOR; SAFETY; UTERINE CERVIX CARCINOMA IN SITU/drug therapy; UTERINE CERVIX DYSPLASIA; FLUOROURACIL/drug therapy; FLUOROURACIL/topical drug administration; IMIQUIMOD/drug therapy; IMIQUIMOD/pharmacology; IMIQUIMOD/topical drug administration ET: Cancer; Drug Literature Index; Gastroenterology TE: fluorouracil/51-21-8; imiquimod/99011-02-6 CR: 51-21-8; 99011-02-6 AB: AU: AU: AU: AU: CNOTE: There are several controversies in the management of anal dysplasia due to uncertainty of its natural history and of its relationship to anal cancer. Different screening recommendations can be found in the literature; however, not all are of proven benefit and safety. Here we review the recent incidence of anal cancer, present the scope of the problem, and offer a safe and effective screening program to manage anal dysplasia, which may potentially counter the rising incidence of anal cancer. © 2004 Elsevier Inc. All rights reserved. Gottesman L Gottesman L Chang LK Chang LK Breen EL Breen EL Bleday R Bleday R Department of Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, United States [email protected] Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/63 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2005360983 Berry JM; Jay N; Palefsky JM; Welton ML Titel: State-of-the-art of high-resolution anoscopy as a tool to manage patients at risk for anal cancer Source: Seminars in Colon and Rectal Surgery; VOL: 15 (4 SPEC. ISS.); p. 218-226 /200512/ DOI: 10.1053/j.scrs.2005.05.001 SU: EMBASE Sprache: English AL: English CY: United States ISSN: 1043-1489 CO: SCRSF PII: S1043148905000345 Institution: Berry JM, Dr., Dysplasia Clinic, University of California, San Francisco School of Medicine, 1600 Divisadero Street, San Francisco, CA 94143, United States, [email protected] COU: United States DT: Journal Article JSC: C.1.8 ... Gastroenterology; D.1 ... General & Abdominal Surgery RN: 0032 Keywords CT: ANOSCOPY/*; ANUS CANCER/*diagnosis; ANUS CANCER/*therapy; CANCER DIAGNOSIS/*; CANCER RISK/*; DIAGNOSTIC PROCEDURE/*; RISK ASSESSMENT/*; ADULT; ARTICLE; CANCER PATIENT; CANCER SCREENING; CARCINOMA IN SITU/therapy; CASE REPORT; COLPOSCOPY; CONDYLOMA/drug therapy; DIGITAL RECTAL EXAMINATION; DYSPLASIA; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/drug therapy; INCIDENCE; MALE; OPERATING ROOM; PRECANCER; SQUAMOUS CELL CARCINOMA; TRAINING; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; ACICLOVIR/drug therapy; ANTIRETROVIRUS AGENT/drug therapy; IMIQUIMOD/drug therapy; NITROGEN/drug therapy; PODOPHYLLIN/drug therapy; PODOPHYLLOTOXIN/drug therapy DN: Aldara; Condylox ET: Cancer; Drug Literature Index; Gastroenterology; Surgery TE: aciclovir/59277-89-3; imiquimod/99011-02-6; nitrogen/7727-37-9; podophyllin/9000-55-9; podophyllotoxin/518-28-5 CR: 59277-89-3; 99011-02-6; 7727-37-9; 9000-55-9; 518-28-5 AB: Anal cancer is increasing in incidence in urban populations worldwide and particularly in HIV-positive men who have sex with men (MSM). The etiologic relationship of both anal and cervical cancer to human papillomavirus (HPV) is well established. The incidence of cervical cancer has decreased significantly as a result of an effective screening program. Women with abnormal cervical cytology are referred for colposcopy, which is used to identify and eradicate the cervical cancer precursors, cervical high-grade squamous intraepithelial lesions (HSIL). High-resolution anoscopy (HRA) or colposcopy of the anus and perianal area is a powerful tool to find and treat the precursors to anal cancer, anal HSIL. The approach to management and treatment of anal HSIL at the UCSF Anal Dysplasia Clinic using HRA in conjunction with anal cytology and digital rectal examination (DRE) is presented as a means to prevent anal cancer and to facilitate the early diagnosis of anal cancer. Principles of HRA, how to perform HRA, findings during HRA, and the use of HRA in the operating room are described. HRA coupled with DRE is an effective way to manage patients at risk for anal cancer. Several cases are described illustrating the practical application of HRA in managing patients with anal HSIL and diagnosing anal cancer. Increased awareness and, at the very least, performance of regular DRE in patients at risk and training more providers in HRA may help to decrease the incidence of anal cancer in populations at risk. © 2004 Elsevier Inc. All rights reserved. Berry JM AU: Berry J. Michael Department of Medicine, Division of Hematology Oncology, University of California San Francisco, San Francisco, CA, United States; Dysplasia Clinic, University of California, San Francisco School of Medicine, 1600 Divisadero Street, San Francisco, CA 94143, United States [email protected] AU: Jay N Jay Naomi Department of Medicine, Division of Infectious Diseases, University of California AU: AU: CNOTE: San Francisco, San Francisco, CA, United States Palefsky JM Palefsky Joel M. Department of Medicine, Division of Infectious Diseases, University of California San Francisco, San Francisco, CA Welton ML Welton Mark Lane Department of Surgery, Stanford University, Stanford University School of Medicine, Stanford, CA, United States Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/64 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2005345598 De Góis Speck NM; Costa RRL; Kesselring F; De Freitas VG; Ribalta JCL; Kobata MP; Taha NS Titel: Grade 3 vulvar and anal intraepithelial neoplasia in a HIV seropositive child - Therapeutic result: Case report Source: Clinical and Experimental Obstetrics and Gynecology; VOL: 32 (2); p. 138-140 /2005/ SU: EMBASE Sprache: English AL: English CY: Canada ISSN: 0390-6663 CO: CEOGA Institution: De Góis Speck NM, Dr., Rua Gabriele D'Annunzio, 1400, 04619-005 São Paulo, SP, Brazil COU: Brazil DT: Journal Article JSC: C.4 ... Obstetrics & Gynecology RN: 0013 Keywords CT: ANUS TUMOR/*disease management; ANUS TUMOR/*drug therapy; ANUS TUMOR/*therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*disease management; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; VULVA TUMOR/*disease management; VULVA TUMOR/*drug therapy; VULVA TUMOR/*therapy; ANAMNESIS; ARTICLE; CANCER GRADING; CARBON DIOXIDE LASER; CASE REPORT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW LEVEL LASER THERAPY; LYMPHOCYTE COUNT; ONSET AGE; PHYSICAL EXAMINATION; RELAPSE; SCHOOL CHILD; TREATMENT FAILURE; VAPORIZATION; VERTICAL TRANSMISSION; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug administration; ANTIRETROVIRUS ET: TE: CR: AB: AU: AU: AU: AU: AU: AU: AGENT/drug combination; ANTIRETROVIRUS AGENT/drug therapy; INDINAVIR/drug combination; INDINAVIR/drug therapy; PODOPHYLLOTOXIN/drug combination; PODOPHYLLOTOXIN/drug therapy; PODOPHYLLOTOXIN/topical drug administration; ZIDOVUDINE/drug combination; ZIDOVUDINE/drug therapy Obstetrics and Gynecology; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Gastroenterology; General Pathology and Pathological Anatomy imiquimod/99011-02-6; indinavir/150378-17-9; indinavir/157810-81-6; indinavir/180683-37-8; podophyllotoxin/518-28-5; zidovudine/30516-87-1 99011-02-6; 150378-17-9; 157810-81-6; 180683-37-8; 518-28-5; 30516-87-1 A case report of a HIV seropositive 8-year-old child with vulvar and anal border neoplasia, both grade 3, and the adopted therapeutic management are presented. The mother reported the history of a progressively growing verrucous lesion in the vulva since the age of three and a half years. On physical examination a pigmented and elevated lesion was observed in the whole vulvar region extending to the anal region and intergluteal sulcus. After biopsies and anatomic pathological examination, antiretroviral therapy, adequate for age, and topical application of podophyllotoxin associated with Thuya officinalis extract was started. Three months afterwards vaporization and CO<inf>2</inf> laser excision were performed in five sequential sessions, thereafter associated with topical imiquimod application. After the first two sessions of laser therapy early relapses occurred. After four weeks of imiquimod use, already a significant improvement of the lesions was observed, making the following laser therapy sessions easier. We conclude that antiretroviral therapy associated with podophyllotoxin and Thuya was not effective regarding regression of the lesions. Laser therapy alone led to early relapses. The local use of imiquimod associated with laser was effective in decreasing and controling the lesions. De Góis Speck NM De Góis Speck NM Department of Gynecology, UNIFESP, Hospital AC Camargo, São Paulo, Brazil; Rua Gabriele D'Annunzio, 1400, 04619-005 São Paulo, SP, Brazil Costa RRL Costa RRL Department of Gynecology, UNIFESP, Hospital AC Camargo, São Paulo, Brazil Kesselring F Kesselring F Department of Gynecology, UNIFESP, Hospital AC Camargo, São Paulo, Brazil De Freitas VG De Freitas VG Department of Gynecology, UNIFESP, Hospital AC Camargo, São Paulo, Brazil Ribalta JCL Ribalta JCL Department of Gynecology, UNIFESP, Hospital AC Camargo, São Paulo, Brazil Kobata MP Kobata MP AU: CNOTE: Department of Gynecology, UNIFESP, Hospital AC Camargo, São Paulo, Brazil Taha NS Taha NS Department of Gynecology, UNIFESP, Hospital AC Camargo, São Paulo, Brazil Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/65 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2005343655 Kong AP; Stamos MJ Titel: Anorectal complaints: Office diagnosis and treatment, part 2 Source: Consultant; VOL: 45 (7); p. 735-739 /200506/ SU: EMBASE Sprache: English AL: English CY: United States ISSN: 0010-7069 CO: CNSLA Institution: Kong AP, Dr., University of California, Irvine, CA, United States COU: United States DT: Review; Journal Article JSC: C.0 ... Clinical Medicine RN: 0003 Keywords CT: ANORECTAL DISEASE/*diagnosis; ANORECTAL DISEASE/*drug therapy; ANORECTAL DISEASE/*etiology; ANORECTAL DISEASE/*surgery; ABSCESS DRAINAGE; ANUS FISTULA/complication; ANUS FISTULA/surgery; ANUS PRURITUS/diagnosis; ANUS PRURITUS/drug therapy; ANUS PRURITUS/etiology; ANUS PRURITUS/therapy; ANUS TUMOR/diagnosis; ANUS TUMOR/radiotherapy; ANUS TUMOR/surgery; BLEEDING; CANCER RADIOTHERAPY; CAUTERIZATION; CLINICAL FEATURE; COLOSTOMY; CONDYLOMA ACUMINATUM/drug therapy; CONDYLOMA ACUMINATUM/etiology; CONDYLOMA ACUMINATUM/surgery; CONDYLOMA ACUMINATUM/therapy; CONSTIPATION; CRYOTHERAPY; ESTHETIC SURGERY; FECES INCONTINENCE; HUMAN; HYGIENE; LOW LEVEL LASER THERAPY; PERIANAL ABSCESS/etiology; PILONIDAL SINUS; PRIORITY JOURNAL; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM BIOPSY; RECTUM FISTULA/complication; RECTUM FISTULA/surgery; RECTUM MUCOSA; RECTUM PROLAPSE/diagnosis; RECTUM PROLAPSE/etiology; RECTUM PROLAPSE/surgery; REVIEW; SIGMOIDOSCOPY; SKIN BIOPSY; VIRUS INFECTION; WART VIRUS; ANALGESIC AGENT/drug therapy; ANALGESIC AGENT/topical drug administration; ANESTHETIC AGENT/drug therapy; ANESTHETIC AGENT/topical drug administration; BULKING AGENT/drug therapy; FLUOROURACIL/drug therapy; ET: TE: CR: AB: AU: AU: CNOTE: HYDROCORTISONE/drug therapy; HYDROCORTISONE/topical drug administration; IMIQUIMOD/drug therapy; INTERFERON/drug therapy; ISPAGULA/drug therapy; PODOPHYLLIN/drug therapy; STARCH; TRICHLOROACETIC ACID/drug therapy; VACCINE/drug therapy Cancer; Drug Literature Index; Gastroenterology; General Pathology and Pathological Anatomy; Surgery fluorouracil/51-21-8; hydrocortisone/50-23-7; imiquimod/99011-02-6; ispagula/77462-61-4; ispagula/8063-16-9; podophyllin/9000-55-9; starch/900525-8; starch/9005-84-9; trichloroacetic acid/14357-05-2; trichloroacetic acid/7603-9 51-21-8; 50-23-7; 99011-02-6; 77462-61-4; 8063-16-9; 9000-55-9; 9005-25-8; 9005-84-9; 14357-05-2; 76-03-9 Symptoms associated with anorectal abscesses include throbbing or aching pain, swelling, drainage or bleeding, constipation, urinary difficulty, and fever. Treatment is surgical drainage. About 50% of anorectal abscesses fail to heal after drainage and result in fistulae. Characteristic findings in pilonidal disease include a painful, fluctuant mass near the posterior midline at the superior aspect of the buttocks and a sinus opening within the intergluteal fold. Treatment consists of drainage of the abscess followed by light daily packing. Patients with rectal prolapse may present with a protruding mass, a history of constipation and incontinence, bleeding, discharge, or a sensation of incomplete emptying. Pruritus ani can be caused by a number of anorectal disorders; however, in about 50% of cases, it is idiopathic. Anal neoplasms appear as unusual masses that arise from the anal or rectal mucosa; biopsy is often needed for diagnosis. Kong AP Kong Allen P. University of California, Irvine, CA, United States; University of California, Irvine Medical Center, Irvine, CA, United States Stamos MJ Stamos Michael J. University of California, Irvine, CA, United States; Department of Clinical Surgery, University of California, Irvine Medical Center, Irvine, CA, United States Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/66 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2005339380 Panther LA; Schlecht HP; Dezube BJ Titel: Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients Source: SU: Sprache: AL: AIDS Reader; VOL: 15 (2); p. 79-82+85-88+91 /200502/ EMBASE English English CY: United States ISSN: 1053-0894 CO: AIREF Institution: Panther LA, Dr., Department of Medicine, Harvard Medical School, Boston, MA, United States COU: United States DT: Review; Journal Article JSC: C.0 ... Clinical Medicine; E.5.3 ... Virology RN: 0054 Keywords CT: ANUS CARCINOMA/*complication; ANUS CARCINOMA/*diagnosis; ANUS CARCINOMA/*drug therapy; ANUS CARCINOMA/*etiology; ANUS CARCINOMA/*prevention; ANUS CARCINOMA/*radiotherapy; ANUS CARCINOMA/*surgery; ANUS DISEASE/*complication; ANUS DISEASE/*diagnosis; ANUS DISEASE/*drug therapy; ANUS DISEASE/*etiology; ANUS DISEASE/*prevention; ANUS DISEASE/*surgery; ANUS DYSPLASIA/*complication; ANUS DYSPLASIA/*diagnosis; ANUS DYSPLASIA/*drug therapy; ANUS DYSPLASIA/*etiology; ANUS DYSPLASIA/*prevention; ANUS DYSPLASIA/*surgery; DYSPLASIA/*complication; DYSPLASIA/*diagnosis; DYSPLASIA/*drug therapy; DYSPLASIA/*etiology; DYSPLASIA/*prevention; DYSPLASIA/*surgery; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; WART VIRUS/*; BONE MARROW SUPPRESSION/side effect; CANCER INVASION; CLINICAL TRIAL; DIAGNOSTIC TEST; DIARRHEA/side effect; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; IMMUNE DEFICIENCY; INCIDENCE; LYMPHOCYTE COUNT; MALE; NONHUMAN; PAPANICOLAOU TEST; PATHOGENESIS; PRECANCER/diagnosis; REVIEW; SKIN TOXICITY/side effect; SQUAMOUS CELL CARCINOMA/complication; SQUAMOUS CELL CARCINOMA/diagnosis; SQUAMOUS CELL CARCINOMA/drug therapy; SQUAMOUS CELL CARCINOMA/etiology; SQUAMOUS CELL CARCINOMA/prevention; SQUAMOUS CELL CARCINOMA/radiotherapy; SQUAMOUS CELL CARCINOMA/surgery; UTERINE CERVIX CANCER; ANTIRETROVIRUS AGENT/drug therapy; CD4 ANTIGEN/endogenous compound; CIDOFOVIR/drug therapy; CISPLATIN/adverse drug reaction; CISPLATIN/drug combination; CISPLATIN/drug therapy; FLUOROURACIL/adverse drug reaction; FLUOROURACIL/drug combination; FLUOROURACIL/drug therapy; HEAT SHOCK PROTEIN 65/clinical trial; HEAT SHOCK PROTEIN 65/drug combination; HEAT SHOCK PROTEIN 65/drug therapy; HEAT SHOCK PROTEIN 65/subcutaneous drug administration; IMIQUIMOD/drug therapy; INTERFERON/drug therapy; MITOMYCIN/adverse drug reaction; MITOMYCIN/drug combination; MITOMYCIN/drug therapy; PROTEIN E7/clinical trial; PROTEIN E7/drug combination; PROTEIN E7/drug therapy; PROTEIN E7/subcutaneous drug administration; VIRUS VACCINE/clinical trial; VIRUS VACCINE/drug combination; VIRUS VACCINE/drug therapy; VIRUS VACCINE/subcutaneous drug administration; ZIDOVUDINE/adverse drug reaction; ZIDOVUDINE/drug therapy ET: TE: CR: AB: AU: AU: AU: CNOTE: Cancer; Drug Literature Index; Adverse Reactions Titles; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Gastroenterology cidofovir/113852-37-2; cisplatin/15663-27-1; cisplatin/26035-31-4; cisplatin/96081-74-2; fluorouracil/51-21-8; imiquimod/99011-02-6; mitomycin/1404-00-8; zidovudine/30516-87-1 113852-37-2; 15663-27-1; 26035-31-4; 96081-74-2; 51-21-8; 99011-02-6; 140400-8; 30516-87-1 The incidence of human papillomavirus (HPV)-related anal squamous cell carcinoma is increasing. It is likely that long-standing HIV-related immunosuppression plays a significant role in the pathogenesis of anal carcinoma; however, a direct HIV-HPV interaction has also been implicated. Using cervical cancer prevention as a paradigm, anal Pap smear screening as part of routine HIV preventive care has been proposed to detect and treat precancerous anal lesions in the hope of decreasing anal cancer rates. All HIV-positive patients with invasive cancer of the anal canal, particularly those with CD4<sup>+</sup> cell counts greater than 200/ mu L and those receiving HAART, should be managed in the same manner as their HIV-negative counterparts. Panther LA Panther Lori A. Department of Medicine, Harvard Medical School, Boston, MA, United States Schlecht HP Schlecht Hans P. Department of Internal Medicine, Division of Infectious Diseases, Harvard Medical School, Boston, MA, United States Dezube BJ Dezube Bruce J. Department of Internal Medicine, Division of Hematology/oncology, Harvard Medical School, Boston, MA, United States; AIDS Malignancy Research and Treatment Center, Beth Israel Deaconess Medical Center, Boston, MA, United States Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/67 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2005221876 Chin-Hong PV; Palefsky JM Titel: Human papillomavirus anogenital disease in HIV-infected individuals Source: DOI: SU: Sprache: AL: CY: Dermatologic Therapy; VOL: 18 (1); p. 67-76 /200501/ 10.1111/j.1529-8019.2005.05009.x EMBASE English English United States ISSN: 1396-0296 CO: DETHF Institution: Chin-Hong PV, Dr., Box 0654, University of California, San Francisco, 521 Parnassus Ave, San Francisco, CA 94143-0654, United States, [email protected] COU: United States DT: Review; Journal Article RN: 0046 Keywords CT: ANUS DISEASE/*diagnosis; ANUS DISEASE/*drug therapy; ANUS DISEASE/*etiology; ANUS DISEASE/*prevention; ANUS DISEASE/*surgery; GENITAL SYSTEM DISEASE/*diagnosis; GENITAL SYSTEM DISEASE/*drug therapy; GENITAL SYSTEM DISEASE/*etiology; GENITAL SYSTEM DISEASE/*prevention; GENITAL SYSTEM DISEASE/*surgery; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*; ANUS CANCER/epidemiology; CANCER SCREENING; COLPOSCOPY; CONDYLOMA ACUMINATUM/drug therapy; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PAPANICOLAOU TEST; PHYSICAL EXAMINATION; PREVALENCE; REVIEW; SKIN DISEASE; UTERINE CERVIX CANCER/epidemiology; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS; 5 FLUOROTRYPTAMINE/drug therapy; ANTIRETROVIRUS AGENT/drug therapy; CIDOFOVIR/drug therapy; IMIQUIMOD/drug therapy; PODOPHYLLOTOXIN/drug therapy; TRICHLOROACETIC ACID/drug therapy; VIRUS VACCINE/drug therapy DN: Aldara/3M, United States; Condylox/Watsons Pharmaceutical, United States MN: 3M, United States; Watsons Pharmaceutical, United States ET: Obstetrics and Gynecology; Dermatology and Venereology; Urology and Nephrology; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology TE: 5 fluorotryptamine/576-16-9; cidofovir/113852-37-2; imiquimod/99011-02-6; podophyllotoxin/518-28-5; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 CR: 576-16-9; 113852-37-2; 99011-02-6; 518-28-5; 14357-05-2; 76-03-9 AB: Human papillomavirus (HPV) is one of the most common sexually transmitted infections and a significant cause of anogenital malignancies, precancer lesions, and cutaneous disease. Human immunodeficiency virus (HIV)-positive individuals have a higher prevalence of HPV infection and HPV-associated anogenital disease compared to age-matched HIV-negative controls. Data suggest that there has been little reduction in HPV-associated disease since the introduction of highly active antiretroviral therapy (HAART). The authors believe that cervical and anal cancer screening using Pap tests should be offered to all HIV-positive individuals, but the infrastructure to identify (via colposcopy and high-resolution anoscopy) and treat precancer lesions must be present. Treatment of HPV-associated anogenital disease depends on the size, location, and grade of the lesion, whereas a variety of ablative and excisional therapies are available. Prophylactic and therapeutic HPV vaccines are promising as future interventions AU: AU: CNOTE: for disease control in at-risk populations such as HIV-infected women and men. Copyright © Blackwell Publishing, Inc., 2005. Chin-Hong PV Chin-Hong Peter V. Department of Medicine, University of California, San Francisco, CA, United States; Box 0654, University of California, San Francisco, 521 Parnassus Ave, San Francisco, CA 94143-0654, United States [email protected] Palefsky JM Palefsky Joel M. Department of Medicine, University of California, San Francisco, CA, United States Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/68 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2005158522 Weyandt GH; Benoit S; Becker JC; Bröcker E-B; Hamm H Titel: Kontrollierte schichtweise abtragung anogenitaler warzen mittels argon-plasma-koagulation Controlled layered removal of anogenital warts by argon-plasma coagulation Source: JDDG - Journal of the German Society of Dermatology; VOL: 3 (4); p. 271-275 /200504/ DOI: 10.1111/j.1610-0387.2005.04757.x SU: EMBASE Sprache: German AL: English; German CY: United Kingdom ISSN: 1610-0379 CO: JJDDA Institution: Weyandt GH, Dr., Klin./Poliklin. Haut-/G., Universität Würzburg, JosefSchneider-Str. 2, D-97080 Würzburg, Germany, [email protected] COU: Germany DT: Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0016 Keywords CT: ARGON PLASMA COAGULATION/*; CONDYLOMA/*drug therapy; CONDYLOMA/*therapy; ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CREAM; DIATHERMY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; RECURRENT ET: TE: CR: AB: AU: AU: AU: AU: AU: CNOTE: DISEASE; RISK FACTOR; TISSUE INJURY; TREATMENT OUTCOME; IMIQUIMOD/drug therapy; IMIQUIMOD/pharmacology; IMIQUIMOD/topical drug administration Dermatology and Venereology; Drug Literature Index imiquimod/99011-02-6 99011-02-6 Background: According to guidelines of the German STD Association, appropriate treatment of extensive anogenital warts with comparable recurrence rates includes cryotherapy, surgical excision, electrosurgery, CO<inf>2</inf>- and Nd:YAG-laser vaporisation. All these procedures are associated with varying degrees of risk for bleeding, release of potentially infectious aerosol, deep thermal destruction, slow wound healing, and scarring. Methods: Using argon-plasma coagulation anogenital warts can be removed in layers in a controlled manner. High frequency current flows through the argon plasma to the tissue, allowing well-controlled, superficial tissue destruction. Results: From January 2001 to March 2003, 54 patients with extensive genital, anal or anogenital warts were treated. After one treatment, 66% of the patients remained disease-free in the following 4 months. Thirteen patients (24%) showed early recurrence after 4 weeks, five patients (9%) at a later date. In these patients, further treatment, in 9 cases combined with topical imiquimod cream, were necessary for complete remission. Conclusion: Compared to other therapeutic procedures, argon-plasma coagulation is a better controlled, quick and low-risk option for the treatment of anogenital warts. Depending on the type of involvement and individual risk factors, postoperative treatment with topical imiquimod cream may be useful. Weyandt GH Weyandt Gerhard H. Klin./Poliklin. Haut-/G., Universität Würzburg, Würzburg, Germany; Klin./Poliklin. Haut-/G., Universität Würzburg, Josef-Schneider-Str. 2, D-97080 Würzburg, Germany [email protected] Benoit S Benoit Sandrine Klin./Poliklin. Haut-/G., Universität Würzburg, Würzburg, Germany Becker JC Becker Jürgen C. Klin./Poliklin. Haut-/G., Universität Würzburg, Würzburg, Germany Bröcker E-B Bröcker Eva-Bettina Klin./Poliklin. Haut-/G., Universität Würzburg, Würzburg, Germany Hamm H Hamm Henning Klin./Poliklin. Haut-/G., Universität Würzburg, Würzburg, Germany Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/69 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2005147227 Abbasakoor F; Boulos PB Titel: Anal intraepithelial neoplasia Source: British Journal of Surgery; VOL: 92 (3); p. 277-290 /200503/ DOI: 10.1002/bjs.4967 SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 0007-1323 CO: BJSUA Institution: Boulos PB, Prof., Colorectal Surgery Unit, Charles Bell House, 67-73 Riding House Street, London W1W 7EJ, United Kingdom, [email protected] COU: United Kingdom DT: Review; Journal Article JSC: D.1 ... General & Abdominal Surgery RN: 0131 Keywords CT: ANAL INTRAEPITHELIAL NEOPLASIA/*diagnosis; ANAL INTRAEPITHELIAL NEOPLASIA/*drug therapy; ANAL INTRAEPITHELIAL NEOPLASIA/*epidemiology; ANAL INTRAEPITHELIAL NEOPLASIA/*surgery; ANAL INTRAEPITHELIAL NEOPLASIA/*therapy; ANUS TUMOR/*diagnosis; ANUS TUMOR/*drug therapy; ANUS TUMOR/*epidemiology; ANUS TUMOR/*surgery; ANUS TUMOR/*therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*etiology; ANUS CANCER; ARGON LASER; BLISTER/side effect; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; COLONOSCOPY; CRYOTHERAPY; CYTOLOGY; DISEASE ASSOCIATION; DISEASE COURSE; ERYTHEMA/side effect; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; INFECTION/drug therapy; INFECTION/side effect; LOW LEVEL LASER THERAPY; MEDLINE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN IRRITATION/side effect; SQUAMOUS CELL CARCINOMA; VACCINATION; VIRUS INFECTION/drug therapy; VIRUS INFECTION/etiology; VIRUS INFECTION/prevention; WART VIRUS; FLUOROURACIL/*adverse drug reaction; FLUOROURACIL/*drug combination; FLUOROURACIL/*drug therapy; FLUOROURACIL/*topical drug administration; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug combination; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug administration; PHOTOFRIN/*adverse drug reaction; PHOTOFRIN/*drug therapy; PHOTOFRIN/*intravenous drug administration; PHOTOSENSITIZING AGENT/*adverse drug reaction; PHOTOSENSITIZING AGENT/*drug therapy; PHOTOSENSITIZING AGENT/*intravenous drug administration; VIRUS DN: ET: TE: CR: AB: AU: AU: CNOTE: VACCINE/*clinical trial; VIRUS VACCINE/*drug therapy; VIRUS VACCINE/*intramuscular drug administration; ZYC 101/*clinical trial; ZYC 101/*drug therapy; ZYC 101/*intramuscular drug administration; AMINOLEVULINIC ACID/adverse drug reaction; AMINOLEVULINIC ACID/drug therapy; ANTIBIOTIC AGENT/drug therapy; ANTIRETROVIRUS AGENT/drug therapy; INDIGO CARMINE; PROTOPORPHYRIN; UNCLASSIFIED DRUG Zyc 101 Cancer; Public Health, Social Medicine and Epidemiology; Drug Literature Index; Adverse Reactions Titles; Surgery aminolevulinic acid/106-60-5; fluorouracil/51-21-8; imiquimod/99011-02-6; indigo carmine/860-22-0; photofrin/85189-42-0; protoporphyrin/553-12-8 106-60-5; 51-21-8; 99011-02-6; 860-22-0; 85189-42-0; 553-12-8 Background: Anal intraepithelial neoplasia (AIN) is believed to be a precursor of anal squamous cell cancer and its incidence is rising in high-risk groups, particularly those infected with the human immunodeficiency virus (HIV). The natural history of AIN is unclear and management strategies are lacking. Methods: This review is based on a literature search (Medline and PubMed) with manual cross-referencing of all articles related to AIN. Results and conclusions: The aetiology of AIN is intricately linked with human papilloma viruses. The pathological processes involved in the progression of AIN are becoming clearer but the natural history, particularly the rate of progression to invasive cancer, remains unknown. There is no standard management for AIN and this is mainly due to difficulties in both diagnosis and treatment. A variety of treatment options have been tried with varying success. Surgery is associated with significant recurrence, particularly in HIV-positive patients. Non surgical approaches with imiquimod, photodynamic therapy and vaccination are appealing, and further work is required. Long-term follow-up of these patients is essential until the natural history of AIN becomes clearer. Copyright © 2005 British Journal of Surgery Society Ltd. Abbasakoor F Abbasakoor F Department of Surgery, Roy. Free and Univ. Coll. Med. Sch., London, United Kingdom Boulos PB Boulos PB Department of Surgery, Roy. Free and Univ. Coll. Med. Sch., London, United Kingdom; Colorectal Surgery Unit, Charles Bell House, 67-73 Riding House Street, London W1W 7EJ, United Kingdom [email protected] Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/70 von 102 ND: Autoren: DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. EM2005140502 Leiman G Titel: Source: Anal screening cytology CytoJournal; VOL: 2 /20050216/ http://www.cytojournal.com/content/2/1/5 ANR: 5 DOI: 10.1186/1742-6413-2-5 SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 1742-6413 EISSN: 1742-6413 Institution: Leiman G, University of Vermont, 111 Colchester Avenue, Burlington, VT 05446, United States, [email protected] COU: United States DT: Review; Journal Article JSC: C.1.3.1 ... Clinical Oncology; C.11.2 ... Pathological Anatomy RN: 0015 Keywords CT: ANUS/*; CYTOLOGY/*; SCREENING TEST/*; ACQUIRED IMMUNE DEFICIENCY SYNDROME/drug therapy; ACQUIRED IMMUNE DEFICIENCY SYNDROME/etiology; ANUS DISEASE/drug therapy; ANUS DISEASE/etiology; ANUS DISEASE/surgery; ANUS DISEASE/therapy; ANUS SURGERY; ANUS TUMOR/surgery; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CAUTERIZATION; CELL STRUCTURE; COLPOSCOPY; CYTOPATHOLOGY; DISEASE CLASSIFICATION; DISEASE COURSE; EPIDEMIC; EPIDEMIOLOGICAL DATA; EPITHELIUM TUMOR/surgery; FATALITY; FOLLOW UP; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/drug therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/etiology; LOW LEVEL LASER THERAPY; MORBIDITY; MORPHOLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; SAMPLE; STRUCTURE ANALYSIS; SURGICAL TECHNIQUE; UTERINE CERVIX CANCER; WART VIRUS; ANTIRETROVIRUS AGENT/drug therapy; IMIQUIMOD/drug therapy; INTERFERON/drug therapy; PODOPHYLLOTOXIN/drug therapy ET: Drug Literature Index; Gastroenterology; General Pathology and Pathological Anatomy TE: imiquimod/99011-02-6; podophyllotoxin/518-28-5 CR: 99011-02-6; 518-28-5 AB: This issue of CytoJournal contains an article on screening for anal intraepithelial neoplasia in high-risk male patients. This accompanying Editorial focuses on current understanding of this relatively new disease entity, with insights as to the potential role of screening cytopathology in the epidemiology, pathophysiology and clinical management of this HIV and HPV related anal lesion, which predominates in male patients living long-term with AIDS. Mention is made of techniques of obtaining samples, methods of preparation, and morphologic AU: CNOTE: classification. Issues of anoscopic confirmation, as well as topical and surgical management are emphasized. The similarity of initial experiences in anal screening to problems encountered early in cervical cancer screening programs several decades ago, are highlighted. © 2005 Leiman; licensee BioMed Central Ltd. Leiman G Leiman Gladwyn University of Vermont, 111 Colchester Avenue, Burlington, VT 05446, United States [email protected] Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/71 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2005112577 Lacey CJN Titel: Therapy for genital human papillomavirus-related disease Source: Journal of Clinical Virology; VOL: 32 (SUPPL.); p. S82-S90 /200503/ BTI: Human Papillomaviruses DOI: 10.1016/j.jcv.2004.10.020 SU: EMBASE Sprache: English AL: English CY: Netherlands ISSN: 1386-6532 CO: JCVIF Institution: Lacey CJN, Hull York Medical School, University of York, Heslington, York YO10 5DD, United Kingdom, [email protected] COU: United Kingdom DT: Review; Journal Article JSC: E.5.3 ... Virology RN: 0071 Keywords CT: CONDYLOMA/*drug therapy; CONDYLOMA/*etiology; CONDYLOMA/*surgery; CONDYLOMA/*therapy; ANUS CANCER/drug therapy; CANCER RISK; CLINICAL TRIAL; CONTACT ALLERGY; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DRUG SAFETY; EDEMA/side effect; ELECTROSURGERY; EXCISION; HUMAN; INFECTION RISK; INFLAMMATION/side effect; LARYNX PAPILLOMATOSIS/drug therapy; LOW LEVEL LASER THERAPY; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PENIS; PENIS CANCER/drug therapy; PHOTODYNAMIC THERAPY; PREGNANCY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; SCALPEL; SIDE EFFECT/side effect; ULCER/side effect; UTERINE CERVIX CARCINOMA IN SITU/drug therapy; MN: ET: TE: CR: AB: AU: CNOTE: VAGINA CANCER/drug therapy; VULVA; VULVA CANCER/drug therapy; WART VIRUS; 3 INDOLEMETHANOL/drug therapy; ANTIRETROVIRUS AGENT/drug therapy; CIDOFOVIR/clinical trial; CIDOFOVIR/drug therapy; CIDOFOVIR/intravenous drug administration; CIDOFOVIR/pharmacoeconomics; CIDOFOVIR/pharmacology; DNA VACCINE/clinical trial; DNA VACCINE/drug therapy; FLUOROURACIL/drug therapy; FLUOROURACIL/pharmacology; IMIQUIMOD/adverse drug reaction; IMIQUIMOD/drug therapy; INTERFERON/drug therapy; PODOPHYLLIN/adverse drug reaction; PODOPHYLLIN/clinical trial; PODOPHYLLIN/drug therapy; PODOPHYLLIN/drug toxicity; PODOPHYLLIN/pharmacoeconomics; PODOPHYLLIN/pharmacology; PODOPHYLLIN/topical drug administration; PODOPHYLLOTOXIN/clinical trial; PODOPHYLLOTOXIN/drug therapy; PODOPHYLLOTOXIN/topical drug administration; TRICHLOROACETIC ACID Glaxo SmithKline Health Policy, Economics and Management; Drug Literature Index; Adverse Reactions Titles; Microbiology: Bacteriology, Mycology, Parasitology and Virology; General Pathology and Pathological Anatomy 3 indolemethanol/700-06-1; cidofovir/113852-37-2; fluorouracil/51-21-8; imiquimod/99011-02-6; podophyllin/9000-55-9; podophyllotoxin/518-28-5; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 700-06-1; 113852-37-2; 51-21-8; 99011-02-6; 9000-55-9; 518-28-5; 14357-05-2; 76-03-9 Genital human papillomavirus (HPV) infection is very common, and often subclinical and usually resolves without any treatment. Genital warts are caused by HPV 6/11 infection and are one of the commonest clinically recognised disease manifestations of genital HPV. Subjects with genital warts usually perceive them as cosmetically disfiguring, often leading to adverse psychological symptoms, and most subjects with genital warts will present requesting treatment. A wide variety of treatments are available including both provider- and patient-applied therapies. Various individual subject and disease factors mediate appropriate therapy choice. Some of the treatments that are used for genital warts can also be used for some cases of intraepithelial neoplasia caused by high-oncogenic risk HPVs occurring at vulval, anal or penile sites. Specific treatment considerations apply to genital warts in pregnancy and laryngeal papillomatosis and these are also discussed. © 2004 Elsevier B.V. All rights reserved. Lacey CJN Lacey Charles J.N. Hull York Medical School, University of York, Heslington, York YO10 5DD, United Kingdom [email protected] Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/72 von 102 ND: PMID: DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. EMM19281719 19281719 Autoren: Krishna S Titel: Comparison of podophyllotoxin and imiquimod as anal condyloma acuminata therapy. Source: Dermatology online journal; VOL: 15 (1); p. 14 /2009/ SU: Medline Sprache: English AL: English CY: United States EISSN: 1087-2108 Institution: Krishna S, DT: Note; Journal Article JSC: C.5 ... Dermatology & Venereology Keywords CT: ANUS DISEASE/*drug therapy; CONDYLOMA ACUMINATUM/*drug therapy; COMPARATIVE STUDY; HUMAN; NOTE; AMINOQUINOLINE DERIVATIVE/*drug therapy; PODOPHYLLOTOXIN/*drug therapy; IMIQUIMOD TE: podophyllotoxin/518-28-5 CR: 518-28-5 AB: Herein we revisit the published evidence for comparison of the efficacy of imiquimod and podophyllotoxin for anal condyloma acuminata. AU: Krishna S Krishna Sreedhar CNOTE: MEDLINE® is the source for the citation and abstract of this record. » Volltext-Angebot » 2/73 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: PMID: Autoren: EMM19265621 19265621 Dianzani C; Pierangeli A; Avola A; Borzomati D; Persichetti P; Degener AM Titel: Intra-anal condyloma: surgical or topical treatment? Source: Dermatology online journal; VOL: 14 (12); p. 8 /2008/ SU: Medline Sprache: English AL: English CY: United States EISSN: 1087-2108 Institution: Dianzani C, Department of Dermatology, "Campus Biomedico," University of Rome, Italy., [email protected] DT: Journal Article JSC: C.5 ... Dermatology & Venereology Keywords CT: TE: CR: AB: AU: AU: AU: AU: AU: AU: CNOTE: ANUS DISEASE/*drug therapy; ANUS DISEASE/*surgery; CONDYLOMA ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*surgery; LOW LEVEL LASER THERAPY/*; SKIN DISEASE/*drug therapy; SKIN DISEASE/*surgery; ADULT; ANAL CANAL; ARTICLE; CASE REPORT; HUMAN; MALE; OINTMENT; PATHOLOGY; RETREATMENT; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VIROLOGY; AMINOQUINOLINE DERIVATIVE/*drug administration; IMIQUIMOD imiquimod/99011-02-6 99011-02-6 Human Papillomavirus infections are the strongest risk factors for genital cancer and are the causative agents of anogenital warts. Although the viral types associated with condylomata usually do not cause carcinoma, in women with a history of these lesions there is an increased risk of intraepithelial neoplasia and cancer. Generally the lesions are not life-threatening, but they provoke significant morbidity, are difficult to treat, and are a source of psychosocial stress. Thus, condylomata represent not only a health problem for the patient but also an economic burden for the society. Considering the individual episodes of care, men experience a longer duration of the lesions and incur greater costs than women. We report a case of a male patient with external and intra-anal condyloma resistant to laser therapy. Initially, surgical intervention appeared required because of florid and intra-anal growth. HPV DNA testing and sequencing revealed the presence of HPV 6. After initial discomfort, the lesions were successfully cleared with topical imiquimod 5 percent cream therapy. Dianzani C Dianzani Caterina Department of Dermatology, "Campus Biomedico," University of Rome, Italy. Pierangeli A Pierangeli Alessandra Department of Dermatology, "Campus Biomedico," University of Rome, Italy. Avola A Avola Alessandra Department of Dermatology, "Campus Biomedico," University of Rome, Italy. Borzomati D Borzomati Domenico Department of Dermatology, "Campus Biomedico," University of Rome, Italy. Persichetti P Persichetti Paolo Department of Dermatology, "Campus Biomedico," University of Rome, Italy. Degener AM Degener Anna Marta Department of Dermatology, "Campus Biomedico," University of Rome, Italy. MEDLINE® is the source for the citation and abstract of this record. » Volltext-Angebot » 2/74 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: PMID: Autoren: EMM17573882 17573882 Kreuter A; Wieland U; Gambichler T; Altmeyer P; Pfister H; Tenner-Racz K; Racz P; Potthoff A; Brockmeyer NH Titel: p16ink4a expression decreases during imiquimod treatment of anal intraepithelial neoplasia in human immunodeficiency virus-infected men and correlates with the decline of lesional high-risk human papillomavirus DNA load. Source: The British journal of dermatology; VOL: 157 (3); p. 523-530 /Sep 2007/ NCT: ClinicalTrials.gov-NCT00365729 SU: Medline Sprache: English AL: English CY: United Kingdom ISSN: 0007-0963 Institution: Kreuter A, Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany., [email protected] DT: Journal Article JSC: C.5 ... Dermatology & Venereology Keywords CT: ANUS TUMOR/*drug therapy; CARCINOMA IN SITU/*drug therapy; PRECANCER/*drug therapy; ADULT; AIDS RELATED COMPLEX/complication; ARTICLE; GENETICS; HOMOSEXUALITY; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; METABOLISM; PAPILLOMA VIRUS; PILOT STUDY; VIROLOGY; VIRUS INFECTION/complication; VIRUS LOAD; AMINOQUINOLINE DERIVATIVE/*drug therapy; ANTINEOPLASTIC AGENT/*drug therapy; CYCLIN DEPENDENT KINASE INHIBITOR 2A/*; IMIQUIMOD; KI 67 ANTIGEN; TUMOR MARKER; VIRUS DNA/drug analysis TE: imiquimod/99011-02-6 CR: 99011-02-6 AB: BACKGROUND: Human papillomavirus (HPV)-associated anogenital cancers and their precursor lesions occur in excess in human immunodeficiency virus (HIV)-infected patients despite the initiation of highly active antiretroviral therapy. In this context, a drastically increased relative risk for anal intraepithelial neoplasia (AIN) exists in HIV-infected men having sex with men (MSM). In a pilot study, imiquimod, a topical immune response modifier, has been reported to be beneficial in the treatment of AIN. OBJECTIVES: To investigate the role of several biomarkers as potential adjuncts in the course of imiquimod treatment for AIN, and to determine whether these markers correlate with the course of highrisk HPV DNA load during imiquimod therapy. METHODS: Immunohistochemical staining was performed for p16(ink4a), minichromosome maintenance protein (MCM), Ki67, proliferating cell nuclear antigen (PCNA) and p21(waf1) expression before and after 16 weeks of imiquimod treatment for AIN. High-risk HPV DNA load determinations were performed by real-time polymerase chain reaction with type-specific primers and probes for HPV types 16, 18, 31 and 33. RESULTS: Histopathological and virological analyses were AU: AU: AU: AU: AU: AU: AU: AU: performed in 21 HIV-infected MSM with histologically confirmed AIN. Eighteen (86%) patients had a complete histological clearance of AIN after imiquimod therapy. As previously shown, lesional high-risk HPV DNA load significantly decreased during imiquimod therapy. Moreover, a significant decline of p16(ink4a), Ki67, MCM and PCNA expression after treatment was observed, while p21(waf1) expression changed nonsignificantly after imiquimod therapy. A significant correlation between the course of high-risk HPV DNA load and p16(ink4a) expression was observed during imiquimod treatment of AIN, whereas the decline of high-risk HPV DNA load did not significantly correlate with MCM, Ki67, PCNA or p21(waf1) expression. CONCLUSIONS: The significant decrease in p16(ink4a) expression in correlation with the drop of lesional high-risk HPV load suggests that p16(ink4a) may be a useful adjunct for the evaluation of treatment response in HPV-associated malignancies and their precursor lesions. Kreuter A Kreuter A Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany. Wieland U Wieland U Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany. Gambichler T Gambichler T Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany. Altmeyer P Altmeyer P Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany. Pfister H Pfister H Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany. Tenner-Racz K Tenner-Racz K Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany. Racz P Racz P Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany. Potthoff A Potthoff A Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany. AU: CNOTE: Brockmeyer NH Brockmeyer NH Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany. MEDLINE® is the source for the citation and abstract of this record. » Volltext-Angebot » 2/75 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2004534385 Pelletier F; Drobacheff-Thiebaut C; Aubin F; Venier A-G; Mougin C; Laurent R Titel: Effects de l'imiquimod sur l'infection périanale latente à papillomavirus humain chez des malades infectés par le virus de l'immunodéficience humaine Effects of imiquimod on latent human papillomavirus anal infection in HIV-infected patients Source: Annales de Dermatologie et de Venereologie; VOL: 131 (11); p. 947-951 /200411/ SU: EMBASE Sprache: French AL: English; French CY: France ISSN: 0151-9638 CO: ADVED Institution: Pelletier F, Service de Dermatologie, CHU Saint-Jacques, 2 place Saint-Jacques, 25030 Besançon Cedex, France COU: France DT: Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0015 Keywords CT: HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*; VERRUCA VULGARIS/*drug therapy; VERRUCA VULGARIS/*etiology; ADOLESCENT; ADULT; AGED; ANAMNESIS; ANUS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERADICATION THERAPY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEXUALLY TRANSMITTED DISEASE; TREATMENT OUTCOME; VIRUS TRANSMISSION; WART VIRUS; IMIQUIMOD/*clinical trial; IMIQUIMOD/*drug therapy; VIRUS DNA ET: Dermatology and Venereology; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology TE: imiquimod/99011-02-6 CR: 99011-02-6 AB: AU: AU: AU: AU: AU: AU: CNOTE: Introduction. High risk human papillomaviruses (HPV) have emerged as risk factors for anal carcinoma particularly in HIV-infected patients who demonstrate a high rate of anal HPV infection. Considering the relationship between the presence of anal infection and the development of neoplastic lesions, we wished to assess the capacity of imiquimod to eradicate latent HPV infection in HIVinfected patients. Patients and methods. We conducted a prospective, randomized, double-blind and vehicle controlled study. Two consecutive anal swabs were taken at 2 month intervals and only patients with two consecutive tests positive for the detection of HPV-DNA (Hybrid Capture II®) were included. Patients with persistent latent HPV infection were divided into 2 groups who applied imiquimod versus vehicle during 6 weeks. HPV-DNA presence was then investigated 2 and 4 months following the onset of treatment. Results. Among the 80 HIV-infected patients, 26 (32.5 p. 100) had 2 positive consecutive assays, and 19 patients were included in the study. After randomization, 9 patients received imiquimod and 10 vehicle. There was no significant difference between treatment groups according to the following criteria: gender, route of HIV transmission, CDC stage, prior medical history of sexually transmitted diseases or anogenital warts. 33.3 p. 100 (3/9) of patients treated with imiquimod were negative at M2, whereas 100 p. 100 (10/10) vehicle treated-patients remained positive (p = 0.08). Similar results were observed at the M4 visit. Discussion. Our study confirmed the increased prevalence of latent HPV-DNA infection in HIV-infected patients. In spite of the low number of treated patients, we did not observe a statistically significant decrease in HPV-DNA in anal swabs from france imquimod-treated patients as compared to placebo-treated patients. Pelletier F Pelletier F Service de Dermatologie, CHU Saint-Jacques, Besançon, France; Service de Dermatologie, CHU Saint-Jacques, 2 place Saint-Jacques, 25030 Besançon Cedex, France Drobacheff-Thiebaut C Drobacheff-Thiebaut C Service de Dermatologie, CHU Saint-Jacques, Besançon, France Aubin F Aubin F Service de Dermatologie, CHU Saint-Jacques, Besançon, France Venier A-G Venier A-G Departement d'Information Medicine, CHU Saint-Jacques, Besançon, France Mougin C Mougin C Lab. de Biol. Cell. et Moleculaire, CHU Jean Minjoz, Besançon, France Laurent R Laurent R Service de Dermatologie, CHU Saint-Jacques, Besançon, France Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/76 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2004506141 Chang GJ; Welton ML Titel: Human papillomavirus, condylomata acuminata, and anal neoplasia Source: Clinics in Colon and Rectal Surgery; VOL: 17 (4); p. 221-230 /200411/ DOI: 10.1055/s-2004-836942 SU: EMBASE Sprache: English AL: English CY: United States ISSN: 1531-0043 CO: CCRSC Institution: Chang GJ, Dr., Department of Surgical Oncology, Unit 444, U.T. M.D. Anderson Cancer Center, 1400 Holcombe Blvd., Houston, TX 77230-1402, United States, [email protected] COU: United States DT: Review; Journal Article JSC: C.1.8 ... Gastroenterology; D.1 ... General & Abdominal Surgery RN: 0095 Keywords CT: ANUS CANCER/*diagnosis; ANUS CANCER/*etiology; ANUS CANCER/*surgery; CONDYLOMA ACUMINATUM/*diagnosis; CONDYLOMA ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*surgery; CONDYLOMA ACUMINATUM/*therapy; WART VIRUS/*; ANUS DISEASE/diagnosis; ANUS DISEASE/drug therapy; ANUS DISEASE/epidemiology; ANUS DISEASE/etiology; ANUS DISEASE/surgery; ANUS DISEASE/therapy; ANUS FISTULA/side effect; ANUS SURGERY; BOWEN DISEASE/etiology; CARBON DIOXIDE LASER; CAUTERIZATION; CHILL/side effect; CONDYLOMA/diagnosis; CONDYLOMA/drug therapy; CONDYLOMA/surgery; CONDYLOMA/therapy; CRYOTHERAPY; DERMATITIS/side effect; DISEASE COURSE; ERYTHEMA/side effect; EXCISION; FATIGUE/side effect; FETUS DEATH; FEVER/side effect; HEADACHE/side effect; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/epidemiology; IMMUNOTHERAPY; LEUKOPENIA/side effect; MYALGIA/side effect; NONHUMAN; PREVALENCE; RECURRENT DISEASE; REVIEW; SCAR/side effect; SEXUALLY TRANSMITTED DISEASE/diagnosis; SEXUALLY TRANSMITTED DISEASE/epidemiology; SEXUALLY TRANSMITTED DISEASE/etiology; SIDE EFFECT/side effect; SKIN NECROSIS/side effect; SYMPTOMATOLOGY; TERATOGENICITY/side effect; UTERINE CERVIX CANCER/etiology; UTERINE CERVIX DYSPLASIA/etiology; VIRUS INFECTION/diagnosis; VIRUS INFECTION/epidemiology; VIRUS INFECTION/etiology; DICHLOROACETIC ACID/*adverse drug reaction; DICHLOROACETIC ACID/*drug administration; DICHLOROACETIC ACID/*drug therapy; DICHLOROACETIC ACID/*topical drug administration; FLUOROURACIL/*drug administration; FLUOROURACIL/*drug therapy; ET: TE: CR: FLUOROURACIL/*topical drug administration; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug administration; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug administration; INTERFERON/*adverse drug reaction; INTERFERON/*drug administration; INTERFERON/*drug therapy; INTERFERON/*intralesional drug administration; INTERFERON/*intramuscular drug administration; INTERFERON/*topical drug administration; PODOPHYLLIN/*adverse drug reaction; PODOPHYLLIN/*drug administration; PODOPHYLLIN/*drug therapy; PODOPHYLLIN/*topical drug administration; TRICHLOROACETIC ACID/*drug administration; TRICHLOROACETIC ACID/*drug therapy; TRICHLOROACETIC ACID/*topical drug administration; 1 CHLORO 2,4 DINITROBENZENE/drug administration; 1 CHLORO 2,4 DINITROBENZENE/drug therapy; 1 CHLORO 2,4 DINITROBENZENE/topical drug administration; ANTINEOPLASTIC AGENT/drug administration; ANTINEOPLASTIC AGENT/drug therapy; ANTINEOPLASTIC AGENT/topical drug administration; BISMUTH DERIVATIVE/drug administration; BISMUTH DERIVATIVE/drug therapy; BISMUTH DERIVATIVE/topical drug administration; BLEOMYCIN/drug administration; BLEOMYCIN/drug therapy; BLEOMYCIN/topical drug administration; CANTHARIDIN/drug administration; CANTHARIDIN/drug therapy; CANTHARIDIN/topical drug administration; COLCHICINE/drug administration; COLCHICINE/drug therapy; COLCHICINE/topical drug administration; DIMETHYL SULFOXIDE/drug administration; DIMETHYL SULFOXIDE/drug therapy; DIMETHYL SULFOXIDE/topical drug administration; IDOXURIDINE/drug administration; IDOXURIDINE/drug therapy; IDOXURIDINE/topical drug administration; LIQUID NITROGEN; MERCURY/drug administration; MERCURY/drug therapy; MERCURY/topical drug administration; PHENOL DERIVATIVE/drug administration; PHENOL DERIVATIVE/drug therapy; PHENOL DERIVATIVE/topical drug administration; SALICYLIC ACID/drug administration; SALICYLIC ACID/drug therapy; SALICYLIC ACID/topical drug administration; SOLCODERM/drug administration; SOLCODERM/drug therapy; SOLCODERM/topical drug administration; SULFONAMIDE/drug administration; SULFONAMIDE/drug therapy; SULFONAMIDE/topical drug administration; TETRACYCLINE/drug administration; TETRACYCLINE/drug therapy; TETRACYCLINE/topical drug administration; THIOTEPA/drug administration; THIOTEPA/drug therapy; THIOTEPA/topical drug administration; VIRUS DNA; VIRUS VACCINE/drug therapy Cancer; Drug Literature Index; Adverse Reactions Titles; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Surgery 1 chloro 2,4 dinitrobenzene/25567-67-3; 1 chloro 2,4 dinitrobenzene/97-00-7; bleomycin/11056-06-7; cantharidin/56-25-7; colchicine/64-86-8; dichloroacetic acid/13425-80-4; dichloroacetic acid/2156-56-1; dichloroacetic acid/79-43-6; dimethyl sulfoxide/67-68-5; fluorouracil/51-21-8; idoxuridine/54-42-2; imiquimod/99011-02-6; mercury/14302-87-5; mercury/7439-97-6; podophyllin/9000-55-9; salicylic acid/63-36-5; salicylic acid/69-72-7; tetracycline/23843-90-5; tetracycline/60-54-8; tetracycline/64-75-5; thiotepa/5224-4; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 25567-67-3; 97-00-7; 11056-06-7; 56-25-7; 64-86-8; 13425-80-4; 2156-56-1; 7943-6; 67-68-5; 51-21-8; 54-42-2; 99011-02-6; 14302-87-5; 7439-97-6; 9000-55-9; 63-36-5; 69-72-7; 23843-90-5; 60-54-8; 64-75-5; 52-24-4; 14357-05-2; 76-03-9 AB: AU: AU: CNOTE: Genital human papillomavirus (HPV) infection is an increasingly common sexually transmitted disease. This virus causes condylomata acuminata and is associated with anal neoplasia. Management options are discussed. Chang GJ Chang George J. Department of Surgical Oncology, Unit 444, U.T. M.D. Anderson Cancer Center, 1400 Holcombe Blvd., Houston, TX 77230-1402, United States; Department of Surgical Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, United States [email protected] Welton ML Welton Mark L. Department of Surgery, Stanford University, School of Medicine, Stanford, CA, United States Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/77 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2004309751 Park JS; Kerner BA Titel: Perianal Paget's disease Source: Seminars in Colon and Rectal Surgery; VOL: 14 (4); p. 218-221 /200312/ DOI: 10.1053/j.scrs.2004.03.007 SU: EMBASE Sprache: English AL: English CY: United States ISSN: 1043-1489 CO: SCRSF PII: S1043148904000168 Institution: Kerner BA, Dr., 5965 East Broad Street, Suite 120, Columbus, OH, United States, [email protected] COU: United States DT: Review; Journal Article JSC: C.1.8 ... Gastroenterology; D.1 ... General & Abdominal Surgery RN: 0016 Keywords CT: PAGET SKIN DISEASE/*diagnosis; PAGET SKIN DISEASE/*drug therapy; PAGET SKIN DISEASE/*radiotherapy; PAGET SKIN DISEASE/*surgery; ADENOCARCINOMA/surgery; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; IMMUNOHISTOCHEMISTRY; NECROSIS/complication; PHOTODYNAMIC THERAPY; RECURRENT DISEASE/complication; REVIEW; IMIQUIMOD/drug therapy; RETINOIC ACID/drug therapy ET: TE: CR: AB: AU: AU: CNOTE: Dermatology and Venereology; Drug Literature Index; Gastroenterology imiquimod/99011-02-6; retinoic acid/302-79-4 99011-02-6; 302-79-4 Perianal Paget's disease is a rare intraepithelial adenocarcinoma of the anal margin. Because of its rarity, delay in diagnosis is common and requires a high index of suspicion. Although its etiology has never been definitively determined, it now appears that 2 types of perianal Paget's disease exist. Primary perianal Paget's disease likely represents intra-epithelial neoplasm from an apocrine source, whereas secondary disease may represent "pagetoid" spread from an anorectal malignancy. Diagnosis of the 2 types of disease can be established from distinct immunohistochemical stain patterns. Wide local excision remains the treatment of choice for primary disease, with or without local invasion. Although local recurrence is high, re-excision can still be curative. Treatment of secondary disease is less clear, though aggressive therapy appears indicated for curative intent. Although adjuvant therapy is desirable, experience is still very limited. © 2004 Elsevier Inc. All rights reserved. Park JS Park John S. Grant Medical Center, Department of Surgery, Section of Colon and Rectal Surgery, Columbus, OH, United States Kerner BA Kerner Bruce A. Grant Medical Center, Department of Surgery, Section of Colon and Rectal Surgery, Columbus, OH, United States; 5965 East Broad Street, Suite 120, Columbus, OH, United States [email protected] Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/78 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2004308623 Hagensee ME; Cameron JE; Leigh JE; Clark RA Titel: Human papillomavirus infection and disease in HIV-infected individuals Source: American Journal of the Medical Sciences; VOL: 328 (1); p. 57-63 /200407/ SU: EMBASE Sprache: English AL: English CY: United States ISSN: 0002-9629 CO: AJMSA Institution: Hagensee ME, Dr., Department of Medicine, LSUHSC, 1542 Tulane Avenue, New Orleans, LA 70112, United States, [email protected] COU: United States DT: JSC: RN: Keywords CT: ET: TE: CR: AB: AU: Review; Journal Article C.0 ... Clinical Medicine 0041 HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*epidemiology; VERRUCA VULGARIS/*drug therapy; VERRUCA VULGARIS/*epidemiology; VERRUCA VULGARIS/*etiology; VERRUCA VULGARIS/*side effect; ANUS DISEASE/drug therapy; ANUS DISEASE/etiology; CARBON DIOXIDE LASER; CLINICAL TRIAL; CONDYLOMA/drug therapy; CONDYLOMA/etiology; CRYOSURGERY; DISEASE ASSOCIATION; ELECTROSURGERY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RISK; MOUTH INFECTION/drug therapy; MOUTH INFECTION/etiology; MOUTH INFECTION/side effect; MOUTH INFECTION/surgery; PATHOPHYSIOLOGY; REVIEW; SEX DIFFERENCE; UTERINE CERVIX DYSPLASIA/etiology; WART VIRUS; ANTIRETROVIRUS AGENT/adverse drug reaction; ANTIRETROVIRUS AGENT/drug therapy; FLUOROURACIL/clinical trial; FLUOROURACIL/drug therapy; IMIQUIMOD/drug therapy; ISOTRETINOIN/clinical trial; ISOTRETINOIN/drug therapy; ISOTRETINOIN/oral drug administration; LIQUID NITROGEN/drug therapy; PODOPHYLLOTOXIN/drug therapy Drug Literature Index; Adverse Reactions Titles; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Internal Medicine fluorouracil/51-21-8; imiquimod/99011-02-6; isotretinoin/4759-48-2; podophyllotoxin/518-28-5 51-21-8; 99011-02-6; 4759-48-2; 518-28-5 The possibility of increases in both oral and anogenital pathologic conditions due to human papillomavirus (HPV) in patients infected with the human immunodeficiency virus (HIV) is of concern and is the focus of numerous current research studies. HIV-infected women are at higher risk for cervical HPV detection, for infection with high-oncogenic-risk types of HPV, for persistent HPV infection, for cervical cytologic abnormalities, and for cervical intraepithelial neoplasms. HIV-infected men are at increased risk for anal HPV infection, for anal infection with high oncogenic-risk types of HPV, for persistent anal HPV infection, and for anal intraepithelial defects. Recent studies have shown an increased risk of oral warts in HIV-infected individuals despite treatment with highly active antiretroviral therapy (HAART). Oral HPV infection rates have not declined since the initiation of HAART, and evidence suggests that the rates may have actually increased in white HIV-infected males. Hagensee ME Hagensee Michael E. Department of Medicine, LA State Univ. Health Science Center, New Orleans, LA, United States; Dept. Microbio., Immunol./Parasitol., LA State Univ. Health Science Center, New Orleans, LA, United States; Department of Medicine, LSUHSC, 1542 Tulane Avenue, New Orleans, LA 70112, United States [email protected] AU: AU: AU: CNOTE: Cameron JE Cameron Jennifer E. Dept. Microbio., Immunol./Parasitol., LA State Univ. Health Science Center, New Orleans, LA, United States Leigh JE Leigh Janet E. School of Dentistry, LA State Univ. Health Science Center, New Orleans, LA, United States Clark RA Clark Rebecca A. Department of Medicine, LA State Univ. Health Science Center, New Orleans, LA, United States Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/79 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2004233715 Kreuter A; Hochdorfer B; Stücker M; Altmeyer P; Weiland U; Conant MA; Brockmeyer NH Titel: Treatment of anal intraepithelial neoplasia in patients with acquired HIV with imiquimod 5% cream [6] Source: Journal of the American Academy of Dermatology; VOL: 50 (6); p. 980-981 /200406/ SU: EMBASE Sprache: English CY: United States ISSN: 0190-9622 CO: JAADD Institution: Network of Competence HIV/AIDS, Dept. of Dermatology and Allergology, Ruhr-University Bochum, Germany COU: Germany DT: Letter; Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0005 Keywords CT: ANUS TUMOR/*drug therapy; CARCINOMA IN SITU/*drug therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; BURNING SENSATION/side effect; CLINICAL ARTICLE; ERYTHEMA/side effect; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LETTER; MALE; PRIORITY JOURNAL; REMISSION; WART VIRUS; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug therapy ET: Drug Literature Index; Adverse Reactions Titles; Microbiology: Bacteriology, TE: CR: AU: AU: AU: AU: AU: AU: AU: CNOTE: Mycology, Parasitology and Virology imiquimod/99011-02-6 99011-02-6 Weiland U Weiland Ulrike Kreuter A Kreuter Alexander Network of Competence HIV/AIDS, Dept. of Dermatology and Allergology, Ruhr-University Bochum, Germany Hochdorfer B Hochdorfer Bettina Network of Competence HIV/AIDS, Dept. of Dermatology and Allergology, Ruhr-University Bochum, Germany Stücker M Stücker Markus Network of Competence HIV/AIDS, Dept. of Dermatology and Allergology, Ruhr-University Bochum, Germany Altmeyer P Altmeyer Peter Network of Competence HIV/AIDS, Dept. of Dermatology and Allergology, Ruhr-University Bochum, Germany Conant MA Conant Markus A. Department of Dermatology, Univ. of California Medical Center, San Francisco, CA, United States Brockmeyer NH Brockmeyer Norbert H. Network of Competence HIV/AIDS, Dept. of Dermatology and Allergology, Ruhr-University Bochum, Germany; Institute of Virology, University of Cologne, Germany Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/80 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2003421405 Majewski S; Pniewski T; Malejczyk M; Jablonska S Titel: Imiquimod is Highly Effective for Extensive, Hyperproliferative Condyloma in Children Source: DOI: SU: Sprache: AL: Pediatric Dermatology; VOL: 20 (5); p. 440-442 /200309/ 10.1046/j.1525-1470.2003.20516.x EMBASE English English CY: United States ISSN: 0736-8046 CO: PEDRD Institution: Jablonska S, Dr., Department of Dermatology, Warsaw School of Medicine, Koszykowa 82A, 02-008 Warsaw, Poland, [email protected] COU: Poland DT: Journal Article JSC: C.5 ... Dermatology & Venereology; C.2 ... Pediatrics & Pediatric Surgery RN: 0014 Keywords CT: CONDYLOMA/*diagnosis; CONDYLOMA/*drug therapy; CONDYLOMA/*etiology; ANUS; ARTICLE; CASE REPORT; CHILD SEXUAL ABUSE; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INFLAMMATION; PREGNANCY; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT OUTCOME; VERRUCA VULGARIS/diagnosis; VERRUCA VULGARIS/drug therapy; VERRUCA VULGARIS/etiology; WART VIRUS; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug administration ET: Dermatology and Venereology; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Pediatrics and Pediatric Surgery TE: imiquimod/99011-02-6 CR: 99011-02-6 AB: We describe a dramatic response to imiquimod of long-lasting, highly proliferative extensive perianal condylomas involving the anal canal in a 19month-old girl. Her mother was free of condyloma and allegedly had no human papillomavirus (HPV) infection during pregnancy. There was no evidence of sexual abuse. Application of 5% imiquimod cream to the child every other day for 3 weeks resulted in almost complete resolution of the warts, with total clearance within another 2 weeks. The inflammatory reaction was moderate. Since there is still discussion of whether imiquimod may be prescribed for small children, this case of very extensive condyloma provides evidence that the compound is safe and highly effective. AU: Majewski S Majewski Slawomir Dept. of Dermatology and Venereology, Warsaw School of Medicine, Warsaw, Poland AU: Pniewski T Pniewski Tomasz Dept. of Dermatology and Venereology, Warsaw School of Medicine, Warsaw, Poland AU: Malejczyk M Malejczyk Magdalena Dept. of Dermatology and Venereology, Warsaw School of Medicine, Warsaw, Poland AU: CNOTE: Jablonska S Jablonska Stefania Dept. of Dermatology and Venereology, Warsaw School of Medicine, Warsaw, Poland; Department of Dermatology, Warsaw School of Medicine, Koszykowa 82A, 02-008 Warsaw, Poland [email protected] Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/81 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2003379255 Bock J-U; Jongen J; Peleikis H-G; Stübinger SH Titel: Proktologische erkrankungen im urologischen alltag Proctologic illnesses in daily urological practice Source: Urologe - Ausgabe A; VOL: 42 (8); p. 1105-1116 /20030801/ DOI: 10.1007/s00120-003-0410-8 SU: EMBASE Sprache: German AL: English; German CY: Germany ISSN: 0340-2592 CO: URGAB Institution: Bock J-U, Dr., Proktologische Praxis, Beselerallee 67, 24105 Kiel, Germany, [email protected] COU: Germany DT: Review; Journal Article JSC: D.5 ... Urological Surgery RN: 0024 Keywords CT: ANUS CARCINOMA/*diagnosis; ANUS CARCINOMA/*surgery; ANUS DISEASE/*diagnosis; ANUS DISEASE/*drug therapy; ANUS DISEASE/*surgery; ANUS FISSURE/*diagnosis; ANUS FISSURE/*drug therapy; ANUS FISSURE/*surgery; HEMORRHOID/*diagnosis; HEMORRHOID/*surgery; ADULT; ANUS FISTULA/diagnosis; ANUS FISTULA/surgery; ANUS PRURITUS/etiology; ANUS SPHINCTER; ANUS SURGERY; ARTERY LIGATION; BOWENOID PAPULOSIS/diagnosis; CLINICAL PRACTICE; CONDYLOMA ACUMINATUM/diagnosis; CONDYLOMA ACUMINATUM/drug therapy; CONDYLOMA ACUMINATUM/surgery; CONSERVATIVE TREATMENT; DIFFERENTIAL DIAGNOSIS; ECZEMA/etiology; ELECTROCOAGULATION; FECES INCONTINENCE/etiology; FIBROMA/diagnosis; FIBROMA/surgery; GONORRHEA/diagnosis; HEMORRHOIDECTOMY; HERPES SIMPLEX/diagnosis; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/diagnosis; PAIN/etiology; PERIANAL ABSCESS/diagnosis; PERIANAL ABSCESS/surgery; PRACTICE GUIDELINE; ET: TE: CR: AB: AU: AU: AU: AU: CNOTE: PROCTITIS/complication; PROCTITIS/diagnosis; RADIATION INJURY/complication; RADIATION INJURY/diagnosis; RECTUM MUCOSA; RECTUM PROLAPSE; REVIEW; SPHINCTEROTOMY; SYPHILIS/diagnosis; THROMBOSIS/complication; BOTULINUM TOXIN/drug therapy; CALCIUM ANTAGONIST/drug therapy; DILTIAZEM/drug therapy; GLYCERYL TRINITRATE/drug therapy; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; NIFEDIPINE/drug therapy; PODOPHYLLOTOXIN/drug therapy Cancer; Urology and Nephrology; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Surgery diltiazem/33286-22-5; diltiazem/42399-41-7; glyceryl trinitrate/55-63-0; imiquimod/99011-02-6; nifedipine/21829-25-4; podophyllotoxin/518-28-5 33286-22-5; 42399-41-7; 55-63-0; 99011-02-6; 21829-25-4; 518-28-5 Nearly two third of adults will suffer from proctologic complaints. The same symptoms could also indicate or mask an anorectal carcinoma. Therefore, the first priority should be to exclude the possibility of a neoplasm of the colon, rectum and the anal canal. Knowledge of the specific anatomy of the anal canal and the patient's history will lead to an exact proctologic diagnosis: perianal thrombosis, acute thrombosed prolapsed haemorrhoidal plexus, an anal fissure, abscess and fistula are located within the highly sensitive anoderma and are characterized by pain. Perianal thrombosis, chronic fissure, abscess and fistula require surgery Conservative treatment is the choice for an acute anal fissure, haemorrhoids grade I-II. Haemorrhoids II-III require surgery, e.g. by haemorrhoidal artery ligation, open or closed resection of the haemorrhoidal plexus, reconstruction of the anal canal or stapled mucosectomy. Perianal diseases such as perianal tags, fibroma or condylomata acuminata are easily diagnosed and treated. Secondary perianal eczema requires treatment of the underlying proctologic disease. If it persists, a biopsy is required. Bock J-U Bock J-U Proktologische Praxis, Kiel, Germany; Anorektale Chirurgie, Park-Klinik, Kiel, Germany; Proktologische Praxis, Beselerallee 67, 24105 Kiel, Germany [email protected] Jongen J Jongen J Proktologische Praxis, Kiel, Germany Peleikis H-G Peleikis H-G Proktologische Praxis, Kiel, Germany Stübinger SH Stübinger SH Klinik für Urologie, Univ. Klin. Schleswig-Holstein, Campus Kiel, Kiel, Germany Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/82 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2003325726 Porter WM; Francis N; Hawkins D; Dinneen M; Bunker CB Titel: Penile intraepithelial neoplasia: Clinical spectrum and treatment of 35 cases Source: British Journal of Dermatology; VOL: 147 (6); p. 1159-1165 /20021201/ DOI: 10.1046/j.1365-2133.2002.05019.x SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 0007-0963 CO: BJDEA Institution: Porter WM, Dr., Department of Dermatology, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN, United Kingdom, [email protected] COU: United Kingdom DT: Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0029 Keywords CT: CARCINOMA IN SITU/*diagnosis; CARCINOMA IN SITU/*drug therapy; CARCINOMA IN SITU/*etiology; PENIS TUMOR/*diagnosis; PENIS TUMOR/*drug therapy; PENIS TUMOR/*etiology; ADULT; AGED; ANAMNESIS; ANUS CANCER; ARTICLE; BOWEN DISEASE; BOWENOID PAPULOSIS; CIRCUMCISION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL OBSERVATION; EROSION/side effect; ERYTHEMA/side effect; ERYTHROPLASIA; FOLLOW UP; GENITAL TRACT INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; MALE; PENIS DISEASE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS; FLUOROURACIL/*drug therapy; FLUOROURACIL/*topical drug administration; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug administration; PREDNISOLONE/*drug therapy; PREDNISOLONE/*oral drug administration; INTERLEUKIN 1/endogenous compound; INTERLEUKIN 12/endogenous compound; INTERLEUKIN 6/endogenous compound; TUMOR NECROSIS FACTOR/endogenous compound DN: Efudix/ICN, United Kingdom MN: ICN, United Kingdom ET: Dermatology and Venereology; Cancer; Urology and Nephrology; Drug Literature Index; Adverse Reactions Titles TE: fluorouracil/51-21-8; imiquimod/99011-02-6; interleukin 12/138415-13-1; prednisolone/50-24-8 CR: 51-21-8; 99011-02-6; 138415-13-1; 50-24-8 AB: Background: Penile intraepithelial neoplasia (PIN) is the term used to describe erythroplasia of Oueyrat (EQ), Bowen's disease (BD) and bowenoid papulosis AU: AU: AU: AU: AU: CNOTE: (BP). These conditions are distinct clinical entities and have different epidemiological and aetiological associations and prognostic implications. Objectives: To describe the presentation and treatment of patients with PIN. Methods: Thirty-five patients presenting with PIN over a 7-year period are described. Results: Our observations include: (i) patients with BP are younger than those with EQ or BD and sometimes have a history of immunosuppression; (ii) patients with BP usually have a history or clinical evidence of previous genital human papillomavirus infection; (iii) patients with EQ often have a concurrent penile dermatosis (lichen sclerosus or lichen planus); (iv) patients with PIN are usually uncircumcised; and (v) response to treatment of BP depends on the integrity of the immune system. Conclusions: We recommend vigorous treatment of all patients with PIN, including circumcision. Smoking should be actively discouraged. Patients should have life-long follow-up and partners of patients with BP should be screened for other forms of intraepithelial neoplasia (cervical and anal). Porter WM Porter WM Department of Dermatology, Chelsea and Westminster Hospital, Imperial College School of Medicine, London SW10 9NH, United Kingdom; Department of Dermatology, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN, United Kingdom [email protected] Francis N Francis N Department of Histopathology, Chelsea and Westminster Hospital, Imperial College School of Medicine, London SW10 9NH, United Kingdom Hawkins D Hawkins D Department of Genitourinary Medicine, Chelsea and Westminster Hospital, Imperial College School of Medicine, London SW10 9NH, United Kingdom Dinneen M Dinneen M Department of Urology, Chelsea and Westminster Hospital, Imperial College School of Medicine, London SW10 9NH, United Kingdom Bunker CB Bunker CB Department of Dermatology, Chelsea and Westminster Hospital, Imperial College School of Medicine, London SW10 9NH, United Kingdom Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/83 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2003238428 Chu NR Titel: Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease Source: Expert Opinion on Biological Therapy; VOL: 3 (3); p. 477-486 /200306/ DOI: 10.1517/14712598.3.3.477 SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 1471-2598 CO: EOBTA Institution: Chu NR, Stressgen Biotechnologies Corp., 350-4243 Glanford Ave., Victoria, BC V8Z 4B9, Canada, [email protected] COU: Canada DT: Review; Journal Article JSC: A.1 ... Pharmacology & Drug Therapy; E.0 ... Experimental Science RN: 0107 Keywords CT: PAPILLOMA VIRUS/*; VACCINATION/*; VIRUS INFECTION/*drug therapy; CHIMERA; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; FUSION GENE; GENE DELIVERY SYSTEM; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; NONHUMAN; REVIEW; SIDE EFFECT/side effect; TREATMENT INDICATION; VIRUS PARTICLE; VACCINE/*drug therapy; VIRUS ANTIGEN/*drug therapy; WART VIRUS VACCINE/*drug therapy; ADJUVANT; COVAL; CYTOTOXIC AGENT/adverse drug reaction; CYTOTOXIC AGENT/drug therapy; CYTOTOXIC AGENT/topical drug administration; HEAT SHOCK PROTEIN; HEPATITIS B CORE ANTIGEN; HPV16 E7 VACCINE/drug therapy; HUMAN PAPILLOMA VIRUS ANTIGEN/drug therapy; HYBRID PROTEIN; IMIQUIMOD/adverse drug reaction; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; NUCLEOPROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG DN: Coval/Stressgen Biotechnologies MN: Stressgen Biotechnologies ET: Immunology, Serology and Transplantation; Drug Literature Index; Adverse Reactions Titles TE: imiquimod/99011-02-6 CR: 99011-02-6 AB: There is a high prevalence of diseases caused by human papillomavirus (HPV) infection. Unfortunately, current treatments are inadequate. However, because there is evidence to support a role for the immune system in host defence against this virus, an immunotherapeutic approach is warranted. The existing immunotherapies are not completely effective, nor are they durable. In addition, natural history studies associated with spontaneous regression have provided little guidance to the design of successful interventions. This state of knowledge has encouraged efforts towards the development of novel immunotherapeutic strategies. Successful preclinical studies of therapeutic vaccine candidates have led to clinical studies for a variety of HPV-associated indications, such as AU: CNOTE: anogenital warts and cervical and anal intraepithelial neoplasia. Immunisation approaches such as adjuvanted peptides, virus-like particles and fusion constructs are discussed. Specifically, chimaeric molecules comprised of mycobacterial heatshock proteins (Hsps) and HPV16 E7 appear promising. Chu NR Chu N. Randall Stressgen Biotechnologies Corp., 350-4243 Glanford Ave., Victoria, BC V8Z 4B9, Canada [email protected] Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/84 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2003005992 Vukasin P Titel: Anal condyloma and HIV-associated anal disease Source: Surgical Clinics of North America; VOL: 82 (6); p. 1199-1211 /200212/ SU: EMBASE Sprache: English AL: English CY: United States ISSN: 0039-6109 CO: SCNAA PII: S0039610902000853 Institution: Vukasin P, Dr., Keck School of Medicine, University of Southern California, 1450 San Pablo Street, Los Angeles, CA 90033, United States, [email protected] COU: United States DT: Review; Journal Article JSC: D.1 ... General & Abdominal Surgery RN: 0074 Keywords CT: ANUS CONDYLOMA/*drug therapy; ANUS CONDYLOMA/*epidemiology; ANUS CONDYLOMA/*surgery; ANUS CONDYLOMA/*therapy; ANUS DISEASE/*drug therapy; ANUS DISEASE/*etiology; ANUS DISEASE/*surgery; ANUS ULCER/*drug therapy; ANUS ULCER/*etiology; ANUS ULCER/*surgery; CONDYLOMA/*drug therapy; CONDYLOMA/*epidemiology; CONDYLOMA/*surgery; CONDYLOMA/*therapy; HUMAN IMMUNODEFICIENCY VIRUS/*; ANUS CARCINOMA/epidemiology; ANUS CARCINOMA/etiology; CARCINOGENIC ACTIVITY; DISEASE ASSOCIATION; ERYTHEMA/side effect; HUMAN; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; SKIN IRRITATION/side effect; ACICLOVIR/drug combination; ACICLOVIR/drug therapy; ANTIBIOTIC AGENT/drug therapy; ANTIVIRUS DN: ET: TE: CR: AB: AU: CNOTE: AGENT/drug therapy; DICHLOROACETIC ACID/drug therapy; DICHLOROACETIC ACID/topical drug administration; FLUOROURACIL/drug therapy; FLUOROURACIL/topical drug administration; IMIQUIMOD/adverse drug reaction; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; INTERFERON/drug therapy; INTERFERON/intralesional drug administration; LIQUID NITROGEN; METRONIDAZOLE/drug combination; METRONIDAZOLE/drug therapy; PODOPHYLLIN/adverse drug reaction; PODOPHYLLIN/drug therapy; PODOPHYLLIN/topical drug administration; STEROID/drug therapy; STEROID/intralesional drug administration Aldara Drug Literature Index; Adverse Reactions Titles; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Gastroenterology; Surgery aciclovir/59277-89-3; dichloroacetic acid/13425-80-4; dichloroacetic acid/215656-1; dichloroacetic acid/79-43-6; fluorouracil/51-21-8; imiquimod/99011-02-6; metronidazole/39322-38-8; metronidazole/443-48-1; podophyllin/9000-55-9 59277-89-3; 13425-80-4; 2156-56-1; 79-43-6; 51-21-8; 99011-02-6; 39322-38-8; 443-48-1; 9000-55-9 Although there are a large variety of anal diagnoses associated with the HIV population, anal condyloma and anal ulcerations make up the vast majority. A large percentage of individuals having multiple concurrent pathologies should also be noted. Thus, this article concentrates on anal condyloma, anal ulceration and HIV, making note of other significant issues. Vukasin P Vukasin Petar Keck School of Medicine, University of Southern California, 1450 San Pablo Street, Los Angeles, CA 90033, United States [email protected] Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/85 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2002435253 Pigot F Titel: Condylomes anaux de l'adulte Anal condyloma in adults Source: Hepato-Gastro; VOL: 9 (6); p. 409-415 /200211/ SU: EMBASE Sprache: French CY: France ISSN: 1253-7020 CO: HEGAF Institution: Pigot F, Hôpital Bagatelle, 33401 Talence Cedex, France, [email protected] COU: France DT: Review; Journal Article JSC: C.1.8 ... Gastroenterology RN: 0019 Keywords CT: ANUS DISEASE/*diagnosis; ANUS DISEASE/*drug therapy; ANUS DISEASE/*etiology; ANUS DISEASE/*surgery; CONDYLOMA/*diagnosis; CONDYLOMA/*drug therapy; CONDYLOMA/*etiology; CONDYLOMA/*surgery; WART VIRUS/*; ADULT; ANUS CANCER/diagnosis; ANUS CANCER/drug therapy; ANUS CANCER/etiology; ANUS CANCER/surgery; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DYSPLASIA/etiology; FEMALE; GENITAL TRACT INFECTION/diagnosis; GENITAL TRACT INFECTION/drug therapy; GENITAL TRACT INFECTION/etiology; GENITAL TRACT INFECTION/surgery; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/drug therapy; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEXUALLY TRANSMITTED DISEASE/diagnosis; SEXUALLY TRANSMITTED DISEASE/drug therapy; SEXUALLY TRANSMITTED DISEASE/etiology; SEXUALLY TRANSMITTED DISEASE/surgery; SQUAMOUS CELL CARCINOMA/diagnosis; SQUAMOUS CELL CARCINOMA/drug therapy; SQUAMOUS CELL CARCINOMA/etiology; SQUAMOUS CELL CARCINOMA/surgery; VIRUS CARCINOGENESIS; VIRUS TRANSMISSION; FLUOROURACIL/*drug therapy; IMIQUIMOD/*clinical trial; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug administration; IMMUNOMODULATING AGENT/*clinical trial; IMMUNOMODULATING AGENT/*drug therapy; IMMUNOMODULATING AGENT/*topical drug administration; PODOPHYLLOTOXIN/*drug therapy; ANTIRETROVIRUS AGENT/drug therapy DN: Aldara; Condyline; Efudix ET: Obstetrics and Gynecology; Cancer; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Gastroenterology TE: fluorouracil/51-21-8; imiquimod/99011-02-6; podophyllotoxin/518-28-5 CR: 51-21-8; 99011-02-6; 518-28-5 AU: Pigot F Pigot François Hôpital Bagatelle, 33401 Talence Cedex, France [email protected] CNOTE: Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/86 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2002403432 Kaspari M; Gutzmer R; Kaspari T; Kapp A; Brodersen JP Titel: Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma Source: British Journal of Dermatology; VOL: 147 (4); p. 757-759 /2002/ DOI: 10.1046/j.1365-2133.2002.04979.x SU: EMBASE Sprache: English AL: English CY: United Kingdom ISSN: 0007-0963 CO: BJDEA Institution: Kaspari M, Department of Dermatology, Hannover Medical University, Ricklinger Strasse 5, 30449 Hannover, Germany, [email protected] COU: Germany DT: Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0011 Keywords CT: ANUS DISEASE/*drug therapy; ANUS DISEASE/*prevention; ANUS DISEASE/*surgery; CONDYLOMA/*drug therapy; CONDYLOMA/*prevention; CONDYLOMA/*surgery; INFECTION PREVENTION/*; SUPPOSITORY/*; TAMPON/*; ADULT; ARTICLE; BURNING SENSATION/side effect; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PRURITUS/side effect; RECURRENT DISEASE; SURGICAL TECHNIQUE; TREATMENT OUTCOME; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug therapy; IMIQUIMOD/*pharmacology DN: Aldara ET: Dermatology and Venereology; Drug Literature Index; Adverse Reactions Titles; Gastroenterology TE: imiquimod/99011-02-6 CR: 99011-02-6 AB: Background: After surgical removal, anal canal condyloma (ACC) has a higher risk of recurrence compared with extragenital warts. Objectives: To reduce local recurrences of ACC using follow-up treatment with imiquimod-containing suppositories (anal tampons). Methods: After ablation of ACC, 10 male patients received treatment with imiquimod suppositories three times weekly for 3-4 months. Results: Treatment with imiquimod anal tampons was well tolerated. Early initial recurrences in some patients cleared after treatment with the imiquimod suppositories. Within a mean follow-up of 9 months no patient demonstrated recurrence of ACC. Conclusions: These data suggest that imiquimod anal tampons may represent a new therapeutic option to prevent recurrences of ACC following ablative surgery. AU: Gutzmer R Gutzmer R Department of Dermatology, Hannover Medical University, Ricklinger Strasse 5, 30449 Hannover, Germany AU: Kaspari M Kaspari Markus AU: AU: AU: CNOTE: Department of Dermatology, Hannover Medical University, Ricklinger Strasse 5, 30449 Hannover, Germany Kaspari T Kaspari T Department of Dermatology, Hannover Medical University, Ricklinger Strasse 5, 30449 Hannover, Germany Kapp A Kapp A Department of Dermatology, Hannover Medical University, Ricklinger Strasse 5, 30449 Hannover, Germany Brodersen JP Brodersen JP Department of Dermatology, Hannover Medical University, Ricklinger Strasse 5, 30449 Hannover, Germany Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/87 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2002188385 Jayne CJ; Kaufman RH Titel: Treatment of vulvar intraepithelial neoplasia 2/3 with imiquimod Source: Journal of Reproductive Medicine for the Obstetrician and Gynecologist; VOL: 47 (5); p. 395-398 /2002/ SU: EMBASE Sprache: English AL: English CY: United States ISSN: 0024-7758 CO: JRPMA Institution: Kaufman RH, Dr., 6624 Fannin, Houston, TX 77030, United States, [email protected] COU: United States DT: Journal Article JSC: C.4 ... Obstetrics & Gynecology RN: 0011 Keywords CT: CARCINOMA IN SITU/*diagnosis; CARCINOMA IN SITU/*drug therapy; VULVA CARCINOMA/*diagnosis; VULVA CARCINOMA/*drug therapy; ADULT; AGED; ARTICLE; CANCER INVASION/complication; CANCER REGRESSION; CLINICAL ARTICLE; CREAM; DIAGNOSTIC ACCURACY; DRUG EFFICACY; EVALUATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PATIENT CARE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR BIOPSY; IMIQUIMOD/*drug therapy; ET: TE: CR: AB: AU: AU: CNOTE: IMIQUIMOD/*pharmaceutics; IMIQUIMOD/*topical drug administration Obstetrics and Gynecology; Cancer; Drug Literature Index; Pharmacy; General Pathology and Pathological Anatomy imiquimod/99011-02-6 99011-02-6 OBJECTIVE: To retrospectively review the charts of 13 women diagnosed with vulvar intraepithelial neoplasia (VIN) 2/3 treated with imiquimod and to evaluate the efficacy of this treatment. STUDY DESIGN: Retrospective review. All 13 women were treated and evaluated by a single gynecologist. The extent of the lesions prior to treatment and the extent and degree of improvement were documented. Biopsy confirmation of disease was obtained for each individual. Response to treatment was categorized as complete regression, at least 75% regression or not improved. RESULTS: The mean duration of treatment was 3.3 months, and follow-up after completion of therapy was 5.5 months. Eight of the 13 women had complete regression of the VIN. Four patients demonstrated 75% regression of disease, and in one diabetic woman no improvement was seen. In two women demonstrating 75% lesion regression, invasive carcinoma of the vulva was found in the area of residual disease. In one instance this was determined to be superficially invasive squamous cell carcinoma (1 mm of invasion), and in the second an anal tag was found to have invasive squamous cell carcinoma. CONCLUSION: Medical management of VIN 2/3 with imiquimod is worth considering. However, careful evaluation of the patient must be carried out prior to the institution of therapy to exclude the presence of invasive squamous cell carcinoma. Jayne CJ Jayne Christopher J. 6624 Fannin, Houston, TX 77030, United States Kaufman RH Kaufman Raymond H. 6624 Fannin, Houston, TX 77030, United States Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/88 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2002110754 Mahé E; Descamps V Titel: Un nouvel anti-viral pour les condylomes ano-génitaux A new antiviral for genito-anal condylomas Source: Presse Medicale; VOL: 31 (10); p. 449-450 /20020316/ SU: EMBASE Sprache: French CY: France ISSN: 0755-4982 CO: PRMEE Institution: Mahé E, Serv. de Dermatol. du Pr Cricks, Hôpital Bichat-Claude Bernard, 75018 Paris, France France Note; Journal Article C.0 ... Clinical Medicine 0007 COU: DT: JSC: RN: Keywords CT: ANOGENITAL CONDYLOMA/*drug therapy; CONDYLOMA/*drug therapy; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERADICATION THERAPY; HERPES VIRUS; HUMAN; IMMUNOCOMPETENCE; NEPHROTOXICITY/side effect; NOTE; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT OUTCOME; CIDOFOVIR/*adverse drug reaction; CIDOFOVIR/*clinical trial; CIDOFOVIR/*drug therapy; CIDOFOVIR/*intravenous drug administration; IMIQUIMOD; PLACEBO DN: Aldara; Vistide ET: Public Health, Social Medicine and Epidemiology; Clinical and Experimental Pharmacology; Drug Literature Index; Adverse Reactions Titles; Microbiology: Bacteriology, Mycology, Parasitology and Virology TE: cidofovir/113852-37-2; imiquimod/99011-02-6 CR: 113852-37-2; 99011-02-6 AU: Mahé E Mahé E Serv. de Dermatol. du Pr Cricks, Hôpital Bichat-Claude Bernard, 75018 Paris, France AU: Descamps V Descamps V Serv. de Dermatol. du Pr Cricks, Hôpital Bichat-Claude Bernard, 75018 Paris, France CNOTE: Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/89 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2002032801 Pfenninger JL; Zainea GG Titel: Common anorectal conditions Source: DOI: SU: Sprache: AL: CY: ISSN: Obstetrics and Gynecology; VOL: 98 (6); p. 1130-1139 /2001/ 10.1016/S0029-7844(01)01687-8 EMBASE English English United States 0029-7844 CO: OBGNA PII: S0029784401016878 Institution: Pfenninger JL, Dr., Natl. Procedures Inst., Midland, MI, Midland, MI, United States COU: United States DT: Journal Article JSC: C.4 ... Obstetrics & Gynecology RN: 0033 Keywords CT: ANORECTAL DISEASE/*disease management; ANORECTAL DISEASE/*drug therapy; ANORECTAL DISEASE/*surgery; ANORECTAL DISEASE/*therapy; ANUS CANCER/drug therapy; ANUS CANCER/radiotherapy; ANUS FISSURE/drug therapy; ANUS FISTULA/surgery; ARTICLE; CANCER SCREENING; CLINICAL FEATURE; COLORECTAL CANCER/surgery; CONDYLOMA ACUMINATUM; ENTERITIS; FAMILY HISTORY; GENERAL PRACTITIONER; HEMORRHOID/surgery; HEMORRHOID/therapy; HUMAN; PAPILLOMA VIRUS; PERIANAL ABSCESS/surgery; POLYP; PRIORITY JOURNAL; RECTUM PROLAPSE/surgery; SEPSIS/drug therapy; SEPSIS/surgery; SEXUALITY; STENOSIS/surgery; ULCER; VIRUS INFECTION; ANESTHETIC AGENT/drug therapy; ANTIBIOTIC AGENT/drug therapy; BOTULINUM TOXIN/drug therapy; BOTULINUM TOXIN/pharmacoeconomics; CORTICOSTEROID/drug therapy; DILTIAZEM/drug therapy; FLUOROURACIL/drug therapy; GLYCERYL TRINITRATE/drug therapy; IMIQUIMOD/drug therapy; IMIQUIMOD/pharmacoeconomics; INTERFERON/drug therapy; LIDOCAINE/drug therapy; LIDOCAINE/topical drug administration; MISOPROSTOL/drug therapy; NIFEDIPINE/drug therapy; NIFEDIPINE/topical drug administration; PHENYTOIN/drug therapy; PODOPHYLLOTOXIN/drug therapy; PODOPHYLLOTOXIN/pharmacoeconomics; SUPPOSITORY BASE/drug therapy; SUPPOSITORY BASE/rectal drug administration; TRICHLOROACETIC ACID/drug therapy ET: Cancer; Health Policy, Economics and Management; Drug Literature Index; Gastroenterology TE: diltiazem/33286-22-5; diltiazem/42399-41-7; fluorouracil/51-21-8; glyceryl trinitrate/55-63-0; imiquimod/99011-02-6; lidocaine/137-58-6; lidocaine/2484767-4; lidocaine/56934-02-2; lidocaine/73-78-9; misoprostol/59122-46-2; misoprostol/59122-48-4; nifedipine/21829-25-4; phenytoin/57-41-0; phenytoin/630-93-3; podophyllotoxin/518-28-5; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 CR: 33286-22-5; 42399-41-7; 51-21-8; 55-63-0; 99011-02-6; 137-58-6; 24847-67-4; 56934-02-2; 73-78-9; 59122-46-2; 59122-48-4; 21829-25-4; 57-41-0; 630-93-3; 518-28-5; 14357-05-2; 76-03-9 AB: Patients with a wide variety of anorectal lesions present to family physicians. Most can be successfully managed in the office setting. A high index of suspicion for cancer should be maintained and all patients should be questioned about relevant family history or other indications for cancer screening. Patients with condylomata acuminata must be examined for human papillomavirus infection AU: AU: CNOTE: elsewhere after treatment of the presenting lesions. Their sexual partners should also be counseled and screened. Both surgical and nonsurgical treatments are available for the pain of anal fissure. Infection in the anorectal area may present as different types of abscesses, cryptitis, fistulae or perineal sepsis. Fistulae may result from localized infection or indicate inflammatory bowel disease. Protrusion of tissue through the anus may be due to hemorrhoids, mucosal prolapse, polyps or other lesions. Pfenninger JL Pfenninger John L National Procedures Institute, Midland, MI, United States Zainea GG Zainea George G Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/90 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2001248617 Pfenninger JL; Zainea GG Titel: Common anorectal conditions: Part II. Lesions Source: American Family Physician; VOL: 64 (1); p. 77-88 /20010701/ SU: EMBASE Sprache: English AL: English CY: United States ISSN: 0002-838X CO: AFPYA Institution: Pfenninger JL, Dr., National Procedures Institute, Midland, MI, United States COU: United States DT: Journal Article JSC: C.0 ... Clinical Medicine RN: 0033 Keywords CT: ANORECTAL DISEASE/*diagnosis; ANORECTAL DISEASE/*disease management; ANORECTAL DISEASE/*drug therapy; ANORECTAL DISEASE/*etiology; ANORECTAL DISEASE/*surgery; ANUS CANCER/surgery; ANUS FISSURE/drug therapy; ANUS FISSURE/surgery; ANUS FISTULA/etiology; ANUS FISTULA/surgery; ARTICLE; CANCER SCREENING; COLORECTAL CANCER/diagnosis; CONDYLOMA ACUMINATUM/disease management; CONDYLOMA ACUMINATUM/drug therapy; CONDYLOMA ACUMINATUM/etiology; CONDYLOMA ACUMINATUM/surgery; FAMILY HISTORY; HEMORRHOID/surgery; HUMAN; INFECTION/surgery; PERIANAL ABSCESS/etiology; PERIANAL ABSCESS/surgery; PROCTITIS/etiology; RECTUM CANCER/surgery; RECTUM POLYP/diagnosis; RECTUM PROLAPSE/surgery; STENOSIS/surgery; WART VIRUS; FLUOROURACIL/*drug therapy; FLUOROURACIL/*pharmacoeconomics; INTERFERON/*drug therapy; INTERFERON/*pharmacoeconomics; TRICHLOROACETIC ACID/*drug therapy; TRICHLOROACETIC ACID/*pharmacoeconomics; DILTIAZEM/drug therapy; GLYCERYL TRINITRATE/drug therapy; GLYCERYL TRINITRATE/topical drug administration; IMIQUIMOD/drug therapy; IMIQUIMOD/pharmacoeconomics; LIDOCAINE/drug therapy; LIDOCAINE/topical drug administration; NIFEDIPINE/drug therapy; PODOPHYLLOTOXIN/drug therapy; PODOPHYLLOTOXIN/pharmacoeconomics; STEROID/drug therapy; STEROID/topical drug administration Aldara; Condylox; Efudex Health Policy, Economics and Management; Drug Literature Index; Gastroenterology; Internal Medicine diltiazem/33286-22-5; diltiazem/42399-41-7; fluorouracil/51-21-8; glyceryl trinitrate/55-63-0; imiquimod/99011-02-6; lidocaine/137-58-6; lidocaine/2484767-4; lidocaine/56934-02-2; lidocaine/73-78-9; nifedipine/21829-25-4; podophyllotoxin/518-28-5; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9 33286-22-5; 42399-41-7; 51-21-8; 55-63-0; 99011-02-6; 137-58-6; 24847-67-4; 56934-02-2; 73-78-9; 21829-25-4; 518-28-5; 14357-05-2; 76-03-9 Patients with a wide variety of anorectal lesions present to family physicians. Most can be successfully managed in the office setting. A high index of suspicion for cancer should be maintained and all patients should be questioned about relevant family history or other indications for cancer screening. Patients with condylomata acuminata must be examined for human papillomavirus infection elsewhere after treatment of the presenting lesions. Their sexual partners should also be counseled and screened. Both surgical and nonsurgical treatments are available for the pain of anal fissure. Infection in the anorectal area may present as different types of abscesses, cryptitis, fistulae or perineal sepsis. Fistulae may result from localized infection or indicate inflammatory bowel disease. Protrusion of tissue through the anus may be due to hemorrhoids, mucosal prolapse, polyps or other lesions. Pfenninger JL Pfenninger JL National Procedures Institute, Midland, MI, United States Zainea GG Zainea GG National Procedures Institute, Midland, MI, United States Copyright 2007 Elsevier B.V., All rights reserved. DN: ET: TE: CR: AB: AU: AU: CNOTE: » Volltext-Angebot » 2/91 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: EM2001181833 Autoren: Menz J Titel: Pruritus ani: Some answers for that maddening itch! Source: Medicine Today; VOL: 2 (5); p. 67-73 /2001/ SU: EMBASE Sprache: English AL: English CY: Australia ISSN: 1443-430X CO: MTNBC DT: Review; Journal Article JSC: C.0 ... Clinical Medicine Keywords CT: ANUS PRURITUS/*drug therapy; ANUS PRURITUS/*etiology; ANUS PRURITUS/*surgery; ANUS PRURITUS/*therapy; ANAMNESIS; ANUS FISSURE; ATOPIC DERMATITIS/drug therapy; BOWEN DISEASE; CANCER; CANDIDIASIS; CLEANING; CLOTHING; CONTACT DERMATITIS; CONTAMINATION; CRYOTHERAPY; DIET THERAPY; DISEASE PREDISPOSITION; ENTEROBIUS VERMICULARIS; FECES; GENERAL PRACTITIONER; HEMORRHOID/surgery; HEMORRHOIDECTOMY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPEREMIA; INFECTION; LICHEN SCLEROSUS ET ATROPHICUS; PAGET SKIN DISEASE; PERSONAL HYGIENE; PODOPHYLLUM/drug therapy; PODOPHYLLUM/topical drug administration; PSORIASIS; PSYCHOLOGICAL ASPECT; RECTUM PROLAPSE; REVIEW; SEBORRHEIC DERMATITIS/drug therapy; SKIN CANCER; SKIN DISEASE/drug therapy; SQUAMOUS CELL CARCINOMA; SWEATING; SYMPTOM; TINEA; ULTRAPROCT; WART VIRUS; ANTHELMINTIC AGENT/drug therapy; ANTIHISTAMINIC AGENT/drug therapy; ANTIINFECTIVE AGENT/drug therapy; ANUSOL; CLOTRIMAZOLE/drug therapy; CLOTRIMAZOLE/topical drug administration; COMBANTRIN 1; CONDYLINE PAINT; DOXEPIN/drug therapy; FEXOFENADINE/drug therapy; FULCHIN; GLYCERYL TRINITRATE; GRISEOFULVIN/drug therapy; GRISEOFULVIN/oral drug administration; HEMOCAINE; HYDROCORTISONE/drug therapy; HYDROCORTISONE/topical drug administration; HYDROCORTISONE ACETATE/drug therapy; HYDROCORTISONE ACETATE/topical drug administration; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration; LIQUID PARAFFIN/drug therapy; LORASTYNE; LORATADINE/drug therapy; MEBENDAZOLE/drug therapy; MENTHOL/drug therapy; MICONAZOLE/drug therapy; MICONAZOLE/topical drug administration; POSALFILIN; PREPARATION H; PROCTOSEDYL; PYRANTEL EMBONATE/drug therapy; RECTINOL; SAMA LOTION; SCHERIPROCT; UNCLASSIFIED DRUG; XYLOPROCT/drug therapy; XYLOPROCT/topical drug administration; ZINC/drug therapy DN: Aldara; Anusol; Canesten; Claratyne; Combantrin 1; Condyline Paint; Daktarin; Deptran; Fulchin; Griseostatin; Grisovin; Hemocaine; Lorastyne; Posalfilin; Preparation H; Proctosedyl; Rectinol; Rectogesic; Sama Lotion; Scheriproct; Sigmacort; Sinequan; Telfast; Ultraproct; Xyloproct ET: Dermatology and Venereology; Cancer; Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Gastroenterology TE: anusol/8053-45-0; clotrimazole/23593-75-1; doxepin/1229-29-4; doxepin/1668-195; fexofenadine/138452-21-8; glyceryl trinitrate/55-63-0; griseofulvin/126-07-8; hydrocortisone acetate/50-03-3; hydrocortisone/50-23-7; imiquimod/99011-02-6; liquid paraffin/8012-95-1; loratadine/79794-75-5; mebendazole/31431-39-7; menthol/1490-04-6; menthol/89-78-1; miconazole/22916-47-8; proctosedyl/805805-7; pyrantel embonate/22204-24-6; zinc/7440-66-6 CR: 8053-45-0; 23593-75-1; 1229-29-4; 1668-19-5; 138452-21-8; 55-63-0; 126-07-8; 50-03-3; 50-23-7; 99011-02-6; 8012-95-1; 79794-75-5; 31431-39-7; 1490-04-6; 8978-1; 22916-47-8; 8058-05-7; 22204-24-6; 7440-66-6 AB: Pruritus ani is a common condition and is more frequent in men than women. Pruritus ani is a symptom rather than a diagnosis. Faecal contamination is a predisposing factor. Local hygiene problems frequently contribute to faecal contamination, and surgical problems such as haemorrhoids, fissures, mucosal prolapse or scars may be causes of anal leakage. Dermatoses, infections or cancers are other possible underlying causes. With the removal of underlying pathology, the itch often resolves. Patients are often reticent in discussing the condition and the general practitioner has an important role to play in supporting the patient. AU: Menz J Menz J CNOTE: Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/92 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2001104477 Smith LE; Hyman N; Savoca P; Simmang C; Stratton M Titel: Potions and lotions Source: Perspectives in Colon and Rectal Surgery; VOL: 13 (2); p. 17-30 /2000/ SU: EMBASE Sprache: English AL: English CY: United States ISSN: 0894-8054 CO: PCRSF Institution: Smith LE, Dr., Section of Colon and Rectal Surgery, Washington Hospital Center, Washington, DC, United States COU: United States DT: Review; Journal Article Keywords CT: HEMORRHOID/*drug therapy; HEMORRHOID/*therapy; LOTION/*; ANUS FISSURE/drug therapy; ANUS FISSURE/therapy; CONDYLOMA/drug therapy; CREAM; DRUG EFFECT; DRUG USE; DYSPLASIA; HERPES; HUMAN; ILEITIS; MEDICAL PRACTICE; OINTMENT; PILONIDAL SINUS/drug therapy; PILONIDAL SINUS/therapy; PROCTITIS/drug therapy; REVIEW; SIDE EFFECT/side effect; SUPPOSITORY; ULCERATIVE COLITIS; ANALPRAM; ANUSOL; BENZOCAINE; DICHLOROACETIC ACID/drug therapy; DICHLOROACETIC ACID/topical drug administration; ENEMA/adverse drug reaction; GLYCERYL TRINITRATE/adverse drug DN: ET: TE: CR: AB: reaction; GLYCERYL TRINITRATE/drug therapy; GLYCERYL TRINITRATE/topical drug administration; HYDROCORTISONE/adverse drug reaction; HYDROCORTISONE/drug therapy; HYDROCORTISONE/topical drug administration; HYDROCORTISONE ACETATE/drug combination; HYDROCORTISONE ACETATE/drug therapy; HYDROCORTISONE ACETATE/topical drug administration; IMIQUIMOD/drug therapy; LIDOCAINE; MINERAL OIL/drug therapy; NEOSPORIN/drug therapy; NON PRESCRIPTION DRUG/adverse drug reaction; NON PRESCRIPTION DRUG/drug therapy; PETROLATUM/drug therapy; PLACEBO; PODOPHYLLIN/drug therapy; PODOPHYLLOTOXIN/drug therapy; POLYSPORIN/drug therapy; PRAMOCAINE/drug combination; PRAMOCAINE/drug therapy; PRAMOCAINE/topical drug administration; SILVER NITRATE/drug therapy; SILVER NITRATE/topical drug administration; TANNIN/drug therapy; TANNIN/topical drug administration; TRICHLOROACETIC ACID/drug therapy; TRICHLOROACETIC ACID/topical drug administration; VANCOMYCIN/drug therapy; VANCOMYCIN/oral drug administration Americaine; Analpram; Anusol; Balneol; Condylox; Cortifoam Public Health, Social Medicine and Epidemiology; Drug Literature Index; Adverse Reactions Titles; Gastroenterology anusol/8053-45-0; benzocaine/1333-08-0; benzocaine/94-09-7; dichloroacetic acid/13425-80-4; dichloroacetic acid/2156-56-1; dichloroacetic acid/79-43-6; glyceryl trinitrate/55-63-0; hydrocortisone acetate/50-03-3; hydrocortisone/50-237; imiquimod/99011-02-6; lidocaine/137-58-6; lidocaine/24847-67-4; lidocaine/56934-02-2; lidocaine/73-78-9; neosporin/8057-37-2; petrolatum/800903-8; podophyllin/9000-55-9; podophyllotoxin/518-28-5; polysporin/118933-134; pramocaine/140-65-8; pramocaine/637-58-1; silver nitrate/7761-88-8; tannin/1401-55-4; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9; vancomycin/1404-90-6; vancomycin/1404-93-9 8053-45-0; 1333-08-0; 94-09-7; 13425-80-4; 2156-56-1; 79-43-6; 55-63-0; 50-033; 50-23-7; 99011-02-6; 137-58-6; 24847-67-4; 56934-02-2; 73-78-9; 8057-37-2; 8009-03-8; 9000-55-9; 518-28-5; 118933-13-4; 140-65-8; 637-58-1; 7761-88-8; 1401-55-4; 14357-05-2; 76-03-9; 1404-90-6; 1404-93-9 Many of the topical ointments, creams, suppositories, and enemas that we use have been formulated by someone with good intentions, but without the benefit of scientific scrutiny. This is not to say that certain remedies and herbs from doctors of old and even contemporaries do not obtain some sort of reaction or response. However, many of these items that are promoted by our mentors have been handed down to their students and residents as the answer for specific ailments. We are the disciples who have gathered for discussion of the products and compounds that we have adopted into our personal practices. It is important for us to insert disclaimers that these products have often been created without absolute scientific certainty, and that they will list the intended results. Like various acrossthe-counter medications, many have caused no harm, but also have yielded no effects. However, calming the patient's anxiety is worthwhile. During this discussion, our experts will point out those medications that have merit and those that may have placebo effect. Our first topic is the treatment of hemorrhoidal symptoms without significant procedures; the benefit of suppositories or other topical remedies. We will also cover medications for anal fissures: selection, application, components of, and benefits or side effects. Pilonidal sinuses care will AU: AU: AU: AU: AU: CNOTE: be addressed by our panelists, including the use of silver nitrate. Options for identifying and treating condyloma, dysplasia, and herpes are reviewed; muscle problems such as proctalgia fugax and levator syndrome; suggestions for ulcerative proctitis and pouchitis; and other conditions of interest to our readers will be examined by our group of panelists. Smith LE Smith LE Section of Colon and Rectal Surgery, Washington Hospital Center, Washington, DC, United States Hyman N Hyman N Section of Colon and Rectal Surgery, Washington Hospital Center, Washington, DC, United States Savoca P Savoca P Section of Colon and Rectal Surgery, Washington Hospital Center, Washington, DC, United States Simmang C Simmang C Section of Colon and Rectal Surgery, Washington Hospital Center, Washington, DC, United States Stratton M Stratton M Section of Colon and Rectal Surgery, Washington Hospital Center, Washington, DC, United States Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/93 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2001041907 Michel C; Schubert B Titel: Maladies sexuellement transmises de l'anus Anal sexually transmitted diseases Source: Revue du Praticien; VOL: 51 (1); p. 50-53 /20010115/ SU: EMBASE Sprache: French AL: English; French CY: France ISSN: 0035-2640 CO: REPRA Institution: Michel C, Service de Dermatologie, Centre Hospitalier de Mulhouse, 68070 Mulhouse Cedex, France, [email protected] COU: France DT: JSC: RN: Keywords CT: DN: ET: TE: CR: AB: AU: AU: Review; Journal Article C.0 ... Clinical Medicine 0015 ANUS DISEASE/*drug therapy; ANUS DISEASE/*etiology; SEXUALLY TRANSMITTED DISEASE/*diagnosis; SEXUALLY TRANSMITTED DISEASE/*etiology; CONDYLOMA/drug therapy; CONDYLOMA/etiology; GENITAL HERPES/drug therapy; GENITAL HERPES/etiology; GENOTYPE; GONORRHEA/drug therapy; GONORRHEA/etiology; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; REVIEW; SYPHILIS/drug therapy; SYPHILIS/etiology; VIRUS TRANSMISSION; BENZATHINE PENICILLIN/*drug therapy; BENZATHINE PENICILLIN/*intramuscular drug administration; CEFTRIAXONE/*drug therapy; CEFTRIAXONE/*intramuscular drug administration; CIPROFLOXACIN/*drug therapy; PENICILLIN DERIVATIVE/*drug therapy; SPECTINOMYCIN/*drug therapy; SPECTINOMYCIN/*intramuscular drug administration; AZITHROMYCIN/drug therapy; COTRIMOXAZOLE; DOXYCYCLINE/drug therapy; DOXYCYCLINE/oral drug administration; FAMCICLOVIR/drug therapy; IMIQUIMOD/drug therapy; VALACICLOVIR/drug therapy Aldara; Bactrim Forte; Ciflox; Extencilline; Oravir; Rocephine; Trobicin; Zelitrex; Zithromax Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology; Gastroenterology azithromycin/83905-01-5; benzathine penicillin/1538-09-6; ceftriaxone/73384-595; ceftriaxone/74578-69-1; ciprofloxacin/85721-33-1; cotrimoxazole/8064-90-2; doxycycline/10592-13-9; doxycycline/17086-28-1; doxycycline/564-25-0; famciclovir/104227-87-4; imiquimod/99011-02-6; spectinomycin/1695-77-8; spectinomycin/21736-83-4; spectinomycin/23312-56-3; valaciclovir/124832-26-4 83905-01-5; 1538-09-6; 73384-59-5; 74578-69-1; 85721-33-1; 8064-90-2; 1059213-9; 17086-28-1; 564-25-0; 104227-87-4; 99011-02-6; 1695-77-8; 21736-83-4; 23312-56-3; 124832-26-4 Sexually transmitted diseases, despite vigorous efforts in prevention, are still existing and may provide portal of entry for human immunodeficiency virus transmission. Syphilis and gonococcal infection are decreasing but remain a problem in developing countries and their return cannot be excluded, despite active therapy. In industrial countries, viral infections are expanding. Herpes genitalis is the most common cause of genito-anal ulceration and anogenital warts have been steadily rising in the past decades. Some human papillomavirus genotypes are oncogenic. No treatment is able to eradicate them. Michel C Michel C Service de Dermatologie, Centre Hospitalier de Mulhouse, 68070 Mulhouse Cedex, France Schubert B Schubert B Service de Dermatologie, Centre Hospitalier de Mulhouse, 68070 Mulhouse Cedex, France CNOTE: Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/94 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2001036716 Pehoushek J; Smith KJ Titel: Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man Source: Archives of Dermatology; VOL: 137 (1); p. 14-16 /2001/ SU: EMBASE Sprache: English CY: United States ISSN: 0003-987X CO: ARDEA Institution: Smith KJ, Department Dermatology/Pathology, National Naval Medical Center, Bethesda, MD 20889-5600, United States, [email protected] COU: United States DT: Journal Article JSC: C.5 ... Dermatology & Venereology RN: 0020 Keywords CT: ANUS CARCINOMA/*drug therapy; CARCINOMA IN SITU/*drug therapy; HUMAN IMMUNODEFICIENCY VIRUS 1/*; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; SQUAMOUS CELL CARCINOMA/*drug therapy; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CREAM; DNA PROBE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; SKIN BIOPSY; TREATMENT OUTCOME; ANTIVIRUS AGENT/*drug combination; ANTIVIRUS AGENT/*drug therapy; FLUOROURACIL/*drug combination; FLUOROURACIL/*drug therapy; FLUOROURACIL/*topical drug administration; IMIQUIMOD/*drug combination; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug administration; INDINAVIR/drug combination; INDINAVIR/drug therapy; LAMIVUDINE/drug therapy; NELFINAVIR/drug combination; NELFINAVIR/drug therapy; STAVUDINE/drug combination; STAVUDINE/drug therapy ET: Dermatology and Venereology; Cancer; Drug Literature Index TE: fluorouracil/51-21-8; imiquimod/99011-02-6; indinavir/150378-17-9; indinavir/157810-81-6; indinavir/180683-37-8; lamivudine/134678-17-4; lamivudine/134680-32-3; nelfinavir/159989-64-7; nelfinavir/159989-65-8; stavudine/3056-17-5 CR: 51-21-8; 99011-02-6; 150378-17-9; 157810-81-6; 180683-37-8; 134678-17-4; 134680-32-3; 159989-64-7; 159989-65-8; 3056-17-5 AU: Pehoushek J Pehoushek J AU: CNOTE: Department Dermatology/Pathology, National Naval Medical Center, Bethesda, MD 20889-5600, United States Smith KJ Smith KJ Department Dermatology/Pathology, National Naval Medical Center, Bethesda, MD 20889-5600, United States Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/95 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: Autoren: EM2000375758 Maw R; Von Krogh G Titel: The management of anal warts: Topical self treatment, ablative therapy, and counselling should all be available Source: British Medical Journal; VOL: 321 (7266); p. 910-911 /20001014/ SU: EMBASE Sprache: English CY: United Kingdom ISSN: 0959-8146 CO: BMJOA Institution: Maw R, Royal Victoria Hospital, Belfast BT12 6BA, United Kingdom, [email protected] COU: United Kingdom DT: Editorial; Journal Article JSC: C.0 ... Clinical Medicine RN: 0013 Keywords CT: CONDYLOMA ACUMINATUM/*drug therapy; CRYOTHERAPY; DRUG EFFICACY; EDITORIAL; ELECTROSURGERY; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; TREATMENT PLANNING; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug administration; PODOPHYLLOTOXIN/*drug therapy; PODOPHYLLOTOXIN/*topical drug administration ET: Dermatology and Venereology; Drug Literature Index TE: imiquimod/99011-02-6; podophyllotoxin/518-28-5 CR: 99011-02-6; 518-28-5 AU: Maw R Maw R Royal Victoria Hospital, Belfast BT12 6BA, United Kingdom AU: Von Krogh G Von Krogh G Royal Victoria Hospital, Belfast BT12 6BA, United Kingdom CNOTE: Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/96 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: PMID: Autoren: EMM14610898 14610898 Gross G Titel: Humane Papillomaviren. Human papillomaviruses Source: Therapeutische Umschau. Revue therapeutique; VOL: 60 (10); p. 595-604 /Oct 2003/ SU: Medline Sprache: German AL: English CY: Switzerland ISSN: 0040-5930 Institution: Gross G, Klinik und Poliklinik fur Dermatologie und Venerologie, Universitat Rostock, Deutschland., [email protected] DT: Journal Article JSC: C.0 ... Clinical Medicine Keywords CT: PAPILLOMA VIRUS/*; SKIN TUMOR/*diagnosis; SKIN TUMOR/*therapy; VIRAL SKIN DISEASE/*diagnosis; VIRAL SKIN DISEASE/*therapy; VIRUS INFECTION/*diagnosis; VIRUS INFECTION/*therapy; ADOLESCENT; ADULT; ANUS TUMOR/diagnosis; ANUS TUMOR/therapy; ARTICLE; BIOPSY; CONDYLOMA ACUMINATUM/diagnosis; CONDYLOMA ACUMINATUM/therapy; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; SKIN; UROGENITAL TRACT TUMOR/diagnosis; UROGENITAL TRACT TUMOR/therapy; VERRUCA VULGARIS/diagnosis; VERRUCA VULGARIS/therapy AB: Human papillomaviruses (HPV) infect exclusively the basal cells of the skin and of mucosal epithelia adjacent to the skin such as the mouth, the upper respiratory tract, the lower genital tract and the anal canal. HPV does not lead to a viremia. Basically there are three different types of HPV infection: Clinically visible lesions, subclinical HPV infections and latent HPV infections. Distinct HPV types induce morphologically and prognostically different clinical pictures. The most common HPV associated benign tumor of the skin is the common wart. Infections of the urogenitoanal tract with specific HPV-types are recognised as the most frequent sexually transmitted viral infections. So-called "high-risk" HPV-types (HPV16, 18 and others) are regarded by the world health organisation as important risk-factors for the development of genital cancer (mainly cervical cancer), anal cancer and upper respiratory tract cancer in both genders. Antiviral substances with a specific anti-HPV effect are so far unknown. Conventional therapies of benign skin warts and of mucosal warts are mainly nonspecific. They comprise tissue-destroying therapies such as electrocautery, cryotherapy and laser. In addition cytotoxic substances such as podophyllotoxin and systemic therapy with retinoids are in use. Systemically and topically administered AU: CNOTE: immunotherapies represent a new approach for treatment. Both interferons and particularly the recently developed imiquimod, an interferon-alpha and cytokineinductor lead to better results and are better tolerated then conventional therapies. HPV-specific vaccines have been developed in the last 5 years and will be used in future for prevention and treatment of benign and malignant HPV-associated tumors of the genitoanal tract in both sexes. Gross G Gross G Klinik und Poliklinik fur Dermatologie und Venerologie, Universitat Rostock, Deutschland. MEDLINE® is the source for the citation and abstract of this record. » Volltext-Angebot » 2/97 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: PMID: Autoren: EMM12835572 12835572 Heinzerling LM; Kempf W; Kamarashev J; Hafner J; Nestle FO Titel: Treatment of verrucous carcinoma with imiquimod and CO2 laser ablation. Source: Dermatology (Basel, Switzerland); VOL: 207 (1); p. 119-122 /2003/ SU: Medline Sprache: English AL: English CY: Switzerland ISSN: 1018-8665 Institution: Heinzerling LM, University Hospital Zurich, Zurich, Switzerland. DT: Journal Article Keywords CT: LASER/*drug therapy; SKIN TUMOR/*therapy; VERRUCOUS CARCINOMA/*therapy; AGED; ARTICLE; CANCER STAGING; CASE REPORT; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; PATHOLOGY; RISK ASSESSMENT; TREATMENT OUTCOME; AMINOQUINOLINE DERIVATIVE/*drug administration; CARBON DIOXIDE; IMIQUIMOD TE: carbon dioxide/124-38-9; imiquimod/99011-02-6 CR: 124-38-9; 99011-02-6 AB: An 82-year-old female patient presented with a large perianal hyperkeratotic tumor extending into the anal canal. Staging did not reveal any metastatic spread. Diagnosis of verrucous carcinoma or Buschke-Lowenstein tumor, respectively, was based on typical clinical and histologic features. Moreover, human papillomavirus 6b DNA sequences could be detected by PCR. Surgical excision could not be performed due to the general health status of the patient; thus, alternative therapy methods were necessary. Treatment with imiquimod cream 5% (Aldara), a topical immune response modifier applied once a day and left for 12 h, led to significant partial tumor regression and clear demarcation of the AU: AU: AU: AU: AU: CNOTE: tumor. The remaining tumor, now feasible for treatment with CO2 laser, was removed in two sessions in local anesthesia. In a third session, tumor parts in the anal canal were vaporized. This case demonstrates that the combination of imiquimod and CO2 laser ablation is an effective treatment option for verrucous carcinoma. Copyright 2003 S. Karger AG, Basel Heinzerling LM Heinzerling LM University Hospital Zurich, Zurich, Switzerland. Kempf W Kempf W University Hospital Zurich, Zurich, Switzerland. Kamarashev J Kamarashev J University Hospital Zurich, Zurich, Switzerland. Hafner J Hafner J University Hospital Zurich, Zurich, Switzerland. Nestle FO Nestle FO University Hospital Zurich, Zurich, Switzerland. MEDLINE® is the source for the citation and abstract of this record. » Volltext-Angebot » 2/98 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: PMID: Autoren: EMM12903534 12903534 Bertagni A; Vagliasindi A; Ascari Raccagni A; Valmori L; Verdecchia GM Titel: Perianal Bowen's disease: a case report and review of the literature. Perianal Bowen's disease: a case report and review of the literature Source: Tumori; VOL: 89 (4 Suppl); p. 16-18 /2003 Jul-Aug/ SU: Medline Sprache: Italian AL: English CY: Italy ISSN: 0300-8916 Institution: Bertagni A, UO di Chirurgia Generale II, Unita di Chirurgia Oncologica, Ospedale GB Morgagni-L Pierantoni, Forli. DT: Review; Journal Article JSC: C.1.3 ... Oncology RN: 0012 Keywords CT: ANUS TUMOR/*complication; ANUS TUMOR/*drug therapy; ANUS TE: CR: AB: AU: AU: AU: AU: TUMOR/*radiotherapy; ANUS TUMOR/*surgery; BOWEN DISEASE/*complication; BOWEN DISEASE/*drug therapy; BOWEN DISEASE/*radiotherapy; BOWEN DISEASE/*surgery; SKIN TUMOR/*complication; SKIN TUMOR/*drug therapy; SKIN TUMOR/*radiotherapy; SKIN TUMOR/*surgery; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CASE REPORT; FEMALE; GASTROINTESTINAL HEMORRHAGE/etiology; HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PAIN/etiology; PAPILLOMA VIRUS; PATHOLOGY; PRURITUS/etiology; REVIEW; VIROLOGY; VIRUS INFECTION; VULVITIS/complication; ANTINEOPLASTIC AGENT/drug therapy; FLUOROURACIL/drug administration; MITOMYCIN/drug administration mitomycin/1404-00-8 1404-00-8 Perianal Bowen's disease is a uncommon, slow growing, intraepidermal squamous-cell carcinoma (carcinoma in situ) of the anal region and may be a precursor to squamous carcinoma of the anus. It is associated with cervical and vulvar intraepithelial neoplasia and have human papillomavirus as a common cause. Both sexes and all races are affected, with the highest prevalence in patients aged 20 to 45 years. The symptoms of anal Bowen's disease are unspecific and the clinical findings are uncharacteristic and include pain, itching, bleeding and a disturbing lump. Biopsy and histopathologic examination is required for diagnosis and to distinguish other perianal dermatoses; thus an anogenital warts that fail to respond to conventional therapy, or change in appearance, warrant a biopsy and, where the technique is available, DNA typing to identify the viral pathogen. Infact the etiologic agent, the human papillomavirus (HPV), has been classified by DNA techniques into at least 42 types, of which 16 and 18 are considered to carry a high risk for cancer. The intraoperative findings is a lesion at the anocutaneous line: perianal or intra-anal tumor, erosion or ulceration as well as lichenoid lesion or hyperpigmentation. The disease has a proclivity for recurrence and there are many controversies concerning treatment that effectiveness remains uncertain and range from aggressive wide local excision with skin grafting when necessary to laser vaporization (argon or CO2), radiotherapy or a new immune response modifier (Imiquimod). We report a case of a 50-years-old woman with recurrence of Bowen's disease associated with vulvar HPV infection and review the literature. Bertagni A Bertagni A UO di Chirurgia Generale II, Unita di Chirurgia Oncologica, Ospedale GB Morgagni-L Pierantoni, Forli. Vagliasindi A Vagliasindi A UO di Chirurgia Generale II, Unita di Chirurgia Oncologica, Ospedale GB Morgagni-L Pierantoni, Forli. Ascari Raccagni A Ascari Raccagni A UO di Chirurgia Generale II, Unita di Chirurgia Oncologica, Ospedale GB Morgagni-L Pierantoni, Forli. Valmori L AU: CNOTE: Valmori L UO di Chirurgia Generale II, Unita di Chirurgia Oncologica, Ospedale GB Morgagni-L Pierantoni, Forli. Verdecchia GM Verdecchia GM UO di Chirurgia Generale II, Unita di Chirurgia Oncologica, Ospedale GB Morgagni-L Pierantoni, Forli. MEDLINE® is the source for the citation and abstract of this record. » Volltext-Angebot » 2/99 von 102 DIMDI: EMBASE (EM00) © 2011 Elsevier B.V. ND: PMID: Autoren: EMM11894692 11894692 Sultan S Titel: Condylomes anaux: une prise en charge encore difficile. Anal condyloma: its management is still difficult Source: Journal de chirurgie; VOL: 138 (5); p. 277-280 /Oct 2001/ SU: Medline Sprache: French AL: English CY: France ISSN: 0021-7697 Institution: Sultan S, Service de Coloproctologie, Hopital des Diaconesses, 18, rue du Sergent-Bauchat, F 75012 Paris. DT: Review; Journal Article JSC: D.1 ... General & Abdominal Surgery RN: 0037 Keywords CT: ANUS DISEASE/*diagnosis; ANUS DISEASE/*therapy; CONDYLOMA ACUMINATUM/*diagnosis; CONDYLOMA ACUMINATUM/*therapy; HUMAN; REVIEW; VIROLOGY AB: Anal condylomas result from papillomavirus infection, the most common sexually transmitted disease. The principal risk is the development of cancer of the anal canal. The risk of contamination is high, even after a single sexual contact. No specific antiviral treatment is available and no consensus has been reached on the appropriate treatment of anal condylomas. Despite the development of various methods (interferon, imiquimod), electrocoagulation remains the treatment of choice. Finally, regular follow-up and treatment of the partner(s) are essential. AU: Sultan S Sultan S Service de Coloproctologie, Hopital des Diaconesses, 18, rue du Sergent-Bauchat, F 75012 Paris. CNOTE: MEDLINE® is the source for the citation and abstract of this record. » Volltext-Angebot » 2/100 von 102 DIMDI: EMBASE (EM47) © 2011 Elsevier B.V. ND: Autoren: EM1998212508 Fleshner PR Titel: Management of anal diseases in the patient infected with human immunodeficiency virus Source: Seminars in Colon and Rectal Surgery; VOL: 9 (2); p. 90-93 /1998/ SU: EMBASE Sprache: English AL: English CY: United States ISSN: 1043-1489 CO: SCRSF Institution: Fleshner PR, Dr., 8737 Beverly Blvd, Los Angeles, CA 90048, United States COU: United States DT: Review; Journal Article JSC: C.1.8 ... Gastroenterology; D.1 ... General & Abdominal Surgery RN: 0032 Keywords CT: ANUS DISEASE/*surgery; ANUS DISEASE/*therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; ANUS FISSURE/drug therapy; ANUS FISSURE/surgery; ANUS FISSURE/therapy; ANUS FISTULA/surgery; ANUS FISTULA/therapy; ANUS SPHINCTER; CAUTERIZATION; CONDYLOMA/drug therapy; CONDYLOMA/surgery; CONDYLOMA/therapy; ERADICATION THERAPY; EXCISION; HEMORRHOID/surgery; HEMORRHOID/therapy; HEMORRHOIDECTOMY; HUMAN; ORAL DRUG ADMINISTRATION; PERIANAL ABSCESS/drug therapy; PERIANAL ABSCESS/surgery; PERIANAL ABSCESS/therapy; REVIEW; TOPICAL DRUG ADMINISTRATION; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT/*drug therapy; ANTIRETROVIRUS AGENT/*drug therapy; ACICLOVIR/drug therapy; ANTIBIOTIC AGENT/drug therapy; BOTULINUM TOXIN; CHLOROACETIC ACID/drug therapy; FLUOROURACIL/drug therapy; GLYCERYL TRINITRATE; IMIQUIMOD/drug therapy; LAXATIVE; PODOPHYLLOTOXIN/drug therapy DN: Aldara; Condylox ET: Immunology, Serology and Transplantation; Drug Literature Index; Gastroenterology; Surgery TE: aciclovir/59277-89-3; chloroacetic acid/14526-03-5; chloroacetic acid/79-11-8; fluorouracil/51-21-8; glyceryl trinitrate/55-63-0; imiquimod/99011-02-6; podophyllotoxin/518-28-5 CR: 59277-89-3; 14526-03-5; 79-11-8; 51-21-8; 55-63-0; 99011-02-6; 518-28-5 AB: Anorectal diseases observed in the general population are common in human AU: CNOTE: immunodeficiency virus-infected (HIV+) patients and may be the primary reason they seek medical care. As more individuals contract the disease and those already infected live longer because of improved antiviral therapy, colorectal surgeons will frequently be involved in the care of these patients. Selective surgical management based on the principles of correct diagnosis will result in low operative morbidity with a high rate of symptom relief and eradication of these anorectal diseases. Fleshner PR Fleshner PR 8737 Beverly Blvd, Los Angeles, CA 90048, United States Copyright 2007 Elsevier B.V., All rights reserved. » Volltext-Angebot » 2/101 von 102 DIMDI: EMBASE (EM47) © 2011 Elsevier B.V. ND: PMID: EMM11363030 11363030 Titel: Warts treatment. Source: Treatment review (no 20); p. 7 /Nov 1995/ SU: Medline Sprache: English CY: United States DT: Journal Article Keywords CT: CONDYLOMA ACUMINATUM/*drug therapy; ANAL CANAL; ARTICLE; BIOSYNTHESIS; GENITAL SYSTEM; HUMAN; PATHOLOGY; ALPHA INTERFERON/*; AMINOQUINOLINE DERIVATIVE/*drug therapy; AMINOQUINOLINE DERIVATIVE/*pharmacology; ANTIVIRUS AGENT/*drug therapy; ANTIVIRUS AGENT/*pharmacology; INTERFERON INDUCING AGENT/*drug therapy; INTERFERON INDUCING AGENT/*pharmacology; IMIQUIMOD TE: imiquimod/99011-02-6 CR: 99011-02-6 CNOTE: MEDLINE® is the source for the citation and abstract of this record. » Volltext-Angebot » 2/102 von 102 DIMDI: EMBASE Alert (EA08) © 2011 Elsevier B.V. ND: Autoren: EA2010704199 Newsom-Davis T; Bower M Titel: HIV-associated anal cancer Source: F1000 Medicine Reports; VOL: 2 (1) /20101208/ http://f1000.com/reports/m/2/85/pdf M2-85 10.3410/M2-85 ANR: DOI: PU: Faculty of 1000 Ltd Sprache: English AL: English CY: United Kingdom EISSN: 1757-5931 Institution: Bower M, Department of Oncology, Chelsea, Westminster Hospital NHS Foundation Trust, 369 Fulham Road, London SW10 9NH, United Kingdom, [email protected] COU: United Kingdom DT: Journal Article RN: 0041 AB: HIV-associated anal carcinoma, a non-AIDS-defining cancer, is a human papillomavirus-associated malignancy with a spectrum of preinvasive changes. The standardized incidence ratio for anal cancer in patients with HIV/AIDS is 2050. Algorithms for anal cancer screening include anal cytology followed by highresolution anoscopy for those with abnormal findings. Outpatient topical treatments for anal intraepithelial neoplasia include infrared coagulation therapy, trichloroacetic acid, and imiquimod. The development of cost-effective national screening programs for HIV-associated anal cancer remains a challenge. © 2010 Faculty of 1000 Ltd. AU: Newsom-Davis T Newsom-Davis Thomas Department of Oncology, Chelsea, Westminster Hospital NHS Foundation Trust, 369 Fulham Road, London SW10 9NH, United Kingdom AU: Bower M Bower Mark Department of Oncology, Chelsea, Westminster Hospital NHS Foundation Trust, 369 Fulham Road, London SW10 9NH, United Kingdom [email protected] PU: Faculty of 1000 Ltd 34-42 Cleveland Street, London, W1T 4LB, United Kingdom CNOTE: Copyright 2010 Elsevier B.V., All rights reserved. javascript: window.close() Anlage 4 - 24.08.2012